,Conditions,Drug,Smiles,Phases,Disease
0,HIV Infections,Enfuvirtide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(=O)N)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC7=CC=CC=C7)C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C,APPROVED,immune_system_disease
4,Status Asthmaticus|Asthma,Montelukast,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,PHASE2|PHASE3,immune_system_disease
5,Status Asthmaticus|Asthma,Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,PHASE2|PHASE3,immune_system_disease
6,Status Asthmaticus|Asthma,Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2|PHASE3,immune_system_disease
7,Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,Copanlisib,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5,PHASE1|PHASE2,immune_system_disease
8,Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,Venetoclax,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,PHASE1|PHASE2,immune_system_disease
9,Multiple Myeloma|Lymphoma,Lenalidomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,PHASE1,immune_system_disease
10,Multiple Myeloma,Bortezomib,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,PHASE2,immune_system_disease
11,Multiple Myeloma,Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE2,immune_system_disease
12,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Cyclophosphamide,C1CNP(=O)(OC1)N(CCCl)CCCl,PHASE2,immune_system_disease
13,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Etoposide,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,PHASE2,immune_system_disease
14,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Carboplatin,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],PHASE2,immune_system_disease
16,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Cytarabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,PHASE2,immune_system_disease
17,Mantle Cell Lymphoma,Fludarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,PHASE2,immune_system_disease
18,Mantle Cell Lymphoma,Mitoxantrone,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,PHASE2,immune_system_disease
20,Rheumatoid Arthritis,Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,APPROVED,immune_system_disease
21,Rheumatoid Arthritis,Sulfasalazine,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,APPROVED,immune_system_disease
22,"Lymphoma, Non-Hodgkin|HIV Infections",Bleomycin,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,PHASE1,immune_system_disease
23,"Lymphoma, Non-Hodgkin|HIV Infections",Vincristine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE1,immune_system_disease
24,"Lymphoma, Non-Hodgkin|HIV Infections",Doxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE1,immune_system_disease
25,"Lymphoma, Non-Hodgkin|HIV Infections",Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,immune_system_disease
26,"Lymphoma, Non-Hodgkin|HIV Infections",Leucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,immune_system_disease
28,HIV Infections,Stavudine,CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO,PHASE2,immune_system_disease
29,HIV Infections,Zidovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],PHASE2,immune_system_disease
31,Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma,Gemcitabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,PHASE2,immune_system_disease
32,Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma,Oxaliplatin,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],PHASE2,immune_system_disease
33,"Severe Combined Immunodeficiency Disease, X-linked",Busulfan,CS(=O)(=O)OCCCCOS(=O)(=O)C,PHASE1|PHASE2,immune_system_disease
35,"Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell",Ibrutinib,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE1|PHASE2,immune_system_disease
36,"Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell",Bendamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,PHASE1|PHASE2,immune_system_disease
37,Diffuse Large B Cell Lymphoma,Prednisone,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,PHASE1,immune_system_disease
38,"Lymphoma, Non-Hodgkin|Blood and Marrow Transplant (BMT)",Ibritumomab,CC(CN(CC(CC1=CC=C(C=C1)NC(=O)NC)N(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,PHASE1,immune_system_disease
39,"Diabetes Mellitus, Type 1",Sirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,PHASE1,immune_system_disease
40,Insomnia,Temazepam,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3,APPROVED,immune_system_disease
42,Clonal Cytopenia of Undetermined Significance|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Lymphoma,Cisplatin,N.N.Cl[Pt]Cl,PHASE2,immune_system_disease
43,Clonal Cytopenia of Undetermined Significance|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Lymphoma,Ifosfamide,C1CN(P(=O)(OC1)NCCCl)CCCl,PHASE2,immune_system_disease
45,Rheumatoid Arthritis,Tofacitinib,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,PHASE1,immune_system_disease
46,Chemotherapeutic Agent Toxicity|Cognitive/Functional Effects|Lymphoma|Neurotoxicity|Radiation Toxicity,Procarbazine,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,PHASE2,immune_system_disease
47,Hodgkin's Disease,Melphalan,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,PHASE2,immune_system_disease
48,Hodgkin's Disease,Tacrolimus,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,PHASE2,immune_system_disease
49,Idiopathic Thrombocytopenic Purpura,Romiplostim,CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C,PHASE2,immune_system_disease
50,Asthma|Heart Rate Fast,Albuterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,APPROVED,immune_system_disease
51,Myasthenia Gravis,Salbutamol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,PHASE2|PHASE3,immune_system_disease
52,Type 1 Diabetes,Pramlintide,CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N,APPROVED,immune_system_disease
53,HIV Infections,Mycophenolate,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,PHASE2,immune_system_disease
54,HIV Infections,Amdoxovir,C1C(OC(O1)CO)N2C=NC3=C(N=C(N=C32)N)N,PHASE2,immune_system_disease
55,Systemic Lupus Erythematosus (SLE),Upadacitinib,CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F,PHASE2,immune_system_disease
56,Abdominal Pain|Inflammatory Bowel Diseases|Eosinophilic Gastroenteritis|Diarrhea|Hematochezia|Weight Loss,Ondansetron,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,APPROVED,immune_system_disease
57,Type 1 Diabetes|Diabetic Kidney Disease|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Sensitivity,Metformin,CN(C)C(=N)N=C(N)N,PHASE1,immune_system_disease
58,Type 1 Diabetes|Diabetic Kidney Disease|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Sensitivity,Iohexol,CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,PHASE1,immune_system_disease
59,Asthma,Budesonide,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,APPROVED,immune_system_disease
61,Juvenile Idiopathic Arthritis|Joint Inflammation,Dexmedetomidine,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,APPROVED,immune_system_disease
62,"Lupus Erythematosus, Systemic",Memantine,CC12CC3CC(C1)(CC(C3)(C2)N)C,PHASE2,immune_system_disease
64,Peripheral T-cell Lymphoma,Pralatrexate,C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1|PHASE2,immune_system_disease
65,Human Immunodeficiency Virus|HIV,Islatravir,C#CC1(C(CC(O1)N2C=NC3=C(N=C(N=C32)F)N)O)CO,PHASE2,immune_system_disease
66,Relapsed or Refractory Diffuse Large B-Cell Lymphoma,Selinexor,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,PHASE1|PHASE2,immune_system_disease
68,Asthma in Children,Triamcinolone,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,PHASE2,immune_system_disease
69,Newly Diagnosed Peripheral T-cell Lymphoma,Rivoceranib,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,APPROVED,immune_system_disease
70,Anaphylaxis|Hypotension|Bronchospasm|Angioedema,Epinephrine,CNCC(C1=CC(=C(C=C1)O)O)O,PHASE2,immune_system_disease
72,DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Romidepsin,CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,PHASE2,immune_system_disease
74,ALK+ Anaplastic Large Cell Lymphoma,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE1|PHASE2,immune_system_disease
75,Multiple Sclerosis,Dexrazoxane,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,PHASE2,immune_system_disease
77,Stage IB-IIB Cutaneous T-Cell Lymphoma,Tricyclazole,CC1=C2C(=CC=C1)SC3=NN=CN23,PHASE2,immune_system_disease
79,Stroke|Inflammation,Fingolimod,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,PHASE2,immune_system_disease
81,IGA Nephropathy,Fostamatinib,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,PHASE2,immune_system_disease
82,Type1diabetes,Dapagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,PHASE1,immune_system_disease
84,Chronic Lymphoid Leukemia,Zanubrutinib,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,PHASE2,immune_system_disease
85,Asthma,Azithromycin,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,APPROVED,immune_system_disease
86,"Drug Monitoring|Carcinoma, Non-Small-Cell Lung|Lung Cancer|Anaplastic Lymphoma Kinase Gene Mutation|Anaplastic Lymphoma Kinase Gene Translocation",Alectinib,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,APPROVED,immune_system_disease
87,"Rhinitis, Allergic, Perennial",Loratadine,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,APPROVED,immune_system_disease
88,"Purpura, Thrombocytopaenic, Idiopathic",Ciprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,PHASE1,immune_system_disease
89,"Purpura, Thrombocytopaenic, Idiopathic",Eltrombopag,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,PHASE1,immune_system_disease
96,Skin Inflammation|Allergic Contact Dermatitis,Betamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE2|PHASE3,immune_system_disease
97,Skin Inflammation|Allergic Contact Dermatitis,Fluticasone,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F,PHASE2|PHASE3,immune_system_disease
98,Follicular Lymphoma|B-Cell Lymphoma|Mantle Cell Lymphoma|Diffuse Large B Cell Lymphoma,Tazemetostat,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,PHASE1,immune_system_disease
100,Hodgkin Disease,Vinblastine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE2,immune_system_disease
101,Hodgkin Disease,Dacarbazine,CN(C)N=NC1=C(NC=N1)C(=O)N,PHASE2,immune_system_disease
102,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes|Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease|Peripheral T-cell Lymphoma,Cyclosporine,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,immune_system_disease
103,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes|Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease|Peripheral T-cell Lymphoma,Pentostatin,C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O,PHASE2,immune_system_disease
104,Asthma,Mometasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C,APPROVED,immune_system_disease
105,"Infections, Human Immunodeficiency Virus and Herpesviridae",Dolutegravir,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,PHASE1,immune_system_disease
106,Neuromyelitis Optica Spectrum Disorder,Azathioprine,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],PHASE2|PHASE3,immune_system_disease
108,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia,Aspacytarabine,C1=CN(C(=O)N=C1NC(=O)CC(C(=O)O)N)C2C(C(C(O2)CO)O)O,PHASE1|PHASE2,immune_system_disease
109,HIV Infections,Lamivudine,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,PHASE2,immune_system_disease
110,HIV Infections,Didanosine,C1CC(OC1CO)N2C=NC3=C2N=CNC3=O,PHASE2,immune_system_disease
111,Peripheral T Cell Lymphoma,Epirubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,immune_system_disease
112,Post-nasal Drip|Seasonal Allergic Rhinitis|Rhinorrhea,Desloratadine,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,PHASE2,immune_system_disease
113,Post-nasal Drip|Seasonal Allergic Rhinitis|Rhinorrhea,Oxybutynin,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,PHASE2,immune_system_disease
115,Relapsing-remitting Multiple Sclerosis,Glatiramer,CC(C(=O)O)N.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N,APPROVED,immune_system_disease
116,HIV Infections|Cachexia|Anorexia|AIDS Wasting Syndrome|HIV Wasting Syndrome,Megestrol,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,PHASE2,immune_system_disease
117,HIV Infections|Pregnancy,Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,PHASE1,immune_system_disease
118,"Healthy Subjects|Infection, Human Immunodeficiency Virus",Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,PHASE1,immune_system_disease
119,"Healthy Subjects|Infection, Human Immunodeficiency Virus",Dextromethorphan,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,PHASE1,immune_system_disease
120,"Healthy Subjects|Infection, Human Immunodeficiency Virus",Flurbiprofen,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,PHASE1,immune_system_disease
121,Atopic Dermatitis,Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,immune_system_disease
122,URTICARIA,Rupatadine,CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2,PHASE2,immune_system_disease
123,"Dermatitis, Atopic",Branebrutinib,CC#CC(=O)NC1CCCN(C1)C2=C(C=C(C3=C2C(=C(N3)C)C)C(=O)N)F,PHASE2,immune_system_disease
124,Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma,Duvelisib,CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,PHASE2,immune_system_disease
125,Rheumatoid Arthritis,Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,PHASE2,immune_system_disease
126,Rheumatoid Arthritis,Folate,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,PHASE2,immune_system_disease
127,"Lymphoma, Non-Hodgkin|Multiple Myeloma",Plerixafor,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3,PHASE2,immune_system_disease
128,Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Diffuse Large B-cell Lymphoma|Non-FL Indolent Non-Hodgkin's Lymphoma|Follicular Lymphoma,Entospletinib,C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6,PHASE2,immune_system_disease
129,Mantle Cell Lymphoma,Chlorambucil,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,PHASE2,immune_system_disease
130,Multiple Sclerosis,Teriflunomide,CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O,PHASE2,immune_system_disease
132,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Mixed Phenotype Acute Leukemia|Acute Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Lymphoma,Mesna,C(CS(=O)(=O)[O-])S.[Na+],PHASE2,immune_system_disease
133,"Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic",Tucidinostat,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,PHASE2|PHASE3,immune_system_disease
134,"Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic",Idarubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,PHASE2|PHASE3,immune_system_disease
135,"Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic",Pegaspargase,CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C,PHASE2|PHASE3,immune_system_disease
136,"Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic",Mercaptopurine,C1=NC2=C(N1)C(=S)N=CN2,PHASE2|PHASE3,immune_system_disease
137,Multiple Myeloma,Thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,PHASE2,immune_system_disease
138,Multiple Myeloma,Pomalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,PHASE1|PHASE2,immune_system_disease
139,Multiple Myeloma,Carfilzomib,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,PHASE2,immune_system_disease
141,Human Immunodeficiency Virus,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,PHASE2,immune_system_disease
142,Human Immunodeficiency Virus,Atorvastatin,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,PHASE2,immune_system_disease
144,Relapsed or Refractory Multiple Myeloma,Vorinostat,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,PHASE2,immune_system_disease
147,Large-B-cell Diffuse Lymphoma|Chronic Lymphoid Leukemia,Tenofovir,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,PHASE2,immune_system_disease
148,"Arthritis, Rheumatoid",Apremilast,CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,PHASE2,immune_system_disease
149,Penicillin Allergy,Phenoxymethylpenicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,APPROVED,immune_system_disease
150,Penicillin Allergy,Penicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,APPROVED,immune_system_disease
151,Chronic Lymphocytic Leukemia,Dasatinib,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,PHASE1|PHASE2,immune_system_disease
152,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Acalabrutinib,CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5,PHASE2,immune_system_disease
155,Healthy,Tretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1,immune_system_disease
156,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Lymphoblastic Lymphoma|Diffuse Large B-cell Lymphoma|Burkitt Lymphoma/Leukemia,Clofarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,PHASE1|PHASE2,immune_system_disease
157,HIV Infections,Efavirenz,C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,PHASE2,immune_system_disease
159,Bronchiolitis Obliterans,Itacitinib,C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F,PHASE1,immune_system_disease
160,Multiple Sclerosis|Fatigue,Ketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE1|PHASE2,immune_system_disease
161,HIV Infections,Zalcitabine,C1CC(OC1CO)N2C=CC(=NC2=O)N,PHASE2,immune_system_disease
162,Allergic Conjunctivitis,Olopatadine,CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,APPROVED,immune_system_disease
163,Multiple Myeloma,Panobinostat,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,PHASE1|PHASE2,immune_system_disease
165,B-cell Lymphoma Refractory,Ozogamicin,CCN(C1COC(CC1OC)OC2C(C(C(OC2OC3C#CC=CC#CC4(CC(=O)C(=C3C4=CCSSC(C)(C)CC(=O)NN=C(C)C5=CC=C(C=C5)OCCCC(=O)N)NC(=O)OC)O)C)NOC6CC(C(C(O6)C)SC(=O)C7=C(C(=C(C(=C7OC)OC)OC8C(C(C(C(O8)C)O)OC)O)I)C)O)O)C(=O)C,PHASE1,immune_system_disease
166,B-cell Lymphoma Refractory,Temsirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,PHASE1,immune_system_disease
167,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia,Thiotepa,C1CN1P(=S)(N2CC2)N3CC3,PHASE2,immune_system_disease
168,Asthma,Methacholine,CC(C[N+](C)(C)C)OC(=O)C,PHASE2,immune_system_disease
169,HIV Infection|LTBI,Isoniazid,C1=CN=CC=C1C(=O)NN,PHASE2,immune_system_disease
170,HIV Infection|LTBI,Rifapentine,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C,PHASE2,immune_system_disease
171,HIV Infection|LTBI,Pyridoxine,CC1=NC=C(C(=C1O)CO)CO,PHASE2,immune_system_disease
175,Type 1 Diabetes,Glucagon,CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CN=CN7)N,PHASE2,immune_system_disease
176,Primary Sjögren's Syndrome,Parsaclisib,CCOC1=C(C(=C(C=C1C(C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)C4CC(=O)NC4,PHASE2,immune_system_disease
180,Multiple Myeloma,Iberdomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5,PHASE1|PHASE2,immune_system_disease
182,Metastatic Pancreatic Cancer,Rintatolimod,C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O,PHASE1|PHASE2,immune_system_disease
183,B-cell Chronic Lymphocytic Leukemia,Forodesine,C1=C(C2=C(N1)C(=O)NC=N2)C3C(C(C(N3)CO)O)O,PHASE1,immune_system_disease
184,Multiple Myeloma in Relapse,Clarithromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,PHASE2,immune_system_disease
185,"Rhinitis, Allergic, Perennial",Levocetirizine,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,APPROVED,immune_system_disease
186,Mycobacterium Avium-intracellulare Infection,Streptomycin,CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O,PHASE2,immune_system_disease
189,Allergic Rhinitis,Azelastine,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,APPROVED,immune_system_disease
191,Multiple Myeloma,Oprozomib,CC1=NC=C(S1)C(=O)NC(COC)C(=O)NC(COC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C,PHASE1|PHASE2,immune_system_disease
192,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Ixazomib,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,PHASE2,immune_system_disease
193,HIV Infections,Indinavir,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,PHASE1,immune_system_disease
194,HIV Infections,Amprenavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,PHASE1,immune_system_disease
195,HIV Infections,Nelfinavir,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,PHASE1,immune_system_disease
196,HIV Infections,Saquinavir,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,PHASE1,immune_system_disease
197,AIDS Dementia Complex|HIV Infections,Nimodipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,PHASE1,immune_system_disease
198,HIV-infection/Aids|Human Herpesvirus 4 Infections|Cytomegalovirus Infections|Human Herpesvirus 8 Infection|Human Papilloma Virus,Darunavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,APPROVED,immune_system_disease
199,Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma,Trabectedin,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O,PHASE1,immune_system_disease
201,Asthma,Ipratropium,CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,APPROVED,immune_system_disease
202,Asthma,Prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,APPROVED,immune_system_disease
203,HIV Infections|AIDS,Cholecalciferol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2,immune_system_disease
204,Multiple Sclerosis|Overactive Detrusor,Darifenacin,C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5,PHASE2,immune_system_disease
205,Breast Cancer|Non-small Cell Lung Cancer|Non-Hodgkins Lymphoma,Vinorelbine,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,PHASE1,immune_system_disease
206,Atopic Dermatitis,Hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,PHASE1,immune_system_disease
207,Mastocytosis,Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,PHASE2|PHASE3,immune_system_disease
208,"Infection, Human Immunodeficiency Virus",Atazanavir,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,APPROVED,immune_system_disease
209,Pediatric Solid Tumor,Irinotecan,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,PHASE1,immune_system_disease
210,"Diabetes Mellitus, Insulin-Dependent",Ladarixin,CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C,PHASE2,immune_system_disease
211,Severe IgE-mediated Asthma,Formoterol,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O,APPROVED,immune_system_disease
212,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|t(9;22)",Ponatinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,PHASE2,immune_system_disease
213,Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy,Zibotentan,CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4,PHASE2,immune_system_disease
214,Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy,Paclitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,PHASE2,immune_system_disease
215,"Hodgkin Disease|Lymphoma, Non-Hodgkin|Multiple Myeloma|Mantle Cell Lymphoma",Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,immune_system_disease
216,IgA Nephropathy|Immunoglobulin A Nephropathy,Atrasentan,CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4,PHASE2,immune_system_disease
217,Acute Lymphoblastic Leukemia|Brain Tumors,Methylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,APPROVED,immune_system_disease
218,HIV Infections,Rilpivirine,CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N,PHASE1,immune_system_disease
219,HIV Infections,Abacavir,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,PHASE2,immune_system_disease
220,HIV Infections,Nevirapine,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,PHASE2,immune_system_disease
221,Primary Mediastinal Large B-cell Lymphoma,Decitabine,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,PHASE1|PHASE2,immune_system_disease
222,Lymphangioleiomyomatosis|Tuberous Sclerosis,Doxycycline,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,APPROVED,immune_system_disease
223,Type 2 Diabetes Mellitus|Insulin Sensitivity/Resistance,Linagliptin,CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,APPROVED,immune_system_disease
224,Type 2 Diabetes Mellitus|Insulin Sensitivity/Resistance,Voglibose,C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO,APPROVED,immune_system_disease
225,B-cell Acute Lymphoblastic Leukemia,Daunorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,PHASE1,immune_system_disease
226,Hypersensitivity,Sugammadex,C(CSCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(O2)C(C9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O,PHASE1,immune_system_disease
227,Chronic Spontaneous Urticaria,Tirabrutinib,CC#CC(=O)N1CCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE2,immune_system_disease
228,"Infections, Human Immunodeficiency Virus and Herpesviridae",Fosamprenavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N,PHASE1,immune_system_disease
229,Atopic Dermatitis,Clobetasol,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C,PHASE1|PHASE2,immune_system_disease
231,Platinum Sensitive Relapsed Ovarian Cancer,Docetaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,PHASE2,immune_system_disease
233,Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia,Navitoclax,CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C,PHASE1|PHASE2,immune_system_disease
234,Multiple Sclerosis,Mirabegron,C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,APPROVED,immune_system_disease
235,Aggressive Systemic Mastocytosis|Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease|Mast Cell Leukemia|Relapsed or Refractory Myeloid Malignancies,Avapritinib,CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N,PHASE1,immune_system_disease
236,HIV Infections,Bupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,PHASE1,immune_system_disease
237,Hematopoietic and Lymphoid System Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Histiocytic and Dendritic Cell Neoplasm|Recurrent Langerhans Cell Histiocytosis|Recurrent Lymphoma|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent WHO Grade 2 Glioma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Histiocytic and Dendritic Cell Neoplasm|Refractory Langerhans Cell Histiocytosis|Refractory Lymphoma|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory WHO Grade 2 Glioma|Wilms Tumor,Selpercatinib,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,PHASE2,immune_system_disease
238,Anaplastic Large Cell Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma,Tipifarnib,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,PHASE2,immune_system_disease
239,"Adult Acute Lymphoblastic Leukemia in Remission|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blastic Phase|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase of Disease|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Disease",Nilotinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,immune_system_disease
240,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",Anlotinib,CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,PHASE2,immune_system_disease
241,HIV Infections,Raluridine,C1C(C(OC1N2C=C(C(=O)NC2=O)Cl)CO)F,PHASE1,immune_system_disease
243,HIV Infections,Raltegravir,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,PHASE1,immune_system_disease
244,HIV Infections,Emtricitabine,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,PHASE1,immune_system_disease
246,"Arthritis, Rheumatoid",Cantharidin,CC12C3CCC(C1(C(=O)OC2=O)C)O3,PHASE1,immune_system_disease
247,Primary Central Nervous System Lymphoma,Temozolomide,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,PHASE2,immune_system_disease
248,HIV/AIDS|HIV Infections,Etravirine,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,PHASE1,immune_system_disease
249,Asthma,Minocycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,PHASE2,immune_system_disease
250,HIV Infections,Bictegravir,C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F,APPROVED,immune_system_disease
252,Advanced Solid Neoplasm|Aggressive Non-Hodgkin Lymphoma|Recurrent Solid Neoplasm|Refractory Mantle Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma|Unresectable Solid Neoplasm,Veliparib,CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N,PHASE1,immune_system_disease
253,Gastric Cancer|Gastroesophageal Junction Adenocarcinoma,Fluorouracil,C1=C(C(=O)NC(=O)N1)F,PHASE2,immune_system_disease
254,Immune Thrombocytopenia|Bruton's Tyrosine Kinase,Orelabrutinib,C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4,PHASE2,immune_system_disease
255,Multiple Sclerosis,Simvastatin,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,APPROVED,immune_system_disease
256,Optic Neuritis|Multiple Sclerosis,Amiloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,PHASE2,immune_system_disease
257,Type 1 Diabetes,Eflornithine,C(CC(C(F)F)(C(=O)O)N)CN,PHASE1,immune_system_disease
259,Allergic Contact Dermatitis,Ethylenediamine,C(CN)N,APPROVED,immune_system_disease
260,Chronic Graft-versus-host-disease,Belumosudil,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,PHASE2,immune_system_disease
262,"Rhinitis, Allergic, Seasonal",Beclomethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)Cl)C,PHASE2,immune_system_disease
263,Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia,Nelarabine,COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N,PHASE1|PHASE2,immune_system_disease
264,"Follicular Lymphoma|Lymphoma, Large B-Cell, Diffuse",Idasanutlin,CC(C)(C)CC1C(C(C(N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F,PHASE1|PHASE2,immune_system_disease
265,Peripheral T Cell Lymphoma,Tenalisib,CCC(C1=C(C(=O)C2=CC=CC=C2O1)C3=CC(=CC=C3)F)NC4=NC=NC5=C4NC=N5,PHASE2,immune_system_disease
268,Primary Central Nervous System Lymphoma,Pemetrexed,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2,immune_system_disease
269,Lymphoma,Pegfilgrastim,CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C,PHASE2,immune_system_disease
270,Sarcoidosis,Corticotropin,CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N,APPROVED,immune_system_disease
271,HIV|Pregnancy,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,PHASE2|PHASE3,immune_system_disease
273,IGA Nephropathy,Enalapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O,APPROVED,immune_system_disease
274,IGA Nephropathy,Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O,APPROVED,immune_system_disease
275,IGA Nephropathy,Methylprednisone,CC1CC2C3CCC4=CC(=O)C=CC4(C3C(=O)CC2(C1(C(=O)CO)O)C)C,APPROVED,immune_system_disease
277,Asthma,Salmeterol,C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O,PHASE1,immune_system_disease
278,ABPA,Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,PHASE2,immune_system_disease
279,"Hepatitis C Virus Infection, Response to Therapy of|Human Immunodeficiency Virus",Sofosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,APPROVED,immune_system_disease
280,"Hepatitis C Virus Infection, Response to Therapy of|Human Immunodeficiency Virus",Velpatasvir,CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC,APPROVED,immune_system_disease
281,"Hepatitis C Virus Infection, Response to Therapy of|Human Immunodeficiency Virus",Ribavirin,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,APPROVED,immune_system_disease
282,Waldenström's Macroglobulinemia,Perifosine,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C,PHASE2,immune_system_disease
284,Rheumatoid Arthritis,Omeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE1,immune_system_disease
285,Rheumatoid Arthritis,Warfarin,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,PHASE1,immune_system_disease
288,HIV Infections|Cytomegalovirus Infections,Valganciclovir,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,APPROVED,immune_system_disease
289,Monoclonal Gammopathies|Overweight|Obesity,Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,APPROVED,immune_system_disease
290,Peripheral T-cell Lymphoma,Belinostat,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,PHASE1,immune_system_disease
292,Immune Thrombocytopenia (ITP),Lusutrombopag,CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl,PHASE2,immune_system_disease
293,Allergic Rhinitis,Cetirizine,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,APPROVED,immune_system_disease
294,Solid Tumors|Lymphoma,Alisertib,COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC,PHASE1,immune_system_disease
295,Solid Tumors|Lymphoma,Esomeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE1,immune_system_disease
296,Solid Tumors|Lymphoma,Rifampin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE1,immune_system_disease
297,Solid Tumors|Lymphoma,Rifampicin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE1,immune_system_disease
299,Methemoglobinemia|Linear IgA Bullous Dermatosis,Dapsone,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,PHASE1,immune_system_disease
300,Asthma,Navarixin,CCC(C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C,PHASE2,immune_system_disease
301,"Asthma, Bronchial",Ciclesonide,CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6,APPROVED,immune_system_disease
302,"Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult Diffuse Large Cell Lymphoma|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Myeloid Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma",Treosulfan,CS(=O)(=O)OCC(C(COS(=O)(=O)C)O)O,PHASE2,immune_system_disease
304,HIV Infections,Medroxyprogesterone,CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,PHASE1,immune_system_disease
305,Advanced Systemic Mastocytosis,Azacitidine,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,PHASE1|PHASE2,immune_system_disease
306,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Defactinib,CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F,PHASE2,immune_system_disease
307,Atopic Dermatitis,Ruxolitinib,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,immune_system_disease
308,"Infections, Human Immunodeficiency Virus and Hepatitis",Levonorgestrel,CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE1,immune_system_disease
309,Hepatitis B,Entecavir,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N,APPROVED,immune_system_disease
310,"Conjunctivitis, Allergic",Mapracorat,CC1=NC2=C(C=C1)C(=CC=C2)NCC(CC(C)(C)C3=CC(=CC4=C3OCC4)F)(C(F)(F)F)O,PHASE2,immune_system_disease
311,HCV-HIV Co-Infection,Asunaprevir,CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C,PHASE2,immune_system_disease
312,HCV-HIV Co-Infection,Daclatasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE2,immune_system_disease
313,Arsenic Trioxide|Childhood ALL,Indigo,C1=CC=C2C(=C1)C(=C(N2)C3=NC4=CC=CC=C4C3=O)O,APPROVED,immune_system_disease
314,Metabolic Syndrome X,Resveratrol,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,PHASE2,immune_system_disease
315,Indolent B-cell Lymphoma|Hepatitis C,Ledipasvir,CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE2,immune_system_disease
316,Infections Joint Prosthetic|Overweight or Obesity|MSSA Colonization|MRSA|Chronic Kidney Diseases|Diabetes|Autoimmune Diseases|Inflammatory Disease|Tobacco Use,Cephalexin,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O,APPROVED,immune_system_disease
317,Infections Joint Prosthetic|Overweight or Obesity|MSSA Colonization|MRSA|Chronic Kidney Diseases|Diabetes|Autoimmune Diseases|Inflammatory Disease|Tobacco Use,Cefadroxil,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O,APPROVED,immune_system_disease
318,Acute Graft Versus Host Disease|Hematopoietic and Lymphoid System Neoplasm,Cholestyramine,CCC(C)C.CCC(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)C[N+](C)(C)C.N.[Cl-],PHASE1,immune_system_disease
319,Acute Graft Versus Host Disease|Hematopoietic and Lymphoid System Neoplasm,Leflunomide,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,PHASE1,immune_system_disease
320,Myeloma,Topotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,PHASE2,immune_system_disease
321,Rheumatoid Arthritis,Fexofenadine,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,PHASE1|PHASE2,immune_system_disease
323,Asthma,Abediterol,C1=CC=C(C=C1)C(COCCCCCCNCC(C2=C3C=CC(=O)NC3=C(C=C2)O)O)(F)F,PHASE1,immune_system_disease
324,Hypersensitivity,Paricalcitol,CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C,PHASE2,immune_system_disease
325,Severe Persistent Asthma,Lovastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE1|PHASE2,immune_system_disease
326,HIV Infections,Dapivirine,CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C,PHASE1,immune_system_disease
327,"Arthritis, Rheumatoid",Bazedoxifene,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,APPROVED,immune_system_disease
328,Penicillin Allergy|Penicillin Reaction,Amoxicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,APPROVED,immune_system_disease
329,Hodgkin Lymphoma,Everolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,PHASE1|PHASE2,immune_system_disease
332,HIV,Maraviroc,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,PHASE1,immune_system_disease
333,Asthma,Levosalbutamol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,PHASE2,immune_system_disease
334,Asthma,Levalbuterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,PHASE2,immune_system_disease
335,HIV Infections,Hydroxyurea,C(=O)(N)NO,PHASE1,immune_system_disease
336,Indolent Systemic Mastocytosis,Midostaurin,CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC,PHASE2,immune_system_disease
338,Thyroid Eye Disease|Ocular Hypertension|Glaucoma,Timolol,CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O,APPROVED,immune_system_disease
339,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Dinaciclib,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,PHASE1,immune_system_disease
340,Type 1 Diabetes,Ergocalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2|PHASE3,immune_system_disease
341,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma|Low Grade Glioma|Malignant Glioma|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Ependymoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Childhood Malignant Germ Cell Tumor|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Rhabdoid Tumor|Wilms Tumor,Olaparib,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE2,immune_system_disease
342,HIV Infections,Methoxsalen,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,PHASE1,immune_system_disease
343,Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Mixed Phenotype Acute Leukemia|Myeloid Neoplasm|Relapsed Acute Biphenotypic Leukemia|Relapsed Acute Myeloid Leukemia|Relapsed Mixed Phenotype Acute Leukemia|Relapsed Myeloid Neoplasm|Refractory Acute Biphenotypic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myeloid Neoplasm|Recurrent Myeloid Sarcoma,Cladribine,C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,PHASE1,immune_system_disease
344,Multiple Myeloma,Tasquinimod,CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O,PHASE1,immune_system_disease
345,Asthma in Children,Tiotropium,C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C,PHASE2,immune_system_disease
346,Asthma,Vilanterol,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl,PHASE2,immune_system_disease
348,Diffuse Large B-Cell Lymphoma|Drug Toxicity,Glucarpidase,[Zn+2].[Zn+2].[Zn+2].[Zn+2],PHASE2,immune_system_disease
351,Healthy Volunteers|Rheumatoid Arthritis,Digoxin,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,PHASE1,immune_system_disease
352,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Ruboxistaurin,CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O,PHASE2|PHASE3,immune_system_disease
353,"Lupus Erythematosus, Systemic",Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,PHASE2,immune_system_disease
354,Pruritus|Atopic Dermatitis,Orvepitant,CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5C(C4)CCC5=O,PHASE2,immune_system_disease
355,Primary Central Nervous System Lymphoma,Isavuconazole,CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O,PHASE1,immune_system_disease
356,Relapsing-Remitting Multiple Sclerosis,Carmustine,C(CCl)NC(=O)N(CCCl)N=O,PHASE2,immune_system_disease
357,AIDS Dementia Complex,Ferumoxytol,O[Fe]=O.O[Fe]=O.[Fe],PHASE2,immune_system_disease
358,Relapsing-Remitting Multiple Sclerosis,Donepezil,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,APPROVED,immune_system_disease
359,"Lymphoma, Follicular",Abexinostat,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PHASE2,immune_system_disease
360,"Lymphoma, Non-Hodgkin|Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma",Acetaminophen,CC(=O)NC1=CC=C(C=C1)O,PHASE2,immune_system_disease
361,Multiple Sclerosis,Dalfampridine,C1=CN=CC=C1N,APPROVED,immune_system_disease
362,Sjogren's Syndrome|Keratoconjunctivitis Sicca,Levocarnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,immune_system_disease
363,Sjogren's Syndrome|Keratoconjunctivitis Sicca,Carnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,immune_system_disease
365,Chronic Lymphocytic Leukemia,Talabostat,B(C1CCCN1C(=O)C(C(C)C)N)(O)O,PHASE2,immune_system_disease
368,Cutaneous T-cell Lymphoma (CTCL),Sapacitabine,CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)C2C(C(C(O2)CO)O)C#N,PHASE2,immune_system_disease
369,HIV Infections,Acitretin,CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC,PHASE1,immune_system_disease
370,Autoimmune Hemolytic Anemia|Failure of Two Rounds of Treatment,Linperlisib,CC(C)(C1CCN(CC1)CC2=C3C(=CC(=C2)F)C(=NC(=N3)N4CCOCC4)C5=CC(=C(N=C5)OC)NS(=O)(=O)C)O,PHASE1,immune_system_disease
371,Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma,Acyclovir,C1=NC2=C(N1COCCO)N=C(NC2=O)N,PHASE1|PHASE2,immune_system_disease
372,Lupus Nephritis,Laquinimod,CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O,PHASE2,immune_system_disease
374,Asthma|Obesity,Roflumilast,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,PHASE2,immune_system_disease
375,Atopic Dermatitis,Pimecrolimus,CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)Cl)C)O)C)OC)OC)C)C,APPROVED,immune_system_disease
376,Autoimmune Pulmonary Alveolar Proteinosis,Pioglitazone,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,PHASE1,immune_system_disease
377,Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia,Tioguanine,C1=NC2=C(N1)C(=S)N=C(N2)N,PHASE1,immune_system_disease
378,Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia,Thioguanine,C1=NC2=C(N1)C(=S)N=C(N2)N,PHASE1,immune_system_disease
379,Multiple Myeloma,Palbociclib,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,PHASE1,immune_system_disease
380,Immune Thrombocytopenia,Terbutaline,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,PHASE2,immune_system_disease
381,Immune Thrombocytopenia,Danazol,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5,PHASE2,immune_system_disease
382,Atopic Dermatitis,Fluocinonide,CC(=O)OCC(=O)C12C(CC3C1(CC(C4(C3CC(C5=CC(=O)C=CC54C)F)F)O)C)OC(O2)(C)C,APPROVED,immune_system_disease
383,Hodgkin's Lymphoma,Entinostat,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,PHASE2,immune_system_disease
384,"Asthma, Bronchial",Calcifediol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,APPROVED,immune_system_disease
386,Asthma,Carbidopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,PHASE1,immune_system_disease
387,Multiple Sclerosis,Isoxsuprine,CC(COC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O,PHASE1|PHASE2,immune_system_disease
388,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia,Umbralisib,CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F,PHASE2,immune_system_disease
389,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Idelalisib,CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,PHASE1,immune_system_disease
390,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Sorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,PHASE1,immune_system_disease
391,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Sunitinib,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,PHASE1,immune_system_disease
392,"Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases",Ranitidine,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,PHASE2,immune_system_disease
393,"Rhinitis, Allergic",Chlorpheniramine,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,PHASE2,immune_system_disease
394,Type 1 Diabetes Mellitus,Alprazolam,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,PHASE1|PHASE2,immune_system_disease
395,Advanced Malignant Solid Neoplasm|Malignant Solid Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Wilms Tumor,Ensartinib,CC1CN(CC(N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)OC(C)C4=C(C=CC(=C4Cl)F)Cl)N,PHASE2,immune_system_disease
396,Allergic Conjunctivitis,Tranilast,COC1=C(C=C(C=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OC,APPROVED,immune_system_disease
397,Acute Lymphocytic Leukemia,Annamycin,CC1C(C(C(C(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)CO)O)I)O)O,PHASE1|PHASE2,immune_system_disease
398,"Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides (MF)|Chronic Lymphocytic Leukemia (CLL)|Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype|Adult T-Cell Leukemia/Lymphoma (ATLL)",Cobomarsen,CC1=CN(C(=O)NC1=O)C2C3C(C(O2)(CO3)COP(=S)(O)OC4C5C(OC4(CO5)COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8C9C(OC8(CO9)COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1C2C(OC1(CO2)CO)N1C=C(C(=NC1=O)N)C)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC12COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC13COC(C1OP(=S)(O)OCC14COC(C1OP(=S)(O)OCC15COC(C1OP(=S)(O)OCC16COC(C1O)C(O6)N1C=NC6=C(N=CN=C61)N)C(O5)N1C=C(C(=O)NC1=O)C)C(O4)N1C=C(C(=O)NC1=O)C)C(O3)N1C=NC3=C(N=CN=C31)N)C(O2)N1C=NC2=C1N=C(NC2=O)N,PHASE1,immune_system_disease
399,Immune Thrombocytopenia,Calcitriol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,immune_system_disease
400,"Multiple Sclerosis, Relapsing-Remitting",Domperidone,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,PHASE2,immune_system_disease
401,Classical Hodgkin Lymphoma|Lymphocyte-Depleted Classical Hodgkin Lymphoma|Lymphocyte-Rich Classical Hodgkin Lymphoma|Mixed Cellularity Classical Hodgkin Lymphoma|Nodular Sclerosis Classical Hodgkin Lymphoma,Fludeoxyglucose,C(C(C(C(C(C=O)F)O)O)O)O,PHASE2,immune_system_disease
402,Chronic Urticaria,Miltefosine,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,PHASE2,immune_system_disease
403,Primary Non Hodgkin Lymphoma of the Central Nervous System,Lomustine,C1CCC(CC1)NC(=O)N(CCCl)N=O,PHASE2,immune_system_disease
405,"Recurrent Acute Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hairy Cell Leukemia|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent T Acute Lymphoblastic Leukemia|Refractory Acute Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Hairy Cell Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory T Acute Lymphoblastic Leukemia|Systemic Mastocytosis",Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,PHASE1,immune_system_disease
407,"Pneumonia, Pneumocystis Carinii|HIV Infections",Sitamaquine,CCN(CC)CCCCCCNC1=CC(=CC2=C(C=CN=C12)C)OC,PHASE2,immune_system_disease
408,"Multiple Myeloma|Multiple Myeloma in Relapse|Multiple Myeloma, Refractory",Marizomib,CC12C(C(=O)NC1(C(=O)O2)C(C3CCCC=C3)O)CCCl,PHASE2,immune_system_disease
409,Eosinophilic Esophagitis,Mesalamine,C1=CC(=C(C=C1N)C(=O)O)O,PHASE2,immune_system_disease
410,Eosinophilic Esophagitis,Mesalazine,C1=CC(=C(C=C1N)C(=O)O)O,PHASE2,immune_system_disease
411,Relapsing-remitting Multiple Sclerosis,Evobrutinib,C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N,PHASE2,immune_system_disease
412,"Multiple Sclerosis, Secondary Progressive",Indapamide,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,PHASE2,immune_system_disease
413,Atopic Dermatitis,Tapinarof,CC(C)C1=C(C=C(C=C1O)C=CC2=CC=CC=C2)O,PHASE2,immune_system_disease
414,HIV Infections,Pravastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O,PHASE1,immune_system_disease
415,HIV Infections,Gemfibrozil,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,PHASE1,immune_system_disease
416,HIV Infections,Rosiglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,PHASE1,immune_system_disease
417,"Nasal Polyps|Asthma, Aspirin-Induced|Aspirin-exacerbated Respiratory Disease|Aspirin-Sensitive Asthma With Nasal Polyps",Ifetroban,CCCCCNC(=O)C1=COC(=N1)C2C3CCC(C2CC4=CC=CC=C4CCC(=O)O)O3,PHASE2,immune_system_disease
418,"Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Biphenotypic Acute Leukemia|Undifferentiated Leukemia|Prolymphocytic Leukemia|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelodysplastic Syndromes|Leukemia, Myeloid|Myelodysplastic Syndrome With Excess Blasts-1|Burkitt Lymphoma|Relapsed T-Cell Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Follicular Lymphoma|Myeloproliferative Neoplasm|Myelofibrosis",Allopurinol,C1=NNC2=C1C(=O)NC=N2,PHASE2,immune_system_disease
419,"Multiple Sclerosis, Relapsing-Remitting",Inosine,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O,PHASE2,immune_system_disease
420,Adult Acute Lymphocytic Leukemia,Vindesine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,APPROVED,immune_system_disease
421,Locally Advanced Rectal Cancer,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,PHASE2,immune_system_disease
422,Multiple Sclerosis,Firategrast,CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)CC(C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC,PHASE2,immune_system_disease
425,Rheumatoid Arthritis,Iguratimod,CS(=O)(=O)NC1=C(C=C2C(=C1)OC=C(C2=O)NC=O)OC3=CC=CC=C3,APPROVED,immune_system_disease
426,HIV Infections,Adefovir,C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N,PHASE1,immune_system_disease
427,"Eczema|Dermatitis|Skin Diseases, Genetic|Dermatitis, Atopic|Skin Diseases",Trimethoprim,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,PHASE2,immune_system_disease
428,Cutaneous T-cell Lymphoma|Cutaneous T-cell Lymphoma Stage I|Mycosis Fungoides|Folliculotropic Mycosis Fungoides|Granulomatous Slack Skin|Syringotropic Mycosis Fungoides|Mycosis Fungoides Variant|Transformed Mycosis Fungoides,Mechlorethamine,CN(CCCl)CCCl,PHASE2,immune_system_disease
429,Advanced Malignant Solid Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma,Larotrectinib,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,PHASE2,immune_system_disease
430,Sarcoidosis|Precapillary Pulmonary Hypertension|Interstitial Lung Disease,Treprostinil,CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,PHASE2,immune_system_disease
432,IGA Glomerulonephritis,Ramipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O,APPROVED,immune_system_disease
433,Multiple Myeloma,Tadalafil,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,PHASE2,immune_system_disease
435,Toxoplasmosis,Pyrimethamine,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,APPROVED,immune_system_disease
436,Toxoplasmosis,Spiramycin,CC1CC=CC=CC(C(CC(C(C(C(CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C,APPROVED,immune_system_disease
437,Toxoplasmosis,Sulfadiazine,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,APPROVED,immune_system_disease
438,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",Guanabenz,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,PHASE1,immune_system_disease
439,"Infection, Human Immunodeficiency Virus",Cabotegravir,CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,PHASE1,immune_system_disease
441,Atopic Dermatitis,Abrocitinib,CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3,APPROVED,immune_system_disease
442,Exercise-Induced Asthma,Oglemilast,CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F,PHASE2,immune_system_disease
443,Multiple Sclerosis,Paracetamol,CC(=O)NC1=CC=C(C=C1)O,APPROVED,immune_system_disease
444,Asthma,Nedocromil,CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O,PHASE1,immune_system_disease
445,Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma,Verapamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,PHASE1,immune_system_disease
448,"Ultraviolet Rays|Immunosuppression|Hypersensitivity, Delayed|Immune Tolerance/Drug Effects",Diphencyprone,C1=CC=C(C=C1)C2=C(C2=O)C3=CC=CC=C3,PHASE1,immune_system_disease
450,Rheumatoid Arthritis|Osteoporosis|Osteopenia,Ibandronate,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,APPROVED,immune_system_disease
451,Methamphetamine Dependence|HIV Infection,Ibudilast,CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C,PHASE2,immune_system_disease
452,"Misoprostol Allergy|Oxytocin Allergy|Tranexamic Acid Allergy|Ethamsylate Allergy|Myoma|Blood Loss, Surgical",Misoprostol,CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O,APPROVED,immune_system_disease
453,"Misoprostol Allergy|Oxytocin Allergy|Tranexamic Acid Allergy|Ethamsylate Allergy|Myoma|Blood Loss, Surgical",Carbetocin,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSCCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,APPROVED,immune_system_disease
455,Rheumatoid Arthritis,Revamilast,C1=CC(=C2C(=C1C(=O)N=C3C(=CN(C=C3Cl)O)Cl)C4=C(O2)C=CN=C4)OC(F)F,PHASE2,immune_system_disease
457,Major Depression|Pain|Abdominal Pain,Reboxetine,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,APPROVED,immune_system_disease
459,"Leukemia, Lymphocytic, Chronic, B-Cell",Ethinylestradiol,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O,PHASE1,immune_system_disease
460,"Leukemia, Lymphocytic, Chronic, B-Cell",Bupropion,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,PHASE1,immune_system_disease
462,"Myeloma-Multiple|Myeloma, Plasma-Cell",Rimiducid,CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)C(CCC6=CC(=C(C=C6)OC)OC)OC(=O)C7CCCCN7C(=O)C(CC)C8=CC(=C(C(=C8)OC)OC)OC,PHASE1,immune_system_disease
463,Solid Tumors|Lymphoma|Multiple Myeloma,Bexarotene,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C,PHASE1,immune_system_disease
464,Atopic Dermatitis,Crisaborole,B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O,APPROVED,immune_system_disease
466,Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma,Alvocidib,CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O,PHASE1,immune_system_disease
467,Allergic Rhinitis,Bilastine,CCOCCN1C2=CC=CC=C2N=C1C3CCN(CC3)CCC4=CC=C(C=C4)C(C)(C)C(=O)O,APPROVED,immune_system_disease
468,Chronic Graft Versus Host Disease|Fasciitis,Glasdegib,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,PHASE1|PHASE2,immune_system_disease
469,Antiphospholipid Syndrome,Fluvastatin,CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,PHASE2,immune_system_disease
470,HIV Infections,Vicriviroc,CC1CN(CCN1C(COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C,PHASE1|PHASE2,immune_system_disease
472,Peripheral Neuropathy|Type 1 Diabetes,Salsalate,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,PHASE2,immune_system_disease
473,Asthma,Tofimilast,CCC1=NN(C2=C1CCN3C2=NN=C3C4=CC=CS4)C5CCCC5,PHASE2,immune_system_disease
474,"Arthritis, Rheumatoid|Atherosclerosis",Sildenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,PHASE2,immune_system_disease
476,Acute Myeloid Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL),Pyronaridine,COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6,PHASE2,immune_system_disease
477,Hereditary Ataxia|Multiple Sclerosis|Cerebellar Ataxia,Riluzole,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,PHASE2,immune_system_disease
478,Type 1 Diabetes,Exenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N,PHASE1,immune_system_disease
479,Acquired Immunodeficiency Syndrome,Dimiracetam,C1CC(=O)N2C1NC(=O)C2,PHASE2,immune_system_disease
480,Rheumatoid Arthritis,Cilostazol,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,PHASE2|PHASE3,immune_system_disease
481,HIV Infections,Nystatin,CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,PHASE1,immune_system_disease
482,"Chronic Idiopathic Thrombocytopenic Purpura|Purpura, Thrombocytopenic, Idiopathic",Avatrombopag,C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl,PHASE2,immune_system_disease
483,Spasticity|Multiple Sclerosis,Baclofen,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,PHASE2,immune_system_disease
484,Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Elsamitrucin,CC1C(C(C(C(O1)OC2C(OC(C(C2(C)O)O)C)OC3=CC=CC4=C3C5=C6C7=C(C=CC(=C7C(=O)O5)C)OC(=O)C6=C4O)N)OC)O,PHASE2,immune_system_disease
485,Multiple Myeloma,Pirarubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6,APPROVED,immune_system_disease
486,Graft-versus-host Disease|Acute-graft-versus-host Disease,Defibrotide,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)OP(=O)(O)O,PHASE2,immune_system_disease
488,"High-grade B-cell Lymphoma|Burkitt Lymphoma|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphatic Diseases|Lymphoma, High-Grade|C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma|C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma|C-Myc Gene Rearrangement",Sepantronium,CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4,PHASE2,immune_system_disease
489,Sarcoidosis|Pulmonary Arterial Hypertension,Bosentan,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,PHASE2|PHASE3,immune_system_disease
491,Bronchial Asthma,Gabapentin,C1CCC(CC1)(CC(=O)O)CN,APPROVED,immune_system_disease
492,Stem Cell Transplantation|Graft vs Host Disease,Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,PHASE1,immune_system_disease
493,Stem Cell Transplantation|Graft vs Host Disease,Voriconazole,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,PHASE1,immune_system_disease
494,Stem Cell Transplantation|Graft vs Host Disease,Micafungin,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O,PHASE1,immune_system_disease
496,Multiple Myeloma,Filanesib,CN(C(=O)N1C(SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC,PHASE1|PHASE2,immune_system_disease
497,Hodgkins Lymphoma,Goserelin,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,immune_system_disease
498,Pompe Disease,Lidocaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,PHASE1,immune_system_disease
499,Allergic Bronchopulmonary Aspergillosis,Deflazacort,CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C,PHASE2|PHASE3,immune_system_disease
500,HIV Infections,Levofloxacin,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,PHASE1,immune_system_disease
501,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Sonidegib,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,PHASE2,immune_system_disease
502,Chronic Urticaria,Hydroxyzine,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,APPROVED,immune_system_disease
503,Head and Neck Cancer|Oral Mucositis,Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,PHASE1,immune_system_disease
505,Hepatocellular Carcinoma,Lenvatinib,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,PHASE2,immune_system_disease
506,Allergic Conjunctivitis,Loteprednol,CC12CC(C3C(C1CCC2(C(=O)OCCl)O)CCC4=CC(=O)C=CC34C)O,PHASE2,immune_system_disease
507,Seasonal Allergic Rhinitis,Epinastine,C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N,PHASE2,immune_system_disease
508,Eosinophilic Esophagitis,Losartan,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,PHASE2,immune_system_disease
512,Type 1 Diabetes Mellitus|Dyslipidemia,Ezetimibe,C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O,PHASE2,immune_system_disease
513,Colorectal Neoplasms|Breast Neoplasms,Cediranib,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,PHASE1|PHASE2,immune_system_disease
514,HIV-1 Infection,Clopidogrel,COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,PHASE2,immune_system_disease
515,Mantle Cell Lymphoma,Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,PHASE2,immune_system_disease
516,Lymphangioleiomyomatosis,Letrozole,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,PHASE2,immune_system_disease
517,HIV Infections,Tucaresol,C1=CC(=C(C(=C1)OCC2=CC=C(C=C2)C(=O)O)C=O)O,PHASE1,immune_system_disease
518,Mantle Cell Lymphoma|B Cell Lymphoma|Multiple Myeloma,Canfosfamide,C1=CC=C(C=C1)C(C(=O)O)NC(=O)C(CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CCC(C(=O)O)N,PHASE2,immune_system_disease
519,Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma|Inflammatory Myofibroblastic Tumors|Solid Tumors,Brigatinib,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC,PHASE1|PHASE2,immune_system_disease
521,Herpes Genitalis|HIV Infection,Valaciclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE2,immune_system_disease
522,Herpes Genitalis|HIV Infection,Valacyclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE2,immune_system_disease
524,"Diabetes Mellitus, Type 1",Dasiglucagon,CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N,PHASE2,immune_system_disease
525,Multiple Myeloma,Amrubicin,CC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)OC5CC(C(CO5)O)O)N,PHASE1|PHASE2,immune_system_disease
526,HIV Infection,Diflunisal,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O,APPROVED,immune_system_disease
527,Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome,Posaconazole,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,PHASE1|PHASE2,immune_system_disease
528,"Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|AML, Adult|CLL|CLL, Relapsed|CLL, Refractory",Pitavastatin,C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F,PHASE1,immune_system_disease
529,Multiple Myeloma,Uproleselan,CCC1CC(CC(C1OC2C(C(C(C(O2)C)O)O)O)OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC,PHASE2,immune_system_disease
530,Allergic Conjunctivitis,Brimonidine,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,PHASE2,immune_system_disease
531,Allergic Conjunctivitis,Oxymetazoline,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,PHASE2,immune_system_disease
534,Immune Thrombocytopenia,Acetylcysteine,CC(=O)NC(CS)C(=O)O,PHASE1|PHASE2,immune_system_disease
535,Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma,Buparlisib,C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,PHASE1,immune_system_disease
536,Multiple Myeloma,Fosaprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F,PHASE1|PHASE2,immune_system_disease
537,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Central Nervous System Neoplasm,Selumetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,PHASE2,immune_system_disease
538,Multiple Myeloma,Pamidronate,C(CN)C(O)(P(=O)(O)O)P(=O)(O)O,PHASE2,immune_system_disease
540,Atopic Dermatitis,Retapamulin,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CC5CCC(C4)N5C)C,APPROVED,immune_system_disease
541,HIV Infections,Delavirdine,CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C,PHASE2,immune_system_disease
543,Acute Lymphoblastic Leukemia,Teniposide,COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=CC=CS8)O)O,APPROVED,immune_system_disease
544,Cutaneous T-Cell Lymphoma,Enzastaurin,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7,PHASE2,immune_system_disease
545,Type 1 Diabetes Mellitus,Sotagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl,PHASE2,immune_system_disease
546,Multiple Myeloma,Atiprimod,CCCC1(CCC2(CC1)CCN(C2)CCCN(CC)CC)CCC,PHASE1|PHASE2,immune_system_disease
547,Lymphoma,Glutamine,C(CC(=O)N)C(C(=O)O)N,PHASE2,immune_system_disease
548,Follicular Lymphoma,Selenomethionine,C[Se]CCC(C(=O)O)N,PHASE2,immune_system_disease
549,Follicular Lymphoma,Allicin,C=CCSS(=O)CC=C,PHASE2,immune_system_disease
550,Follicular Lymphoma,Quercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,PHASE2,immune_system_disease
552,Acute Myeloid Leukemia|Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Multiple Myeloma,Birabresib,CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C,PHASE1,immune_system_disease
553,Atopic Dermatitis|Atopic Dermatitis Eczema|Atopic Dermatitis Flare,Dicloxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,immune_system_disease
554,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Erdafitinib,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,PHASE2,immune_system_disease
555,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Ulixertinib,CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl,PHASE2,immune_system_disease
556,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Vemurafenib,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,PHASE2,immune_system_disease
557,HIV Infections,Rosuvastatin,CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,PHASE1,immune_system_disease
558,Lymphoma,Metronidazole,CC1=NC=C(N1CCO)[N+](=O)[O-],PHASE2,immune_system_disease
559,Lymphoma,Tetracycline,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,PHASE2,immune_system_disease
560,Neurocognitive Disturbance|HIV Infection,Rivastigmine,CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C,APPROVED,immune_system_disease
561,"Peripheral T-Cell Lymphoma (PTCL NOS)|Nodal Lymphomas of T Follicular Helper (TFH)|Follicular T-cell Lymphoma (FTCL)|AITL|ALCL|HSTCL|EATL I,II|MEITL, EATL Type II|Nasal Lymphoma",Cerdulatinib,CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N,PHASE2|PHASE3,immune_system_disease
563,Multiple Sclerosis|MS,Isoxaflutole,CS(=O)(=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C2=C(ON=C2)C3CC3,PHASE1,immune_system_disease
564,"Hepatitis C|Renal Insufficiency, Chronic|Disorder of Transplanted Kidney",Grazoprevir,CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1,APPROVED,immune_system_disease
565,"Hepatitis C|Renal Insufficiency, Chronic|Disorder of Transplanted Kidney",Elbasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC,APPROVED,immune_system_disease
566,Advanced Solid Tumor|Lymphoma,Milademetan,CC1(CCC2(CC1)C3(C(C(N2)C(=O)NC4CCC(OC4)C(=O)N)C5=C(C(=NC=C5)Cl)F)C6=C(C=C(C=C6)Cl)NC3=O)C,PHASE1,immune_system_disease
567,Relapsing Remitting Multiple Sclerosis,Simethicone,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,APPROVED,immune_system_disease
568,Relapsing Remitting Multiple Sclerosis,Loperamide,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,APPROVED,immune_system_disease
570,"Neoplasms, Haematologic",Afuresertib,CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl,PHASE1,immune_system_disease
571,HIV Infections,Calanolide A,CCCC1=CC(=O)OC2=C1C3=C(C=CC(O3)(C)C)C4=C2C(C(C(O4)C)C)O,PHASE1,immune_system_disease
572,"NMO Spectrum Disorder|Spasticity, Muscle",Nabiximols,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,PHASE2,immune_system_disease
573,Systemic Lupus Erythematosus,Levothyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,APPROVED,immune_system_disease
574,Type 1 Diabetes,Sitagliptin,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,APPROVED,immune_system_disease
575,Graves Disease|Relapse|Treatment|Drug Withdrawal,Methimazole,CN1C=CNC1=S,APPROVED,immune_system_disease
576,"Diabetes Mellitus, Type 1|Hypoglycemia|Hypoglycemia Unawareness",Naloxone,C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,APPROVED,immune_system_disease
577,"Diabetes Mellitus, Type 1|Hypoglycemia|Hypoglycemia Unawareness",Diazoxide,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,APPROVED,immune_system_disease
578,Urticaria,Ebastine,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,APPROVED,immune_system_disease
579,Advanced Solid Tumors|Lymphomas,Darinaparsin,C[As](C)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N,PHASE1,immune_system_disease
580,Asthma,Sulforaphane,CS(=O)CCCCN=C=S,PHASE1,immune_system_disease
581,Hodgkin Lymphoma|Refractory Hodgkin Lymphoma,Pentamidine,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,PHASE1,immune_system_disease
582,Human Immunodeficiency Virus|Acquired Immunodeficiency Syndrome|Opiate Addiction|Drug Dependence,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,APPROVED,immune_system_disease
584,GERD,Citalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,immune_system_disease
585,"Lupus Erythematosus, Cutaneous",Alitretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE2,immune_system_disease
586,Staphylococcus Aureus|HIV Infections,Mupirocin,CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)C(C)O,APPROVED,immune_system_disease
588,Diabetic Nephropathies,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,PHASE2,immune_system_disease
589,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Trametinib,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,PHASE2,immune_system_disease
590,HIV Infections,Racivir,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,PHASE2,immune_system_disease
591,Chronic Heart Failure,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,APPROVED,immune_system_disease
592,Children With Confirmed HIV Infection|Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose|Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment,Rifabutin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)C,PHASE1,immune_system_disease
593,"Sclerosis, Multiple|Autoimmune Diseases of the Nervous System|Nervous System Diseases|Autoimmune Diseases",Melatonin,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,PHASE1|PHASE2,immune_system_disease
594,Atopic Dermatitis,Halobetasol,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C)F,PHASE2,immune_system_disease
595,Atopic Dermatitis,Ulobetasol,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C)F,PHASE2,immune_system_disease
596,HIV/AIDS,Albuvirtide,CCC(C)C(C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)O)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)CCN2C(=O)C=CC2=O)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CC3=CNC=N3)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)O)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC6=CNC7=CC=CC=C76)NC(=O)C,PHASE1,immune_system_disease
597,Ebola|HIV/AIDS,Remdesivir,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,PHASE2,immune_system_disease
598,Medicaments Substances in Therapeutic Use,Etodolac,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,APPROVED,immune_system_disease
599,Visceral Hypersensitivity|Irritable Bowel Syndrome,Rifaximin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,PHASE2,immune_system_disease
600,Peripheral T-cell Lymphomas,Endostar,CN(CC(=O)C1=CC=CC=C1)N=O,PHASE2,immune_system_disease
601,Metastatic Distal Bile Duct Adenocarcinoma|Metastatic Gallbladder Carcinoma|Metastatic Intrahepatic Cholangiocarcinoma|Recurrent Distal Bile Duct Adenocarcinoma|Recurrent Gallbladder Carcinoma|Recurrent Intrahepatic Cholangiocarcinoma|Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Gallbladder Cancer AJCC v8|Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|Unresectable Liver and Intrahepatic Bile Duct Carcinoma,Cobimetinib,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,PHASE2,immune_system_disease
603,"Endothelial Dysfunction|Diabetes Mellitus, Type 1|Biomarkers|Endothelial Progenitor Cells|SGLT 2 Inhibitors|Incretins|Glucose Excursions|FMD|FPF|Arterial Stiffness",Semaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,APPROVED,immune_system_disease
604,"Endothelial Dysfunction|Diabetes Mellitus, Type 1|Biomarkers|Endothelial Progenitor Cells|SGLT 2 Inhibitors|Incretins|Glucose Excursions|FMD|FPF|Arterial Stiffness",Empagliflozin,C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,APPROVED,immune_system_disease
605,Asthma|Electrophilic Fatty Acids,Indomethacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,PHASE1,immune_system_disease
606,Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Biphenotypic Leukemia|Refractory Acute Myeloid Leukemia,Cedazuridine,C1CN(C(=O)NC1O)C2C(C(C(O2)CO)O)(F)F,PHASE2,immune_system_disease
607,Focal Segmental Glomerulosclerosis|Minimal Change Disease|Immunoglobulin A Nephropathy|IgA Vasculitis|Alport Syndrome,Sparsentan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC,PHASE2,immune_system_disease
608,"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",Tegavivint,CC1CC(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=C4C=CC(=CC4=C3N=O)S(=O)(=O)N5CC(CC(C5)C)C)NO)C,PHASE1,immune_system_disease
609,Acquired Immunodeficiency Syndrome|Healthy Volunteers|HIV/AIDS|HIV Diarrhea|Human Immunodeficiency Virus,Crofelemer,COC1=CC=CC=C1CNC(=O)C2=NOC(=C2)C3=CC=CC=C3,APPROVED,immune_system_disease
610,Multiple Myeloma,Vactosertib,CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4,PHASE1,immune_system_disease
611,"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|Coronavirus Disease 2019 (COVID-19)|Immunocompromised|Hospitalization|Child, Hospitalized",Nirmatrelvir,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C,PHASE2,immune_system_disease
613,Graves' Ophthalmopathy,Propylthiouracil,CCCC1=CC(=O)NC(=S)N1,APPROVED,immune_system_disease
614,Bronchiolitis Obliterans|Acute Obliterating Bronchiolitis,Erythromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,APPROVED,immune_system_disease
615,Allergic Conjunctivitis,Lifitegrast,CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl,PHASE2,immune_system_disease
616,HIV Infection|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Erlotinib,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,PHASE1,immune_system_disease
618,Coronary Artery Disease|Type 1 Diabetes Mellitus,Regadenoson,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N,APPROVED,immune_system_disease
619,"Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Chronic Lymphocytic Leukemia|Lymphoproliferative Disorders|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma",Pacritinib,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,PHASE1,immune_system_disease
620,Lung Cancer|Anaplastic Lymphoma Kinase Gene Translocation|ROS1 Rearrangement|Relapsed Cancer|MET Amplification|Resistant Cancer|NSCLC,Lorlatinib,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PHASE1|PHASE2,immune_system_disease
621,Lung Cancer|Anaplastic Lymphoma Kinase Gene Translocation|ROS1 Rearrangement|Relapsed Cancer|MET Amplification|Resistant Cancer|NSCLC,Crizotinib,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,PHASE1|PHASE2,immune_system_disease
622,Lung Cancer|Anaplastic Lymphoma Kinase Gene Translocation|ROS1 Rearrangement|Relapsed Cancer|MET Amplification|Resistant Cancer|NSCLC,Binimetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,PHASE1|PHASE2,immune_system_disease
623,Human Immunodeficiency Virus Type 1 (HIV-1),Cobicistat,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,PHASE1,immune_system_disease
624,"Infection, Human Immunodeficiency Virus",Moxifloxacin,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,PHASE1,immune_system_disease
625,HIV Infections,Aprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,PHASE1,immune_system_disease
626,Asthma,Indacaterol,CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC,PHASE2,immune_system_disease
627,Multiple Sclerosis,Pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,PHASE1,immune_system_disease
628,HIV Infections,Capravirine,CC(C)C1=C(N(C(=N1)COC(=O)N)CC2=CC=NC=C2)SC3=CC(=CC(=C3)Cl)Cl,PHASE2,immune_system_disease
629,Breast Cancer,Anastrozole,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,APPROVED,immune_system_disease
631,ALK-activated Tumors,Ceritinib,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,PHASE1,immune_system_disease
632,Asthma,Olodaterol,CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O,PHASE2,immune_system_disease
633,Atopic Dermatitis,Metoprolol,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,PHASE1,immune_system_disease
634,HIV Infections,Atevirdine,CCNC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)OC,PHASE2,immune_system_disease
635,Osteoarthritis|Rheumatoid Arthritis|Lower Back Pain|Joint Pain|Muscle Pain,Buprenorphine,CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,APPROVED,immune_system_disease
636,HIV Infections,Tipranavir,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,PHASE2,immune_system_disease
637,Human Immunodeficiency Virus (HIV) Infection,Doravirine,CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F,PHASE1,immune_system_disease
640,Refractory Multiple Myeloma,Tivantinib,C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,PHASE2,immune_system_disease
641,Lymphoma|Multiple Myeloma,Tinzaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2,immune_system_disease
642,Relapsing-remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Primary-progressive Multiple Sclerosis,Norethindrone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE2,immune_system_disease
643,Relapsing-remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Primary-progressive Multiple Sclerosis,Norethisterone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE2,immune_system_disease
644,Asthma,Fevipiprant,CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O,PHASE2,immune_system_disease
646,Infectious Mononucleosis,Valomaciclovir,CC(C)C(C(=O)OCCC(CN1C=NC2=C1N=C(NC2=O)N)CO)N,PHASE1|PHASE2,immune_system_disease
647,"Pulmonary Disease, Chronic Obstructive|Asthma|Community Acquired Pneumonia",Varenicline,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,APPROVED,immune_system_disease
648,Allergic Conjunctivitis,Ketotifen,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,PHASE2,immune_system_disease
649,Lymphoblastic Leukemia,Ziftomenib,CC1=C(C=CC2=C1C=C(N2CC(C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F,PHASE1|PHASE2,immune_system_disease
650,Hematologic Malignancy|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia|Hodgkin's Disease,Ciclopirox,CC1=CC(=O)N(C(=C1)C2CCCCC2)O,PHASE1,immune_system_disease
651,Multiple Myeloma,Acetylcarnitine,CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C,PHASE2,immune_system_disease
652,Multiple Myeloma,Nirogacestat,CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F,PHASE2,immune_system_disease
656,Multiple Sclerosis,Famciclovir,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,PHASE2,immune_system_disease
657,"Attention Deficit Disorder With Hyperactivity|Diabetes Mellitus, Type 1",Lisdexamfetamine,CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N,PHASE2,immune_system_disease
659,Graves' Ophthalmopathy,Bimatoprost,CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O,APPROVED,immune_system_disease
660,Sarcoidosis; Antimycobacterial Therapy,Ethambutol,CCC(CO)NCCNC(CC)CO,PHASE2,immune_system_disease
663,Lymphoma|Advanced Cancer,Tolbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,PHASE1,immune_system_disease
664,Lymphoma|Advanced Cancer,Tasisulam,C1=CC(=C(C=C1Cl)Cl)C(=O)NS(=O)(=O)C2=CC=C(S2)Br,PHASE1,immune_system_disease
665,Pompe Disease|Hypersensitivity Reaction,Miglustat,CCCCN1CC(C(C(C1CO)O)O)O,PHASE1,immune_system_disease
666,Hairy Cell Leukemia,Encorafenib,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,PHASE2,immune_system_disease
667,Inflammatory Disorder of Immune System|Sepsis,Morphine,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,APPROVED,immune_system_disease
668,Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN,Pemigatinib,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,PHASE1|PHASE2,immune_system_disease
670,Discoid Lupus Erythematosus,Delgocitinib,CC1CN(C12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N,PHASE2,immune_system_disease
671,Type1 Diabetes Mellitus,Methyldopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N,PHASE2,immune_system_disease
673,Multiple Myeloma,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,PHASE2,immune_system_disease
674,Asthma,Cysteamine,C(CS)N,PHASE1,immune_system_disease
675,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Triple-Negative Breast Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,Cabozantinib,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,PHASE1,immune_system_disease
676,Bronchial Asthma,Carbamazepine,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,APPROVED,immune_system_disease
677,"Leukemia, Mast-Cell|Mantle-cell Lymphoma",Granisetron,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,PHASE2,immune_system_disease
678,Metastatic Castration-sensitive Prostate Cancer,Apalutamide,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,APPROVED,immune_system_disease
679,HIV Associated Cognitive Motor Complex,Galantamine,CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O,PHASE2,immune_system_disease
680,Asthma,Benzocaine,CCOC(=O)C1=CC=C(C=C1)N,PHASE2,immune_system_disease
681,Asthma,Oxyquinoline,C1=CC2=C(C(=C1)O)N=CC=C2,PHASE2,immune_system_disease
682,Asthma,Procaterol,CCC(C(C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C,PHASE2,immune_system_disease
683,Lung Cancer|Sarcoidosis|Interstitial Pneumonia,Propofol,CC(C)C1=C(C(=CC=C1)C(C)C)O,APPROVED,immune_system_disease
684,Multiple Sclerosis|Sleep|Pain,Cannabidiol,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,PHASE2,immune_system_disease
685,Multiple Sclerosis|Sleep|Pain,Dronabinol,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,PHASE2,immune_system_disease
686,Non Hodgkin's Lymphoma,Levoleucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,immune_system_disease
687,Immune Reconstitution Inflammatory Syndrome|Immune Reconstitution Syndrome|Tuberculosis|HIV-infection/Aids,Naproxen,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,PHASE2|PHASE3,immune_system_disease
688,Lymphoma|Chronic Lymphocytic Leukemia|Solid Tumors,Ketoconazole,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,PHASE1,immune_system_disease
689,Rheumatoid Arthritis,Cetrorelix,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C,PHASE2,immune_system_disease
690,Chemotherapy-Induced Nausea and Vomiting|Non Hodgkin's Lymphoma,Palonosetron,C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5,PHASE2,immune_system_disease
691,"Lymphoma, Low-Grade|Lymphoma, Small Lymphocytic|Lymphoma, Mixed-Cell, Follicular|Lymphoma, Small Cleaved-Cell, Follicular",Pixantrone,C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN,PHASE1,immune_system_disease
692,Healthy|Type 1 Diabetes,Lisofylline,CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O,PHASE1|PHASE2,immune_system_disease
693,Complication of Transplanted Lung,Aztreonam,CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N,APPROVED,immune_system_disease
694,Dry Eye Syndromes|Sjögren Syndrome,Rebamipide,C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl,APPROVED,immune_system_disease
695,Asthma,Laninamivir,CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N,PHASE1,immune_system_disease
696,HIV Infections,Thymopentin,CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)N,PHASE2,immune_system_disease
698,Allergic Rhinitis|Tachyphylaxis|Rhinitis Medicamentosa,Prazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,APPROVED,immune_system_disease
699,Immune Thrombocytopenia,Hetrombopag,CC1=C(C(=O)N(N1)C2=CC3=C(CCCC3)C=C2)N=NC4=CC=CC(=C4O)C5=CC=C(O5)C(=O)O,PHASE1,immune_system_disease
700,Atopic Dermatitis|Psoriasis,Desoximetasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)CO)C)O)F)C,APPROVED,immune_system_disease
701,Solid Tumors|Lymphoma,Imetelstat,CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OCC1C(CC(O1)N2C=C(C(=O)NC2=O)C)NP(=S)(O)OCC3C(CC(O3)N4C=NC5=C(N=CN=C54)N)NP(=S)(O)OCC6C(CC(O6)N7C=NC8=C7N=C(NC8=O)N)NP(=S)(O)OCC9C(CC(O9)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)NP(=O)(OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)N)S)O,PHASE1,immune_system_disease
702,Progressive Multiple Sclerosis,Dexchlorpheniramine,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,PHASE1,immune_system_disease
703,Systemic Lupus Erythematosus,Lisinopril,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,PHASE2,immune_system_disease
704,Systemic Lupus Erythematosus,Benazepril,CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O,PHASE2,immune_system_disease
705,Multiple Myeloma|Non-Hodgkin's Lymphoma,Meloxicam,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,PHASE2,immune_system_disease
706,NSAID-induced Gastroduodenal Injury|Ulcers|Rheumatoid Arthritis|Osteoarthritis,Cobiprostone,CCC(C)CC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F,PHASE2,immune_system_disease
707,"Diabetes Mellitus, Type 1|Diabetic Nephropathy",Alagebrium,CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C,PHASE2,immune_system_disease
709,Chronic Lymphocytic Leukemia,Ceralasertib,CC1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=N)(=O)C)C4=C5C=CNC5=NC=C4,PHASE1,immune_system_disease
710,Non-Hodgkin's Lymphoma,Dulanermin,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,PHASE1|PHASE2,immune_system_disease
711,Lupus Nephritis,Voclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,immune_system_disease
712,Castration-Sensitive Prostate Carcinoma|Metastatic Prostatic Adenocarcinoma|Stage IV Prostate Cancer|Stage IVA Prostate Cancer|Stage IVB Prostate Cancer,Abiraterone,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,PHASE2,immune_system_disease
713,Hereditary Angioedema (HAE),Icatibant,C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O,PHASE1,immune_system_disease
714,Severe Asthma|Moderate or Severe Major Depressive Disorder,Escitalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,immune_system_disease
716,Asthma,Ambrisentan,CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,PHASE2,immune_system_disease
717,DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Vismodegib,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,PHASE1,immune_system_disease
719,Type 1 Diabetes,Acetazolamide,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,PHASE1|PHASE2,immune_system_disease
721,Asthma|Distal Lung Inflammation,Flunisolide,CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C,PHASE1|PHASE2,immune_system_disease
723,Ataxia Telangiectasia|Growth Failure,Clonidine,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,APPROVED,immune_system_disease
726,Impaired Processing Speed|Cognitive Impairment|Multiple Sclerosis,Amphetamine,CC(CC1=CC=CC=C1)N,PHASE2|PHASE3,immune_system_disease
727,Type 1 Diabetes,Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,PHASE2,immune_system_disease
728,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma,Pazopanib,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,PHASE1|PHASE2,immune_system_disease
729,"Epstein-Barr Virus Associated Lymphoproliferative Disorder|EBV-Related PTLD|EBV Related Non-Hodgkin's Lymphoma|Extranodal NK/T-cell Lymphoma|EBV-Positive DLBCL, Nos|EBV Associated Lymphoma|EBV-Related Hodgkin Lymphoma|EBV Related PTCL, Nos",Nanatinostat,C1C2C(C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO,PHASE2,immune_system_disease
730,Diabetes Mellitus|Cardiovascular Diseases|Insulin Sensitivity/Resistance|Metabolic Disease|Natriuretic Peptides|Metabolism|Energy Expenditure,Sacubitril,CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O,PHASE2,immune_system_disease
731,Type1 Diabetes Mellitus|Hypoglycemia Unawareness,Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,immune_system_disease
732,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Capivasertib,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,PHASE2,immune_system_disease
733,Hepatocellular Carcinoma,Regorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,PHASE2,immune_system_disease
734,B-Cell Prolymphocytic Leukemia|Chronic Lymphocytic Leukemia|Peripheral T-Cell Lymphoma|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|T-Cell Prolymphocytic Leukemia,Letermovir,COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O,PHASE2,immune_system_disease
735,Bronchiolitis Obliterans|Graft Vs Host Disease,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,PHASE1,immune_system_disease
736,Multiple Myeloma,Ciforadenant,CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5,PHASE1,immune_system_disease
737,Alcohol-induced Cue-craving|Alcohol Sensitivity,Atomoxetine,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,PHASE1,immune_system_disease
738,Non-GCB/ABC Diffuse Large B-Cell Lymphoma|With and Without MyD88 and/or CD79B Mutations,Mivavotinib,CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)NC4CCCCC4N,PHASE2,immune_system_disease
740,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Afatinib,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,PHASE2,immune_system_disease
743,Chronic Lymphocytic Leukemia,Imiquimod,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,PHASE2,immune_system_disease
744,Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Primary Central Nervous System Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm,Pevonedistat,C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N,PHASE1,immune_system_disease
745,Chronic Graft Versus Host Disease,Ponesimod,CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C,PHASE2,immune_system_disease
746,Allergic Rhinitis,Esketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE1,immune_system_disease
747,Antiphospholipid Antibody Syndrome,Rivaroxaban,C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl,APPROVED,immune_system_disease
749,Chronic Lymphocytic Leukemia,Oblimersen,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)([O-])OC3CC(OC3COP(=O)(OC4CC(OC4COP(=S)([O-])OC5CC(OC5COP(=S)([O-])OC6CC(OC6COP(=S)([O-])OC7CC(OC7COP(=S)([O-])OC8CC(OC8COP(=S)([O-])OC9CC(OC9COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1COP(=S)([O-])OC1CC(OC1CO)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)[S-])N1C=NC2=C(N=CN=C21)N)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],PHASE1|PHASE2,immune_system_disease
751,Ann Arbor Stage I Mantle Cell Lymphoma|Ann Arbor Stage II Mantle Cell Lymphoma|Ann Arbor Stage III Mantle Cell Lymphoma|Ann Arbor Stage IV Mantle Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,Enzalutamide,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,PHASE2,immune_system_disease
752,Rheumatoid Arthritis,Celecoxib,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,APPROVED,immune_system_disease
754,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes,Biotin,C1C2C(C(S1)CCCCC(=O)O)NC(=O)N2,PHASE2,immune_system_disease
755,Insulin Sensitivity,Eritoran,CCCCCCCCCCCC(=O)CC(=O)NC1C(C(C(OC1OP(=O)(O)O)COC2C(C(C(C(O2)COC)OP(=O)(O)O)OCCC(CCCCCCC)OC)NC(=O)CCCCCCCCCC=CCCCCCC)O)OCCCCCCCCCC,PHASE2,immune_system_disease
757,Hematologic Malignancy|Acute Leukemia|Remission|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|AML|TP53|Intrachromosomal Amplification of Chromosome 21|Cytogenetic Abnormality|CNS Leukemia|Minimal Residual Disease|Myelodysplasia|Juvenile Myelomonocytic Leukemia|Somatic Mutation|PTPN11 Gene Mutation|N-RAS Gene Amplification|Neurofibromatosis 1|NF1 Mutation|CBL Gene Mutation|Monosomy 7|Chromosome Abnormality|Fetal Hemoglobin,Levetiracetam,CCC(C(=O)N)N1CCCC1=O,PHASE2,immune_system_disease
758,Multiple Sclerosis (Primary or Secondary Progressive Phase).,Erythropoietin,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],PHASE2,immune_system_disease
759,"Arthritis, Rheumatoid",Gadobutrol,C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Gd+3],PHASE1,immune_system_disease
760,Eosinophilic Esophagitis,Etrasimod,C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F,PHASE2,immune_system_disease
761,Eosinophilic Asthma|Asthma,Dexpramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE2,immune_system_disease
762,Eosinophilic Asthma|Asthma,Pramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE2,immune_system_disease
764,Henoch-Schönlein Purpura Nephritis,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,PHASE1|PHASE2,immune_system_disease
765,"Cardiovascular Diseases|Arthritis, Rheumatoid",Colchicine,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,PHASE2,immune_system_disease
766,Seasonal Allergic Rhinitis,Bepotastine,C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O,PHASE2,immune_system_disease
767,Rheumatoid Arthritis,Paroxetine,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,PHASE1|PHASE2,immune_system_disease
768,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Ebselen,C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2,PHASE2|PHASE3,immune_system_disease
770,Diffuse Large B-cell Lymphoma,Valproate,CCCC(CCC)C(=O)O,PHASE1|PHASE2,immune_system_disease
772,HIV Infections,Famotidine,C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N,PHASE1,immune_system_disease
773,"Neurofibroma, Plexiform|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Promyelocytic, Acute|Sarcoma",Pexidartinib,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F,PHASE1,immune_system_disease
774,EBV Lymphomas|Lympho-proliferative Diseases,Ganciclovir,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,PHASE2,immune_system_disease
775,Pediatric Cancer|Solid Tumors|Lymphoma,Eribulin,CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O,PHASE1,immune_system_disease
776,Atopic Dermatitis,Omiganan,CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC3C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N8CCCC8C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)N)N,PHASE2,immune_system_disease
777,"Diabetes Mellitus, Type 1",Benfotiamine,CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOP(=O)(O)O)SC(=O)C2=CC=CC=C2)C,PHASE1|PHASE2,immune_system_disease
779,Pruritus|Atopic Dermatitis,Serlopitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2CCC3CN(CC3C2C4=CC=C(C=C4)F)C5=CC(=O)CC5,PHASE2,immune_system_disease
781,Graft-versus-host Disease Prevention,Piperacillin,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,PHASE2,immune_system_disease
782,Graft-versus-host Disease Prevention,Tazobactam,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,PHASE2,immune_system_disease
783,Advanced Solid Tumors|Lymphomas,Camptothecin,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,PHASE1,immune_system_disease
784,Rheumatoid Arthritis,Milnacipran,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,APPROVED,immune_system_disease
787,Recurrent Miscarriage|Antiphospholipid Syndrome,Enoxaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,immune_system_disease
788,HIV|Human Immunodeficiency Virus,Disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,PHASE1|PHASE2,immune_system_disease
789,Solid Tumor|Glioma|Angioimmunoblastic T-cell Lymphoma|Intrahepatic Cholangiocarcinoma|Chondrosarcoma,Enasidenib,CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O,PHASE1|PHASE2,immune_system_disease
791,Invasive Pulmonary Aspergillosis|Lymphoblastic Leukaemia|Myeloblastic Leukaemia|Lymphoblastic Leukemia|Myeloblastic Leukemia,Amphotericin B,CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,PHASE2,immune_system_disease
792,Cancer,Birinapant,CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC,PHASE1,immune_system_disease
793,Atopic Dermatitis,Antroquinonol,CC1C(C(C(=C(C1=O)OC)OC)O)CC=C(C)CCC=C(C)CCC=C(C)C,PHASE2,immune_system_disease
794,HIV Infections|Peripheral Nervous System Disease,Mexiletine,CC1=C(C(=CC=C1)C)OCC(C)N,PHASE2,immune_system_disease
795,HIV Infections|Peripheral Nervous System Disease,Benzatropine,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2,immune_system_disease
796,HIV Infections|Peripheral Nervous System Disease,Benztropine,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2,immune_system_disease
797,Hepatitis B,Alendronate,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,PHASE1,immune_system_disease
798,Optic Neuritis|Multiple Sclerosis,Phenytoin,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,PHASE2,immune_system_disease
799,Relapsing Multiple Sclerosis,Ozanimod,CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N,PHASE2|PHASE3,immune_system_disease
800,Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,Leuprorelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,immune_system_disease
801,Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,Degarelix,CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C,PHASE2,immune_system_disease
802,HIV Infections,Emivirine,CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2,PHASE2,immune_system_disease
803,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Taselisib,CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C,PHASE2,immune_system_disease
804,"Asthma, Aspirin-Induced|Aspirin Exacerbated Asthma",Prasugrel,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,PHASE2,immune_system_disease
805,Multiple Sclerosis,Rolipram,COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3,PHASE2,immune_system_disease
806,HIV Infections,Dinitrochlorobenzene,C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Cl,PHASE1,immune_system_disease
807,HIV-1-infection,Lenacapavir,CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)C(CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C(C7CC7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C,PHASE2|PHASE3,immune_system_disease
808,"Dermatitis, Atopic",Fluvoxamine,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,PHASE1,immune_system_disease
810,Allergic Conjunctivitis|Rhinoconjunctivitis,Alcaftadine,CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1,APPROVED,immune_system_disease
811,Asthma,Setipiprant,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54,PHASE2,immune_system_disease
812,Fertility Preservation|Alkylating Agents|Lymphoma,Triptorelin,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,PHASE2|PHASE3,immune_system_disease
813,Sjögren Syndrome,Remibrutinib,CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C,PHASE2,immune_system_disease
814,Insulin Sensitivity,Gemcabene,CC(C)(CCCCOCCCCC(C)(C)C(=O)O)C(=O)O,PHASE2,immune_system_disease
815,Drug-Drug Interaction|HIV Infection,Artenimol,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C,APPROVED,immune_system_disease
816,HIV Infections,Mifepristone,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,PHASE1|PHASE2,immune_system_disease
817,HIV Infections,Bevirimat,CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O,PHASE2,immune_system_disease
818,"C3 Glomerulonephritis|Dense Deposit Disease|C3 Glomerulopathy|Immune Complex Mediated Membranoproliferative Glomerulonephritis|Membranoproliferative Glomerulonephritis Types I, II, and III",Danicopan,CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4CC(CC4C(=O)NC5=NC(=CC=C5)Br)F,PHASE2,immune_system_disease
819,Allergic Rhinitis,Ketorolac,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,PHASE1,immune_system_disease
820,Allergic Rhinitis,Tromethamine,C(C(CO)(CO)N)O,PHASE1,immune_system_disease
822,Relapsing Remitting Multiple Sclerosis,Flupirtine,CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N,PHASE2,immune_system_disease
823,Allergic Rhinitis|Upper Respiratory Infection,Doxylamine,CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C,PHASE1,immune_system_disease
824,Peripheral T-cell Lymphoma,Fenretinide,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C,PHASE2,immune_system_disease
825,Atopic Dermatitis,Ivermectin,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,PHASE2,immune_system_disease
826,Multiple Sclerosis|Fatigue|Insomnia,Suvorexant,CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl,APPROVED,immune_system_disease
827,Multiple Sclerosis|Primary Progressive Multiple Sclerosis,Idebenone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,PHASE1|PHASE2,immune_system_disease
828,Eosinophilic Bronchitis|Cough Variant Asthma,Bambuterol,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,APPROVED,immune_system_disease
829,Platinum-Sensitive Biliary Tract Cancer,Pamiparib,CC12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F,PHASE2,immune_system_disease
830,Multiple Sclerosis,Mangafodipir,[H+].[H+].[H+].[H+].CC1=NC=C(C(=C1O)CN(CCN(CC2=C(C(=NC=C2COP(=O)([O-])[O-])C)O)CC(=O)[O-])CC(=O)[O-])COP(=O)([O-])[O-].[Mn+2],PHASE1,immune_system_disease
831,Type1 Diabetes Mellitus|Enterovirus,Pleconaril,CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F,PHASE2,immune_system_disease
833,Acute HIV Infection|HIV CNS Involvement,Telmisartan,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,PHASE2,immune_system_disease
834,Hypertension,Fludrocortisone,CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F,APPROVED,immune_system_disease
835,HIV Infections|HIV Wasting Syndrome,Nandrolone,CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34,PHASE1,immune_system_disease
836,HIV Infections,Pyridostigmine,C[N+]1=CC=CC(=C1)OC(=O)N(C)C,PHASE2,immune_system_disease
837,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle Cell Lymphoma|Advanced Solid Tumor|Marginal Zone Lymphoma,Repaglinide,CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,PHASE1,immune_system_disease
838,Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus,Reparixin,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C,PHASE2,immune_system_disease
839,Multiple Myeloma,Plitidepsin,CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O,PHASE2,immune_system_disease
840,Mantle-Cell Lymphoma,Obatoclax,CC1=CC(=C(N1)C=C2C(=CC(=C3C=C4C=CC=CC4=N3)N2)OC)C,PHASE1|PHASE2,immune_system_disease
842,HIV,Tesamorelin,CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N,PHASE1,immune_system_disease
843,Multiple Sclerosis,Liothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,PHASE1,immune_system_disease
844,Transgender Health|Gender Dysphoria|Transgender Women|Human Immunodeficiency Virus,Spironolactone,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,PHASE1,immune_system_disease
846,Metastatic Fallopian Tube Carcinoma|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Ovarian Endometrioid Tumor|Ovarian High Grade Serous Adenocarcinoma|Platinum-Sensitive Ovarian Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7,Berzosertib,CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N,PHASE1,immune_system_disease
847,Atopic Dermatitis,Gentamicin,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,PHASE1,immune_system_disease
849,Lymphoma,Amifostine,C(CN)CNCCSP(=O)(O)O,PHASE2,immune_system_disease
852,Lymphangioleiomyomatosis,Nintedanib,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,PHASE2,immune_system_disease
853,"Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor",Entrectinib,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,PHASE2,immune_system_disease
854,Non-hodgkin's Lymphoma,Chiauranib,COC1=CC2=NC=CC(=C2C=C1)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=CC=C5N,PHASE1|PHASE2,immune_system_disease
855,Asthma,Zileuton,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,APPROVED,immune_system_disease
856,Actinic Keratosis,Calcipotriol,CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C,PHASE2,immune_system_disease
857,Actinic Keratosis,Calcipotriene,CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C,PHASE2,immune_system_disease
859,Constipation|Fecal Incontinence|Multiple Sclerosis,Bisacodyl,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,PHASE2,immune_system_disease
860,"Diabetes Mellitus, Type 1",Canagliflozin,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,PHASE2,immune_system_disease
861,Depression|Relapsing-remitting Multiple Sclerosis,Venlafaxine,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,APPROVED,immune_system_disease
862,Depression|Relapsing-remitting Multiple Sclerosis,Fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,APPROVED,immune_system_disease
863,Human Immunodeficiency Virus (HIV)-1 Infection,Elvucitabine,C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F,PHASE2,immune_system_disease
864,Hodgkin Lymphoma,Mocetinostat,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4,PHASE1|PHASE2,immune_system_disease
865,Type 1 Diabetes Mellitus,Glyburide,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,APPROVED,immune_system_disease
866,Antiphospholipid Syndrome|Thrombosis,Apixaban,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,APPROVED,immune_system_disease
867,Mitochondrial Diseases|Drug Resistant Epilepsy|Leigh Disease|Leigh Syndrome|Mitochondrial Encephalopathy (MELAS)|Pontocerebellar Hypoplasia Type 6 (PCH6)|Alpers Disease|Alpers Syndrome,Vatiquinone,CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C,PHASE2|PHASE3,immune_system_disease
868,Multiple Myeloma,Opaganib,C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl,PHASE1|PHASE2,immune_system_disease
869,"Diabetes Mellitus, Type 1",Albiglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N,PHASE2,immune_system_disease
870,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Axitinib,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4,PHASE2,immune_system_disease
871,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Bosutinib,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,PHASE2,immune_system_disease
873,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Tucatinib,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,PHASE2,immune_system_disease
874,Cytomegalovirus Retinitis|HIV Infections,Foscarnet,C(=O)(O)P(=O)(O)O,PHASE1,immune_system_disease
875,HIV Infections,Glycovir,CCCCN1CC(C(C(C1COC(=O)CCC)OC(=O)CCC)OC(=O)CCC)OC(=O)CCC,PHASE2,immune_system_disease
876,HIV Infections,Celgosivir,CCCC(=O)OC1CN2CCC(C2C(C1O)O)O,PHASE2,immune_system_disease
877,Sarcoidosis|Pulmonary Arterial Hypertension,Iloprost,CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O,APPROVED,immune_system_disease
878,Type 1 Diabetes|Hypoglycemia,Pitolisant,C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl,PHASE1,immune_system_disease
879,"Diabetes Mellitus, Type 1",Deoxyspergualin,C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O,PHASE2,immune_system_disease
880,Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia,Noscapine,CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,PHASE1|PHASE2,immune_system_disease
881,Rheumatoid Arthritis,Teriparatide,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N,APPROVED,immune_system_disease
882,Thyroid Eye Disease|Graves Orbitopathy|Endocrine System Diseases|Eye Diseases|Thyroid Associated Ophthalmopathy|Graves Ophthalmopathy|Thyroid Diseases|Orbital Diseases|Proptosis|IGF1R|Exophthalmos|Hashimoto,Linsitinib,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,PHASE2|PHASE3,immune_system_disease
883,Muscle Spasticity,Tizanidine,C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl,PHASE1|PHASE2,immune_system_disease
884,Recurrent Ovarian Cancer|Recurrent Epithelial Cancer of Ovary|Recurrent Epithelial Ovarian Cancer|Recurrent Fallopian Tube Cancer|Peritoneal Cancer|Recurrent Carcinoma of Ovary|Adenocarcinoma of Ovary,Niraparib,C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N,PHASE2,immune_system_disease
886,Lupus Nephritis,Tamibarotene,CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C,PHASE2,immune_system_disease
890,"Dermatitis, Atopic|Eczema",Desonide,CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)C,APPROVED,immune_system_disease
891,Atopic Dermatitis|Eczema|Chronic Pruritus,Tradipitant,C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl,PHASE2,immune_system_disease
892,Allergic Asthma,Pemirolast,CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3,PHASE2,immune_system_disease
893,HIV Infections,Telinavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)C(CC(=O)N)NC(=O)C2=NC3=CC=CC=C3C=C2)O)C(=O)NC(C)(C)C,PHASE1,immune_system_disease
894,Lymphangioleiomyomatosis|Lymphangiomyomas|Pleural Effusions|Ascites,Octreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,PHASE2,immune_system_disease
895,Rheumatoid Arthritis,Loxoprofen,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O,PHASE2,immune_system_disease
896,Multiple Myeloma,Plinabulin,CC(C)(C)C1=C(N=CN1)C=C2C(=O)NC(=CC3=CC=CC=C3)C(=O)N2,PHASE2,immune_system_disease
897,Rhinitis|Seasonal Rhinitis,Phenylephrine,CNCC(C1=CC(=CC=C1)O)O,PHASE2,immune_system_disease
898,Vincristine Induced Neurotoxicity|Acute Lymphoblastic Leukaemia,Mecobalamin,[CH3-].CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)[N-]6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co+3],PHASE2|PHASE3,immune_system_disease
899,HIV Infections|Condyloma Acuminata,Cidofovir,C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O,PHASE1,immune_system_disease
900,Dense Deposit Disease,Sulodexide,CNC1=C2C(=NC=N1)N(C=N2)C3C(C(C(O3)CO)O)OC,PHASE1,immune_system_disease
902,Major Depressive Disorder,Desipramine,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,APPROVED,immune_system_disease
903,Rheumatoid Arthritis,Filgotinib,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,PHASE2,immune_system_disease
904,Pruritus|Atopic Dermatitis,Asimadoline,CN(C(CN1CCC(C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2,immune_system_disease
905,Sickle Cell Disease|Graft Versus Host Disease,Meperidine,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,PHASE1,immune_system_disease
907,Thyroid-Associated Ophthalmopathy,Lanreotide,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,PHASE2,immune_system_disease
908,Multiple Sclerosis|Fatigue,Mitoquinone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,PHASE1|PHASE2,immune_system_disease
909,Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Lymphoplasmacytic Lymphoma|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma,Imexon,C1C2N1C(=O)N=C2N,PHASE2,immune_system_disease
910,Type 1 Diabetes Mellitus|Hypercalciuria,Chlorthalidone,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,PHASE2,immune_system_disease
911,Graves´ Disease,Diclofenac,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,APPROVED,immune_system_disease
912,IgA Nephropathy|CKD Associated With Type 1 Diabetes|Focal Segmental Glomerulosclerosis|Autosomal Dominant Polycystic Kidney,Bardoxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C,PHASE2,immune_system_disease
913,HIV Infections,Peldesine,C1=CC(=CN=C1)CC2=CNC3=C2N=C(NC3=O)N,PHASE1,immune_system_disease
914,HIV Infections,Vesnarinone,COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC,PHASE1,immune_system_disease
915,Advanced NSCLC With EGFR Mutation,Gefitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,PHASE2,immune_system_disease
917,HIV Coinfection|Malaria,Artemether,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC)C,APPROVED,immune_system_disease
918,Type 1 Diabetes,Saxagliptin,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,APPROVED,immune_system_disease
919,Drug-drug Interaction|Autoimmune Diseases|Fibrotic Disease,Rabeprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,PHASE1,immune_system_disease
920,Systemic Lupus Erythematosus,Afimetoran,CC1=C(C2=NC=NN2C=C1C3=C(C4=C(N3)C=CC(=C4)C5CCN(CC5)CC(=O)N)C(C)C)C,PHASE2,immune_system_disease
921,Allergic Reactions,Brompheniramine,CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2,PHASE1,immune_system_disease
922,Rheumatoid Arthritis (RA),Niclosamide,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O,PHASE1|PHASE2,immune_system_disease
923,P Acnes Colonization,Adapalene,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,APPROVED,immune_system_disease
924,Type 1 Diabetes,Leptin,CC(C)CC(C(=NC(CCC(=N)O)C(=NCC(=NC(CO)C(=NC(CC(C)C)C(=NC(CCC(=N)O)C(=NC(CC(=O)O)C(=NC(CCSC)C(=NC(CC(C)C)C(=NC(CC1=CNC2=CC=CC=C21)C(=NC(CCC(=N)O)C(=NC(CC(C)C)C(=NC(CC(=O)O)C(=NC(CC(C)C)C(=NC(CO)C(=O)N3CCCC3C(=NCC(=NC(CS)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N,PHASE1,immune_system_disease
925,"Proteinuric Kidney Disease|Diabetic Nephropathy|Hypertensive Nephrosclerosis|IgA Nephropathy|Focal Segmental Glomerulosclerosis|Glomerulopathy (Obesity-associated)|Glomerulonephritis, Membranous",Aliskiren,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,APPROVED,immune_system_disease
926,HIV Infections|Peripheral Neuropathy,Duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,PHASE2,immune_system_disease
927,HIV Infections,Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],PHASE1,immune_system_disease
928,"Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts 10 Percent or More of Bone Marrow Nucleated Cells|Blasts 10 Percent or More of Peripheral Blood White Cells|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia",Gilteritinib,CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5,PHASE2,immune_system_disease
930,Ependymoma|Medulloblastoma|Glioblastoma|Primary Brain Tumor,Indoximod,CN1C=C(C2=CC=CC=C21)CC(C(=O)O)N,PHASE1,immune_system_disease
931,Prostate Cancer Metastatic,Rucaparib,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,PHASE2,immune_system_disease
932,Hepatitis C|Human Immunodeficiency Virus,Boceprevir,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,PHASE2,immune_system_disease
933,Hereditary Angioedema Types I and II,Ecallantide,CCC(C)C1C(=O)NC(C(=O)NCC(=O)NCC(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4CCCC4C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N5CCCC5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C(CCC(=O)O)N)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)C(C)O)CC1=CC=CC=C1)C(C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O,PHASE2,immune_system_disease
934,Multiple Sclerosis,Topiramate,CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,PHASE2,immune_system_disease
935,Cutaneous T-Cell Lymphoma,Tazarotene,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,PHASE1|PHASE2,immune_system_disease
936,HIV Infection,Lactoferrin,CCC(C)C(C(=NC(C(C)O)C(=NC(CS)C(=NC(C(C)C)C(=NC(CCCNC(=N)N)C(=NC(CCCNC(=N)N)C(=NC(C)C(=NC(CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C(C(CO)N=C(C2CCCN2C(=O)C(C)N=C(CN=C(C(CC(C)C)N=C(C(CCCCN)N=C(C(CCCCN)N=C(C(CCSC)N=C(C(CCCNC(=N)N)N=C(C(CC3=CNC4=CC=CC=C43)N=C(C(CCC(=N)O)N=C(C(CC5=CNC6=CC=CC=C65)N=C(C(CCCNC(=N)N)N=C(C(CCCNC(=N)N)N=C(C(CS)N=C(C(CCCCN)N=C(C(CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O,PHASE2,immune_system_disease
938,Granulomatosis With Polyangiitis|Wegener Granulomatosis,Sulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,PHASE1|PHASE2,immune_system_disease
939,HIV Infections,Lentinan,C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)O)O)OC3C(C(C(C(O3)CO)O)OC4C(C(C(C(O4)CO)O)OC5C(C(C(C(O5)COC6C(C(C(C(O6)CO)O)O)O)O)OC7C(C(C(C(O7)CO)O)O)O)O)O)O)O)O)O)O)O,PHASE2,immune_system_disease
940,"Lymphoma, T-Cell|Mycosis Fungoides|Hematologic Neoplasms",Isotretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE2,immune_system_disease
941,Diabetes|Hypoglycemia,Vildagliptin,C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N,APPROVED,immune_system_disease
943,Acute Lymphoblastic Leukemia,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,PHASE2|PHASE3,immune_system_disease
945,Human Immunodeficiency Virus Type 1 (HIV-1) Infection,Vesatolimod,CCCCOC1=NC(=C2C(=N1)N(CC(=O)N2)CC3=CC=CC(=C3)CN4CCCC4)N,PHASE1,immune_system_disease
947,Type 1 Diabetes Mellitus,Lixisenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N,PHASE1,immune_system_disease
948,Peanut Allergy,Vancomycin,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,PHASE1|PHASE2,immune_system_disease
949,"Multiple Sclerosis, Relapsing-Remitting",Clemastine,CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C,PHASE2,immune_system_disease
950,Asthma,Zavegepant,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O,PHASE1,immune_system_disease
951,Immune Thrombocytopenia (ITP)|Cold Agglutinin Disease (CAD),Iptacopan,CCOC1CCN(C(C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC,PHASE2,immune_system_disease
953,Relapsed/Refractory Diffuse Large B Cell Lymphoma,Poseltinib,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)OC=C4,PHASE2,immune_system_disease
954,"Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-Small Cell Lung Cancer|Carcinoma, Esophageal|Malignant Pleural Mesotheliomas",Tetrahydrouridine,C1CN(C(=O)NC1O)C2C(C(C(O2)CO)O)O,PHASE1|PHASE2,immune_system_disease
956,"Lupus Erythematosus, Systemic|Sjogren's Syndrome",Dehydroepiandrosterone,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C,PHASE2,immune_system_disease
957,"Lupus Erythematosus, Systemic|Sjogren's Syndrome",Prasterone,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C,PHASE2,immune_system_disease
958,Lymphoma|Solid Neoplasm,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,PHASE1,immune_system_disease
959,Colorectal Neoplasms Malignant,Fruquintinib,CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC,PHASE2,immune_system_disease
960,Leukemias|Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Adult T Cell Leukemia (ATL)|Chronic Myeloid Leukemia (CML-BP)|Chronic Lymphocytic Leukemia (CLL)|Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML),Terameprocol,CC(CC1=CC(=C(C=C1)OC)OC)C(C)CC2=CC(=C(C=C2)OC)OC,PHASE1,immune_system_disease
961,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Pancreatic Carcinoma|Refractory T-Cell Non-Hodgkin Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,Molibresib,CCNC(=O)CC1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C,PHASE1,immune_system_disease
964,Allergic Conjunctivitis,Reproxalap,CC(C)(C1=C(C=C2C=C(C=CC2=N1)Cl)N)O,PHASE1|PHASE2,immune_system_disease
966,Diffuse B-Cell Lymphoma,Avadomide,CC1=NC2=CC=CC(=C2C(=O)N1C3CCC(=O)NC3=O)N,PHASE1,immune_system_disease
967,Multiple Myeloma,Pasireotide,C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,PHASE2,immune_system_disease
968,Asthma,Gallopamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC,PHASE2,immune_system_disease
969,Relapsed/Refractory B Cell Malignancies|Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Treatment-Naive B Cell Malignancies,Navtemadlin,CC(C)C(CS(=O)(=O)C(C)C)N1C(C(CC(C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,PHASE1|PHASE2,immune_system_disease
970,Bronchial Asthma,Lamotrigine,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,APPROVED,immune_system_disease
972,"Leukemia, B-Cell, Chronic",Acadesine,C1=NC(=C(N1C2C(C(C(O2)CO)O)O)N)C(=O)N,PHASE1|PHASE2,immune_system_disease
973,Cardiac Sarcoidosis,Dotatate,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O,APPROVED,immune_system_disease
974,Recurrent Adult Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia,Volasertib,CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,PHASE1,immune_system_disease
976,Hepatitis B,Resiquimod,CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N,PHASE1|PHASE2,immune_system_disease
977,Sarcoidosis-associated Pulmonary Hypertension,Selexipag,CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3,PHASE2,immune_system_disease
979,HIV Infections,Fostemsavir,CC1=NN(C=N1)C2=NC=C(C3=C2N(C=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)COP(=O)(O)O)OC,PHASE1,immune_system_disease
981,"Lupus Erythematosus, Discoid|Lupus Erythematosus, Subacute Cutaneous",Deucravacitinib,CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4,PHASE2,immune_system_disease
982,Asthma,Glycopyrrolate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],PHASE2,immune_system_disease
983,Asthma,Glycopyrronium,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,PHASE2,immune_system_disease
984,HIV Infections,Tamoxifen,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,PHASE2,immune_system_disease
985,Polyarticular Course Juvenile Idiopathic Arthritis,Givinostat,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,PHASE2,immune_system_disease
987,Pain|Chronic Disease,Tropisetron,CN1C2CCC1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,PHASE2,immune_system_disease
989,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Uprosertib,CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)NC(CC3=CC(=C(C=C3)F)F)CN)Cl,PHASE2,immune_system_disease
990,Secondary-progressive Multiple Sclerosis,Siponimod,CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O,PHASE2|PHASE3,immune_system_disease
991,Multiple Myeloma|Diarrhea,Colesevelam,CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-],PHASE2,immune_system_disease
992,HIV Infection,Deferiprone,CC1=C(C(=O)C=CN1C)O,PHASE1,immune_system_disease
993,Multiple Myeloma,Ricolinostat,C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO,PHASE1|PHASE2,immune_system_disease
994,HIV Infections,Alovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)F,PHASE2,immune_system_disease
995,Lupus Membranous Nephropathy,Lanraplenib,C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N,PHASE2,immune_system_disease
996,Pneumoperitoneum|Neuromuscular Blockade|Surgery|Immune Suppression,Rocuronium,CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C,APPROVED,immune_system_disease
997,Malignancies|B-Cell Lymphoma,Aroplatin,CC(C)(C)CCCCCC(=O)[O-].CC(C)(C)CCCCCC(=O)[O-].C1CCC(C(C1)N)N.[Pt+2],PHASE1,immune_system_disease
999,Multiple Sclerosis,Nerispirdine,CCCN(C1=C(C=NC=C1)F)N2C=C(C3=CC=CC=C32)C,PHASE2,immune_system_disease
1000,HIV Infections|Contraception|Drug-drug Interaction,Etonogestrel,CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,immune_system_disease
1001,Recurrent Multiple Myeloma|Refractory Multiple Myeloma,Telaglenastat,C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F,PHASE1,immune_system_disease
1002,"Carcinoma, Small Cell Lung",Glufosfamide,C(CCl)NP(=O)(NCCCl)OC1C(C(C(C(O1)CO)O)O)O,PHASE2,immune_system_disease
1003,Ataxia Telangiectasia,Triheptanoin,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,PHASE2,immune_system_disease
1004,Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,Eprenetapopt,COCC1(C(=O)C2CCN1CC2)CO,PHASE2,immune_system_disease
1005,Hodgkin's Lymphoma,Resminostat,CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)C=CC(=O)NO,PHASE2,immune_system_disease
1006,Sarcoidosis,Riociguat,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,APPROVED,immune_system_disease
1008,Rheumatoid Arthritis,Diacerein,CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O,PHASE2,immune_system_disease
1009,Multiple Myeloma,Dovitinib,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,PHASE1,immune_system_disease
1010,Solid Tumors and Lymphomas,Alobresib,CC1=C(C(=NO1)C)C2=CC(=C3C(=C2)NC(=N3)C4CC4)C(C5=CC=CC=N5)(C6=CC=CC=N6)O,PHASE1,immune_system_disease
1011,Solid Tumors and Lymphomas,Exemestane,CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C,PHASE1,immune_system_disease
1012,Solid Tumors and Lymphomas,Fulvestrant,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,PHASE1,immune_system_disease
1013,Hematological Malignancies|Multiple Myeloma|Hodgkin's Lymphoma|Cutaneous T Cell Lymphoma,Tinostamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO,PHASE1,immune_system_disease
1015,"B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Recurrent Adult Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|T Acute Lymphoblastic Leukemia",Sapanisertib,CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,PHASE2,immune_system_disease
1016,Multiple Sclerosis|Neurogenic Bladder|Spinal Cord Diseases,Solifenacin,C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5,APPROVED,immune_system_disease
1018,Rheumatoid Arthritis,Etoricoxib,CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C,APPROVED,immune_system_disease
1019,Placental Malaria Infection|HIV Infections|Stillbirth|Prematurity|Neonatal Deaths,Sulfadoxine,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,APPROVED,immune_system_disease
1021,Advanced Solid Tumors|Lymphoma,Quarfloxin,CN1CCCC1CCNC(=O)C2=CN3C4=CC5=CC=CC=C5C=C4OC6=C3C(=CC(=C6N7CCC(C7)C8=NC=CN=C8)F)C2=O,PHASE1,immune_system_disease
1023,"Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Tuberculosis, MDR|Tuberculosis|Drug-Resistant Tuberculosis",Pretomanid,C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F,PHASE2|PHASE3,immune_system_disease
1024,"Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Tuberculosis, MDR|Tuberculosis|Drug-Resistant Tuberculosis",Bedaquiline,CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O,PHASE2|PHASE3,immune_system_disease
1025,"Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Tuberculosis, MDR|Tuberculosis|Drug-Resistant Tuberculosis",Pyrazinamide,C1=CN=C(C=N1)C(=O)N,PHASE2|PHASE3,immune_system_disease
1026,Pulmonary Lymphangioleiomyomatosis,Saracatinib,CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl,PHASE1,immune_system_disease
1027,Multiple Myeloma,Tecemotide,CCCCCCCCCCCCCCCC(=O)NCCCCC(C(=O)NCC(=O)O)NC(=O)C1CCCN1C(=O)C2CCCN2C(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)CNC(=O)C3CCCN3C(=O)C(C)NC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C5CCCN5C(=O)C(C)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC6=CN=CN6)NC(=O)C(C)NC(=O)C7CCCN7C(=O)C8CCCN8C(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CO)N,PHASE2,immune_system_disease
1029,Rheumatoid Arthritis,Puerarin,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3C4C(C(C(C(O4)CO)O)O)O)O)O,PHASE2,immune_system_disease
1031,Systemic Lupus Erythematosus,Cenerimod,CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OCC(CO)O,PHASE2,immune_system_disease
1032,Eosinophilic Esophagitis (EoE),Bethanechol,CC(C[N+](C)(C)C)OC(=O)N,PHASE2,immune_system_disease
1033,Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent WHO Grade 2 Glioma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory WHO Grade 2 Glioma|Wilms Tumor,Ivosidenib,C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N,PHASE2,immune_system_disease
1035,"Hepatitis C, Chronic|HIV Infection",Telaprevir,CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5,PHASE2,immune_system_disease
1036,Bronchial Asthma,Oxcarbazepine,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,APPROVED,immune_system_disease
1039,Type 1 Diabetes,Bromocriptine,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,PHASE2,immune_system_disease
1040,Acute Myeloid Leukemia|Acute Lymphoid Leukemia,Deferasirox,C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O,PHASE1,immune_system_disease
1041,Lupus Nephritis,Artesunate,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C,APPROVED,immune_system_disease
1043,Castration-Sensitive Prostate Carcinoma|Metastatic Prostate Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8,Bicalutamide,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,PHASE2,immune_system_disease
1044,Castration-Sensitive Prostate Carcinoma|Metastatic Prostate Adenocarcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8,Talazoparib,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,PHASE2,immune_system_disease
1045,Tumor Lysis Syndrome,Febuxostat,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,PHASE1|PHASE2,immune_system_disease
1046,Glomerulonephritis|IGA Nephropathy,Probucol,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,APPROVED,immune_system_disease
1047,Myasthenia Gravis|Ocular Myasthenia Gravis,Apraclonidine,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl,PHASE2,immune_system_disease
1048,"Rhinitis, Allergic, Perennial and Seasonal",Levocabastine,CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F,PHASE2,immune_system_disease
1049,"Asthma, Exercise-Induced",Reproterol,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O,PHASE2,immune_system_disease
1050,"Lymphoma, Non-Hodgkin|HIV Infections",Mitoguazone,CC(=NN=C(N)N)C=NN=C(N)N,PHASE2,immune_system_disease
1051,Smoldering Multiple Myeloma,Hiltonol,C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O.C(CCNC(=O)O)CN.C(C(=O)O)O,PHASE1,immune_system_disease
1052,Smoldering Multiple Myeloma,Citarinostat,C1=CC=C(C=C1)N(C2=CC=CC=C2Cl)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO,PHASE1,immune_system_disease
1053,Sarcoidosis|Fatigue|Sleepiness,Armodafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE2|PHASE3,immune_system_disease
1054,Sarcoidosis|Fatigue|Sleepiness,Modafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE2|PHASE3,immune_system_disease
1056,Philadelphia Chromosome|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Mixed Phenotype Acute Leukemia,Flumatinib,CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,immune_system_disease
1057,Cardiac Steatosis|Hepatic Steatosis,Eplerenone,CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC,PHASE2,immune_system_disease
1058,Multiple Sclerosis,Nabilone,CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O,APPROVED,immune_system_disease
1060,Multiple Myeloma,Osalmid,C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)O)O,PHASE1|PHASE2,immune_system_disease
1062,HIV Infections|Human Immunodeficiency Virus,Dexelvucitabine,C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F,PHASE2,immune_system_disease
1063,Angioedema,Cortisone,CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4(C(=O)CO)O)C,PHASE2,immune_system_disease
1064,HIV Infections,Oxazepam,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,PHASE1,immune_system_disease
1066,"Eczema, Atopic",Palmidrol,CCCCCCCCCCCCCCCC(=O)NCCO,PHASE2|PHASE3,immune_system_disease
1067,Recurrent Anaplastic Large Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma,Onalespib,CC(C)C1=CC(=C(C=C1O)O)C(=O)N2CC3=C(C2)C=C(C=C3)CN4CCN(CC4)C,PHASE2,immune_system_disease
1070,"Lymphoma, T-Cell, Cutaneous",Quisinostat,CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO,PHASE2,immune_system_disease
1072,Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Biphenotypic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome,Omacetaxine,COC1=CC23CCCN2CCC4=CC5=C(C=C4C3C1O)OCO5,PHASE1|PHASE2,immune_system_disease
1073,Diltiazem Skin Sensitivity.,Diltiazem,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,PHASE1,immune_system_disease
1074,Metastatic Castration-Resistant Prostate Cancer|Metastatic Castration-Sensitive Prostate Cancer|Non-Metastatic Castration-Resistant Prostate Cancer,Relugolix,CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC,PHASE1,immune_system_disease
1075,Asthma,Gefapixant,CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC,PHASE2,immune_system_disease
1077,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Dabrafenib,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,PHASE2,immune_system_disease
1079,Rheumatoid Arthritis,Roxithromycin,CCC1C(C(C(C(=NOCOCCOC)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,APPROVED,immune_system_disease
1080,"Leukemia, Lymphocytic, Acute|Leukemia, Nonlymphocytic, Acute|Leukemia, Myeloid, Chronic|Myelodysplastic Syndromes",Vosaroxin,CNC1CN(CC1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O,PHASE1,immune_system_disease
1082,Multiple Sclerosis,Dantrolene,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],PHASE1|PHASE2,immune_system_disease
1083,Asthma,Cavosonstat,C1=CC(=C(C=C1C(=O)O)Cl)C2=NC3=C(C=C2)C=C(C=C3)O,PHASE2,immune_system_disease
1084,Rheumatoid Arthritis,Ticagrelor,CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F,APPROVED,immune_system_disease
1086,Infertility|Autoimmune Thyroiditis,Thyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,PHASE2,immune_system_disease
1088,Wegener's Granulomatosis,Gusperimus,C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O,PHASE2,immune_system_disease
1089,"Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Neutropenia|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Phenobarbital,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,PHASE1,immune_system_disease
1090,HIV Infections,Chlorhexidine,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,PHASE2,immune_system_disease
1092,Bronchial Asthma,Apocynin,CC(=O)C1=CC(=C(C=C1)O)OC,PHASE1,immune_system_disease
1093,Primary Sjogren|Secondary Sjogren|Xerostomia,Pilocarpine,CCC1C(COC1=O)CC2=CN=CN2C,APPROVED,immune_system_disease
1094,Multiple Sclerosis|Bladder Dysfunction,Alfuzosin,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC,PHASE2|PHASE3,immune_system_disease
1095,"IgA Nephropathy (IgAN)|Berger Disease|Glomerulonephritis, IgA",Cemdisiran,CC(=O)NC1C(C(C(OC1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)NC(=O)CCCCCCCCCCC(=O)N4CC(CC4COP(=O)(O)O)O)CO)O)O,PHASE2,immune_system_disease
1097,HIV-1-infection|Methamphetamine-dependence,Metamfetamine,CC(CC1=CC=CC=C1)NC,APPROVED,immune_system_disease
1098,HIV-1-infection|Methamphetamine-dependence,Methamphetamine,CC(CC1=CC=CC=C1)NC,APPROVED,immune_system_disease
1099,HIV-infection/AIDS,Cenicriviroc,CCCCOCCOC1=CC=C(C=C1)C2=CC3=C(C=C2)N(CCCC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)CC5=CN=CN5CCC)CC(C)C,PHASE1,immune_system_disease
1100,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Cabazitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC,PHASE1,immune_system_disease
1101,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Dacomitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4,PHASE1,immune_system_disease
1102,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Darolutamide,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,PHASE1,immune_system_disease
1103,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Neratinib,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,PHASE1,immune_system_disease
1104,Neoplasms,Daniquidone,C1C2=C(C=CC(=C2)N)N=C3N1C(=O)C4=CC=CC=C43,PHASE1,immune_system_disease
1105,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Ipatasertib,CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,PHASE2,immune_system_disease
1106,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Osimertinib,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE2,immune_system_disease
1107,"Mild Persistent Asthma, Uncomplicated",Nadolol,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,PHASE2,immune_system_disease
1108,Allergic Rhinitis,Emedastine,CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C,APPROVED,immune_system_disease
1109,"Nystagmus, Congenital|Nystagmus, Acquired|Multiple Sclerosis",Neramexane,CC1(CC(CC(C1)(C)N)(C)C)C,PHASE2,immune_system_disease
1110,Adult Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Agatolimod,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC(=C1C)C(=O)NC(=C)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)O,PHASE1|PHASE2,immune_system_disease
1111,Acute Myeloid Leukemia|Blasts 20 Percent or More of Bone Marrow Nucleated Cells|High Risk Myelodysplastic Syndrome|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory High Risk Myelodysplastic Syndrome,Quizartinib,CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3,PHASE1|PHASE2,immune_system_disease
1112,Multiple Myeloma,Fluphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,PHASE1,immune_system_disease
1113,Multiple Sclerosis|Constipation,Lubiprostone,CCCCC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F,APPROVED,immune_system_disease
1114,Vernal Keratoconjunctivitis|Cyclosporine 0.05% Eye Drops,Tobramycin,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N,PHASE1,immune_system_disease
1115,Rheumatoid Arthritis,Aceclofenac,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,APPROVED,immune_system_disease
1116,Multiple Myeloma,Roneparstat,CC(=O)NC1C(C(C(OC1OC2C(C(C(OC2C(=O)O)OC3C(OC(C(C3O)NC(=O)C)OC(CO)C(C(=O)O)OC(CO)O)CO)OS(=O)(=O)O)O)CO)O)O,PHASE1,immune_system_disease
1118,HIV Infections,Lumefantrine,CCCCN(CCCC)CC(C1=CC(=CC2=C1C3=C(C2=CC4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O,APPROVED,immune_system_disease
1119,Mast Cell Activation Syndrome,Masitinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,PHASE2,immune_system_disease
1120,Stroke|Cerebrovascular Disorders|Ischemic Stroke|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Cardiovascular Diseases|Propranolol|Beta Blocker|Molecular Mechanisms of Pharmacological Action|Immunologic Factors|Physiological Effects of Drugs,Ceftriaxone,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,PHASE2,immune_system_disease
1122,Primary Central Nervous System Lymphoma|Non-Hodgkin Lymphoma of Extranodal Site,Paxalisib,CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C,PHASE2,immune_system_disease
1123,"Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Lymphoma, Non-Hodgkin|Hodgkin's Lymphoma|Multiple Myeloma",Clioquinol,C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1,PHASE1,immune_system_disease
1124,Asthma,Alfacalcidol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,immune_system_disease
1125,Seasonal Allergic Rhinitis,Xylometazoline,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C,APPROVED,immune_system_disease
1126,Skin Alterations Associated With Atopic Dermatitis,Sertaconazole,C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl,PHASE2,immune_system_disease
1127,Relapsing Multiple Sclerosis,Fenebrutinib,CC1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8,PHASE2,immune_system_disease
1128,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Futibatinib,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,PHASE2,immune_system_disease
1129,Allergy,Meglumine,CNCC(C(C(C(CO)O)O)O)O,APPROVED,immune_system_disease
1130,"Bacterial Infections|Pneumonia, Pneumocystis Carinii|HIV Infections",Atovaquone,C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O,PHASE2,immune_system_disease
1131,Advanced Cancer|Colorectal Cancer|Mantle Cell Lymphoma,Merestinib,CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F,PHASE1,immune_system_disease
1132,Allergic Rhinitis,Doxazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,APPROVED,immune_system_disease
1133,Multiple Myeloma,Ganetespib,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O,PHASE1,immune_system_disease
1135,Gout,Allopurinol,C1=NNC2=C1C(=O)NC=N2,PHASE2,metabolic_disease
1136,Necrobiosis Lipoidica,Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,PHASE2,metabolic_disease
1137,Necrobiosis Lipoidica,Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,metabolic_disease
1138,Insulin Resistance|Hypermetabolism|Hyperglycemia,Metformin,CN(C)C(=N)N=C(N)N,PHASE2|PHASE3,metabolic_disease
1139,Genetics Disease|Type2 Diabetes|Heart Failure,Sitagliptin,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,APPROVED,metabolic_disease
1140,"Severe Combined Immunodeficiency Disease, X-linked",Busulfan,CS(=O)(=O)OCCCCOS(=O)(=O)C,PHASE1|PHASE2,metabolic_disease
1141,Type 2 Diabetes Mellitus|Hypertension,Acetylcysteine,CC(=O)NC(CS)C(=O)O,APPROVED,metabolic_disease
1142,PreDiabetes|Impaired Glucose Tolerance|Obesity|Blood Pressure,Sacubitril,CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O,APPROVED,metabolic_disease
1143,PreDiabetes|Impaired Glucose Tolerance|Obesity|Blood Pressure,Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O,APPROVED,metabolic_disease
1144,"Diabetes Mellitus, Type 1",Sirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,PHASE1,metabolic_disease
1145,Mucopolysaccharidosis I,Cyclosporine,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE1|PHASE2,metabolic_disease
1147,Mucopolysaccharidosis I,Azathioprine,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],PHASE1|PHASE2,metabolic_disease
1148,Hypoglycemia,Glucagon,CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CN=CN7)N,PHASE1,metabolic_disease
1149,Hyperlipidemias,Teduglutide,CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N,PHASE2|PHASE3,metabolic_disease
1150,Hyponatremia,Tolvaptan,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C,PHASE2,metabolic_disease
1151,"Diabetes Mellitus, Type 2",Donepezil,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,PHASE2,metabolic_disease
1152,"Dyslipidemias|Atherosclerosis|Diabetes Mellitus, Type 2",Atorvastatin,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,APPROVED,metabolic_disease
1153,"Dyslipidemias|Atherosclerosis|Diabetes Mellitus, Type 2",Ezetimibe,C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O,APPROVED,metabolic_disease
1154,Type 1 Diabetes,Pramlintide,CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N,APPROVED,metabolic_disease
1155,Type 1 Diabetes|Diabetic Kidney Disease|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Sensitivity,Iohexol,CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,PHASE1,metabolic_disease
1156,Hypertension|Dyslipidemia,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,APPROVED,metabolic_disease
1157,Hypertension|Dyslipidemia,Ciprofibrate,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,APPROVED,metabolic_disease
1158,"Diabetes Mellitus, Type 2",Lixisenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N,PHASE1,metabolic_disease
1159,Male Osteoporosis,Teriparatide,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N,APPROVED,metabolic_disease
1160,Male Osteoporosis,Cinacalcet,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,APPROVED,metabolic_disease
1161,End-Stage Renal Disease,Levocarnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,metabolic_disease
1162,End-Stage Renal Disease,Carnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,metabolic_disease
1163,Type 2 Diabetes Mellitus,Dapagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,PHASE1,metabolic_disease
1164,"Idiopathic Infantile Hypercalcaemia - Severe Form|Genetic Disease|Hypercalcemia, Idiopathic, of Infancy|Hypercalciuric Hypercalcemia|Idiopathic Infantile Hypercalcemia - Mild Form|Hypercalciuria",Rifampin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE2,metabolic_disease
1165,"Idiopathic Infantile Hypercalcaemia - Severe Form|Genetic Disease|Hypercalcemia, Idiopathic, of Infancy|Hypercalciuric Hypercalcemia|Idiopathic Infantile Hypercalcemia - Mild Form|Hypercalciuria",Rifampicin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE2,metabolic_disease
1167,Pompe Disease,Bortezomib,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,APPROVED,metabolic_disease
1168,Pompe Disease,Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,APPROVED,metabolic_disease
1169,Vitamin D2 Supplementation in Vitamin D Insufficiency,Ergocalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,APPROVED,metabolic_disease
1170,Hepatic Encephalopathy,Lactulose,C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O,APPROVED,metabolic_disease
1171,Diabetes,Ramipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O,PHASE2|PHASE3,metabolic_disease
1172,Diabetes,Candesartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,PHASE2|PHASE3,metabolic_disease
1173,"Diabetes Mellitus, Type 2",Albiglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N,PHASE1,metabolic_disease
1174,"Diabetes Mellitus, Type 2",Moxifloxacin,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,PHASE1,metabolic_disease
1175,Type 2 Diabetes Mellitus,Pioglitazone,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,APPROVED,metabolic_disease
1176,Dyslipidemia,Fluvastatin,CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,APPROVED,metabolic_disease
1177,Osteoporosis,Etidronate,CC(O)(P(=O)(O)O)P(=O)(O)O,APPROVED,metabolic_disease
1178,Gestational Diabetes,Resveratrol,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,APPROVED,metabolic_disease
1179,"Diabetes Mellitus, Type 2|Hyperglycemia|Perioperative/Postoperative Complications",Salsalate,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,PHASE1,metabolic_disease
1180,Congenital Adrenal Hyperplasia,Hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,APPROVED,metabolic_disease
1181,Congenital Adrenal Hyperplasia,Prednisone,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,APPROVED,metabolic_disease
1182,Congenital Adrenal Hyperplasia,Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,APPROVED,metabolic_disease
1183,Hyperkalemia,Albuterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,APPROVED,metabolic_disease
1184,Hyperkalemia,Salbutamol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,APPROVED,metabolic_disease
1185,Glucocorticoid Induced Osteoporosis,Alendronate,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,PHASE2,metabolic_disease
1186,Transfusional Iron Overload|Transfusional Hemosiderosis,Deferasirox,C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O,PHASE2,metabolic_disease
1187,Transfusional Iron Overload|Transfusional Hemosiderosis,Deferoxamine,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,PHASE2,metabolic_disease
1188,Osteoporosis|Achlorhydria|GERD|Hip Fracture,Omeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,APPROVED,metabolic_disease
1189,Hyperlipidemia|Atherosclerosis,Rosuvastatin,CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,APPROVED,metabolic_disease
1190,Hypoglycemia|Glucose Metabolism Disorders,Dasiglucagon,CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N,PHASE2,metabolic_disease
1191,Amyotrophic Lateral Sclerosis (ALS),Olanzapine,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,PHASE2|PHASE3,metabolic_disease
1192,"Diabetes Mellitus, Type 2|Glucose Metabolism Disorders (Including Diabetes Mellitus)",Semaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,APPROVED,metabolic_disease
1193,Type 2 Diabetes,Saxagliptin,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,APPROVED,metabolic_disease
1194,Type 2 Diabetes,Vildagliptin,C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N,APPROVED,metabolic_disease
1195,HIV Infections|Cachexia|Anorexia|AIDS Wasting Syndrome|HIV Wasting Syndrome,Megestrol,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,PHASE2,metabolic_disease
1196,Hypertension|Obesity|Diabetes,Amlodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,APPROVED,metabolic_disease
1197,Hypogonadism|Diabetes|Sarcopenia|Osteoporosis|Depression,Anastrozole,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,PHASE2,metabolic_disease
1199,"Diabetes Mellitus, Type 2",Canagliflozin,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,PHASE1,metabolic_disease
1200,Osteoporosis in Postmenopausal Women,Eldecalcitol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(C(C3=C)O)OCCCO)O)C,APPROVED,metabolic_disease
1201,Type 2 Diabetes Mellitus|Impaired Glucose Tolerance,Exenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N,APPROVED,metabolic_disease
1202,Charcot Arthropathy|Diabetes Complications,Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,PHASE2|PHASE3,metabolic_disease
1203,"Diabetes Mellitus, Type 2|Essential Hypertension",Lacidipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C,APPROVED,metabolic_disease
1204,Dyslipidemias|High Cholesterol|Hypercholesterolemia,Obicetrapib,CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O,PHASE2,metabolic_disease
1205,Type 2 Diabetes,Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,APPROVED,metabolic_disease
1206,Hypertension,Losartan,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,APPROVED,metabolic_disease
1207,Permanent Atrial Fibrillation|Venous Thrombosis|Pulmonary Embolism|Anticoagulation Treatment at Least > or = to 12-month,Rivaroxaban,C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl,APPROVED,metabolic_disease
1208,Permanent Atrial Fibrillation|Venous Thrombosis|Pulmonary Embolism|Anticoagulation Treatment at Least > or = to 12-month,Fluindione,C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)F,APPROVED,metabolic_disease
1209,Permanent Atrial Fibrillation|Venous Thrombosis|Pulmonary Embolism|Anticoagulation Treatment at Least > or = to 12-month,Warfarin,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,APPROVED,metabolic_disease
1210,Diabetes Mellitus Type 2,Roflumilast,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,PHASE2,metabolic_disease
1211,Type 2 Diabetes,Cholecalciferol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2|PHASE3,metabolic_disease
1212,Abdominal Obesity Metabolic Syndrome,Galantamine,CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O,APPROVED,metabolic_disease
1213,Non-Alcoholic Fatty Liver Disease|Type2 Diabetes,Gliclazide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,APPROVED,metabolic_disease
1214,Amyloidosis|Systemic Light Chain Amyloidosis,Carfilzomib,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,PHASE1,metabolic_disease
1215,"Osteoporosis, Postmenopausal",Risedronate,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,APPROVED,metabolic_disease
1216,Familial Hypercholesterolemia,Colesevelam,CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-],APPROVED,metabolic_disease
1217,Pmm2-CDG|CDG1A,Acetazolamide,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,PHASE2|PHASE3,metabolic_disease
1218,HIV Infections,Nelfinavir,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,APPROVED,metabolic_disease
1219,HIV Infections,Efavirenz,C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,APPROVED,metabolic_disease
1220,Metabolic Syndrome,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,PHASE2,metabolic_disease
1221,Type 2 Diabetes,Tesaglitazar,CCOC(CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O,PHASE2,metabolic_disease
1222,Glycogen Storage Disease Type V|McArdle Disease,Valproate,CCCC(CCC)C(=O)O,PHASE2,metabolic_disease
1223,Enteropathy|Celiac Disease|CVID Enteropathy|Collagenous Sprue|Autoimmune Enteropathy,Budesonide,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,APPROVED,metabolic_disease
1224,Celiac Disease,Simvastatin,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE1,metabolic_disease
1225,Type 2 Diabetes Mellitus,Glimepiride,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,APPROVED,metabolic_disease
1226,Polycystic Ovary Syndrome,Mirabegron,C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,PHASE1,metabolic_disease
1227,Osteoporosis,Raloxifene,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,PHASE1,metabolic_disease
1228,Thalassemia|Iron Overload|Hemochromatosis,Nifedipine,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,PHASE1,metabolic_disease
1229,REM Sleep Behavior Disorder|Parkinson Disease|Synucleinopathies,Rasagiline,C#CCNC1CCC2=CC=CC=C12,PHASE2|PHASE3,metabolic_disease
1230,Osteoporosis,Odanacatib,CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F,PHASE1,metabolic_disease
1231,Hypertension|Impaired Glucose Tolerance,Telmisartan,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,APPROVED,metabolic_disease
1232,Arterial Hypertension|Dyslipidemias|Blood Pressure|Lipid Metabolism Disorders,Perindopril,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O,APPROVED,metabolic_disease
1233,"Diabetes Mellitus, Insulin-Dependent",Ladarixin,CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C,PHASE2,metabolic_disease
1234,"Cystoid Macular Edema, Postoperative|Diabetes Mellitus",Ketorolac,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,APPROVED,metabolic_disease
1235,"Diabetes Mellitus, Type 2",Linagliptin,CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,PHASE2,metabolic_disease
1237,Type 2 Diabetes Mellitus|Insulin Sensitivity/Resistance,Voglibose,C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO,APPROVED,metabolic_disease
1238,Anemia|Iron Deficiency,Erythropoietin,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],APPROVED,metabolic_disease
1239,Metabolic Syndrome,Orlistat,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,PHASE1|PHASE2,metabolic_disease
1240,Metabolic Syndrome,Diltiazem,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,PHASE1|PHASE2,metabolic_disease
1241,Renal Transplant Recipients|Posttransplant Diabetes Mellitus|Posttransplant Impaired Glucose Tolerance,Nateglinide,CC(C)C1CCC(CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)O,APPROVED,metabolic_disease
1242,Multiple Myeloma|Lymphoma|Amyloidosis,Ixazomib,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,PHASE2,metabolic_disease
1243,"Diabetes Mellitus, Type 2",Metoprolol,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,PHASE1,metabolic_disease
1244,"Diabetes Mellitus, Type 2",Lisinopril,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,PHASE1,metabolic_disease
1245,"Drug Metabolism, Poor, CYP2D6-RELATED",Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,PHASE1,metabolic_disease
1246,"Drug Metabolism, Poor, CYP2D6-RELATED",Metoclopramide,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,PHASE1,metabolic_disease
1248,Chronic Kidney Disease|Type 2 Diabetes|Diabetic Nephropathy,Bardoxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C,PHASE2,metabolic_disease
1249,Cerebral Amyloid Angiopathy,Minocycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,PHASE1|PHASE2,metabolic_disease
1250,HIV/AIDS|HIV-1-infection|Osteopenia,Dolutegravir,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,PHASE2,metabolic_disease
1251,NAFLD|Pre-diabetes,Metadoxine,CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)NC1C(=O)O,APPROVED,metabolic_disease
1252,Amyotrophic Lateral Sclerosis,Memantine,CC12CC3CC(C1)(CC(C3)(C2)N)C,PHASE2|PHASE3,metabolic_disease
1253,Cachexia; Cancer|Anorexia,Mirtazapine,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,PHASE2,metabolic_disease
1254,Amyotrophic Lateral Sclerosis,Riluzole,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,PHASE2|PHASE3,metabolic_disease
1255,Schizophrenia,Aripiprazole,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,APPROVED,metabolic_disease
1256,Schizophrenia,Haloperidol,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,APPROVED,metabolic_disease
1257,Brain Tumor|Metabolic Disturbance|Inflammatory Response|Oxygen Deficiency,Dexmedetomidine,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,APPROVED,metabolic_disease
1258,Friedreich Ataxia,Etravirine,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,PHASE2,metabolic_disease
1259,"Diabetes Mellitus, Type 2",Tadalafil,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,PHASE2,metabolic_disease
1261,Type 1 Diabetes,Eflornithine,C(CC(C(F)F)(C(=O)O)N)CN,PHASE1,metabolic_disease
1262,Beta-Thalassemia,Deferitrin,CC1(CSC(=N1)C2=C(C=C(C=C2)O)O)C(=O)O,PHASE1|PHASE2,metabolic_disease
1263,Amyotrophic Lateral Sclerosis (ALS),Tamoxifen,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,PHASE2,metabolic_disease
1264,Kidney Diseases,Tacrolimus,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,APPROVED,metabolic_disease
1266,"Atrial Fibrillation or Pulmonary Embolism|Need of Long Term Oral Anticoagulation Therapy (OAT)|Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location",Phenprocoumon,CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,APPROVED,metabolic_disease
1269,21-hydroxylase Deficiency,Abiraterone,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,PHASE1,metabolic_disease
1270,Hypertriglyceridemia,Maraviroc,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,PHASE1,metabolic_disease
1271,"Diabetes Mellitus, Type 2",Evogliptin,CC(C)(C)OCC1C(=O)NCCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N,PHASE2,metabolic_disease
1272,Psoriasis Vulgaris,Calcipotriol,CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C,PHASE2,metabolic_disease
1273,Wilson Disease,Bupropion,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,PHASE1,metabolic_disease
1274,Pulmonary Hypertension,Ranolazine,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,APPROVED,metabolic_disease
1275,Hyperinsulinism|Insulin Resistance|Insulin Sensitivity|Glucose Intolerance|Hypertension,Vigabatrin,C=CC(CCC(=O)O)N,PHASE2,metabolic_disease
1277,Familial Amyotrophic Lateral Sclerosis,Pyrimethamine,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,PHASE1|PHASE2,metabolic_disease
1279,Methemoglobinemia|Linear IgA Bullous Dermatosis,Dapsone,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,PHASE1,metabolic_disease
1280,Type 2 Diabetes|Overweight|Obesity|Masked Hypertension,Mitiglinide,C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)O,APPROVED,metabolic_disease
1281,Hermansky-Pudlak Syndrome (HPS)|Pulmonary Fibrosis|Oculocutaneous Albinism|Platelet Storage Pool Deficiency|Metabolic Disease,Zileuton,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,PHASE1|PHASE2,metabolic_disease
1282,Hermansky-Pudlak Syndrome (HPS)|Pulmonary Fibrosis|Oculocutaneous Albinism|Platelet Storage Pool Deficiency|Metabolic Disease,Pravastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O,PHASE1|PHASE2,metabolic_disease
1283,Hermansky-Pudlak Syndrome (HPS)|Pulmonary Fibrosis|Oculocutaneous Albinism|Platelet Storage Pool Deficiency|Metabolic Disease,Erythromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,PHASE1|PHASE2,metabolic_disease
1284,Coronary Artery Disease,Gefarnate,CC(=CCCC(=CCCC(=CCCC(=O)OCC=C(C)CCC=C(C)C)C)C)C,PHASE2|PHASE3,metabolic_disease
1285,Metabolic Syndrome X,Eplerenone,CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC,APPROVED,metabolic_disease
1286,Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD),Ipragliflozin,C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F,APPROVED,metabolic_disease
1287,Osteoporosis,Ibandronate,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,PHASE2,metabolic_disease
1289,Sepsis|Hypoperfusion|Hyperlactatemia,Dobutamine,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,PHASE2,metabolic_disease
1290,Wilson Disease,Tetrathiomolybdate,[SH-].[SH-].S=[Mo]=S,PHASE2,metabolic_disease
1291,Glycogen Storage Disease Type V,Triheptanoin,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,PHASE2,metabolic_disease
1293,Amyotrophic Lateral Sclerosis (ALS),Pimozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,PHASE2,metabolic_disease
1294,"Hypertension|Atherosclerosis|Diabetes Mellitus, Type 2|Renin Hypertension",Fimasartan,CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C,APPROVED,metabolic_disease
1295,Insulin Resistance|Hyperinsulinemia|Dyslipidemias,Alpelisib,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,PHASE1,metabolic_disease
1296,Castration-resistant Prostate Cancer,Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCS)O,PHASE1|PHASE2,metabolic_disease
1297,Obesity|Overweight|Overnutrition,Betahistine,CNCCC1=CC=CC=N1,PHASE1,metabolic_disease
1298,Metastatic Colorectal Cancers|Metastatic Gastric Cancers|Metastatic Oesophageal Cancers|Metastatic Pancreatic Cancers|Metastatic Biliary Cancers|Metastatic Breast Cancers,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,PHASE1,metabolic_disease
1299,Iron-deficiency,Lactoferrin,CCC(C)C(C(=NC(C(C)O)C(=NC(CS)C(=NC(C(C)C)C(=NC(CCCNC(=N)N)C(=NC(CCCNC(=N)N)C(=NC(C)C(=NC(CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C(C(CO)N=C(C2CCCN2C(=O)C(C)N=C(CN=C(C(CC(C)C)N=C(C(CCCCN)N=C(C(CCCCN)N=C(C(CCSC)N=C(C(CCCNC(=N)N)N=C(C(CC3=CNC4=CC=CC=C43)N=C(C(CCC(=N)O)N=C(C(CC5=CNC6=CC=CC=C65)N=C(C(CCCNC(=N)N)N=C(C(CCCNC(=N)N)N=C(C(CS)N=C(C(CCCCN)N=C(C(CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O,APPROVED,metabolic_disease
1300,Fatty Liver Disease|Fatty Liver,Itopride,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC,PHASE2,metabolic_disease
1301,"Dyslipidemia|Atherosclerosis|Diabetes Mellitus, Type 2",Policosanol,CCCO,APPROVED,metabolic_disease
1302,Prehypertension|Gout|Pulse Wave Velocity|Hypertension|24 Hour Blood Pressure,Febuxostat,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,APPROVED,metabolic_disease
1304,Fanconi Anemia,Plerixafor,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3,PHASE1|PHASE2,metabolic_disease
1305,"Diabetes Mellitus, Type 2|Vascular Diseases",Rosiglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,APPROVED,metabolic_disease
1306,Hypoparathyroidism,Calcitriol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,PHASE2,metabolic_disease
1307,"Disorder Related to Renal Transplantation|Exercise, Aerobic|Muscle Strength",Everolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,APPROVED,metabolic_disease
1308,"Type 2 Diabetes|Diabetes Mellitus, Type 2",Tirzepatide,CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N,APPROVED,metabolic_disease
1310,Menopause|Postmenopausal Bone Loss|Breast Cancer,Tibolone,CC1CC2=C(CCC(=O)C2)C3C1C4CCC(C4(CC3)C)(C#C)O,PHASE2,metabolic_disease
1311,Obstructive Sleep Apnea,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,PHASE2,metabolic_disease
1313,HIV Infections|HIV Wasting Syndrome,Thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,PHASE2,metabolic_disease
1314,Postmenopausal Osteoporosis,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,PHASE1,metabolic_disease
1315,Type2 Diabetes|Major Depressive Disorder,Vortioxetine,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,APPROVED,metabolic_disease
1316,Chronic Kidney Disease,Sevelamer,C=CCN.C1C(O1)CCl,APPROVED,metabolic_disease
1317,Amyotrophic Lateral Sclerosis,Zilucoplan,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCCC(C(=O)O)NC(=O)C(C1CCCCC1)NC(=O)C2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC4=CNC5=C4C=CC=N5)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(C(C)(C)C)NC(=O)C(CC(=O)O)N(C)C(=O)C7CC(=O)NCCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O,PHASE2|PHASE3,metabolic_disease
1318,Type 2 Diabetes,Acarbose,CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO,APPROVED,metabolic_disease
1320,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Ruboxistaurin,CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O,PHASE2|PHASE3,metabolic_disease
1321,Amyotrophic Lateral Sclerosis,Ezogabine,CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N,PHASE2,metabolic_disease
1322,Hyperkalemia|Resistant Hypertension,Spironolactone,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,PHASE2,metabolic_disease
1323,Type 2 Diabetes Mellitus,Gemigliptin,C1CC(CN(C1=O)CC(CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F,APPROVED,metabolic_disease
1324,Diabetes,Phentermine,CC(C)(CC1=CC=CC=C1)N,PHASE2,metabolic_disease
1325,Diabetes,Topiramate,CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,PHASE2,metabolic_disease
1327,Porphyria Cutanea Tarda,Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,PHASE2,metabolic_disease
1328,SIAD - Syndrome of Inappropriate Antidiuresis|Hyponatremia,Empagliflozin,C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,PHASE2|PHASE3,metabolic_disease
1329,"Diabetes Mellitus, Type 2|Hypertension",Ertugliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl,PHASE2,metabolic_disease
1331,Amyotrophic Lateral Sclerosis,Fasudil,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3,PHASE2,metabolic_disease
1332,Primary Mitochondrial Disease,Elamipretide,CC1=CC(=CC(=C1CC(C(=O)NC(CCCCN)C(=O)NC(CC2=CC=CC=C2)C(=O)N)NC(=O)C(CCCN=C(N)N)N)C)O,PHASE2,metabolic_disease
1333,Bone Marrow Failure Syndrome|Congenital Amegakaryocytic Thrombocytopenia|Congenital Pure Red Cell Aplasia|Hereditary Sideroblastic Anemia|Myeloid Neoplasms With Germline GATA2 Mutation|Paroxysmal Nocturnal Hemoglobinuria|Shwachman-Diamond Syndrome,Treosulfan,CS(=O)(=O)OCC(C(COS(=O)(=O)C)O)O,PHASE2,metabolic_disease
1334,Bone Marrow Failure Syndrome|Congenital Amegakaryocytic Thrombocytopenia|Congenital Pure Red Cell Aplasia|Hereditary Sideroblastic Anemia|Myeloid Neoplasms With Germline GATA2 Mutation|Paroxysmal Nocturnal Hemoglobinuria|Shwachman-Diamond Syndrome,Fludarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,PHASE2,metabolic_disease
1335,Insulin Resistance|Diabetes Mellitus|Abnormal Glucose Metabolism,Liothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,PHASE2,metabolic_disease
1336,"Hypertension|Diabetes Mellitus, Type 2|Blood Pressure|Obesity|Cardiac Hypertrophy|Microalbuminuria|Vascular Stiffness",Glyburide,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,APPROVED,metabolic_disease
1337,Hereditary Hemochromatosis,Psyllium,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,PHASE1,metabolic_disease
1338,Chronic Kidney Diseases|Hemodialysis Complication|Hyperphosphatemia,Cholestyramine,CCC(C)C.CCC(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)C[N+](C)(C)C.N.[Cl-],APPROVED,metabolic_disease
1341,Amyotrophic Lateral Sclerosis,Verdiperstat,CC(C)OCCN1C2=C(C(=O)NC1=S)NC=C2,PHASE2|PHASE3,metabolic_disease
1342,Amyotrophic Lateral Sclerosis,Pridopidine,CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C,PHASE2|PHASE3,metabolic_disease
1343,"Hepatitis C, Chronic|DIABETES MELLITUS Type 2",Ribavirin,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,APPROVED,metabolic_disease
1344,Obesity|Metabolic Disease,Colchicine,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,PHASE1|PHASE2,metabolic_disease
1346,Hypertension|Abdominal Obesity,Aliskiren,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,PHASE2,metabolic_disease
1347,"Non-Alcoholic Fatty Liver Disease|Diabetes Mellitus, Type 2",Levothyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,PHASE2,metabolic_disease
1348,Type 2 Diabetes Mellitus,Alogliptin,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N,PHASE2|PHASE3,metabolic_disease
1349,Hypoxia|Altitude|Heart Failure,Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,APPROVED,metabolic_disease
1350,Hypoxia|Altitude|Heart Failure,Nebivolol,C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O,APPROVED,metabolic_disease
1351,Severe Hypertriglyceridemia|Mixed Dyslipidaemia,Gemcabene,CC(C)(CCCCOCCCCC(C)(C)C(=O)O)C(=O)O,PHASE2,metabolic_disease
1352,Type 1 Diabetes Mellitus,Alprazolam,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,PHASE1|PHASE2,metabolic_disease
1353,"Diabetes Mellitus, Type 2",Zanamivir,CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N,PHASE2,metabolic_disease
1354,Type 2 Diabetes Mellitus,Hydrochlorothiazide,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,APPROVED,metabolic_disease
1355,"Diabetes Mellitus, Type 2",Repaglinide,CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,APPROVED,metabolic_disease
1356,Lipodystrophy,Leptin,CC(C)CC(C(=NC(CCC(=N)O)C(=NCC(=NC(CO)C(=NC(CC(C)C)C(=NC(CCC(=N)O)C(=NC(CC(=O)O)C(=NC(CCSC)C(=NC(CC(C)C)C(=NC(CC1=CNC2=CC=CC=C21)C(=NC(CCC(=N)O)C(=NC(CC(C)C)C(=NC(CC(=O)O)C(=NC(CC(C)C)C(=NC(CO)C(=O)N3CCCC3C(=NCC(=NC(CS)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N,PHASE2,metabolic_disease
1357,"Infant, Newborn, Diseases|Pregnancy in Diabetics|Infant, Diabetic Mother|Hypoglycemia|Infant, Large for Gestational Age",Diazoxide,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,PHASE2|PHASE3,metabolic_disease
1358,Type 2 Diabetes|Non-alcoholic Fatty Liver Disease,Lobeglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC,APPROVED,metabolic_disease
1359,Essential Hypertension Complicated by Type 2 Diabetes Mellitus,Azilsartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O,APPROVED,metabolic_disease
1360,Alkaptonuria,Nitisinone,C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-],PHASE2,metabolic_disease
1361,Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans,Cilostazol,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,APPROVED,metabolic_disease
1362,Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans,Probucol,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,APPROVED,metabolic_disease
1363,Prediabetic State|Non-alcoholic Fatty Liver Disease|Type 2 Diabetes Mellitus,Cenicriviroc,CCCCOCCOC1=CC=C(C=C1)C2=CC3=C(C=C2)N(CCCC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)CC5=CN=CN5CCC)CC(C)C,PHASE2,metabolic_disease
1364,Mucopolysaccharidosis I|Mucopolysaccharidosis VI|Mannosidosis|Mucolipidosis Type II (I-cell Disease),Cyclophosphamide,C1CNP(=O)(OC1)N(CCCl)CCCl,PHASE2,metabolic_disease
1366,Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma,Cabozantinib,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,PHASE2,metabolic_disease
1369,Microvascular Coronary Artery Disease,Sildenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,PHASE1,metabolic_disease
1370,Canavan Disease,Levetiracetam,CCC(C(=O)N)N1CCCC1=O,PHASE1|PHASE2,metabolic_disease
1371,Amyotrophic Lateral Sclerosis,Trametinib,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,PHASE1|PHASE2,metabolic_disease
1372,Obesity|Hypertension,Trimethaphan,C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5,PHASE1,metabolic_disease
1373,Neimann-Pick Disease,Vorinostat,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,PHASE1|PHASE2,metabolic_disease
1374,"Ultraviolet Rays|Immunosuppression|Hypersensitivity, Delayed|Immune Tolerance/Drug Effects",Diphencyprone,C1=CC=C(C=C1)C2=C(C2=O)C3=CC=CC=C3,PHASE1,metabolic_disease
1375,Neurodegenerative Disease|Iron Overload,Deferiprone,CC1=C(C(=O)C=CN1C)O,PHASE2,metabolic_disease
1376,Type 2 Diabetes,Anagliptin,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCCC3C#N,APPROVED,metabolic_disease
1377,"Osteoporosis, Postmenopausal",Abaloparatide,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C)(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC1=CN=CN1)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)N)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(C)N,APPROVED,metabolic_disease
1378,Morbid Obesity|Bariatric Surgery Candidate,Bupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,PHASE1,metabolic_disease
1379,Dyslipidemia (Fredrickson Type Ⅱa)|Dyslipidemia (Fredrickson Type Ⅱb),Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,PHASE1,metabolic_disease
1380,HIV Infection|Lipodystrophy|HIV Infections,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,APPROVED,metabolic_disease
1381,Diabetes Mellitus|Tuberculin (Skin Test) Positive,Isoniazid,C1=CN=CC=C1C(=O)NN,APPROVED,metabolic_disease
1382,G6PD Normal|G6PD Deficient|Healthy,Primaquine,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,PHASE1,metabolic_disease
1384,Minimal Hepatic Encephalopathy,Rifaximin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,PHASE1|PHASE2,metabolic_disease
1385,Gout,Arhalofenate,CC(=O)NCCOC(=O)C(C1=CC=C(C=C1)Cl)OC2=CC=CC(=C2)C(F)(F)F,PHASE2,metabolic_disease
1386,Obesity,Propofol,CC(C)C1=C(C(=CC=C1)C(C)C)O,PHASE1,metabolic_disease
1387,Obesity,Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,PHASE1,metabolic_disease
1388,Wilson Disease,Celecoxib,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,PHASE1,metabolic_disease
1389,Osteoarthritis,Relacatib,CC1CCC(C(=O)CN1S(=O)(=O)C2=CC=CC=N2)NC(=O)C(CC(C)C)NC(=O)C3=CC4=CC=CC=C4O3,PHASE1,metabolic_disease
1390,Osteoarthritis,Acetaminophen,CC(=O)NC1=CC=C(C=C1)O,PHASE1,metabolic_disease
1391,Osteoarthritis,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,PHASE1,metabolic_disease
1392,Chronic Kidney Disease Requiring Chronic Dialysis|Hyperphosphatemia,Tenapanor,CN1CC(C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)C5CN(CC6=C5C=C(C=C6Cl)Cl)C,APPROVED,metabolic_disease
1393,Stable Angina Pectoris,Atenolol,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,APPROVED,metabolic_disease
1394,AL Amyloidosis,Melphalan,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,PHASE1,metabolic_disease
1395,Hyponatremia,Conivaptan,CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,APPROVED,metabolic_disease
1396,Pompe Disease,Duvoglustat,C1C(C(C(C(N1)CO)O)O)O,PHASE2,metabolic_disease
1397,Pompe Disease,Clenbuterol,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O,PHASE1|PHASE2,metabolic_disease
1398,Major Depression|Diabetes Mellitus,Escitalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,metabolic_disease
1399,Indigestion|Diabetes Mellitus,Ondansetron,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,PHASE2,metabolic_disease
1400,Levator Ani Syndrome,Diazepam,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,APPROVED,metabolic_disease
1401,Gout|Moderate Renal Impairment,Naproxen,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,PHASE2,metabolic_disease
1402,Gout|Moderate Renal Impairment,Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,PHASE2,metabolic_disease
1403,HIV Infections|Lipodystrophy,Stavudine,CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO,APPROVED,metabolic_disease
1404,HIV Infections|Lipodystrophy,Lamivudine,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,APPROVED,metabolic_disease
1405,Major Depressive Disorder,Fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,APPROVED,metabolic_disease
1406,Gastroparesis|Diabetes Mellitus,Cisapride,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,APPROVED,metabolic_disease
1407,Cancer Cachexia,Macimorelin,CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CNC4=CC=CC=C43)NC=O)N,PHASE2,metabolic_disease
1408,Ataxia Telangiectasia,Betamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE1,metabolic_disease
1409,Osteoporosis,Demeclocycline,CN(C)C1C2CC3C(C4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O,APPROVED,metabolic_disease
1410,Osteoporosis,Tetracycline,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,APPROVED,metabolic_disease
1411,Systemic Sclerosis|Limited Cutaneous Systemic Sclerosis,Mycophenolate,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,PHASE2,metabolic_disease
1412,Non-small Cell Lung Cancer,Gefitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,PHASE2,metabolic_disease
1413,Depression,Etomidate,CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2,APPROVED,metabolic_disease
1414,Depression,Ketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,APPROVED,metabolic_disease
1415,Post-Bariatric Hypoglycemia,Pasireotide,C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,PHASE2,metabolic_disease
1416,Dyslipidemias,Saroglitazar,CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O,PHASE2,metabolic_disease
1417,Progeria|Hutchinson-Gilford Syndrome,Lonafarnib,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,PHASE2,metabolic_disease
1418,Pompe Disease,Lidocaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,PHASE1,metabolic_disease
1419,Alzheimer's Disease,Tricaprylin,CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC,PHASE2,metabolic_disease
1420,Type 2 Diabetes Mellitus|Chronic Kidney Diseases,Cotadutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CO)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)C)C(=O)NC(C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)N)C(=O)O,PHASE2,metabolic_disease
1421,Friedreich Ataxia,Vatiquinone,CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C,PHASE2|PHASE3,metabolic_disease
1422,Lynch Syndrome|Colon Cancer|Colon Neoplasm,Mesalamine,C1=CC(=C(C=C1N)C(=O)O)O,PHASE2,metabolic_disease
1423,Lynch Syndrome|Colon Cancer|Colon Neoplasm,Mesalazine,C1=CC(=C(C=C1N)C(=O)O)O,PHASE2,metabolic_disease
1424,Depression,Sertraline,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,APPROVED,metabolic_disease
1425,"Heart Diseases|Coronary Disease|Coronary Artery Disease|Cardiovascular Diseases|Myocardial Ischemia|Artery Occlusion|Aspirin Sensitivity|Clopidogrel, Poor Metabolism of|Platelet Dysfunction|Platelet Thrombus",Clopidogrel,COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,APPROVED,metabolic_disease
1426,Functional Iron Deficiency|Trauma|Anemia,Oxandrolone,CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C,PHASE2,metabolic_disease
1427,Leber's Hereditary Optic Neuropathy (LHON),Idebenone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,APPROVED,metabolic_disease
1428,MPS IVA|MPS VI,Vosoritide,CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CN=CN5)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO,PHASE1|PHASE2,metabolic_disease
1429,Heart Diseases|Hyperglycemia,Remifentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC,APPROVED,metabolic_disease
1430,Xeroderma Pigmentosum,Afamelanotide,CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C,PHASE2,metabolic_disease
1431,Hypertrophic Cardiomyopathy,Perhexiline,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,PHASE2,metabolic_disease
1432,"Diabetes Mellitus, Type 2|Diabetic Cardiomyopathies",Trimetazidine,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,PHASE2,metabolic_disease
1433,Gastrointestinal Hemorrhage|Crohn Disease|Celiac Disease|Intestinal Diseases|Inflammatory Bowel Diseases,Prucalopride,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl,APPROVED,metabolic_disease
1434,Hypertension|Metabolic Syndrome,Bisoprolol,CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O,APPROVED,metabolic_disease
1435,"Osteoporosis, Postmenopausal",Melatonin,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,APPROVED,metabolic_disease
1436,Congenital Hyperinsulinism|Insulinoma,Fluorodopa,C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N,PHASE1,metabolic_disease
1437,Gaucher Disease|HCV,Ledipasvir,CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,APPROVED,metabolic_disease
1438,Gaucher Disease|HCV,Sofosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,APPROVED,metabolic_disease
1440,Type 2 Diabetes Mellitus,Bosentan,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,APPROVED,metabolic_disease
1441,Type 2 Diabetes Mellitus,Captopril,CC(CS)C(=O)N1CCCC1C(=O)O,APPROVED,metabolic_disease
1442,Frontotemporal Lobar Degeneration,Tolcapone,CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],PHASE2,metabolic_disease
1444,"Complications of Diabetes Mellitus|Diabetes Mellitus|Diabetes Mellitus, Type 2",Diacerein,CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O,PHASE2,metabolic_disease
1446,Amyotrophic Lateral Sclerosis,Dexpramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE1,metabolic_disease
1447,Amyotrophic Lateral Sclerosis,Pramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE1,metabolic_disease
1448,Amyotrophic Lateral Sclerosis,Cimetidine,CC1=C(N=CN1)CSCCNC(=NC)NC#N,PHASE1,metabolic_disease
1449,Mitochondrial Disease,Flurbiprofen,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,PHASE1,metabolic_disease
1450,Mitochondrial Disease,Dextromethorphan,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,PHASE1,metabolic_disease
1451,Hepatic Encephalopathy,Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],PHASE2,metabolic_disease
1452,Hepatic Encephalopathy,Metronidazole,CC1=NC=C(N1CCO)[N+](=O)[O-],PHASE2,metabolic_disease
1453,"Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndromes|Primary Immunodeficiency|Anemia, Aplastic|Hemoglobinopathies|Cytopenia|Fanconi Anemia|Diamond Blackfan Anemia|Thalassemia|Anemia, Sickle Cell",Rimiducid,CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)C(CCC6=CC(=C(C=C6)OC)OC)OC(=O)C7CCCCN7C(=O)C(CC)C8=CC(=C(C(=C8)OC)OC)OC,PHASE1|PHASE2,metabolic_disease
1454,Prostate Cancer,Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,metabolic_disease
1455,Prostate Cancer,Apalutamide,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,PHASE2,metabolic_disease
1456,Endothelial Dysfunction|Type 2 Diabetes Mellitus,Benfotiamine,CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOP(=O)(O)O)SC(=O)C2=CC=CC=C2)C,APPROVED,metabolic_disease
1457,Amyloidosis,Lenalidomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,PHASE1|PHASE2,metabolic_disease
1458,Fatty Liver|Liver Dysfunction|Insulin Resistance,Amoxicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,PHASE2,metabolic_disease
1459,Fatty Liver|Liver Dysfunction|Insulin Resistance,Azithromycin,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,PHASE2,metabolic_disease
1461,Nonalcoholic Fatty Liver Disease|HIV,Aramchol,CCCCCCCCCCCCCCCCCCCC(=O)NC1CCC2(C(C1)CC(C3C2CC(C4(C3CCC4C(C)CCC(=O)O)C)O)O)C,PHASE2,metabolic_disease
1462,Chronic Kidney Disease|Type 2 Diabetes Mellitus,Finerenone,CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C,PHASE2,metabolic_disease
1463,Type 2 Diabetes,Paricalcitol,CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C,PHASE2,metabolic_disease
1464,Type 2 Diabetes Mellitus,Tesofensine,CCOCC1C2CCC(N2C)CC1C3=CC(=C(C=C3)Cl)Cl,PHASE2,metabolic_disease
1466,Nephrolithiasis|Nephrocalcinosis|Hypercalciuria,Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,PHASE2,metabolic_disease
1467,Type 1 Diabetes Mellitus,Sotagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl,PHASE2,metabolic_disease
1468,Osteoporosis,Menatetrenone,CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,APPROVED,metabolic_disease
1469,Primary Sclerosing Cholangitis|Inflammatory Bowel Disease,Vancomycin,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,PHASE1,metabolic_disease
1471,Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation,Mercaptopurine,C1=NC2=C(N1)C(=S)N=CN2,PHASE2,metabolic_disease
1473,Type 2 Diabetes,Rivoglitazone,CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4,PHASE2|PHASE3,metabolic_disease
1474,Chronic Obstructive Pulmonary Disease (COPD),Tesamorelin,CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N,PHASE2,metabolic_disease
1475,Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension,Olmesartan,CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O,APPROVED,metabolic_disease
1476,Endothelial Dysfunction|Bone Disease,Isosorbide,C1C(C2C(O1)C(CO2)O)O,APPROVED,metabolic_disease
1477,Prediabetic State|Hypertension|Dyslipidemias,Pitavastatin,C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F,APPROVED,metabolic_disease
1478,Hypercholesterolemia|Acute Coronary Syndrome,Bezafibrate,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,APPROVED,metabolic_disease
1479,Type 2 Diabetes Mellitus|Secondary Hypogonadism,Enclomiphene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE2,metabolic_disease
1480,Diabetes Mellitus|Diabetes Mellitus Complications|Gastroparesis,Relamorelin,C1CC(CNC1)C(=O)NC(CC2=CSC3=CC=CC=C32)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N,PHASE2,metabolic_disease
1481,Sleep|Insomnia|Insulin Resistance,Eszopiclone,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,APPROVED,metabolic_disease
1482,Diabetes Mellitus Type 2|Non Alcoholic Fatty Liver Disease|Obesity,Amlexanox,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,PHASE2,metabolic_disease
1483,Phenylketonuria,Sapropterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,metabolic_disease
1484,Bariatric Surgery Candidate|Glucose Intolerance|Insulin Resistance,Morphine,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,APPROVED,metabolic_disease
1485,Starvation,Glutamine,C(CC(=O)N)C(C(=O)O)N,APPROVED,metabolic_disease
1486,HIV Infections|Lipodystrophy,Abacavir,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,PHASE2,metabolic_disease
1487,HIV Infections|Lipodystrophy,Zidovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],PHASE2,metabolic_disease
1488,HIV Infections|Lipodystrophy,Nevirapine,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,PHASE2,metabolic_disease
1489,"Diabetes Mellitus, Type 1|Hypoglycemia|Hypoglycemia Unawareness",Naloxone,C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,APPROVED,metabolic_disease
1490,Pharmacokinetics of Dextromethorphan|Pharmacokinetics of Caffeine|Prostate Cancer,Enzalutamide,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,PHASE1,metabolic_disease
1491,Premature Ovarian Failure,Ethinylestradiol,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O,APPROVED,metabolic_disease
1492,Premature Ovarian Failure,Norethindrone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,metabolic_disease
1493,Premature Ovarian Failure,Norethisterone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,metabolic_disease
1495,Metabolic Syndrome,Treamid,C1=CN=C(N1)CCNC(=O)CCCC(=O)NCCC2=NC=CN2,PHASE1,metabolic_disease
1496,Schizophrenia|Diabetes Mellitus,Risperidone,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,APPROVED,metabolic_disease
1497,Healthy Volunteers|Overweight,Sucralose,C(C1C(C(C(C(O1)OC2(C(C(C(O2)CCl)O)O)CCl)O)O)Cl)O,PHASE2,metabolic_disease
1498,Amyotrophic Lateral Sclerosis,Inosine,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O,PHASE1,metabolic_disease
1499,"Obstetric Labour, Premature",Ketoconazole,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,PHASE1,metabolic_disease
1500,Amyotrophic Lateral Sclerosis,Biotin,C1C2C(C(S1)CCCCC(=O)O)NC(=O)N2,PHASE2,metabolic_disease
1502,Type 2 Diabetes Mellitus,Amantadine,C1C2CC3CC1CC(C2)(C3)N,PHASE2,metabolic_disease
1503,HF - Heart Failure|Diabetes Mellitus,Bumetanide,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,APPROVED,metabolic_disease
1504,Myeloma,Pomalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,PHASE1,metabolic_disease
1505,Metabolic Syndrome|Coronary Microvascular Dysfunction,Vericiguat,COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N,PHASE2,metabolic_disease
1507,Transthyretin Amyloid Cardiomyopathy,Tafamidis,C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl,APPROVED,metabolic_disease
1508,Fanconi Anemia,Eltrombopag,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,PHASE2,metabolic_disease
1510,Coronary Artery Disease|Type 1 Diabetes Mellitus,Regadenoson,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N,APPROVED,metabolic_disease
1511,ALS,Perampanel,C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4,PHASE2,metabolic_disease
1512,Type 2 Diabetes Mellitus,Octreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,PHASE1,metabolic_disease
1513,"Anemia, Iron Deficiency|Heavy Menstrual Bleeding",Ferumoxytol,O[Fe]=O.O[Fe]=O.[Fe],APPROVED,metabolic_disease
1514,Gouty Arthritis,Etoricoxib,CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C,PHASE2,metabolic_disease
1516,"Gangliosidoses, GM2|Sandhoff Disease|Tay-Sachs Disease",Leucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1|PHASE2,metabolic_disease
1517,Amyloidosis,Doxycycline,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,PHASE2,metabolic_disease
1518,Type 2 Diabetes Mellitus,Bexagliflozin,C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,PHASE1,metabolic_disease
1519,Type 2 Diabetes Mellitus,Probenecid,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,PHASE1,metabolic_disease
1520,Type 2 Diabetes Mellitus,Verapamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,PHASE1,metabolic_disease
1521,Amyotrophic Lateral Sclerosis,Arimoclomol,C1CCN(CC1)CC(CON=C(C2=C[N+](=CC=C2)[O-])Cl)O,PHASE2|PHASE3,metabolic_disease
1522,Primary Hyperoxaluria,Stiripentol,CC(C)(C)C(C=CC1=CC2=C(C=C1)OCO2)O,PHASE2,metabolic_disease
1523,Type 2 Diabetes Mellitus|Insulin Resistance,Mifepristone,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,PHASE2,metabolic_disease
1524,Amyotrophic Lateral Sclerosis,Rabeprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,PHASE1,metabolic_disease
1526,Schizophrenia,Ziprasidone,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,APPROVED,metabolic_disease
1527,Polycystic Ovary Syndrome,Etonogestrel,CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,metabolic_disease
1528,"Osteoporosis, Postmenopausal",Bazedoxifene,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,APPROVED,metabolic_disease
1529,Secondary Hyperparathyroidism,Etelcalcetide,CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C,PHASE2,metabolic_disease
1530,Hypertension|Type 2 Diabetes Mellitus,Indapamide,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,APPROVED,metabolic_disease
1532,Obesity,Lenomorelin,CCCCCCCC(=O)OCC(C(=O)NC(CO)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)N2CCCC2C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC=N3)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)N6CCCC6C(=O)NC(CCCNC(=N)N)C(=O)O)NC(=O)CN,PHASE1,metabolic_disease
1533,Osteogenesis Imperfecta|Osteoporosis|Paget Disease of Bone,Pamidronate,C(CN)C(O)(P(=O)(O)O)P(=O)(O)O,APPROVED,metabolic_disease
1534,"Inherited Mitochondrial Disease, Including Leigh Syndrome",Cysteamine,C(CS)N,PHASE2,metabolic_disease
1536,Adrenoleukodystrophy|Metachromatic Leukodystrophy|Globoid Cell Leukodystrophy|Tay Sachs Disease|Sandhoffs Disease|Wolman Disease|I-Cell Disease|Sanfilippo Syndrome|GM1 Gangliosidosis,Clofarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,PHASE2,metabolic_disease
1537,Adrenoleukodystrophy|Metachromatic Leukodystrophy|Globoid Cell Leukodystrophy|Tay Sachs Disease|Sandhoffs Disease|Wolman Disease|I-Cell Disease|Sanfilippo Syndrome|GM1 Gangliosidosis,Hydroxyurea,C(=O)(N)NO,PHASE2,metabolic_disease
1538,Cardiac Arrest,Ubiquinol,CC1=C(C(=C(C(=C1O)OC)OC)O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,PHASE2,metabolic_disease
1539,"Attention Deficit Disorder With Hyperactivity|Diabetes Mellitus, Type 1",Lisdexamfetamine,CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N,PHASE2,metabolic_disease
1540,"Attention Deficit Disorder With Hyperactivity|Diabetes Mellitus, Type 1",Methylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,PHASE2,metabolic_disease
1541,Lymphoma|Advanced Cancer,Tolbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,PHASE1,metabolic_disease
1542,Lymphoma|Advanced Cancer,Tasisulam,C1=CC(=C(C=C1Cl)Cl)C(=O)NS(=O)(=O)C2=CC=C(S2)Br,PHASE1,metabolic_disease
1543,Metabolic Syndrome|Hypertension,Enalapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O,APPROVED,metabolic_disease
1544,Diabetes Mellitus Type 2|Hyperglycemia,Glipizide,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,APPROVED,metabolic_disease
1545,Pompe Disease|Hypersensitivity Reaction,Miglustat,CCCCN1CC(C(C(C1CO)O)O)O,PHASE1,metabolic_disease
1546,Type 1 Diabetes,Pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,PHASE2,metabolic_disease
1547,Amyotrophic Lateral Sclerosis,Tretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1|PHASE2,metabolic_disease
1549,Obesity|Hypoandrogenism,Clomiphene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE2,metabolic_disease
1550,Obesity|Hypoandrogenism,Clomifene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE2,metabolic_disease
1551,Frontotemporal Dementia,Citalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,metabolic_disease
1552,Light Chain (AL) Amyloidosis|Cardiac Involvement,Epigallocatechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O,PHASE2,metabolic_disease
1553,Hepatic Failure|Hepatic Impairment|Chronic Hepatitis C Infection With Hepatic Coma,Buprenorphine,CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,APPROVED,metabolic_disease
1554,Hepatic Failure|Hepatic Impairment|Chronic Hepatitis C Infection With Hepatic Coma,Promethazine,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,APPROVED,metabolic_disease
1556,Type 2 Diabetes Mellitus,Gemfibrozil,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,PHASE1,metabolic_disease
1557,Type 1 Diabetes Mellitus,Atazanavir,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,PHASE1,metabolic_disease
1558,Type1 Diabetes Mellitus,Methyldopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N,PHASE2,metabolic_disease
1559,Bone Marrow Failure Syndrome|Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Acquired Neutropenia in Newborn|Acquired Anemia Hemolytic|Acquired Thrombocytopenia|Hemophagocytic Lymphohistiocytoses|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|Common Variable Immunodeficiency|X-linked Lymphoproliferative Disease|Severe Combined Immunodeficiency|Hurler Syndrome|Mannosidosis|Adrenoleukodystrophy,Thiotepa,C1CN1P(=S)(N2CC2)N3CC3,PHASE1|PHASE2,metabolic_disease
1560,HIV Infections|Fatty Liver Disease,Rilpivirine,CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N,APPROVED,metabolic_disease
1561,HIV Infections|Fatty Liver Disease,Tenofovir,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,APPROVED,metabolic_disease
1562,HIV Infections|Fatty Liver Disease,Emtricitabine,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,APPROVED,metabolic_disease
1563,Schizophrenia|Schizoaffective Disorder,Paliperidone,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,APPROVED,metabolic_disease
1564,Diabetes Mellitus|Hemodialysis,Tinzaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,metabolic_disease
1565,Type 2 Diabetes Mellitus,Teneligliptin,CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5,PHASE1,metabolic_disease
1566,"CLOPIDOGREL, POOR METABOLISM of (Disorder)",Ticagrelor,CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F,PHASE2|PHASE3,metabolic_disease
1567,Peritoneal Dialysis|Hypertriglyceridemia,Icodextrin,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,APPROVED,metabolic_disease
1568,Blood Pressure|Diabetes|Obesity|Insulin Resistance|Diuretics Drug Reactions|Sympathetic Nerve Activity,Clonidine,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,PHASE1,metabolic_disease
1569,HIV Seropositivity|Metabolic Syndrome|Fatty Liver,Raltegravir,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,APPROVED,metabolic_disease
1570,Amyotrophic Lateral Sclerosis,Tideglusib,C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43,PHASE2,metabolic_disease
1571,Hyperkalemia,Levosalbutamol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,APPROVED,metabolic_disease
1572,Hyperkalemia,Levalbuterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,APPROVED,metabolic_disease
1573,ALS (Amyotrophic Lateral Sclerosis),Ciprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,PHASE1,metabolic_disease
1574,Hypercholesterolemia,Lapaquistat,CC(C)(CN1C2=C(C=C(C=C2)Cl)C(OC(C1=O)CC(=O)N3CCC(CC3)CC(=O)O)C4=C(C(=CC=C4)OC)OC)CO,PHASE2,metabolic_disease
1575,"Blood Glucose, Low|Hypoglycemia",Gemifloxacin,CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F,PHASE1,metabolic_disease
1576,Healthy|Type 1 Diabetes,Lisofylline,CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O,PHASE1|PHASE2,metabolic_disease
1577,Amyotrophic Lateral Sclerosis|Respiratory Function|Scopolamine,Atropine,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,PHASE2,metabolic_disease
1578,Amyotrophic Lateral Sclerosis|Respiratory Function|Scopolamine,Edaravone,CC1=NN(C(=O)C1)C2=CC=CC=C2,PHASE2,metabolic_disease
1579,"Parkinson Disease|Gait Analysis|Therapy, Directly Observed|Metabolic Disease",Terazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,APPROVED,metabolic_disease
1580,Pulmonary Arterial Hypertension,Ambrisentan,CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,APPROVED,metabolic_disease
1581,Osteoporosis|Bullous Pemphigoid,Clobetasol,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C,APPROVED,metabolic_disease
1582,Type 2 Diabetes Mellitus|Pulmonary Function,Mecobalamin,[CH3-].CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)[N-]6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co+3],PHASE2|PHASE3,metabolic_disease
1583,Schizophrenia|Schizoaffective Disorder|Obesity|Hypertension|Smoking,Rimonabant,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,PHASE2,metabolic_disease
1584,Heart Failure|Hyperuricemia,Benzbromarone,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,APPROVED,metabolic_disease
1585,Type 2 Diabetes Mellitus,Dihydromyricetin,C1=C(C=C(C(=C1O)O)O)C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O,PHASE2,metabolic_disease
1586,"Diabetes Mellitus, Type 1|Diabetic Nephropathy",Alagebrium,CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C,PHASE2,metabolic_disease
1587,Amyotrophic Lateral Sclerosis (ALS),Masitinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,PHASE2|PHASE3,metabolic_disease
1588,Phenylketonuria,Tetrahydrobiopterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,metabolic_disease
1589,Obesity|Blood Pressure,Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,APPROVED,metabolic_disease
1590,Polycystic Ovary Syndrome,Drospirenone,CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,APPROVED,metabolic_disease
1591,Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment,Alfacalcidol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,PHASE2,metabolic_disease
1594,Macular Edema Following Cataract Surgery,Triethylenetetramine,C(CNCCNCCN)N,PHASE2,metabolic_disease
1595,Macular Edema Following Cataract Surgery,Trientine,C(CNCCNCCN)N,PHASE2,metabolic_disease
1596,Pregnancy Related|Cannabis Use,Dronabinol,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,APPROVED,metabolic_disease
1598,Anorexia|Weight Loss|Cachexia,Flurandrenolone,CC1(OC2CC3C4CC(C5=CC(=O)CCC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C)F)C,PHASE2,metabolic_disease
1599,Lesch-Nyhan Disease,Ecopipam,CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl,PHASE1,metabolic_disease
1600,Hypertension|Abdominal Obesity|Metabolic Syndrome,Moxonidine,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,APPROVED,metabolic_disease
1601,Type1 Diabetes Mellitus|Hypoglycemia Unawareness,Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,metabolic_disease
1602,Amyotrophic Lateral Sclerosis,Enoxacin,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,PHASE1|PHASE2,metabolic_disease
1603,Aortic Valve Stenosis,Ataciguat,C1COCCN1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=CC(=C3)Cl)NS(=O)(=O)C4=CC=C(S4)Cl,PHASE2,metabolic_disease
1604,Insulin Resistance|Type 2 Diabetes Mellitus|Obesity|Androgen Deficiency|Metabolic Disease,Acyline,CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)C)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C)NC(=O)C(CO)NC(=O)C(CC4=CN=CC=C4)NC(=O)C(CC5=CC=C(C=C5)Cl)NC(=O)C(CC6=CC7=CC=CC=C7C=C6)NC(=O)C,PHASE1|PHASE2,metabolic_disease
1605,Insulin Resistance|Type 2 Diabetes Mellitus|Obesity|Androgen Deficiency|Metabolic Disease,Letrozole,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,PHASE1|PHASE2,metabolic_disease
1606,"Adrenal Hyperplasia, Congenital",Cortisone,CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4(C(=O)CO)O)C,PHASE2,metabolic_disease
1607,Diabetes Mellitus Type 2,Taspoglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C)(C)C(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,PHASE2,metabolic_disease
1608,Healthy,Licarbazepine,C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O,PHASE1,metabolic_disease
1609,Type 2 Diabetes Mellitus,Tofogliflozin,CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2,APPROVED,metabolic_disease
1610,Multiple Myeloma|Amyloidosis,Pegfilgrastim,CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C,PHASE1,metabolic_disease
1611,Type2diabetes,Henagliflozin,CCOC1=C(C=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl)F,APPROVED,metabolic_disease
1612,Osteoporosis,Ronacaleret,CC(C)(CC1CC2=CC=CC=C2C1)NCC(COC3=C(C(=CC(=C3)CCC(=O)O)F)F)O,PHASE1,metabolic_disease
1613,Congenital Hyperinsulinism,Lanreotide,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,APPROVED,metabolic_disease
1614,Crohn Disease,Xanthohumol,CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C,PHASE2,metabolic_disease
1615,Idiopathic Pulmonary Hemosiderosis|Leflunomide,Leflunomide,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,PHASE1|PHASE2,metabolic_disease
1616,Type 2 Diabetes,Mosapride,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,APPROVED,metabolic_disease
1617,Insulin Sensitivity,Eritoran,CCCCCCCCCCCC(=O)CC(=O)NC1C(C(C(OC1OP(=O)(O)O)COC2C(C(C(C(O2)COC)OP(=O)(O)O)OCCC(CCCCCCC)OC)NC(=O)CCCCCCCCCC=CCCCCCC)O)OCCCCCCCCCC,PHASE2,metabolic_disease
1618,Overweight and Obesity|Insulin Resistance,Amiloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,PHASE2|PHASE3,metabolic_disease
1620,Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorders,Ramelteon,CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3,APPROVED,metabolic_disease
1621,Osteoporosis,Apomine,CC(C)OP(=O)(C(CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OC(C)C)OC(C)C)OC(C)C,PHASE1|PHASE2,metabolic_disease
1623,Microbial Colonization,Duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,PHASE1,metabolic_disease
1624,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Ebselen,C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2,PHASE2|PHASE3,metabolic_disease
1625,AL Amyloidosis,Venetoclax,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,PHASE1|PHASE2,metabolic_disease
1626,AL Amyloidosis,Bendamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,PHASE1|PHASE2,metabolic_disease
1627,"Frontotemporal Dementia|Dementia|Aphasia, Primary Progressive|Pick Disease of the Brain|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Neurocognitive Disorders|Mental Disorders|Neurodegenerative Diseases|Frontotemporal Lobar Degeneration|TDP-43 Proteinopathies|Proteostasis Deficiencies|Metabolic Disease|Aphasia|Speech Disorders|Language Disorders|Communication Disorders|Neurobehavioral Manifestations|Neurologic Manifestations",Rotigotine,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,PHASE2,metabolic_disease
1628,Schizophrenia|Schizoaffective Disorder,Clozapine,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,APPROVED,metabolic_disease
1629,Type 2 Diabetes,Trelagliptin,CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N,APPROVED,metabolic_disease
1630,Acquired Hyperinsulinemic Hypoglycemia,Avexitide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)N,PHASE2,metabolic_disease
1632,"Carcinoma, Renal Cell",Sorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,PHASE1,metabolic_disease
1633,Fabry Disease,Migalastat,C1C(C(C(C(N1)CO)O)O)O,PHASE2,metabolic_disease
1634,Healthy Volunteers,Esomeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE1,metabolic_disease
1635,Nonalcoholic Fatty Liver Disease (NAFLD)|Type 2 Diabetes (T2DM),Lanifibranor,C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2,PHASE2,metabolic_disease
1636,Type 2 Diabetes Mellitus,Omarigliptin,CS(=O)(=O)N1C=C2CN(CC2=N1)C3CC(C(OC3)C4=C(C=CC(=C4)F)F)N,APPROVED,metabolic_disease
1637,Type 2 Diabetes Mellitus,Beraprost,CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O,APPROVED,metabolic_disease
1638,Multiple Myeloma|Myeloma-Associated Amyloidosis,Selinexor,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,PHASE2,metabolic_disease
1640,Congenital Adrenal Hyperplasia,Nevanimibe,CC(C)C1=C(C(=CC=C1)C(C)C)NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C,PHASE2,metabolic_disease
1641,Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Advanced Solid Tumors,Tazemetostat,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,PHASE1,metabolic_disease
1642,Advanced Solid Tumors|Lymphomas,Lenvatinib,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,PHASE1,metabolic_disease
1643,"Amino Acid Metabolism, Inborn Errors",Ataluren,C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F,PHASE2,metabolic_disease
1644,Erythropoietic Protoporphyria,Colestipol,C1C(O1)CCl.C(CNCCNCCNCCN)N,PHASE2|PHASE3,metabolic_disease
1645,Coronary Calcification|Endstage Renal Disease|Parathyroid Hormone,Doxercalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,metabolic_disease
1646,Metastatic Seminoma,Carboplatin,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],PHASE2,metabolic_disease
1648,Type I Gaucher Disease,Ambroxol,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,PHASE1|PHASE2,metabolic_disease
1650,Psychosis,Lumateperone,CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,APPROVED,metabolic_disease
1651,Cancers With DNA Repair-Deficiency,Olaparib,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE2,metabolic_disease
1652,Cancers With DNA Repair-Deficiency,Trabectedin,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O,PHASE2,metabolic_disease
1653,Malignant Gliomas|CNS|Brain Cancer|Cancer,Perifosine,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C,PHASE2,metabolic_disease
1654,Type 2 Diabetes,Yohimbine,COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O,PHASE2,metabolic_disease
1655,Osteopenia/Osteoporosis,Calcifediol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2,metabolic_disease
1656,"Diabetes Mellitus, Type 2",Imeglimin,CC1N=C(NC(=N1)N(C)C)N,APPROVED,metabolic_disease
1657,Type1 Diabetes Mellitus|Enterovirus,Pleconaril,CC1=CC(=CC(=C1OCCCC2=CC(=NO2)C)C)C3=NOC(=N3)C(F)(F)F,PHASE2,metabolic_disease
1658,Diabetes Mellitus|Hypoglycemia|Autonomic Failure,Epinephrine,CNCC(C1=CC(=C(C=C1)O)O)O,PHASE2,metabolic_disease
1659,Obesity|Cardiovascular Disease|Hypertension|Diabetes,Nesiritide,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C3CCCN3C(=O)C(CO)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC4=CN=CN4)C(=O)O)CC(C)C)CO)CO)CO)CO,PHASE1,metabolic_disease
1660,Hyperlipidemia|HIV,Darunavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,PHASE1,metabolic_disease
1661,Hyperlipidemia|HIV,Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,PHASE1,metabolic_disease
1662,HIV Infections|HIV Wasting Syndrome,Nandrolone,CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34,PHASE1,metabolic_disease
1663,Familial Hypercholesterolemia,Implitapide,CC1=CC(=NC2=C1C3=CC=CC=C3N2CC4=CC(=CC=C4)C(C5CCCC5)C(=O)NC(CO)C6=CC=CC=C6)C,PHASE2,metabolic_disease
1664,Type 1 Diabetes,Terbutaline,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,PHASE1,metabolic_disease
1665,ATM Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Homologous Recombination Deficiency|Prostate Carcinoma Metastatic in the Bone|PSA Level Greater Than or Equal to Two|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7,Docetaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,PHASE2,metabolic_disease
1666,ATM Gene Mutation|BRCA1 Gene Mutation|BRCA2 Gene Mutation|Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Homologous Recombination Deficiency|Prostate Carcinoma Metastatic in the Bone|PSA Level Greater Than or Equal to Two|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7,Rucaparib,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,PHASE2,metabolic_disease
1668,Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus,Reparixin,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C,PHASE2,metabolic_disease
1669,Silicosis|Progressive Massive Fibrosis|Complicated Silicosis,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,PHASE2,metabolic_disease
1670,Erectile Dysfunction,Vardenafil,CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C,APPROVED,metabolic_disease
1671,Dyslipidemia,Dalcetrapib,CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C,PHASE2,metabolic_disease
1672,"Esophageal Adenocarcinoma|Esophagus SCC|Cholangiocarcinoma|Urothelial/Bladder Cancer, Nos|Endometrial Cancer",Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,PHASE2,metabolic_disease
1673,"Cardiovascular Diseases|Cardiovascular Risk Factor|Triglycerides High|Diabetes Mellitus, Type 2",Icosapent,CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O,APPROVED,metabolic_disease
1674,Type 2 Diabetes,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,APPROVED,metabolic_disease
1675,Dyslipidemia,Evacetrapib,CC1=CC(=C2C(=C1)C(CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C,PHASE1,metabolic_disease
1679,Sporadic Amyotrophic Lateral Sclerosis,Mexiletine,CC1=C(C(=CC=C1)C)OCC(C)N,PHASE2,metabolic_disease
1681,"Malaria, Falciparum|G6PD Deficiency",Artenimol,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C,APPROVED,metabolic_disease
1682,EGFR Gene Amplification|EGFR Gene Mutation|Glioblastoma|Recurrent Glioblastoma|Supratentorial Glioblastoma|TP53 wt Allele,Fludeoxyglucose,C(C(C(C(C(C=O)F)O)O)O)O,PHASE2,metabolic_disease
1683,EGFR Gene Amplification|EGFR Gene Mutation|Glioblastoma|Recurrent Glioblastoma|Supratentorial Glioblastoma|TP53 wt Allele,Osimertinib,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE2,metabolic_disease
1684,Achlorhydria,Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,PHASE1,metabolic_disease
1685,Hypoglycemia; Iatrogenic,Somatostatin,CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)C(C)N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O,PHASE1,metabolic_disease
1686,Diabetic Kidney Disease,Fulacimstat,CN1C2=C(C=C(C=C2)N3C=C(C(=O)N(C3=O)C4CCC5=C4C=CC=C5C(F)(F)F)C(=O)O)OC1=O,PHASE2,metabolic_disease
1687,Homozygous Familial Hypercholesterolemia,Lomitapide,C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F,PHASE2,metabolic_disease
1688,"Cirrhosis, Liver|Metagonimiasis",Entecavir,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N,APPROVED,metabolic_disease
1689,Acute Leukemia|Immune Deficiency Disorder|Congenital Hematological Disorder|Metabolism Disorder|Aplastic Anemia|Myelodysplastic Syndromes|Chronic Leukemia|Lymphoma|Multiple Myeloma|Solid Tumor,Mesna,C(CS(=O)(=O)[O-])S.[Na+],PHASE1,metabolic_disease
1690,Sarcopenia|Osteopenia,Anamorelin,CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N,PHASE1,metabolic_disease
1691,Abdominal Obesity|Insulin Resistance|Hypertriglyceridemia,Acipimox,CC1=CN=C(C=[N+]1[O-])C(=O)O,PHASE2,metabolic_disease
1692,"Gaucher Disease, Type 1|Cerebroside Lipidosis Syndrome|Glucocerebrosidase Deficiency Disease|Glucosylceramide Beta-Glucosidase Deficiency Disease|Gaucher Disease, Non-Neuronopathic Form",Eliglustat,CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O,PHASE2,metabolic_disease
1693,Myocardial Infarction|Diabetes Mellitus|Peripheral Arterial Disease,Vorapaxar,CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C,APPROVED,metabolic_disease
1694,Type 2 Diabetes,Bromocriptine,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,APPROVED,metabolic_disease
1695,Insulin Resistance|Hepatitis C,Daclatasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,APPROVED,metabolic_disease
1696,Parkinson's Disease,Istradefylline,CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C,PHASE1,metabolic_disease
1697,Amyotrophic Lateral Sclerosis,Talampanel,CC1CC2=CC3=C(C=C2C(=NN1C(=O)C)C4=CC=C(C=C4)N)OCO3,PHASE2,metabolic_disease
1699,Type 1 Diabetes|Hypoglycemia,Pitolisant,C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl,PHASE1,metabolic_disease
1700,"Diabetes Mellitus, Type 1",Deoxyspergualin,C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O,PHASE2,metabolic_disease
1702,Tumor-Induced Osteomalacia,Dotatate,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O,PHASE1,metabolic_disease
1703,HIV Infections,Saquinavir,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,PHASE1,metabolic_disease
1704,HIV Infections,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,PHASE1,metabolic_disease
1705,Metabolic Disease,Oseltamivir,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,APPROVED,metabolic_disease
1709,Hiv|HIV Infections|HIV Lipodystrophy|Osteoporosis|Renal Insufficiency|Weight Gain|Obesity,Doravirine,CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F,APPROVED,metabolic_disease
1710,Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer,Paclitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,PHASE2,metabolic_disease
1711,Type 2 Diabetes Mellitus,Neuropeptide Y,CCC(C)C(C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C6CCCN6C(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C7CCCN7C(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C8CCCN8C(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C9CCCN9C(=O)C(CC1=CC=C(C=C1)O)N,APPROVED,metabolic_disease
1712,Type 2 Diabetes Mellitus,Enalaprilat,CC(C(=O)N1CCCC1C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O,APPROVED,metabolic_disease
1714,Amyotrophic Lateral Sclerosis|Alzheimer Disease|Mild Cognitive Impairment,Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE1|PHASE2,metabolic_disease
1718,Fabry Disease|Neuropathic Pain,Gabapentin,C1CCC(CC1)(CC(=O)O)CN,PHASE2,metabolic_disease
1719,Type 1 Diabetes Mellitus|Hypercalciuria,Chlorthalidone,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,PHASE2,metabolic_disease
1720,Celiac Disease,Prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,PHASE2|PHASE3,metabolic_disease
1721,Celiac Disease,Teriflunomide,CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O,PHASE1|PHASE2,metabolic_disease
1722,Gout,Bucillamine,CC(C)(C(=O)NC(CS)C(=O)O)S,PHASE2,metabolic_disease
1723,Atrial Fibrillation|T2DM (Type 2 Diabetes Mellitus)|Chronic Kidney Diseases,Dabigatran,CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N,APPROVED,metabolic_disease
1725,Breast Cancer,Epirubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,metabolic_disease
1726,Breast Cancer,Fluorouracil,C1=C(C(=O)NC(=O)N1)F,PHASE2,metabolic_disease
1727,Subarachnoid Hemorrhage,Epoprostenol,CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O,PHASE2,metabolic_disease
1728,Subarachnoid Hemorrhage,Prostacyclin,CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O,PHASE2,metabolic_disease
1729,Type 2 Diabetes Mellitus,Rebaudioside A,CC12CCCC(C1CCC34C2CCC(C3)(C(=C)C4)OC5C(C(C(C(O5)CO)O)OC6C(C(C(C(O6)CO)O)O)O)OC7C(C(C(C(O7)CO)O)O)O)(C)C(=O)OC8C(C(C(C(O8)CO)O)O)O,PHASE1,metabolic_disease
1730,Type 2 Diabetes Mellitus,Retagliptin,COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,PHASE1,metabolic_disease
1731,Cancer Cachexia,Ruxolitinib,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,metabolic_disease
1732,Amyotrophic Lateral Sclerosis,Reldesemtiv,C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F,PHASE2,metabolic_disease
1733,Autoimmune Diseases|Fibrosis,Belumosudil,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,PHASE1,metabolic_disease
1734,Amyotrophic Lateral Sclerosis,Fingolimod,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,PHASE2,metabolic_disease
1735,Hyperglycemia|Sepsis,Dopamine,C1=CC(=C(C=C1CCN)O)O,PHASE1,metabolic_disease
1736,Cachexia|Lung Cancer,Clarithromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,PHASE2,metabolic_disease
1737,Pre-diabetes,Epicatechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,metabolic_disease
1738,Pre-diabetes,Catechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,metabolic_disease
1739,Secondary Hypothyroidism|Hypopituitarism|Hyperlipidemias,Thyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,APPROVED,metabolic_disease
1740,Secondary Hypothyroidism|Hypopituitarism|Hyperlipidemias,Triiodothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,APPROVED,metabolic_disease
1742,"Neuropathic Pain|Type 2 Diabetes Mellitus|Diabetic Neuropathy, Painful",Cetirizine,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,APPROVED,metabolic_disease
1744,Body Weight|Impaired Glucose Tolerance in Obese,Cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C,PHASE1|PHASE2,metabolic_disease
1745,Schizophrenia,Quetiapine,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,APPROVED,metabolic_disease
1746,Chronic Myeloid Leukemia,Nilotinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE1,metabolic_disease
1747,"Diabetes Mellitus, Type 2",Quercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,PHASE2,metabolic_disease
1748,Hemodialysis-Induced Symptom|Mitochondrial Diseases,Icatibant,C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O,PHASE2,metabolic_disease
1749,"Niemann-Pick Disease, Type C",Adrabetadex,CC(COCC1C2CC(C(O1)OC3C(OC(C(C3O)OCC(C)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(O2)C(C8O)O)COCC(C)O)CO)COCC(C)O)CO)CO)CO)O)O,PHASE2|PHASE3,metabolic_disease
1750,Hypertension|Diabetes Mellitus,Benazepril,CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O,APPROVED,metabolic_disease
1752,Oral Candidiases,Miconazole,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,APPROVED,metabolic_disease
1754,Hyperlipidemias,Antroquinonol,CC1C(C(C(=C(C1=O)OC)OC)O)CC=C(C)CCC=C(C)CCC=C(C)C,PHASE2,metabolic_disease
1755,"Diabetes Mellitus, Type 2|Overweight or Obesity",Beinaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CNC=N6)N,APPROVED,metabolic_disease
1756,Hypercholesterolemia,Inclisiran,CC(=O)NC1C(C(C(OC1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)NC(=O)CCCCCCCCCCC(=O)N4CC(CC4COP(=O)(O)O)O)CO)O)O,APPROVED,metabolic_disease
1757,Obesity,Nabilone,CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O,PHASE2,metabolic_disease
1759,Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Squamous Cell Carcinoma of the Esophagus,Oxaliplatin,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],PHASE1|PHASE2,metabolic_disease
1760,Renal Failure|Hyponatremia|Sepsis|Hepatic Encephalopathy|Gastrointestinal Bleeding,Midodrine,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,APPROVED,metabolic_disease
1761,Acute Gouty Arthritis,Triamcinolone,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,PHASE2,metabolic_disease
1762,Atherosclerosis,Darapladib,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,PHASE1,metabolic_disease
1763,Diabetic Autonomic Neuropathy,Quinapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O,APPROVED,metabolic_disease
1764,Amyotrophic Lateral Sclerosis,Lacosamide,CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1,PHASE1|PHASE2,metabolic_disease
1765,Metabolic Syndrome,Goserelin,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,metabolic_disease
1766,FAP|Familial Amyloid Polyneuropathy|TTR|Transthyretin|Amyloidosis,Inotersen,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5C(OC(C5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)OC8C(OC(C8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(OC1C(OC(C1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)O,PHASE2|PHASE3,metabolic_disease
1767,Diabetes Mellitus Type II|Acute Coronary Syndrome,Prasugrel,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,APPROVED,metabolic_disease
1768,Iron Deficiency Anemia|B12 Deficiency Anemia,Hydroxocobalamin,CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2],APPROVED,metabolic_disease
1770,Type 2 Diabetes Mellitus|Insomnia|Sleep Disorder|Inflammation,Suvorexant,CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl,APPROVED,metabolic_disease
1771,Mitochondrial Diseases|Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation|MELAS|Subacute Necrotizing Encephalomyelopathy,Sonlicromanol,CC1=C(C2=C(CCC(O2)(C)C(=O)NC3CCCNC3)C(=C1O)C)C,PHASE2,metabolic_disease
1772,"Diabetes Mellitus, Type 2",Digoxin,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,PHASE1,metabolic_disease
1773,Psychotic Disorders,Perphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,APPROVED,metabolic_disease
1774,Hypertension|Metabolic Syndrome X,Cilnidipine,CC1=C(C(C(=C(N1)C)C(=O)OCC=CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC,APPROVED,metabolic_disease
1775,Hypercholesterolemia,Laropiprant,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F,APPROVED,metabolic_disease
1777,Hepatitis C,Elbasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC,APPROVED,metabolic_disease
1778,"Type 2 Diabetes Mellitus|Diabetes Mellitus, Type 2",Furosemide,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,PHASE1,metabolic_disease
1779,Schizophrenia; Psychosis|Metabolic Syndrome|Flupentixol|Antipsychotic Agents|Central Nervous System Diseases|Clinical Therapy|Olanzapine|Quetiapine,Flupenthixol,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,APPROVED,metabolic_disease
1780,Schizophrenia; Psychosis|Metabolic Syndrome|Flupentixol|Antipsychotic Agents|Central Nervous System Diseases|Clinical Therapy|Olanzapine|Quetiapine,Flupentixol,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,APPROVED,metabolic_disease
1781,Insulin Resistance,Triflusal,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,PHASE2,metabolic_disease
1782,Hypercholesterolemia,Nattokinase,B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,APPROVED,metabolic_disease
1783,Gout|Hyperuricemia|Arthritis|Joint Disease|Renal Insufficiency,Ulodesine,C1C(C(CN1CC2=CNC3=C2N=CNC3=O)O)CO,PHASE2,metabolic_disease
1784,Type 2 Diabetes Mellitus,Ursodiol,CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,PHASE2,metabolic_disease
1785,Amyotrophic Lateral Sclerosis,Quinidine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE1|PHASE2,metabolic_disease
1786,Acute Gouty Arthritis,Lumiracoxib,CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O,APPROVED,metabolic_disease
1787,Epilepsy|Seizures|Bipolar Disorder|Bipolar Depression,Lamotrigine,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,PHASE1|PHASE2,metabolic_disease
1788,Solid Tumor|Clear Cell Renal Cell Carcinoma|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer|CRC|RCC|ccRCC,Talazoparib,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,PHASE1|PHASE2,metabolic_disease
1789,Celiac Disease,Larazotide,CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)N1CCCC1C(=O)NCC(=O)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)CN,PHASE2,metabolic_disease
1790,Alzheimer's Disease,Bexarotene,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C,PHASE1,metabolic_disease
1791,X-Linked Adrenoleukodystrophy|Adrenomyeloneuropathy,Sobetirome,CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O,PHASE1,metabolic_disease
1792,Type 1 Diabetes Mellitus,Treprostinil,CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,PHASE1,metabolic_disease
1793,Gout|Chronic Kidney Disease (CKD),Lesinurad,C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O,APPROVED,metabolic_disease
1794,Lipid Metabolism Disorder,Lovastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE1,metabolic_disease
1795,"Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Trazodone,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,PHASE2|PHASE3,metabolic_disease
1796,Diabetes Complications|Diabetes; Nephropathy (Manifestation),Roxadustat,CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,PHASE2,metabolic_disease
1800,Gestational Diabetes Mellitus,Isoxaflutole,CS(=O)(=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C2=C(ON=C2)C3CC3,PHASE2,metabolic_disease
1801,Arterial Hypertension|Diabetes|Hypokalemia|Hyponatremia,Cicletanine,CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl,PHASE1|PHASE2,metabolic_disease
1803,"Diabetes Mellitus, Type 2",Dorzagliatin,CC(C)CC(C(=O)NC1=NN(C=C1)CC(CO)O)N2CC(=CC2=O)OC3=CC=CC=C3Cl,PHASE2,metabolic_disease
1804,Primary Hypercholesterolemia,Eprotirome,CC(C)C1=C(C=CC(=C1)OC2=C(C=C(C=C2Br)NC(=O)CC(=O)O)Br)O,PHASE2,metabolic_disease
1805,Obesity|Polycystic Ovary Syndrome,Sibutramine,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,APPROVED,metabolic_disease
1806,Type 2 Diabetes|Hypertension,Aprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,PHASE2,metabolic_disease
1807,Cancer|Pancreatic Cancer|Pancreatic Carcinoma,Gemcitabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,PHASE1|PHASE2,metabolic_disease
1809,"QTc Prolongation, Hyperglycemia, Hypoglycemia",Levofloxacin,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,APPROVED,metabolic_disease
1810,Parkinson Disease,Ropinirole,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,PHASE2,metabolic_disease
1811,Fabry Disease,Lucerastat,CCCCN1CC(C(C(C1CO)O)O)O,PHASE1,metabolic_disease
1812,Obesity|Insulin Resistance,Fenretinide,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C,PHASE2,metabolic_disease
1813,Diabetes,Apixaban,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,APPROVED,metabolic_disease
1814,Diabetes,Edoxaban,CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C,APPROVED,metabolic_disease
1815,Congenital Adrenal Hyperplasia (CAH),Fludrocortisone,CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F,APPROVED,metabolic_disease
1816,Congenital Adrenal Hyperplasia (CAH),Flutamide,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,APPROVED,metabolic_disease
1817,Friedreich Ataxia,Artesunate,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C,PHASE1|PHASE2,metabolic_disease
1818,ALS (Amyotrophic Lateral Sclerosis),Lunasine,CC(C)C1CC2=C(C3=C(C(=CC=C3)OC)[N+](=C2O1)C)OC,PHASE2,metabolic_disease
1819,Alzheimer Disease,Azeliragon,CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC,PHASE2,metabolic_disease
1820,Metabolic Acidosis,Meglumine,CNCC(C(C(C(CO)O)O)O)O,PHASE2,metabolic_disease
1821,MItochondrial Myopathies,Omaveloxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C,PHASE2,metabolic_disease
1822,Amyotrophic Lateral Sclerosis,Bosutinib,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,PHASE1|PHASE2,metabolic_disease
1823,Prostate Cancer|Metabolic Syndrome|Hypogonadism|Fatty Liver,Triptorelin,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,APPROVED,metabolic_disease
1824,Osteoporosis,Lasofoxifene,C1CCN(C1)CCOC2=CC=C(C=C2)C3C(CCC4=C3C=CC(=C4)O)C5=CC=CC=C5,PHASE2,metabolic_disease
1825,Hypertension,Trandolapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O,APPROVED,metabolic_disease
1827,Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Lobular Carcinoma|Metastatic Breast Lobular Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8,Fluciclovine,C1C(CC1(C(=O)O)N)F,PHASE1,metabolic_disease
1828,Cytomegalovirus Infections|HIV Infections|Hypocalcemia,Foscarnet,C(=O)(O)P(=O)(O)O,APPROVED,metabolic_disease
1829,Breast Cancer|Metastatic Triple-Negative Breast Cancer,Eribulin,CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O,PHASE2,metabolic_disease
1830,Type 2 Diabetes Mellitus,Fasiglifam,CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)C(CO4)CC(=O)O)C)OCCCS(=O)(=O)C,PHASE2,metabolic_disease
1831,"Acute Intermittent Porphyria (AIP)|Acute Hepatic Porphyria (AHP)|Porphyria, Acute Intermittent|Acute Porphyria",Givosiran,CC1CC(CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCOC4C(C(C(C(O4)CO)O)O)NC(=O)C)O,PHASE1,metabolic_disease
1832,HIV Infections,Enfuvirtide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(=O)N)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC7=CC=CC=C7)C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C,APPROVED,metabolic_disease
1833,Insulin Resistance|Healthy|Obesity,Phentolamine,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,PHASE1,metabolic_disease
1834,Mucopolysaccharidosis VI,Odiparcil,CC1=CC(=O)OC2=C1C=CC(=C2)OC3C(C(C(CS3)O)O)O,PHASE2,metabolic_disease
1835,Fungal Disease,Ibrexafungerp,CC(C)C(C)C1(CCC2(C3CCC4C5(COCC4(C3=CCC2(C1C(=O)O)C)CC(C5OCC(C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C,PHASE1,metabolic_disease
1836,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Didanosine,C1CC(OC1CO)N2C=NC3=C2N=CNC3=O,APPROVED,metabolic_disease
1837,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Indinavir,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,APPROVED,metabolic_disease
1838,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Amprenavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,APPROVED,metabolic_disease
1839,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Tipranavir,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,APPROVED,metabolic_disease
1840,Hypertension|Insulin Resistance,Norepinephrine,C1=CC(=C(C=C1C(CN)O)O)O,PHASE1,metabolic_disease
1841,Pre-Diabetes,Neomycin,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N,PHASE2,metabolic_disease
1842,Pre-Diabetes,Clindamycin,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,PHASE2,metabolic_disease
1843,Primary Mitochondrial Myopathy,Bocidelpar,CC1=CN=C(N1CC2=CC=CC=C2OCCCC(C)CC(=O)O)C3=CC=C(C=C3)C(F)(F)F,PHASE2|PHASE3,metabolic_disease
1844,Multiple Myeloma|Amyloidosis,Vinorelbine,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,PHASE2,metabolic_disease
1845,Cardiovascular Disease|High Cardiovascular Risk|Obesity|Overweight|Type 2 Diabetes,Lorcaserin,CC1CNCCC2=C1C=C(C=C2)Cl,APPROVED,metabolic_disease
1846,Hypertriglyceridemia|Obesity,Setmelanotide,CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5,PHASE2,metabolic_disease
1847,B-Cell Non-Hodgkin Lymphoma,Doxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,metabolic_disease
1848,B-Cell Non-Hodgkin Lymphoma,Vincristine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE2,metabolic_disease
1849,Amyloidosis,Idelalisib,CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,PHASE2,metabolic_disease
1850,Menkes Disease|Occipital Horn Syndrome,Droxidopa,C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O,PHASE1|PHASE2,metabolic_disease
1851,Recurrent Malignant Glioma,Irinotecan,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,PHASE2,metabolic_disease
1852,Dyslipidemia,Muraglitazar,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC,PHASE2|PHASE3,metabolic_disease
1853,Atherosclerosis|Heterozygous Familial Hypercholesterolemia,Pactimibe,CCCCCCCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)CC(=O)O)C,PHASE2|PHASE3,metabolic_disease
1854,Venous Thromboembolism|Deep Venous Thrombosis|Pulmonary Embolus|Reconstructive Surgery,Enoxaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2,metabolic_disease
1855,HIV Infections,Sulforaphane,CS(=O)CCCCN=C=S,APPROVED,metabolic_disease
1856,Panic Disorder,Paroxetine,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,APPROVED,metabolic_disease
1857,Amyotrophic Lateral Sclerosis,Nitrofural,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)N,PHASE2,metabolic_disease
1858,Amyotrophic Lateral Sclerosis,Nitrofurazone,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)N,PHASE2,metabolic_disease
1859,Post-menopausal Osteoporosis,Phylloquinone,CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C,PHASE2|PHASE3,metabolic_disease
1860,"Gaucher Disease, Type 1|Type 1 Gaucher Disease|Gaucher Disease",Afegostat,C1C(C(C(CN1)O)O)CO,PHASE2,metabolic_disease
1861,"Diabetes Mellitus, Type I|Diabetes Mellitus, Insulin-Dependent, 1|Type 1 Diabetes Mellitus|Insulin-Dependent Diabetes Mellitus 1|IDDM",Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,metabolic_disease
1862,Acute Gout Flare|Gout Attack|Gout Flare|Gouty Arthritis|Gout|Arthritis|Joint Pain,Dapansutrile,CS(=O)(=O)CCC#N,PHASE2|PHASE3,metabolic_disease
1863,Hyperlipidemia,Tetraethylammonium,CC[N+](CC)(CC)CC,PHASE2,metabolic_disease
1864,Hyperlipidemia,Bradykinin,C1CC(N(C1)C(=O)C2CCCN2C(=O)C(CCCN=C(N)N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CO)C(=O)N4CCCC4C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCN=C(N)N)C(=O)O,PHASE2,metabolic_disease
1866,Gout Attack,Diclofenac,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,PHASE2,metabolic_disease
1867,Amyloidosis|Immunoglobulin Light Chain Deposition,Ibrutinib,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE2,metabolic_disease
1868,Lean Body Mass|Cannabis|Cancer|Nausea|Cachexia|Emesis|Appetitive Behavior,Cannabidiol,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,PHASE1,metabolic_disease
1870,Dehydrated Hereditary Stomatocytosis,Senicapoc,C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N,PHASE1|PHASE2,metabolic_disease
1871,"Hepatic Encephalopathy|Cirrhosis, Liver",Rifamycin,CC1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,PHASE2,metabolic_disease
1872,Glucose Intolerance|Overweight and Obesity|Drug Effect|Adiposity,Cyanocobalamin,CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)[N-]6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[C-]#N.[Co+3],APPROVED,metabolic_disease
1873,MELAS Syndrome,Citrulline,C(CC(C(=O)O)N)CNC(=O)N,PHASE1,metabolic_disease
1874,Type 2 Diabetes Mellitus,Bethanechol,CC(C[N+](C)(C)C)OC(=O)N,PHASE1,metabolic_disease
1876,"Diabetes Mellitus, Type 1",Abrocitinib,CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3,PHASE2,metabolic_disease
1877,Irritable Bowel Syndrome With Diarrhea,Eluxadoline,CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N,APPROVED,metabolic_disease
1878,"Diabetes Mellitus, Insulin-Dependent",Sulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,PHASE2,metabolic_disease
1879,"Diabetes Mellitus, Insulin-Dependent",Ganciclovir,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,PHASE2,metabolic_disease
1880,"Diabetes Mellitus, Insulin-Dependent",Trimethoprim,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,PHASE2,metabolic_disease
1881,"Diabetes Mellitus, Insulin-Dependent",Pentamidine,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,PHASE2,metabolic_disease
1882,Frontotemporal Dementia,Flortaucipir,C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4,PHASE1,metabolic_disease
1883,Contraceptive Usage,Ulipristal,CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,APPROVED,metabolic_disease
1884,Infantile Neuroaxonal Dystrophy,Desipramine,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,APPROVED,metabolic_disease
1885,Hepatic Encephalopathy|Liver Cirrhosis,Flumazenil,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,PHASE1|PHASE2,metabolic_disease
1886,"Diabetes Mellitus, Type II|Periodontitis",Chlorhexidine,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,PHASE2,metabolic_disease
1887,Anti-Psychotic|Management of Manifestations of Psychotic Disorders|Treatment of Schizophrenia|Control Nausea and Vomiting|Relief of Restlessness and Apprehension Before Surgery|Acute Intermittent Porphyria|Adjunct in the Treatment of Tetanus|Control Manifestations of the Manic Type of Mani-depressive Illness|Relief of Intractable Hiccups,Chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,PHASE1,metabolic_disease
1888,Albinism,Levodopa,C1=CC(=C(C=C1CC(C(=O)O)N)O)O,PHASE2,metabolic_disease
1889,Metastatic Colorectal Cancer,Fruquintinib,CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC,PHASE1|PHASE2,digestive_system_disease
1890,Hepatitis B,Entecavir,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N,PHASE2|PHASE3,digestive_system_disease
1892,Gastric Cancer,Rivoceranib,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,PHASE2,digestive_system_disease
1893,Gastric Cancer,Oxaliplatin,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],PHASE2,digestive_system_disease
1894,Gastric Cancer,Morphine,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,APPROVED,digestive_system_disease
1895,Gastric Cancer,Ropivacaine,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,digestive_system_disease
1896,Irritable Bowel Syndrome,Eluxadoline,CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N,PHASE2,digestive_system_disease
1897,Colorectal Cancer,Erlotinib,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,PHASE1,digestive_system_disease
1899,Esophagus Cancer|Chemoradiotherapy|Oligometastatic Disease|Immunotherapy,Paclitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,PHASE2,digestive_system_disease
1900,Esophagus Cancer|Chemoradiotherapy|Oligometastatic Disease|Immunotherapy,Cisplatin,N.N.Cl[Pt]Cl,PHASE2,digestive_system_disease
1902,Prader-Willi Syndrome|Hyperphagia,Livoletide,CC(C)C1C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCC(=O)N)CC3=CN=CN3)CCC(=O)O)CO)CCC(=O)N,PHASE2|PHASE3,digestive_system_disease
1903,Esophageal Neoplasm,Tegafur,C1CC(OC1)N2C=C(C(=O)NC2=O)F,PHASE2,digestive_system_disease
1904,HIV Infection|Hepatitis C Infection,Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],PHASE2,digestive_system_disease
1905,HIV Infection|Hepatitis C Infection,Ribavirin,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,PHASE2,digestive_system_disease
1906,"Carcinoma, Hepatocellular",Meclizine,CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,PHASE1,digestive_system_disease
1907,Biliary Carcinoma,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,PHASE2,digestive_system_disease
1908,Hepatocellular Carcinoma,Sorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,PHASE2,digestive_system_disease
1909,Hepatocellular Carcinoma,Metformin,CN(C)C(=N)N=C(N)N,PHASE2,digestive_system_disease
1911,Metastatic Gastric Cancer|Locally Advanced Gastric Cancer,Leucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2,digestive_system_disease
1912,Gastrointestinal Tumors|Pancreatic Tumors|Gastrointestinal Neuroendocrine Tumors|Pancreatic Neuroendocrine Tumors,Everolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,PHASE2,digestive_system_disease
1913,Colorectal Cancer,Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,PHASE2|PHASE3,digestive_system_disease
1914,Colorectal Cancer,Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2|PHASE3,digestive_system_disease
1915,Chronic Hepatitis C,Pioglitazone,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,APPROVED,digestive_system_disease
1916,Chronic Hepatitis C,Acarbose,CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO,APPROVED,digestive_system_disease
1918,Hepatitis B,Tenofovir,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,PHASE2,digestive_system_disease
1919,Biliary Tract Cancer,Gemcitabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,PHASE1|PHASE2,digestive_system_disease
1920,Stomach Ulcer,Rebamipide,C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl,APPROVED,digestive_system_disease
1921,Carcinoma of the Oesophagus,Olaparib,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE1,digestive_system_disease
1922,Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma,Poziotinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C,PHASE2,digestive_system_disease
1924,Non-alcoholic Steatohepatitis,Atorvastatin,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,PHASE2,digestive_system_disease
1925,Non-alcoholic Steatohepatitis,Levocarnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,digestive_system_disease
1926,Non-alcoholic Steatohepatitis,Carnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,digestive_system_disease
1927,Esophagus Adenocarcinoma|Esophagus Squamous Cell Carcinoma|Gastroesophageal Junction Adenocarcinoma,Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,PHASE2,digestive_system_disease
1928,Pancreatic Neuroendocrine Tumors,Sunitinib,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,PHASE2,digestive_system_disease
1929,HCV HIV,Ledipasvir,CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,APPROVED,digestive_system_disease
1930,HCV HIV,Sofosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,APPROVED,digestive_system_disease
1932,Abdominal Pain|Inflammatory Bowel Diseases|Eosinophilic Gastroenteritis|Diarrhea|Hematochezia|Weight Loss,Ondansetron,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,APPROVED,digestive_system_disease
1933,Colonic Neoplasms,Levoleucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1|PHASE2,digestive_system_disease
1934,Liver Transplant With Clinically Significant Portal Hypertension,Somatostatin,CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)C(C)N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O,PHASE1,digestive_system_disease
1935,Hepatocellular Carcinoma (HCC),Icaritin,CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)C,PHASE2,digestive_system_disease
1936,Cystic Fibrosis|Systemic Inflammation,Simvastatin,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE1|PHASE2,digestive_system_disease
1937,Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma|Stage I Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer,Fluorouracil,C1=C(C(=O)NC(=O)N1)F,PHASE2,digestive_system_disease
1938,Pancreatic Adenocarcinoma|Resectable Pancreatic Carcinoma|Stage I Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer,Nelfinavir,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,PHASE2,digestive_system_disease
1941,Gastric Cancer|Stomach Cancer,Floxuridine,C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O,PHASE2,digestive_system_disease
1942,Crohn's Disease,Teduglutide,CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N,PHASE2,digestive_system_disease
1943,Esophageal Cancer|Gastric Cancer|Stomach Cancer,Vinorelbine,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,PHASE2,digestive_system_disease
1944,Cystic Fibrosis,Miglustat,CCCCN1CC(C(C(C1CO)O)O)O,PHASE2|PHASE3,digestive_system_disease
1945,Hepatic Encephalopathy,Lactulose,C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O,APPROVED,digestive_system_disease
1946,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,Lenvatinib,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,PHASE1,digestive_system_disease
1947,Pancreatic Cancer|Visceral Pain,Pregabalin,CC(C)CC(CC(=O)O)CN,APPROVED,digestive_system_disease
1948,Gastric Cancer|Histone Deacetylase Inhibitor,Vorinostat,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,PHASE1|PHASE2,digestive_system_disease
1949,Gastrointestinal Stromal Tumors,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,digestive_system_disease
1952,Morbid Obesity|Postoperative Pain|Postoperative Bowel Function|Postoperative Ambulation,Levobupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,PHASE2|PHASE3,digestive_system_disease
1953,Osteoporosis|Achlorhydria|GERD|Hip Fracture,Omeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,APPROVED,digestive_system_disease
1954,Bowel Dysfunction|Postoperative Complications|Neuromuscular Blockade,Sugammadex,C(CSCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(O2)C(C9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O,APPROVED,digestive_system_disease
1955,Bowel Dysfunction|Postoperative Complications|Neuromuscular Blockade,Neostigmine,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,APPROVED,digestive_system_disease
1956,Hepatocellular Carcinoma,Doxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2|PHASE3,digestive_system_disease
1957,Hepatic Impairment,Betrixaban,CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl,PHASE1,digestive_system_disease
1958,"Hepatitis, Chronic",Lamivudine,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,APPROVED,digestive_system_disease
1959,"Hepatitis, Chronic",Telbivudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,APPROVED,digestive_system_disease
1960,HIV Infections|Cachexia|Anorexia|AIDS Wasting Syndrome|HIV Wasting Syndrome,Megestrol,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,PHASE2,digestive_system_disease
1962,Colorectal Cancer,Irinotecan,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,PHASE1,digestive_system_disease
1963,Non-alcoholic Steatohepatitis|Fibrosis|Liver Diseases,Emricasan,CC(C(=O)NC(CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C,PHASE2,digestive_system_disease
1964,Colo-rectal Cancer,Pemetrexed,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2,digestive_system_disease
1965,Hepatocellular Carcinoma|Liver Cirrhoses,Pravastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O,PHASE2,digestive_system_disease
1966,Cystic Fibrosis|Pseudomonas Aeruginosa,Tobramycin,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N,PHASE2,digestive_system_disease
1967,Achalasia,Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,APPROVED,digestive_system_disease
1968,Achalasia,Oxycodone,CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,APPROVED,digestive_system_disease
1970,Advanced Hepatocellular Carcinoma,Regorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,PHASE2,digestive_system_disease
1971,Metabolic Associated Fatty Liver Disease,Dapagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,APPROVED,digestive_system_disease
1972,Hepatitis C,Telaprevir,CCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3CCCC3CN2C(=O)C(C(C)(C)C)NC(=O)C(C4CCCCC4)NC(=O)C5=NC=CN=C5,PHASE2|PHASE3,digestive_system_disease
1976,Eosinophilic Esophagitis,Budesonide,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,APPROVED,digestive_system_disease
1977,Eosinophilic Esophagitis,Fluticasone,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F,APPROVED,digestive_system_disease
1978,Breast Cancer|Lung Cancer|Colon Cancer|Pancreatic Cancer|Head and Neck Cancer|Kidney Cancer|Sarcoma|Hepatocellular Cancer,Pazopanib,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,PHASE1,digestive_system_disease
1979,Breast Cancer|Lung Cancer|Colon Cancer|Pancreatic Cancer|Head and Neck Cancer|Kidney Cancer|Sarcoma|Hepatocellular Cancer,Ixabepilone,CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C,PHASE1,digestive_system_disease
1980,Irritable Bowel Syndrome,Mesalamine,C1=CC(=C(C=C1N)C(=O)O)O,PHASE2,digestive_system_disease
1981,Irritable Bowel Syndrome,Mesalazine,C1=CC(=C(C=C1N)C(=O)O)O,PHASE2,digestive_system_disease
1983,BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Locally Advanced Hepatocellular Carcinoma|Recurrent Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma,Cabozantinib,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,PHASE2,digestive_system_disease
1984,End Stage Liver Disease,Desflurane,C(C(F)(F)F)(OC(F)F)F,APPROVED,digestive_system_disease
1985,End Stage Liver Disease,Propofol,CC(C)C1=C(C(=CC=C1)C(C)C)O,APPROVED,digestive_system_disease
1986,Clostridium Difficile,Metronidazole,CC1=NC=C(N1CCO)[N+](=O)[O-],PHASE2,digestive_system_disease
1987,Immunoglobulin G Subclass 4 Related Disease|IgG4-related Disease|Autoimmune Pancreatitis|IgG4-related Sclerosing Cholangitis|Retroperitoneal Fibrosis,Lenalidomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,PHASE1,digestive_system_disease
1989,Primary Biliary Cholangitis|Liver Stiffness,Setanaxib,CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl,PHASE2|PHASE3,digestive_system_disease
1990,Hepatic Insufficiency,Tirzepatide,CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N,PHASE1,digestive_system_disease
1991,Ulcerative Colitis|Inflammatory Bowel Diseases|Acute Severe Colitis,Ceftriaxone,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,PHASE2,digestive_system_disease
1992,Esophageal Cancer,Tricyclazole,CC1=C2C(=CC=C1)SC3=NN=CN23,PHASE2,digestive_system_disease
1993,Crohn's Disease|Crohn Disease,Cyclophosphamide,C1CNP(=O)(OC1)N(CCCl)CCCl,PHASE1|PHASE2,digestive_system_disease
1994,Chronic Hepatitis C,Colchicine,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,PHASE2,digestive_system_disease
1995,Pulmonary Aspiration of Gastric Contents|Adverse Effects in the Therapeutic Use of Other and Unspecified General Anaesthetics|Pulmonary Aspiration During Anaesthetic Induction,Glutamine,C(CC(=O)N)C(C(=O)O)N,PHASE2,digestive_system_disease
1996,HEPATITIS,Mycophenolate,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,APPROVED,digestive_system_disease
1997,HEPATITIS,Tacrolimus,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,APPROVED,digestive_system_disease
2000,Gastroesophageal Reflux Disease,Esomeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE2,digestive_system_disease
2001,Non-alcoholic Fatty Liver Disease,Tofogliflozin,CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2,APPROVED,digestive_system_disease
2002,Non-alcoholic Fatty Liver Disease,Glimepiride,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,APPROVED,digestive_system_disease
2003,Oral Mucositis (Ulcerative) Due to Radiation,Dexpanthenol,CC(C)(CO)C(C(=O)NCCCO)O,PHASE2,digestive_system_disease
2004,Nonalcoholic Steatohepatitis (NASH),Miricorilant,C1CC(CCC1C2=CC=CC=C2)C3=C(C(=O)NC(=O)N3)CC4=CC(=CC=C4)C(F)(F)F,PHASE1,digestive_system_disease
2005,Inflammatory Bowel Disease 11,Prednisone,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,APPROVED,digestive_system_disease
2006,Irritable Bowel Syndrome,Lubiprostone,CCCCC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F,PHASE1,digestive_system_disease
2008,Hepatitis C|Chronic Hepatitis C,Miravirsen,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3C4C(OC3(CO4)COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6C7C(OC6(CO7)CO)N8C=CC(=NC8=O)N)N9C=CC(=NC9=O)N)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC12COC(C1OP(=S)(O)OCC13COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC4=C(N=CN=C41)N)OP(=S)(O)OCC14COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=NC5=C(N=CN=C51)N)OP(=S)(O)OCC15COC(C1OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC16COC(C1OP(=S)(O)OCC17COC(C1O)C(O7)N1C=CC(=NC1=O)N)C(O6)N1C=CC(=NC1=O)N)C(O5)N1C=CC(=NC1=O)N)C(O4)N1C=CC(=NC1=O)N)C(O3)N1C=C(C(=O)NC1=O)C)C(O2)N1C=NC2=C1N=C(NC2=O)N,PHASE1,digestive_system_disease
2009,Gastroparesis,Buspirone,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,PHASE2,digestive_system_disease
2010,Non-Alcoholic Fatty Liver Disease|Type2 Diabetes,Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,APPROVED,digestive_system_disease
2011,Non-Alcoholic Fatty Liver Disease|Type2 Diabetes,Gliclazide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,APPROVED,digestive_system_disease
2012,Cholangiocarcinoma|Tumor|Klatskin Tumor,Temoporfin,C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=CC(=CC=C7)O)C8=CC(=CC=C8)O)C9=CC(=CC=C9)O,PHASE2,digestive_system_disease
2013,Colorectal Cancer Metastatic,Tocotrienol,CC(=CCCC(=CCCC(=CCCC1(CCC2=C(O1)C=CC(=C2)O)C)C)C)C,PHASE2,digestive_system_disease
2014,Hepatitis C Virus,Daclatasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE2,digestive_system_disease
2016,Laryngopharyngeal Reflux,Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,APPROVED,digestive_system_disease
2017,HIV Infections|Non-Alcoholic Fatty Liver Disease,Semaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,PHASE2,digestive_system_disease
2019,Metastatic Pancreatic Cancer,Rintatolimod,C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O,PHASE1|PHASE2,digestive_system_disease
2020,"Hepatitis C, Chronic",Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,APPROVED,digestive_system_disease
2021,Advanced Gastrointestinal Tumors,Minnelide,CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2OCOP(=O)([O-])[O-])O7)COC6=O)C.[Na+].[Na+],PHASE1,digestive_system_disease
2023,Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Gimatecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)C=NOC(C)(C)C)O,PHASE2,digestive_system_disease
2024,"Hepatitis B, Chronic|Fibrosis",Emtricitabine,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,APPROVED,digestive_system_disease
2025,Ulcerative Colitis|Inflammatory Bowel Disease,Rosiglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,PHASE2,digestive_system_disease
2026,Hepatocellular Carcinoma,Artesunate,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C,PHASE1,digestive_system_disease
2027,Active Peptic Ulcer Disease/GI Bleeding,Misoprostol,CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O,APPROVED,digestive_system_disease
2029,Pancreatitis,Ketorolac,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,APPROVED,digestive_system_disease
2030,Severe Hepatic Impairment,Rifaximin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,APPROVED,digestive_system_disease
2031,Advanced Cancer|Anorexia|Weight Loss|Insomnia,Mirtazapine,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,PHASE2,digestive_system_disease
2032,Stomach Neoplasms|Esophagogastric Junction Disorder|Neoadjuvant Therapy|Chemoradiotherapy|Immunotherapy|Gastrectomy|Adenocarcinoma|Adjuvant Therapy,Gimeracil,C1=C(C(=CNC1=O)Cl)O,PHASE2,digestive_system_disease
2033,Stomach Neoplasms|Esophagogastric Junction Disorder|Neoadjuvant Therapy|Chemoradiotherapy|Immunotherapy|Gastrectomy|Adenocarcinoma|Adjuvant Therapy,Oteracil,C1(=NC(=O)NC(=O)N1)C(=O)O,PHASE2,digestive_system_disease
2034,Solid Tumor|Gastrointestinal Cancer|Breast Cancer,Azacitidine,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,PHASE1|PHASE2,digestive_system_disease
2035,Gastrointestinal Neoplasms|Thromboembolic Event,Enoxaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,digestive_system_disease
2036,Prolonged Postoperative Ileus,Diatrizoate,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,PHASE2|PHASE3,digestive_system_disease
2038,Gastroesophageal Reflux Disease,Atovaquone,C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O,PHASE1,digestive_system_disease
2039,Gastroesophageal Reflux Disease,Proguanil,CC(C)N=C(N)N=C(N)NC1=CC=C(C=C1)Cl,PHASE1,digestive_system_disease
2040,Gastroesophageal Reflux Disease,Tegoprazan,CC1=NC2=C(N1)C=C(C=C2OC3CCOC4=C3C(=CC(=C4)F)F)C(=O)N(C)C,PHASE1,digestive_system_disease
2041,Gastroesophageal Reflux Disease,Vonoprazan,CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3,PHASE1,digestive_system_disease
2042,Esophageal Stenosis|Anastomotic Stenosis,Mitomycin,CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N,PHASE2,digestive_system_disease
2043,Esophageal Stenosis|Anastomotic Stenosis,Mitomycin C,CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N,PHASE2,digestive_system_disease
2044,Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Cancer,Topotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,PHASE1|PHASE2,digestive_system_disease
2045,Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Cancer,Gefitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,PHASE1|PHASE2,digestive_system_disease
2046,Cystic Fibrosis,Lucinactant,CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)O)NC(=O)C(CCCCN)N.CC(=O)O,PHASE2,digestive_system_disease
2047,"Hepatitis B, Chronic",Adefovir,C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N,APPROVED,digestive_system_disease
2048,Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer,Cobimetinib,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,PHASE2,digestive_system_disease
2051,Pancreatic Cancer,Vatalanib,C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4,PHASE1|PHASE2,digestive_system_disease
2052,Gastric Cancer,Docetaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,PHASE2,digestive_system_disease
2053,Neuroendocrine|Neuroendocrine Tumor|Neuroendocrine Cancer|Neuroendocrine Carcinoma|Carcinoid|Carcinoid Tumor|Islet Cell Tumor|Apudoma,Dotatate,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O,PHASE1|PHASE2,digestive_system_disease
2054,Peritoneal Dialysis Associated Peritonitis,Cefepime,C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-],APPROVED,digestive_system_disease
2055,Peritoneal Dialysis Associated Peritonitis,Cefazolin,CC1=NN=C(S1)SCC2=C(N3C(C(C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O,APPROVED,digestive_system_disease
2056,Peritoneal Dialysis Associated Peritonitis,Ceftazidime,CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-],APPROVED,digestive_system_disease
2057,Pancreatic Cancer|Unresectable Pancreatic Cancer|Metastatic Pancreatic Cancer|KRAS P.G12C,Sotorasib,CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,PHASE1|PHASE2,digestive_system_disease
2058,Pancreas Cancer,Lurbinectedin,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O,PHASE2,digestive_system_disease
2059,Cirrhosis,Ramelteon,CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3,APPROVED,digestive_system_disease
2060,Gastrointestinal Cancer,Pemigatinib,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,PHASE2,digestive_system_disease
2063,Liver Cirrhosis|Portal Hypertension|Anticoagulant-induced Bleeding|Thrombosis,Rivaroxaban,C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl,PHASE1|PHASE2,digestive_system_disease
2064,GIST,Vandetanib,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,PHASE2,digestive_system_disease
2065,Achalasia,Olinciguat,C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NCC(C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F,PHASE2,digestive_system_disease
2068,GIST,Ponatinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,PHASE2,digestive_system_disease
2069,Acute Appendicitis,Ertapenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O,PHASE2,digestive_system_disease
2070,Acute Appendicitis,Levofloxacin,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,PHASE2,digestive_system_disease
2072,"Ischemic Reperfusion Injury|Insufficiency; Hepatic, Postoperative|Liver Tumour",Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,PHASE2,digestive_system_disease
2074,Hepatitis C|HIV,Atazanavir,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,PHASE1,digestive_system_disease
2075,Hepatitis C|HIV,Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,PHASE1,digestive_system_disease
2076,Hepatitis C|HIV,Cobicistat,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,PHASE1,digestive_system_disease
2077,Colorectal Cancer|Pancreas Cancer,Dovitinib,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,PHASE2,digestive_system_disease
2078,Bowel Disease,Bupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,digestive_system_disease
2079,Metastatic Pancreatic Carcinoma|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma,Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,PHASE1,digestive_system_disease
2080,Metastatic Pancreatic Carcinoma|Stage II Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma,Trametinib,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,PHASE1,digestive_system_disease
2081,Hepatocellular Carcinoma,Thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,PHASE1|PHASE2,digestive_system_disease
2082,Esophageal Varices,Octreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,APPROVED,digestive_system_disease
2085,Non-alcoholic Fatty Liver Disease,Mitoquinone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2,digestive_system_disease
2086,Gastritis,Nizatidine,CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C,APPROVED,digestive_system_disease
2087,Colorectal Cancer,Romidepsin,CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,PHASE1,digestive_system_disease
2089,Pouchitis,Ciprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,APPROVED,digestive_system_disease
2090,Esophageal Squamous Cell Carcinoma,Carboplatin,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],PHASE1|PHASE2,digestive_system_disease
2091,Liver Diseases|Hepatic Insufficiency,Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE1,digestive_system_disease
2093,"Non-Alcoholic Fatty Liver Disease|Obesity|Obesity, Abdominal|Liver Fat|Fatty Liver",Tesamorelin,CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N,PHASE2,digestive_system_disease
2095,Hepatitis C Virus,Rosuvastatin,CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,PHASE1,digestive_system_disease
2096,Hepatitis C Virus,Digoxin,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,PHASE1,digestive_system_disease
2097,Stress Urinary Incontinence|Fecal Incontinence,Citalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,PHASE1,digestive_system_disease
2098,Stress Urinary Incontinence|Fecal Incontinence,Reboxetine,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,PHASE1,digestive_system_disease
2099,Hepatitits C,Simeprevir,CC1=C(C=CC2=C1N=C(C=C2OC3CC4C(C3)C(=O)N(CCCCC=CC5CC5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC,PHASE2,digestive_system_disease
2100,Ulcerative Colitis|Inflammatory Bowel Diseases,Psyllium,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,PHASE2,digestive_system_disease
2101,Hepatitis C,Ombitasvir,CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE1,digestive_system_disease
2102,Hepatitis C,Paritaprevir,CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8,PHASE1,digestive_system_disease
2103,Gastric Cancer,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,PHASE2,digestive_system_disease
2104,Hepatitis C|HCV|HIV|AIDS,Efavirenz,C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,PHASE1,digestive_system_disease
2105,Healthy|Hepatic Insufficiency,Canagliflozin,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,PHASE1,digestive_system_disease
2106,Primary Biliary Cirrhosis,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,PHASE2,digestive_system_disease
2107,"Hepatitis B, Chronic",Thymalfasin,CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C,PHASE1|PHASE2,digestive_system_disease
2108,"Cirrhosis, Liver|Ascites Hepatic",Ularitide,CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C3CCCN3C(=O)C(C)NC(=O)C(C(C)O)N)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC5=CC=C(C=C5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C,PHASE2,digestive_system_disease
2109,Barrett's Esophagus,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,APPROVED,digestive_system_disease
2110,Barrett's Esophagus,Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,APPROVED,digestive_system_disease
2111,Hepatic Insufficiency,Nintedanib,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,PHASE1,digestive_system_disease
2113,NAFLD|PCOS,Bicalutamide,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,PHASE1,digestive_system_disease
2114,Liver Abscess,Moxifloxacin,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,APPROVED,digestive_system_disease
2115,Gastric Cancer,Anlotinib,CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,PHASE1|PHASE2,digestive_system_disease
2116,Non Small-cell Lung Cancer|Renal-cell Cancer|Gastrointestinal Stroma Tumor,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,APPROVED,digestive_system_disease
2117,Thrombocytopenia,Avatrombopag,C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl,PHASE2,digestive_system_disease
2118,Pancreatectomy for Chronic Pancreatitis,Reparixin,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C,PHASE2|PHASE3,digestive_system_disease
2120,Colorectal Neoplasms,Levocetirizine,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,PHASE2,digestive_system_disease
2121,"Hepatitis C, Chronic",Silibinin,COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O,PHASE2|PHASE3,digestive_system_disease
2122,Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin,Rabeprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,PHASE2|PHASE3,digestive_system_disease
2123,Esophagitis,Pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,PHASE2,digestive_system_disease
2125,Crohn Disease,Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,APPROVED,digestive_system_disease
2126,NASH - Nonalcoholic Steatohepatitis,Namodenoson,CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O,PHASE2,digestive_system_disease
2127,"Hepatitis D, Chronic",Ezetimibe,C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O,PHASE2,digestive_system_disease
2128,"Hepatitis B, Chronic",Hydronidone,CC1=CN(C(=O)C=C1)C2=CC=C(C=C2)O,PHASE2,digestive_system_disease
2129,Primary Sclerosing Cholangitis,Elafibranor,CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)C=CC(=O)C2=CC=C(C=C2)SC,PHASE2,digestive_system_disease
2131,Crohn's Disease,Semapimod,CC(=NN=C(N)N)C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(=NN=C(N)N)C)C(=NN=C(N)N)C)C(=NN=C(N)N)C,PHASE2,digestive_system_disease
2132,"Liver Cirrhosis, Biliary",Ursodiol,CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,PHASE2,digestive_system_disease
2134,Hepatitis C,Grazoprevir,CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1,PHASE2,digestive_system_disease
2135,Hepatitis C,Elbasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC,PHASE2,digestive_system_disease
2136,Colorectal Cancer|Pancreatic Cancer|Metastatic Cancer|Advanced Cancer,Pexidartinib,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F,PHASE1,digestive_system_disease
2137,"Hepatitis C Virus Infection, Response to Therapy of|Human Immunodeficiency Virus",Velpatasvir,CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC,APPROVED,digestive_system_disease
2138,Hepatitis C Viral Infection|Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 4,Faldaprevir,CC(C)C(=O)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3Br)OC)C(=C2)OC4CC(N(C4)C(=O)C(C(C)(C)C)NC(=O)OC5CCCC5)C(=O)NC6(CC6C=C)C(=O)O,PHASE2,digestive_system_disease
2139,"Hepatitis C, Chronic",Sovaprevir,CC(C)(C)C(CC(=O)N1CCCCC1)C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7,PHASE2,digestive_system_disease
2140,Wilson Disease,Bupropion,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,PHASE1,digestive_system_disease
2141,Hepatitis C,Mericitabine,CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)(C)F)OC(=O)C(C)C,PHASE2,digestive_system_disease
2142,ColoRectal Cancer,Raltitrexed,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,PHASE2,digestive_system_disease
2143,Common Cold,Acetaminophen,CC(=O)NC1=CC=C(C=C1)O,PHASE1,digestive_system_disease
2144,Common Cold,Dextromethorphan,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,PHASE1,digestive_system_disease
2145,Common Cold,Phenylephrine,CNCC(C1=CC(=CC=C1)O)O,PHASE1,digestive_system_disease
2146,Advanced Hepatocellular Carcinoma,Mitoxantrone,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,PHASE1,digestive_system_disease
2147,Esophageal Squamous Cell Carcinoma|Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma,Epacadostat,C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F,PHASE2,digestive_system_disease
2148,Hemorrhoids,Iferanserin,CN1CCCCC1CCC2=CC=CC=C2NC(=O)C=CC3=CC=CC=C3,PHASE2,digestive_system_disease
2149,Ulcerative Colitis,Etrasimod,C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F,PHASE2,digestive_system_disease
2150,"Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma",Tucidinostat,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,PHASE2,digestive_system_disease
2151,Familial Adenomatous Polyposis|Duodenal Neoplasms|Duodenal Polyps,Celecoxib,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,PHASE2|PHASE3,digestive_system_disease
2152,Gastrointestinal Stromal Tumors,Temozolomide,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,PHASE2,digestive_system_disease
2153,Advanced Hepatocellular Carcinoma,Enzalutamide,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,PHASE2,digestive_system_disease
2154,Portal Hypertension,Alverine,CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2,PHASE2,digestive_system_disease
2155,Hepatitis C,Asunaprevir,CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C,PHASE1,digestive_system_disease
2157,Liver Fibrosis|Chronic Liver Disease,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,PHASE2,digestive_system_disease
2158,Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD),Ipragliflozin,C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F,APPROVED,digestive_system_disease
2160,Metastatic Colorectal Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Carcinoma|Refractory Colorectal Carcinoma|Refractory Lung Small Cell Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Pancreatic Carcinoma|Stage III Colorectal Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Colorectal Carcinoma|Unresectable Lung Small Cell Carcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Pancreatic Carcinoma,Berzosertib,CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N,PHASE1,digestive_system_disease
2161,Pancreatic Cancer,Paricalcitol,CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C,PHASE1,digestive_system_disease
2162,Cystic Fibrosis,Ivacaftor,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,PHASE2,digestive_system_disease
2163,Colorectal Cancer,Trifluridine,C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,PHASE2,digestive_system_disease
2164,Colorectal Cancer,Tipiracil,C1CC(=N)N(C1)CC2=C(C(=O)NC(=O)N2)Cl,PHASE2,digestive_system_disease
2165,Gastritis|Dyspepsia|Helicobacter Pylori Infection|Gastric Cancer|Peptic Ulcer,Amoxicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,APPROVED,digestive_system_disease
2166,Gastritis|Dyspepsia|Helicobacter Pylori Infection|Gastric Cancer|Peptic Ulcer,Tetracycline,CC1(C2CC3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,APPROVED,digestive_system_disease
2167,Gastritis|Dyspepsia|Helicobacter Pylori Infection|Gastric Cancer|Peptic Ulcer,Furazolidone,C1COC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-],APPROVED,digestive_system_disease
2168,Gastro Oesophageal Cancer,Epirubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,digestive_system_disease
2169,"Short Bowel Syndrome|Infection, Bacterial",Ofloxacin,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,PHASE1,digestive_system_disease
2170,"Short Bowel Syndrome|Infection, Bacterial",Sulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,PHASE1,digestive_system_disease
2171,Hepatitis D,Lonafarnib,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,PHASE2,digestive_system_disease
2172,Colorectal Carcinoma,Doxycycline,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,PHASE2,digestive_system_disease
2173,Wilson Disease,Tetrathiomolybdate,[SH-].[SH-].S=[Mo]=S,PHASE2,digestive_system_disease
2174,Hepatic Impairment,Pimodivir,C1CC2CCC1C(C2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O,PHASE1,digestive_system_disease
2175,Chronic Hepatitis C,Vaniprevir,CCC1CC1(C(=O)NS(=O)(=O)C2CC2)NC(=O)C3CC4CN3C(=O)C(NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C,PHASE1,digestive_system_disease
2176,Non-alcoholic Fatty Liver Disease,Sitagliptin,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,APPROVED,digestive_system_disease
2177,Hepatitis C|Telaprevir|HIV,Darunavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,PHASE1,digestive_system_disease
2178,Hepatitis C|Telaprevir|HIV,Fosamprenavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N,PHASE1,digestive_system_disease
2179,Insulin Resistance|Hyperinsulinemia|Dyslipidemias,Alpelisib,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,PHASE1,digestive_system_disease
2180,Esophageal Squamous Cell Carcinoma,Endostar,CN(CC(=O)C1=CC=CC=C1)N=O,PHASE2,digestive_system_disease
2181,Esophageal Squamous Cell Carcinoma,Icotinib,C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4,PHASE2,digestive_system_disease
2182,NAFLD - Nonalcoholic Fatty Liver Disease|Type2 Diabetes,Empagliflozin,C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,APPROVED,digestive_system_disease
2183,Primary Biliary Cirrhosis,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,PHASE2,digestive_system_disease
2184,"Portopulmonary Hypertension|Pulmonary Hypertension|Cirrhosis, Liver",Ambrisentan,CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,APPROVED,digestive_system_disease
2185,"Portopulmonary Hypertension|Pulmonary Hypertension|Cirrhosis, Liver",Tadalafil,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,APPROVED,digestive_system_disease
2186,Primary Sclerosing Cholangitis,Cenicriviroc,CCCCOCCOC1=CC=C(C=C1)C2=CC3=C(C=C2)N(CCCC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)CC5=CN=CN5CCC)CC(C)C,PHASE2,digestive_system_disease
2187,Fatty Liver Disease|Fatty Liver,Itopride,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC,PHASE2,digestive_system_disease
2188,Hepatitis C|Addict Heroin,Glecaprevir,CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C,APPROVED,digestive_system_disease
2189,Chronic Hepatitis B,Selgantolimod,CCCCC(C)(CO)NC1=NC(=NC2=C1N=CC(=C2)F)N,PHASE2,digestive_system_disease
2190,Malignant Female Reproductive System Neoplasm|Recurrent Cervical Carcinoma|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Vaginal Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IV Vaginal Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVA Vaginal Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Stage IVB Vaginal Cancer AJCC v8,Talazoparib,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,PHASE1,digestive_system_disease
2191,Immune-Mediated Colitis,Tofacitinib,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,PHASE2,digestive_system_disease
2192,GastroEsophageal Cancer,Lapatinib,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,PHASE2,digestive_system_disease
2193,"Mucosal Inflammation|Contraceptive; Complications, Intrauterine",Etonogestrel,CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,digestive_system_disease
2194,"Mucosal Inflammation|Contraceptive; Complications, Intrauterine",Levonorgestrel,CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,digestive_system_disease
2195,Crohn Disease,Vancomycin,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,PHASE2,digestive_system_disease
2196,Crohn Disease,Neomycin,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N,PHASE2,digestive_system_disease
2197,Crohn Disease,Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,PHASE2,digestive_system_disease
2199,Colorectal Cancer Metastatic|C-met Overexpression,Tivantinib,C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,PHASE2,digestive_system_disease
2200,Pancreatic Cancer,Niraparib,C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N,PHASE2,digestive_system_disease
2201,Cystic Fibrosis,Cavosonstat,C1=CC(=C(C=C1C(=O)O)Cl)C2=NC3=C(C=C2)C=C(C=C3)O,PHASE2,digestive_system_disease
2202,Chemotherapeutic Agent Toxicity|Head and Neck Cancer|Mucositis|Radiation Toxicity|Xerostomia,Amifostine,C(CN)CNCCSP(=O)(O)O,PHASE2,digestive_system_disease
2204,Non-Alcoholic Fatty Liver Disease,Cholecalciferol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2,digestive_system_disease
2205,Metastatic Colorectal Cancer,Napabucasin,CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O,PHASE1|PHASE2,digestive_system_disease
2206,Colorectal Cancer|Metastatic Cancer,Binimetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,PHASE2,digestive_system_disease
2207,HCV Infection,Norgestimate,CCC12CCC3C(C1CCC2(C#C)OC(=O)C)CCC4=CC(=NO)CCC34,PHASE1,digestive_system_disease
2208,Neoplasm,Erdafitinib,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,PHASE2,digestive_system_disease
2210,Irritable Bowel Syndrome,Vibegron,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O,PHASE2,digestive_system_disease
2211,Pancreatic Cancer,Ruxolitinib,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,digestive_system_disease
2212,Hepatic Impairment,Aramchol,CCCCCCCCCCCCCCCCCCCC(=O)NC1CCC2(C(C1)CC(C3C2CC(C4(C3CCC4C(C)CCC(=O)O)C)O)O)C,PHASE1,digestive_system_disease
2213,Opioid-Induced Disorders|Esophagus Disorder,Naloxegol,COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O,PHASE2,digestive_system_disease
2214,Hepatic Impairment,Deferasirox,C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O,PHASE1,digestive_system_disease
2215,Postoperative Ileus|Ileus,Simethicone,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,APPROVED,digestive_system_disease
2216,Postoperative Nausea and Vomiting|Post Operative Pain|Emergence Delirium,Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE1,digestive_system_disease
2217,Postoperative Nausea and Vomiting|Post Operative Pain|Emergence Delirium,Dexmedetomidine,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,PHASE1,digestive_system_disease
2218,Eosinophilic Esophagitis,Mometasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C,PHASE2,digestive_system_disease
2219,Cirrhosis|Portal Hypertension|Variceal Hemorrhage,Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,PHASE2|PHASE3,digestive_system_disease
2220,ADVANCED HEPATOCELLULAR CARCINOMA (HCC),Galunisertib,CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N,PHASE1,digestive_system_disease
2221,"Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Polycystic Kidney, Autosomal Dominant",Lanreotide,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,PHASE2|PHASE3,digestive_system_disease
2223,Advanced Malignant Solid Neoplasm|Hodgkin Lymphoma|Metastatic Malignant Neoplasm|Metastatic Malignant Solid Neoplasm|Non-Hodgkin Lymphoma|Stage III Breast Cancer AJCC v7|Stage III Colon Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colon Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colon Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Triple-Negative Breast Carcinoma|Unresectable Malignant Neoplasm|Unresectable Solid Neoplasm,Veliparib,CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N,PHASE1,digestive_system_disease
2224,Appendicitis Acute,Epinephrine,CNCC(C1=CC(=C(C=C1)O)O)O,PHASE2,digestive_system_disease
2225,Gastroesophageal Reflux Disease,Dexlansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,APPROVED,digestive_system_disease
2226,Gastrointestinal Cancer,Nilotinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,digestive_system_disease
2227,Sarcoma|Melanoma|Squamous Cell Carcinoma of Head and Neck|Breast Neoplasms|Uterine Cervical Neoplasms|Vulvar Neoplasms|Penile Neoplasms|Anus Neoplasms,Ganciclovir,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,PHASE1,digestive_system_disease
2228,Hepatic Impairment,Saroglitazar,CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O,PHASE1,digestive_system_disease
2229,Postoperative Ileus|Bladder Cancer,Prucalopride,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl,PHASE2,digestive_system_disease
2230,Cirrhosis,Imipenem,CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O,APPROVED,digestive_system_disease
2231,Cirrhosis,Cefotaxime,CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,APPROVED,digestive_system_disease
2232,Cryptosporidiosis,Clofazimine,CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl,PHASE2,digestive_system_disease
2233,Gastric Cancer,Telatinib,CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl,PHASE2,digestive_system_disease
2235,Advanced or Metastatic Gastric Cancer|Advanced or Metastatic Liver Cancer|Advanced or Metastatic CRC|Advanced or Metastatic Non Squamous NSCLC,Tromethamine,C(C(CO)(CO)N)O,PHASE1,digestive_system_disease
2237,Malignant Solid Neoplasm|Ovarian Low Grade Serous Adenocarcinoma|Pancreatic Carcinoma|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8,Palbociclib,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,PHASE2,digestive_system_disease
2238,Bone Marrow Failure Syndrome|Congenital Amegakaryocytic Thrombocytopenia|Congenital Pure Red Cell Aplasia|Hereditary Sideroblastic Anemia|Myeloid Neoplasms With Germline GATA2 Mutation|Paroxysmal Nocturnal Hemoglobinuria|Shwachman-Diamond Syndrome,Treosulfan,CS(=O)(=O)OCC(C(COS(=O)(=O)C)O)O,PHASE2,digestive_system_disease
2239,Bone Marrow Failure Syndrome|Congenital Amegakaryocytic Thrombocytopenia|Congenital Pure Red Cell Aplasia|Hereditary Sideroblastic Anemia|Myeloid Neoplasms With Germline GATA2 Mutation|Paroxysmal Nocturnal Hemoglobinuria|Shwachman-Diamond Syndrome,Fludarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,PHASE2,digestive_system_disease
2240,Hepatitis C,Samatasvir,CC(C)C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C=C3)C4=CSC5=C4SC=C5C6=CC=C(C=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)NC(=O)OC,PHASE1,digestive_system_disease
2241,Gastroesophageal Reflux Disease|Heartburn,Amiloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,PHASE1,digestive_system_disease
2242,"Carcinoma, Hepatocellular",Axitinib,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4,PHASE1,digestive_system_disease
2243,Fatty Liver|Hepatitis,Orlistat,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,APPROVED,digestive_system_disease
2244,Non-alcoholic Steatohepatitis,Mebrofenin,CC1=CC(=C(C(=C1NC(=O)CN(CC(=O)O)CC(=O)O)C)Br)C,PHASE1,digestive_system_disease
2245,Preterm Infant|Feeding Intolerance|Necrotizing Enterocolitis,Melatonin,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,APPROVED,digestive_system_disease
2246,"Hepatitis C, Chronic",Taribavirin,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=N)N,PHASE2,digestive_system_disease
2247,Peptic Ulcers,Naproxen,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,APPROVED,digestive_system_disease
2248,"Non-Alcoholic Fatty Liver Disease|Diabetes Mellitus, Type 2",Levothyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,PHASE2,digestive_system_disease
2249,Hepatic Impairment,Istradefylline,CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C,PHASE1,digestive_system_disease
2250,Adenomatous Polyposis Coli,Sulindac,CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,PHASE2,digestive_system_disease
2251,Esophageal Carcinoma|Neoadjuvant Immunotherapy,Nedaplatin,C(C(=O)O)O.N.N.[Pt],PHASE1|PHASE2,digestive_system_disease
2252,Oral Mucositis Due to Chemotherapy,Miconazole,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,PHASE2,digestive_system_disease
2255,Spinal Cord Injury|Neurogenic Bowel,Glycopyrrolate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],PHASE1,digestive_system_disease
2256,"Hepatitis C, Chronic|Fibrosis",Prazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,PHASE2,digestive_system_disease
2257,Hepatitis C Virus,Dasabuvir,CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O,APPROVED,digestive_system_disease
2258,Non-alcoholic Fatty Liver Disease,Rifampin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,APPROVED,digestive_system_disease
2259,Non-alcoholic Fatty Liver Disease,Rifampicin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,APPROVED,digestive_system_disease
2260,Fecal Incontinence,Loperamide,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2|PHASE3,digestive_system_disease
2261,Cirrhosis|Portal Hypertension,Spironolactone,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,APPROVED,digestive_system_disease
2262,Hepatopulmonary Syndrome,Norfloxacin,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,PHASE2,digestive_system_disease
2263,Variceal Bleeding|Cirrhosis,Nadolol,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,APPROVED,digestive_system_disease
2264,Pancreatic Neoplasms,Surufatinib,CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,PHASE2,digestive_system_disease
2265,Pancreas Cancer,Vemurafenib,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,PHASE2,digestive_system_disease
2268,Colorectal Cancer,Idasanutlin,CC(C)(C)CC1C(C(C(N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F,PHASE1|PHASE2,digestive_system_disease
2270,Metastatic Colorectal Adenocarcinoma|Metastatic Pancreatic Ductal Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,Imiquimod,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,PHASE1,digestive_system_disease
2272,ERCP|Pancreatitis,Valdecoxib,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,PHASE2|PHASE3,digestive_system_disease
2273,Cystic Fibrosis,Aztreonam,CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N,PHASE2,digestive_system_disease
2274,Nonalcoholic Fatty Liver|Nonalcoholic Steatohepatitis,Elobixibat,CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)C1)OCC(=O)NC(C3=CC=CC=C3)C(=O)NCC(=O)O)SC)C4=CC=CC=C4)CCCC,PHASE2,digestive_system_disease
2276,"Hemorrhoids, Internal",Polidocanol,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,PHASE2,digestive_system_disease
2277,Mucositis,Triamcinolone,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,PHASE1|PHASE2,digestive_system_disease
2278,Hepatic Impairment|Normal Hepatic Function,Esketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE1,digestive_system_disease
2279,Type 2 Diabetes|Non-alcoholic Fatty Liver Disease,Lobeglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC,APPROVED,digestive_system_disease
2280,Brain Cancer,Palonosetron,C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5,PHASE2,digestive_system_disease
2281,Short Bowel Syndrome|Anticoagulation,Apixaban,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,APPROVED,digestive_system_disease
2282,Metastatic Colorectal Cancer|MSS,Maraviroc,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,PHASE1,digestive_system_disease
2284,"Melanoma|Solid Tumor|CRAF Gene Amplification|RAF1 Gene Amplification|BRAF Gene Fusion|BRAF Fusion|CRAF Gene Fusion|CRAF Fusion|RAF1 Gene Fusion|RAF1 Fusion|Thyroid Cancer, Papillary|Spitzoid Melanoma|Pilocytic Astrocytoma|Pilocytic Astrocytoma, Adult|Non Small Cell Lung Cancer|Non-Small Cell Adenocarcinoma|Colorectal Cancer|Pancreatic Acinar Carcinoma|Spitzoid Malignant Melanoma|Bladder Cancer|Bladder Urothelial Carcinoma|MAP Kinase Family Gene Mutation|RAS Mutation|RAF Mutation|MEK Mutation",Tovorafenib,CC(C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl,PHASE1|PHASE2,digestive_system_disease
2285,"Melanoma|Solid Tumor|CRAF Gene Amplification|RAF1 Gene Amplification|BRAF Gene Fusion|BRAF Fusion|CRAF Gene Fusion|CRAF Fusion|RAF1 Gene Fusion|RAF1 Fusion|Thyroid Cancer, Papillary|Spitzoid Melanoma|Pilocytic Astrocytoma|Pilocytic Astrocytoma, Adult|Non Small Cell Lung Cancer|Non-Small Cell Adenocarcinoma|Colorectal Cancer|Pancreatic Acinar Carcinoma|Spitzoid Malignant Melanoma|Bladder Cancer|Bladder Urothelial Carcinoma|MAP Kinase Family Gene Mutation|RAS Mutation|RAF Mutation|MEK Mutation",Pimasertib,C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NCC(CO)O,PHASE1|PHASE2,digestive_system_disease
2287,NAFLD - Nonalcoholic Fatty Liver Disease,Losartan,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,PHASE2,digestive_system_disease
2288,Bile Acid Malabsorption|Chronic Diarrhea,Colesevelam,CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-],APPROVED,digestive_system_disease
2289,Hypertension,Aliskiren,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,APPROVED,digestive_system_disease
2290,Hypertension,Ramipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O,APPROVED,digestive_system_disease
2292,HCV Infection,Voxilaprevir,CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C,PHASE1,digestive_system_disease
2293,Irritable Bowel Syndrome Characterized by Constipation,Linaclotide,CC1C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)CNC(=O)C(NC2=O)C(C)O)C(=O)NC(CC4=CC=C(C=C4)O)C(=O)O)C(=O)NC(CSSCC(C(=O)N3)N)C(=O)NC(C(=O)N5CCCC5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O,APPROVED,digestive_system_disease
2295,"Hepatitis C, Chronic|HIV",Boceprevir,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,APPROVED,digestive_system_disease
2296,Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney,Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,digestive_system_disease
2297,Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney,Leuprorelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,digestive_system_disease
2298,Colorectal Neoplasms,Vicriviroc,CC1CN(CCN1C(COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C,PHASE2,digestive_system_disease
2299,Chronic Hepatitis B,Clevudine,CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)F,APPROVED,digestive_system_disease
2300,"Carcinoma, Hepatocellular",Idarubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,PHASE2,digestive_system_disease
2302,Hepatitis C,Uprifosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)Cl)O)OC3=CC=CC=C3,PHASE2,digestive_system_disease
2303,Hepatitis C,Ruzasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C(=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)F)C9=CN=C(S9)C1CC1)NC(=O)OC,PHASE2,digestive_system_disease
2304,Crohn's Disease,Promethazine,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,PHASE2,digestive_system_disease
2305,Gastric Cancer,Varlitinib,CC1COC(=N1)NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=NC=CS5)Cl,PHASE2|PHASE3,digestive_system_disease
2306,"Hepatitis C, Chronic",Tegobuvir,C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F,PHASE2,digestive_system_disease
2308,Biliary Atresia,Maralixibat,CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC,PHASE2,digestive_system_disease
2309,"Hepatitis C, Chronic|Hepacivirus",Narlaprevir,CCCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3C(C3(C)C)CN2C(=O)C(C(C)(C)C)NC(=O)NC4(CCCCC4)CS(=O)(=O)C(C)(C)C,PHASE2|PHASE3,digestive_system_disease
2310,Colorectal Cancer|Chemotherapy Effect|Surgery|Metastasis|Survival,Lobaplatin,CC(C(=O)[O-])[O-].C1CC(C1CN)CN.[Pt+4],PHASE2,digestive_system_disease
2311,Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor,Copanlisib,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5,PHASE2,digestive_system_disease
2313,Liver Disease,Sirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,APPROVED,digestive_system_disease
2315,Metastatic Colon Adenocarcinoma|Metastatic Colorectal Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8,Tucatinib,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,PHASE2,digestive_system_disease
2316,Gastrointestinal Neoplasms,Ulixertinib,CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl,PHASE1,digestive_system_disease
2318,Reflux Oesophagitis,Ranitidine,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,PHASE1,digestive_system_disease
2319,Hepatocellular Carcinoma,Chiauranib,COC1=CC2=NC=CC(=C2C=C1)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=CC=C5N,PHASE1|PHASE2,digestive_system_disease
2320,Levator Ani Syndrome,Diazepam,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,APPROVED,digestive_system_disease
2321,Pancreatic Cancer,Rubitecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O,PHASE2|PHASE3,digestive_system_disease
2322,Hepatic Impairment,Tivozanib,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,PHASE1,digestive_system_disease
2323,Gastroesophageal Reflux,Fexofenadine,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,PHASE2,digestive_system_disease
2324,Pancreas Cancer,Bleomycin,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,PHASE1,digestive_system_disease
2325,Colorectal Cancer Metastatic,Masitinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,PHASE2|PHASE3,digestive_system_disease
2326,Crohn Disease|Ulcerative Colitis,Deucravacitinib,CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4,PHASE2,digestive_system_disease
2327,"Renal Insufficiency, Chronic|Hepatic Insufficiency|Healthy",Diclofenac,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,PHASE1,digestive_system_disease
2328,Mesothelioma|Adenocarcinoma of Lung|Pancreatic Neoplasms,Pentostatin,C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O,PHASE1|PHASE2,digestive_system_disease
2329,"Hepatitis C, Chronic",Odalasvir,CC(C)C(C(=O)N1C2CCCCC2CC1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)C1CC2CCCCC2N1C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE2,digestive_system_disease
2330,Gastroparesis|Diabetes Mellitus,Cisapride,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,APPROVED,digestive_system_disease
2331,Pediatric Ulcerative Colitis,Vamorolone,CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1(C(=O)CO)O)C)C,PHASE1|PHASE2,digestive_system_disease
2332,Metastatic Pancreatic Adenocarcinoma|Refractory Malignant Solid Neoplasm|Stage IV Pancreatic Cancer AJCC v8,Disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,PHASE1,digestive_system_disease
2334,"Cystic Fibrosis|Osteoporosis|Bone Diseases, Metabolic",Alendronate,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,APPROVED,digestive_system_disease
2336,Hepatocellular Carcinoma,Orantinib,CC1=C(NC(=C1CCC(=O)O)C)C=C2C3=CC=CC=C3NC2=O,PHASE1|PHASE2,digestive_system_disease
2337,"Colitis, Ulcerative",Tetomilast,CCOC1=C(C=C(C=C1)C2=NC(=CS2)C3=NC(=CC=C3)C(=O)O)OCC,PHASE2,digestive_system_disease
2338,Lung Cancer|Esophageal Cancer|Mesothelioma|Gastrointestinal Neoplasms|Breast Cancer,Plicamycin,CC1C(C(CC(O1)OC2CC(OC(C2O)C)OC3=CC4=CC5=C(C(=O)C(C(C5)C(C(=O)C(C(C)O)O)OC)OC6CC(C(C(O6)C)O)OC7CC(C(C(O7)C)O)OC8CC(C(C(O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O,PHASE2,digestive_system_disease
2339,Hepatocellular Carcinoma,Perflutren,C(C(F)(F)F)(C(F)(F)F)(F)F,PHASE1,digestive_system_disease
2340,"Hypertension, Portal",Perflubutane,C(C(C(F)(F)F)(F)F)(C(F)(F)F)(F)F,PHASE2,digestive_system_disease
2341,Adult Glioblastoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Cancer|Solid Neoplasm|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7,Sapanisertib,CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,PHASE1,digestive_system_disease
2342,"Hepatorenal Syndrome|Cirrhosis|Kidney Failure, Acute",Midodrine,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,PHASE2,digestive_system_disease
2343,Metastatic Colon Adenocarcinoma|Metastatic Colorectal Carcinoma|Metastatic Rectal Adenocarcinoma|Recurrent Colorectal Carcinoma|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Rectal Cancer AJCC v8|Stage IIIB Colon Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Rectal Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Rectal Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Rectal Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Rectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Colorectal Carcinoma|Unresectable Rectal Adenocarcinoma,Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,PHASE1|PHASE2,digestive_system_disease
2344,Irritable Bowel Syndrome,Ibodutant,CC1=CC2=C(C=C1)C=C(S2)C(=O)NC3(CCCC3)C(=O)NC(CC4=CC=CC=C4)C(=O)NCC5CCN(CC5)CC6CCOCC6,PHASE2,digestive_system_disease
2345,Irritable Bowel Syndrome With Constipation,Escitalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,PHASE2|PHASE3,digestive_system_disease
2346,Chronic Anal Fissure,Nifedipine,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,PHASE1|PHASE2,digestive_system_disease
2347,Cystic Fibrosis,Tezacaftor,CC(C)(CO)C1=CC2=CC(=C(C=C2N1CC(CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F,PHASE2,digestive_system_disease
2348,Stem Cell Transplantation|Graft vs Host Disease,Voriconazole,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,PHASE1,digestive_system_disease
2349,Stem Cell Transplantation|Graft vs Host Disease,Micafungin,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O,PHASE1,digestive_system_disease
2350,Stage II Colorectal Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8,Duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,PHASE2|PHASE3,digestive_system_disease
2351,Gastroesophageal Reflux|Respiratory Aspiration|Idiopathic Pulmonary Fibrosis|Lung Transplantation,Cromolyn,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,PHASE1,digestive_system_disease
2352,Non-Small Cell Lung Carcinoma (NSCLC)|Colorectal Cancer (CRC)|Other Solid Tumors,Selinexor,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,PHASE1|PHASE2,digestive_system_disease
2353,Hepatitis C|Kidney Transplant; Complications|Heart Transplant Infection,Pibrentasvir,CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC,APPROVED,digestive_system_disease
2354,Infantile Colic|Infantile Functional Gastrointestinal Disorders,Nepadutant,CC(C)CC1C(=O)NC(C(=O)NC2CC(=O)NCC(C(=O)N1)NC(=O)C(NC(=O)C(NC2=O)CC3=CNC4=CC=CC=C43)CC5=CC=CC=C5)CC(=O)NC6C(C(C(C(O6)CO)O)O)NC(=O)C,PHASE1,digestive_system_disease
2355,Healthy,Erythromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,PHASE2|PHASE3,digestive_system_disease
2356,"Liver Cirrhosis, Alcoholic",Baclofen,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,PHASE1|PHASE2,digestive_system_disease
2357,Nonalcoholic Fatty Liver Disease,Exenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N,APPROVED,digestive_system_disease
2358,"KRAS G12C Mutant Solid Tumors|Carcinoma, Non-Small Cell Lung|Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Non-Small Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Colorectal Cancer|Colorectal Carcinoma|Colorectal Neoplasms|Colorectal Tumors|Neoplasms, Colorectal",Ribociclib,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,PHASE1|PHASE2,digestive_system_disease
2359,MALT Lymphoma,Bortezomib,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,PHASE2,digestive_system_disease
2360,Gastroparesis,Haloperidol,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,APPROVED,digestive_system_disease
2361,Ulcerative Colitis,Azathioprine,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],APPROVED,digestive_system_disease
2362,Ulcerative Colitis,Prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,APPROVED,digestive_system_disease
2363,Ulcerative Colitis,Hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,APPROVED,digestive_system_disease
2364,Cystic Fibrosis,Lefamulin,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CCC(CC4O)N)C,PHASE1,digestive_system_disease
2365,Oral Mucositis,Chlorhexidine,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,APPROVED,digestive_system_disease
2366,Non-alcoholic Steatohepatitis|Type2 Diabetes,Alogliptin,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N,APPROVED,digestive_system_disease
2367,Hepatic Impairment|Healthy Participants,Linzagolix,COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC,PHASE1,digestive_system_disease
2368,Sickle Cell Disease|Thalassemia|Severe Congenital Neutropenia|Diamond-Blackfan Anemia|Shwachman-Diamond Syndrome,Busulfan,CS(=O)(=O)OCCCCOS(=O)(=O)C,PHASE2|PHASE3,digestive_system_disease
2370,NAFLD|TYPE 2 DIABETES|METABOLIC SYNDROME,Resveratrol,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,PHASE2|PHASE3,digestive_system_disease
2371,Colon Adenocarcinoma|Microsatellite Stable Colon Carcinoma|Stage IIB Colon Cancer AJCC v8|Stage IIC Colon Cancer AJCC v8|Stage III Colon Cancer AJCC v8,Encorafenib,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,PHASE2|PHASE3,digestive_system_disease
2372,Cystic Fibrosis,Trimethoprim,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,PHASE2,digestive_system_disease
2373,Cystic Fibrosis,Mupirocin,CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)C(C)O,PHASE2,digestive_system_disease
2374,Gastrointestinal Motility Disorder,Talinolol,CC(C)(C)NCC(COC1=CC=C(C=C1)NC(=O)NC2CCCCC2)O,PHASE1,digestive_system_disease
2376,Renal Insufficiency|Hepatic Insufficiency,Nevirapine,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,PHASE1,digestive_system_disease
2377,Liver Transplant|Hepatitis C,Cyclosporine,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,APPROVED,digestive_system_disease
2378,Gastroparesis,Lisinopril,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,PHASE1,digestive_system_disease
2380,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands,Selumetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,PHASE1,digestive_system_disease
2381,Congenital Hyperinsulinism|Insulinoma,Fluorodopa,C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N,PHASE1,digestive_system_disease
2382,Angiodysplasia,Pasireotide,C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,PHASE2,digestive_system_disease
2383,Colorectal Neoplasms|Breast Neoplasms,Cediranib,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,PHASE1|PHASE2,digestive_system_disease
2384,Primary Sclerosing Cholangitis,Volixibat,CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC(=CC=C3)NC(=O)NC4C(C(C(C(O4)COS(=O)(=O)O)O)OCC5=CC=CC=C5)O)CC,PHASE2,digestive_system_disease
2385,Irritable Bowel Syndrome,Dronabinol,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,PHASE2,digestive_system_disease
2387,Cystic Fibrosis,Colistin,CCC(C)CCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)C(C)O,APPROVED,digestive_system_disease
2389,Hepatic Impairment,Phentermine,CC(C)(CC1=CC=CC=C1)N,PHASE1,digestive_system_disease
2390,Hepatic Impairment,Topiramate,CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,PHASE1,digestive_system_disease
2391,Gastroenteritis Escherichia Coli,Aspartame,COC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)N,PHASE1,digestive_system_disease
2392,Hepatitis B,Birinapant,CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC,PHASE1,digestive_system_disease
2393,Pancreatic Adenocarcinoma,Temsirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,PHASE1,digestive_system_disease
2394,Nonalcoholic Steatohepatitis (NASH),Firsocostat,CC1=C(SC2=C1C(=O)N(C(=O)N2CC(C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5,PHASE1,digestive_system_disease
2396,Coronary Artery Disease|Gastroesophageal Reflux Disease,Indobufen,CCC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,APPROVED,digestive_system_disease
2397,Hepatocellular Carcinoma,Clemizole,C1CCN(C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl,PHASE2,digestive_system_disease
2399,Colon Cancer|Colorectal Cancer|Rectal Cancer,Pegfilgrastim,CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C,PHASE2,digestive_system_disease
2400,Irritable Bowel Syndrome,Doxepin,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,PHASE2,digestive_system_disease
2401,Irritable Bowel Syndrome,Nortriptyline,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,digestive_system_disease
2403,Bile Duct Obstruction|Pancreatic Cancer|Gallbladder Cancer|Bile Duct Cancer,Ulipristal,CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,APPROVED,digestive_system_disease
2404,Irritable Bowel Syndrome,Paroxetine,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,APPROVED,digestive_system_disease
2405,Gastric Carcinoma,Tesetaxel,CC1=C2C3C(C4(CCC5C(C4C(C(C2(C)C)(CC1OC(=O)C(C(C6=C(C=CC=N6)F)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)C)OC(O3)CN(C)C,PHASE1|PHASE2,digestive_system_disease
2406,Pancreas Cancer,Plerixafor,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3,PHASE1,digestive_system_disease
2407,Gastroesophageal Reflux Disease,Lesogaberan,C(C(C[P+](=O)O)F)N,PHASE2,digestive_system_disease
2409,Metastatic Colorectal Cancer,Dabigatran,CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N,PHASE1,digestive_system_disease
2410,Crohn's Disease,Rifabutin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)C,APPROVED,digestive_system_disease
2411,Crohn's Disease,Clarithromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,APPROVED,digestive_system_disease
2412,Colorectal Cancer Metastatic,Anisodamine,CN1C2CC(CC1C(C2)O)OC(=O)C(CO)C3=CC=CC=C3,PHASE2,digestive_system_disease
2413,Marginal Ulcers,Famotidine,C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N,APPROVED,digestive_system_disease
2414,Liver Disease|Fungal Infection,Anidulafungin,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O,APPROVED,digestive_system_disease
2416,Hemorrhoids,Ketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,APPROVED,digestive_system_disease
2417,Irritable Bowel Syndrome With Constipation,Plecanatide,CC1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)CNC(=O)C(NC2=O)C(C)O)C(=O)NC(CC(C)C)C(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)N)N,PHASE2,digestive_system_disease
2418,Postoperative Ileus,Mosapride,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,APPROVED,digestive_system_disease
2419,Advanced Hepatocellular Carcinoma,Tegavivint,CC1CC(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=C4C=CC(=CC4=C3N=O)S(=O)(=O)N5CC(CC(C5)C)C)NO)C,PHASE1|PHASE2,digestive_system_disease
2420,"Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute|Renal Insufficiency|Liver Disease|Neoplasms",Pevonedistat,C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N,PHASE1,digestive_system_disease
2421,Acute Diverticulitis,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,APPROVED,digestive_system_disease
2422,Pancreas Cancer,Bethanechol,CC(C[N+](C)(C)C)OC(=O)N,PHASE2,digestive_system_disease
2423,Cancer|Gastrointestinal Neoplasms,Tamoxifen,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,PHASE1,digestive_system_disease
2424,Cystic Fibrosis,Lumacaftor,CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O,PHASE1,digestive_system_disease
2425,Crohn's Disease,Tamibarotene,CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C,PHASE2,digestive_system_disease
2426,Hepatocellular Carcinoma (HCC),Melphalan,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,PHASE2,digestive_system_disease
2427,Fatty Liver|Liver Dysfunction|Insulin Resistance,Azithromycin,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,PHASE2,digestive_system_disease
2428,Adult Subjects With Anal Fissures.,Diltiazem,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,PHASE1,digestive_system_disease
2429,Colorectal Cancer,Minocycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,PHASE2,digestive_system_disease
2430,Hepatic Impairment,Tepotinib,CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N,PHASE1,digestive_system_disease
2431,Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation,Mercaptopurine,C1=NC2=C(N1)C(=S)N=CN2,PHASE2,digestive_system_disease
2432,Hepatocellular Carcinoma,Pentamidine,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,PHASE1,digestive_system_disease
2433,Binge-Eating Disorder,Methylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,PHASE2,digestive_system_disease
2436,Crohn Disease|Inflammatory Bowel Diseases|Cannabis,Cannabidiol,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,PHASE2|PHASE3,digestive_system_disease
2437,Appendicitis,Gentamicin,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,APPROVED,digestive_system_disease
2438,"Childhood Hepatocellular Carcinoma|Childhood Malignant Liver Neoplasm|Fibrolamellar Carcinoma|Hepatoblastoma|Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Etoposide,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,PHASE2|PHASE3,digestive_system_disease
2439,"Childhood Hepatocellular Carcinoma|Childhood Malignant Liver Neoplasm|Fibrolamellar Carcinoma|Hepatoblastoma|Hepatocellular Malignant Neoplasm, Not Otherwise Specified",Vincristine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE2|PHASE3,digestive_system_disease
2442,Non-Alcoholic Fatty Liver Disease,Gemcabene,CC(C)(CCCCOCCCCC(C)(C)C(=O)O)C(=O)O,PHASE2,digestive_system_disease
2443,Colorectal Cancer,Niclosamide,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O,PHASE2,digestive_system_disease
2444,Hepatitis B|Cholestasis,Ademetionine,C[S+](CCC(C(=O)[O-])N)CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O,APPROVED,digestive_system_disease
2445,Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Primary Malignant Central Nervous System Neoplasm|Locally Advanced Sarcoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Primary Malignant Central Nervous System Neoplasm|Metastatic Sarcoma|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,Avapritinib,CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N,PHASE2,digestive_system_disease
2447,Diabetes Mellitus|Diabetes Mellitus Complications|Gastroparesis,Relamorelin,C1CC(CNC1)C(=O)NC(CC2=CSC3=CC=CC=C32)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N,PHASE2,digestive_system_disease
2448,Chronic Hepatitis C,Quercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,PHASE1,digestive_system_disease
2449,Severe Hepatic Impairment,Vortioxetine,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,PHASE1,digestive_system_disease
2450,Chronic Hepatitis B,Vesatolimod,CCCCOC1=NC(=C2C(=N1)N(CC(=O)N2)CC3=CC=CC(=C3)CN4CCCC4)N,PHASE2,digestive_system_disease
2451,Diabetes Mellitus Type 2|Non Alcoholic Fatty Liver Disease|Obesity,Amlexanox,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,PHASE2,digestive_system_disease
2452,Hyperinsulinemia|Insulin Resistance|Non-Alcoholic Fatty Liver Disease|Prediabetic State,Diazoxide,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,PHASE1,digestive_system_disease
2453,"Rhabdomyosarcoma|Malignant Peripheral Nerve Sheath Tumors|Chondrosarcoma|Sarcoma, Ewing's|Sarcoma, Alveolar Soft Part|Chordoma|Epithelioid Sarcoma|Giant Cell Tumor of Bone|Hemangiopericytoma|Gastrointestinal Stromal Tumor (GIST)",Dasatinib,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,PHASE2,digestive_system_disease
2454,Advanced Esophageal Squamous Cell Carcinoma,Afatinib,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,PHASE2,digestive_system_disease
2455,Hepatic Impairment,Enasidenib,CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O,PHASE1,digestive_system_disease
2456,Cystic Fibrosis|Cystic Fibrosis Pulmonary Exacerbation|Pseudomonas Aeruginosa Infection,Ceftolozane,CC(C)(C(=O)O)ON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-],APPROVED,digestive_system_disease
2457,Cystic Fibrosis|Cystic Fibrosis Pulmonary Exacerbation|Pseudomonas Aeruginosa Infection,Tazobactam,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,APPROVED,digestive_system_disease
2458,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic Endometrioid Adenocarcinoma|Metastatic Fallopian Tube Carcinoma|Metastatic HER2 Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Breast Carcinoma|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8,Abexinostat,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PHASE1,digestive_system_disease
2459,Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic Endometrioid Adenocarcinoma|Metastatic Fallopian Tube Carcinoma|Metastatic HER2 Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Breast Carcinoma|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8,Fulvestrant,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,PHASE1,digestive_system_disease
2460,Erectile Dysfunction|Sigmoid Colon Cancer|Rectal Cancer,Udenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C,PHASE2,digestive_system_disease
2461,Ulcerative Colitis|Pouchitis|Ileitis|Inflammatory Bowel Disease,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,PHASE1|PHASE2,digestive_system_disease
2462,Cushing's Disease|Acromegaly|Neuroendocrine Tumors|Pituitary Tumors|Ectopic ACTH Secreting (EAS) Tumors|Dumping Syndrome|Prostate Cancer|Melanoma Negative for bRAF|Melanoma Negative for nRAS,Cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C,APPROVED,digestive_system_disease
2463,Gastrointestinal Cancer,Rocuronium,CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C,APPROVED,digestive_system_disease
2464,Colorectal Adenocarcinoma|CpG Island Methylator Phenotype|Metastatic Microsatellite Stable Colorectal Carcinoma|Refractory Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,Guadecitabine,C1C(C(OC1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)OC4CC(OC4CO)N5C=NC(=NC5=O)N)O,PHASE1|PHASE2,digestive_system_disease
2465,Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer AJCC v6 and v7,Triapine,C1=CC(=C(N=C1)C=NNC(=S)N)N,PHASE1,digestive_system_disease
2466,Cystic Fibrosis,Telavancin,CCCCCCCCCCNCCNC1(CC(OC(C1O)C)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)C,APPROVED,digestive_system_disease
2467,Hepatitis C,Buprenorphine,CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,PHASE1,digestive_system_disease
2468,Hepatitis C,Naloxone,C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,PHASE1,digestive_system_disease
2470,Hepatocellular Carcinoma,Pirarubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6,PHASE2|PHASE3,digestive_system_disease
2472,Pancreatic Cancer,Pomalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,PHASE1|PHASE2,digestive_system_disease
2473,Cirrhosis|Ascites Hepatic,Terlipressin,C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N,PHASE2,digestive_system_disease
2474,Hepatic Impairment,Hydrocodone,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,PHASE1,digestive_system_disease
2475,Colorectal Cancer,Decitabine,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,PHASE1,digestive_system_disease
2476,Hepatic Insufficiency,Evacetrapib,CC1=CC(=C2C(=C1)C(CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C,PHASE1,digestive_system_disease
2479,Advanced Hepatocellular Carcinoma,Itacitinib,C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F,PHASE1,digestive_system_disease
2480,Refractory Reflux Esophagitis,Trimebutine,CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C,APPROVED,digestive_system_disease
2481,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",Gabapentin,C1CCC(CC1)(CC(=O)O)CN,APPROVED,digestive_system_disease
2482,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",Orphenadrine,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,APPROVED,digestive_system_disease
2483,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",Lidocaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,APPROVED,digestive_system_disease
2484,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",Tramadol,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,APPROVED,digestive_system_disease
2485,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",Hydromorphone,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4,APPROVED,digestive_system_disease
2486,Colorectal Cancer,Enzastaurin,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7,PHASE2,digestive_system_disease
2487,Microbial Colonization|Extreme Prematurity|Early-Onset Neonatal Sepsis|Late-Onset Neonatal Sepsis|Necrotizing Enterocolitis of Newborn|Death; Neonatal,Ampicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)C,APPROVED,digestive_system_disease
2488,Colon Adenocarcinoma|Rectal Adenocarcinoma|Stage III Colorectal Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,Clobetasol,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C,PHASE2,digestive_system_disease
2489,Gastrointestinal Stromal Tumor,Ganetespib,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O,PHASE2,digestive_system_disease
2491,Cystic Fibrosis,Meropenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O,APPROVED,digestive_system_disease
2493,Crohn Disease,Ozanimod,CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N,PHASE2|PHASE3,digestive_system_disease
2494,Malignant Tumors of the Digestive System|Trombocitopenia,Hetrombopag,CC1=C(C(=O)N(N1)C2=CC3=C(CCCC3)C=C2)N=NC4=CC=CC(=C4O)C5=CC=C(O5)C(=O)O,APPROVED,digestive_system_disease
2495,Chronic Cholecystitis,Remifentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC,APPROVED,digestive_system_disease
2497,Acquired Immunodeficiency Syndrome|Healthy Volunteers|HIV/AIDS|HIV Diarrhea|Human Immunodeficiency Virus,Crofelemer,COC1=CC=CC=C1CNC(=O)C2=NOC(=C2)C3=CC=CC=C3,APPROVED,digestive_system_disease
2499,Intensive Care Unit|Mechanical Ventilation|Anesthesia|Liver Failure|Pharmacokinetics,Remimazolam,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=NC2CCC(=O)OC)C4=CC=CC=N4,APPROVED,digestive_system_disease
2501,Constipation,Docusate,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,APPROVED,digestive_system_disease
2502,Constipation,Bisacodyl,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,APPROVED,digestive_system_disease
2503,Constipation,Methylnaltrexone,C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,APPROVED,digestive_system_disease
2504,Gastroesophageal Reflux in Neonates,Montmorillonite,O.[O-2].[O-2].[O-2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.[Al+3].[Al+3],APPROVED,digestive_system_disease
2505,Crohn Disease|CARD9 S12N Risk Allele,Posaconazole,CCC(C(C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5CC(OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,APPROVED,digestive_system_disease
2506,Postoperative Ileus,Pyridostigmine,C[N+]1=CC=CC(=C1)OC(=O)N(C)C,PHASE2|PHASE3,digestive_system_disease
2507,Intestinal Failure|Short Bowel Syndrome,Glucagon,CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CN=CN7)N,PHASE1|PHASE2,digestive_system_disease
2508,Locally Advanced Unresectable Pancreatic Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8,Telotristat,CC1=NN(C=C1)C2=C(C=CC(=C2)Cl)C(C(F)(F)F)OC3=NC(=NC(=C3)C4=CC=C(C=C4)CC(C(=O)O)N)N,PHASE2,digestive_system_disease
2509,Cystic Fibrosis,Omadacycline,CC(C)(C)CNCC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,APPROVED,digestive_system_disease
2510,Hepatocellular Carcinoma,Sitravatinib,COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,PHASE2,digestive_system_disease
2511,Self Efficacy,Ginsenosides,CC(=CCCC(C)(C1CCC2(C1CCC3C2(CCC4C3(CCC(C4(C)C)O)C)C)C)O)C,PHASE2,digestive_system_disease
2513,Cystic Fibrosis,Sildenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,PHASE2|PHASE3,digestive_system_disease
2514,"Hepatitis C, Chronic",Danoprevir,CC(C)(C)OC(=O)NC1CCCCCC=CC2CC2(NC(=O)C3CC(CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6,PHASE2,digestive_system_disease
2515,Liver Metastasis|Colorectal Neoplasms|Liver Neoplasms|Neoplasm Metastasis,Talaporfin,CCC1=C(C2=CC3=C(C(=C(N3)C=C4C(C(C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=O)O)CC(=O)NC(CC(=O)O)C(=O)O)CCC(=O)O)C)C)C=C)C,PHASE2,digestive_system_disease
2516,NASH - Nonalcoholic Steatohepatitis,Seladelpar,CCOC(COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C,PHASE2,digestive_system_disease
2518,Fecal Incontinence,Oxymetazoline,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,PHASE1,digestive_system_disease
2520,Hepatorenal Syndrome,Ifetroban,CCCCCNC(=O)C1=COC(=N1)C2C3CCC(C2CC4=CC=CC=C4CCC(=O)O)O3,PHASE2,digestive_system_disease
2521,"Steatohepatitis, Nonalcoholic",Montelukast,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,PHASE1|PHASE2,digestive_system_disease
2522,Advanced Hepatocellular Carcinoma|BCLC Stage A Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma,Futibatinib,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,PHASE2,digestive_system_disease
2523,"Carcinoma, Non-small-cell Lung|Mesothelioma|Pancreatic Neoplasms",Defactinib,CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F,PHASE1|PHASE2,digestive_system_disease
2524,Irritable Bowel Syndrome,Ramosetron,CN1C=C(C2=CC=CC=C21)C(=O)C3CCC4=C(C3)NC=N4,APPROVED,digestive_system_disease
2525,Liver Cancer|Metastatic Cancer,Pyrazoloacridine,CN(C)CCCN1C2=C3C(=C(C=C2)[N+](=O)[O-])NC4=C(C3=N1)C=C(C=C4)OC,PHASE2,digestive_system_disease
2526,Crohn's Disease,Dehydroepiandrosterone,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C,PHASE2,digestive_system_disease
2527,Crohn's Disease,Prasterone,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C,PHASE2,digestive_system_disease
2528,"Malnutrition|Intestinal Diseases, Parasitic",Mebendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,APPROVED,digestive_system_disease
2529,Pancreas Cancer,Entinostat,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,PHASE1,digestive_system_disease
2531,Anaemia,Daprodustat,C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O,PHASE1,digestive_system_disease
2532,Irritable Bowel Syndrome,Otilonium,CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC,APPROVED,digestive_system_disease
2533,Radiation Enteritis,Sapropterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,digestive_system_disease
2534,Radiation Enteritis,Tetrahydrobiopterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,digestive_system_disease
2535,Hepatic Impairment,Fosmanogepix,C1=CC=NC(=C1)OCC2=CC=C(C=C2)CC3=NOC(=C3)C4=C([N+](=CC=C4)COP(=O)(O)[O-])N,PHASE1,digestive_system_disease
2536,Nonalcoholic Steatohepatitis,Cilofexor,C1CC1C2=C(C(=NO2)C3=C(C=CC=C3Cl)Cl)COC4=CC(=C(C=C4)C5(CN(C5)C6=NC=CC(=C6)C(=O)O)O)Cl,PHASE2,digestive_system_disease
2538,HIV|Hepatitis C|Liver Fibrosis,Raltegravir,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,PHASE2,digestive_system_disease
2539,Diarrhea-predominant Irritable Bowel Syndrome,Rifamycin,CC1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,PHASE2,digestive_system_disease
2540,GIARDIASIS,Tinidazole,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,APPROVED,digestive_system_disease
2541,"Cancer-associated Thrombosis|Esophageal Cancer|Stomach Cancer|Hepatocellular Carcinoma|Pancreatic Cancer|Duodenal Cancer|Esophagogastric Junction Cancer|Malignant Gastrointestinal Stromal Tumor|Ampulla of Vater Cancer|Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)",Dalteparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2,digestive_system_disease
2542,Advanced Solid Malignancies|Non-Small Cell Lung Cancer (NSCLC)|Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)|Colorectal Carcinoma (CRC),Abiraterone,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,PHASE1,digestive_system_disease
2543,Hepatic Impairment,Gemigliptin,C1CC(CN(C1=O)CC(CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F,PHASE1,digestive_system_disease
2544,IBS-C and IBS With Mixed Bowel Habits,Tegaserod,CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC,APPROVED,digestive_system_disease
2545,Inflammatory Bowel Diseases|Clostridioides Difficile Infection,Sucralose,C(C1C(C(C(C(O1)OC2(C(C(C(O2)CCl)O)O)CCl)O)O)Cl)O,PHASE1,digestive_system_disease
2546,Cancer,Vismodegib,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,PHASE1,digestive_system_disease
2547,Muscle Cramp|Cirrhosis,Ropinirole,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,APPROVED,digestive_system_disease
2549,Hepatic Impairment,Vadadustat,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O,PHASE1,digestive_system_disease
2550,Hypertension,Amlodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,APPROVED,digestive_system_disease
2551,Hepatic Impairment,Fevipiprant,CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O,PHASE1,digestive_system_disease
2552,Liver Dysfunction,Evogliptin,CC(C)(C)OCC1C(=O)NCCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N,PHASE1,digestive_system_disease
2553,Drug-Induced Liver Injury,Tiopronin,CC(C(=O)NCC(=O)O)S,PHASE2,digestive_system_disease
2554,Cholecystolithiasis,Droperidol,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,APPROVED,digestive_system_disease
2555,Gastrointestinal Diseases,Paracetamol,CC(=O)NC1=CC=C(C=C1)O,PHASE2,digestive_system_disease
2557,Neoplasm Metastasis|Colorectal Neoplasms|Breast Cancer,Prexasertib,COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N,PHASE1,digestive_system_disease
2558,Cancer,Afuresertib,CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl,PHASE1,digestive_system_disease
2559,Hepatitis C,Armodafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,APPROVED,digestive_system_disease
2560,Hepatitis C,Modafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,APPROVED,digestive_system_disease
2561,Metastatic Pancreatic Cancer,Proglumide,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,PHASE1,digestive_system_disease
2562,"Fatty Liver, Nonalcoholic",Cilostazol,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,PHASE1|PHASE2,digestive_system_disease
2563,Pancreatitis,Aprotinin,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(C(=O)NC(C(=O)NCC(=O)N6CCCC6C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCCNC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CCC(=O)N)C(C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)C)CCCCN)C(C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)NC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)NC(C)C(=O)O)C(C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)C(C)CC,PHASE1,digestive_system_disease
2564,Malignant Bowel Obstruction,Metoclopramide,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,PHASE2,digestive_system_disease
2565,Parkinson's Disease,Trimethobenzamide,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C(=C2)OC)OC)OC,APPROVED,digestive_system_disease
2566,Fistulizing Crohn's Disease,Filgotinib,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,PHASE2,digestive_system_disease
2567,Hepatitis C,Ravidasvir,CC(C)C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)C7CCCN7C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE2|PHASE3,digestive_system_disease
2568,Irritable Bowel Syndrome,Tiropramide,CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=CC=C2,APPROVED,digestive_system_disease
2569,Cirrhosis|Erectile Dysfunction,Vardenafil,CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C,APPROVED,digestive_system_disease
2570,Primary Sclerosing Cholangitis,Sulfasalazine,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,PHASE2,digestive_system_disease
2571,Colorectal Cancer|Metastatic Colorectal Cancer,Onvansertib,CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO,PHASE2,digestive_system_disease
2572,Cystic Fibrosis,Teicoplanin,CCCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)OC1C(C(C(C(O1)CO)O)O)NC(=O)C)Cl)CO)O)O,PHASE1,digestive_system_disease
2573,Cytomegalovirus Infections,Valganciclovir,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,PHASE1,digestive_system_disease
2574,Gastrointestinal Injury|Ischemic Heart Disease,Clopidogrel,COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,APPROVED,digestive_system_disease
2575,Appendicitis Perforated,Piperacillin,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,PHASE2,digestive_system_disease
2576,"Stomach Cancer, Adenocarcinoma",Savolitinib,CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C,PHASE2,digestive_system_disease
2577,HIV Infections|Fatty Liver Disease,Dolutegravir,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,APPROVED,digestive_system_disease
2578,HIV Infections|Fatty Liver Disease,Rilpivirine,CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N,APPROVED,digestive_system_disease
2579,Non Alcoholic Steatohepatitis (NASH),Tropifexor,C1CC1C2=C(C(=NO2)C3=CC=CC=C3OC(F)(F)F)COC4CC5CCC(C4)N5C6=NC7=C(C=C(C=C7S6)C(=O)O)F,PHASE2,digestive_system_disease
2580,Non Alcoholic Steatohepatitis (NASH),Licogliflozin,CCC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4,PHASE2,digestive_system_disease
2581,"Cirrhosis, Liver|Volume Overload|Fluid Overload",Furosemide,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,APPROVED,digestive_system_disease
2582,Diseases of Oesophagus Stomach and Duodenum,Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,PHASE1,digestive_system_disease
2583,Ovarian Carcinoma|Fallopian Tube Cancer|Peritoneal Cancer|Breast Carcinoma,Alisertib,COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC,PHASE2,digestive_system_disease
2584,Ascites|Cirrhosis,Eplerenone,CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC,PHASE2,digestive_system_disease
2585,Metastatic Colorectal Cancer (MCRC),Brivanib,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C,PHASE1|PHASE2,digestive_system_disease
2586,Migraine|Pain|Nausea|Vomiting|Aura,Sumatriptan,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,PHASE2,digestive_system_disease
2587,Non Alcoholic Steatohepatitis,Idebenone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,PHASE1|PHASE2,digestive_system_disease
2589,Non Hodgkin's Lymphoma,Pralatrexate,C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,digestive_system_disease
2590,Stomatitis,Benzydamine,CN(C)CCCOC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3,PHASE2,digestive_system_disease
2591,"Hepatitis C, Chronic",Celgosivir,CCCC(=O)OC1CN2CCC(C2C(C1O)O)O,PHASE2,digestive_system_disease
2592,Moderate Hepatic Impairment,Belzutifan,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,PHASE1,digestive_system_disease
2593,Prostate,Doxazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,APPROVED,digestive_system_disease
2594,Hepatic Insufficiency,Alitretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1|PHASE2,digestive_system_disease
2596,Eosinophilic Esophagitis,Beclomethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)Cl)C,PHASE1,digestive_system_disease
2597,Erythropoietic Protoporphyria|X-linked Protoporphyria,Cimetidine,CC1=C(N=CN1)CSCCNC(=NC)NC#N,PHASE2,digestive_system_disease
2599,Gastrointestinal Hemorrhage|Portal Hypertension|Cirrhosis,Isosorbide,C1C(C2C(O1)C(CO2)O)O,APPROVED,digestive_system_disease
2600,Bowel Disease|Liver Diseases|Pancreas Disease|Anesthesia; Functional,Sufentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC,PHASE2|PHASE3,digestive_system_disease
2601,Hepatic Impairment|Healthy Volunteers,Bocidelpar,CC1=CN=C(N1CC2=CC=CC=C2OCCCC(C)CC(=O)O)C3=CC=C(C=C3)C(F)(F)F,PHASE1,digestive_system_disease
2603,Colorectal Neoplasm,Modufolin,C1C2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1|PHASE2,digestive_system_disease
2604,Esophagitis,Ilaprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=C(N2)C=C(C=C3)N4C=CC=C4)OC,PHASE2,digestive_system_disease
2605,Cryptosporidiosis|HIV Infections,Letrazuril,C1=CC(=CC=C1C(C#N)C2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C=N3)Cl)F,PHASE1,digestive_system_disease
2607,Brain and Central Nervous System Tumors|Kidney Cancer|Liver Cancer|Retinoblastoma|Sarcoma,Mesna,C(CS(=O)(=O)[O-])S.[Na+],PHASE1,digestive_system_disease
2608,Fecal Incontinence,Clonidine,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,PHASE2,digestive_system_disease
2609,Hepatitis C Virus Infection,Mifepristone,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,PHASE2,digestive_system_disease
2610,Cancer,Dabrafenib,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,PHASE1|PHASE2,digestive_system_disease
2611,Crohn's Disease,Laquinimod,CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O,PHASE2,digestive_system_disease
2613,Hepatic Impairment,Iloperidone,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,PHASE1,digestive_system_disease
2614,Hepatic Impairment,Siremadlin,CC(C)N1C2=C(C(=O)N(C2C3=CC=C(C=C3)Cl)C4=CC(=CN(C4=O)C)Cl)N=C1C5=CN=C(N=C5OC)OC,PHASE1,digestive_system_disease
2615,Diabetes Mellitus|Iron Metabolism Disorders|Gastroduodenal Ulcer|Optic Atrophy|Sensorineural Hearing Loss|Platelet Dysfunction,Deferiprone,CC1=C(C(=O)C=CN1C)O,PHASE2|PHASE3,digestive_system_disease
2616,Diabetes Mellitus|Iron Metabolism Disorders|Gastroduodenal Ulcer|Optic Atrophy|Sensorineural Hearing Loss|Platelet Dysfunction,Acetylcysteine,CC(=O)NC(CS)C(=O)O,PHASE2|PHASE3,digestive_system_disease
2618,Cholecystitis,Cefotetan,CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O,PHASE1,digestive_system_disease
2619,Severe Hepatic Impairment,Dacomitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4,PHASE1,digestive_system_disease
2621,Healthy|NAFLD,Phenytoin,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,PHASE1,digestive_system_disease
2622,Chronic Hepatitis B,Oxymatrine,C1CC2C3CCC[N+]4(C3C(CCC4)CN2C(=O)C1)[O-],APPROVED,digestive_system_disease
2623,Cirrhosis|Ascites|Nosocomial Spontaneous Bacterial Peritonitis,Daptomycin,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,PHASE2|PHASE3,digestive_system_disease
2624,Hyperinsulinemic Hypoglycemia|Postprandial Hypoglycemia,Dasiglucagon,CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N,PHASE2,digestive_system_disease
2627,Gall Stone Disease,Esmolol,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,APPROVED,digestive_system_disease
2628,Gall Stone Disease,Vecuronium,CC(=O)OC1CC2CCC3C(C2(CC1N4CCCCC4)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C,APPROVED,digestive_system_disease
2629,Gall Stone Disease,Atropine,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,APPROVED,digestive_system_disease
2630,"Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma",Alvocidib,CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O,PHASE1,digestive_system_disease
2631,HIV Infection|Hepatitis C,Zidovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],APPROVED,digestive_system_disease
2632,Colorectal Cancer,Neratinib,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,PHASE1|PHASE2,digestive_system_disease
2633,Hepatic Insufficiency,Ipatasertib,CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,PHASE1,digestive_system_disease
2634,Inflammatory Bowel Diseases,Nifuroxazide,C1=CC(=CC=C1C(=O)NN=CC2=CC=C(O2)[N+](=O)[O-])O,PHASE2|PHASE3,digestive_system_disease
2635,Short Bowel Syndrome|Vitamin E Deficiency,Tocofersolan,CC1=C(C(=C(C2=C1OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C)OC(=O)CCC(=O)OCCO)C,PHASE2,digestive_system_disease
2637,Ulcerative Colitis,Roflumilast,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,APPROVED,digestive_system_disease
2638,Esophageal Cancer,Ferumoxytol,O[Fe]=O.O[Fe]=O.[Fe],PHASE1,digestive_system_disease
2639,Liver Failure,Lofexidine,CC(C1=NCCN1)OC2=C(C=CC=C2Cl)Cl,PHASE1,digestive_system_disease
2640,Cystic Fibrosis,Tiotropium,C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C,PHASE1,digestive_system_disease
2641,Hepatitis B|Besifovir Dipivoxil Maleate|Tenofovir Disoproxil Fumarate,Besifovir,C1CC1(CN2C=NC3=CN=C(N=C32)N)OCP(=O)(O)O,APPROVED,digestive_system_disease
2642,Metastatic Colorectal Cancer,Valproate,CCCC(CCC)C(=O)O,PHASE2,digestive_system_disease
2643,Non-alcoholic Steatohepatitis,Cotadutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CO)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)C)C(=O)NC(C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)N)C(=O)O,PHASE1,digestive_system_disease
2646,"Carcinoma, Hepatocellular",Tirapazamine,C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-],PHASE2,digestive_system_disease
2647,Resectable Pancreatic Ductal Adenocarcinoma|Stage 0 Pancreatic Cancer AJCC v8|Stage I Pancreatic Cancer AJCC v8|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8,Pyrvinium,CC1=CC(=C(N1C2=CC=CC=C2)C)C=CC3=[N+](C4=C(C=C3)C=C(C=C4)N(C)C)C,PHASE1,digestive_system_disease
2648,Diabetes Mellitus,Lixisenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N,PHASE1,digestive_system_disease
2650,Helminthiasis|Amoebiasis,Quinfamide,C1CC2=C(C=CC(=C2)OC(=O)C3=CC=CO3)N(C1)C(=O)C(Cl)Cl,APPROVED,digestive_system_disease
2651,Variegate Porphyria,Afamelanotide,CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C,PHASE2,digestive_system_disease
2652,Healthy Volunteers,Galicaftor,C1CC1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4CC(OC5=C4C=CC(=C5)OC(F)F)C6=CC=C(C=C6)C(=O)O,PHASE1,digestive_system_disease
2653,Hepatitis C,Eltrombopag,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,PHASE1,digestive_system_disease
2654,Hepatitis C,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,PHASE1,digestive_system_disease
2655,Crohn Disease,Xanthohumol,CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C,PHASE2,digestive_system_disease
2656,Cryptosporidiosis|HIV Infections,Paromomycin,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N,PHASE2,digestive_system_disease
2657,Liver Cirrhosis,Edoxaban,CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C,PHASE2,digestive_system_disease
2658,Cystic Fibrosis,Brensocatib,CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)CC(C#N)NC(=O)C4CNCCCO4)OC1=O,PHASE2,digestive_system_disease
2659,Gastric Motility Disorder,Codeine,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,APPROVED,digestive_system_disease
2660,Inflammation|Crohn's Disease,Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,PHASE2,digestive_system_disease
2661,Diarrhea- Predominant Irritable Bowel Syndrome|Quality of Life,Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,APPROVED,digestive_system_disease
2662,Crohn's Disease,Methoxsalen,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,PHASE2,digestive_system_disease
2663,Ulcerative Colitis,Apremilast,CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,PHASE2,digestive_system_disease
2664,Insomnia|Hepatic Insufficiency,Suvorexant,CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl,PHASE1,digestive_system_disease
2665,Crohn's Disease|Inflammatory Bowel Disease,Ranolazine,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,PHASE2,digestive_system_disease
2666,Non-Small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer,Ibrutinib,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE1|PHASE2,digestive_system_disease
2667,Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma,Dinaciclib,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,PHASE1,digestive_system_disease
2668,Mucositis|Nephrotoxicity|Ototoxicity,Tempol,CC1(CC(CC(N1[O])(C)C)O)C,PHASE2,digestive_system_disease
2669,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Chemotherapy-Induced Peripheral Neuropathy|Digestive System Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8,Lorcaserin,CC1CNCCC2=C1C=C(C=C2)Cl,PHASE1,digestive_system_disease
2670,Colorectal Neoplasm|Digestive System Neoplasm,Flucytosine,C1=NC(=O)NC(=C1F)N,PHASE1|PHASE2,digestive_system_disease
2672,Hepatic Impairment,Danicopan,CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4CC(CC4C(=O)NC5=NC(=CC=C5)Br)F,PHASE1,digestive_system_disease
2673,Hepatocellular Carcinoma,Sonidegib,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,PHASE1,digestive_system_disease
2674,Colon Cancer|Minimal Residual Disease,Piritramide,C1CCN(CC1)C2(CCN(CC2)CCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)N,APPROVED,digestive_system_disease
2675,Colorectal Cancer|Non-Small Cell Lung Cancer,Osimertinib,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE1,digestive_system_disease
2676,Hepatic Impairment|Healthy,Lazertinib,CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC,PHASE1,digestive_system_disease
2677,Neoplasms|Pancreatic Neoplasms,Glufosfamide,C(CCl)NP(=O)(NCCCl)OC1C(C(C(C(O1)CO)O)O)O,PHASE1|PHASE2,digestive_system_disease
2678,Hepatic Insufficiency,Alisporivir,CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C,PHASE1,digestive_system_disease
2679,Crohn Disease|Ulcerative Colitis,Warfarin,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,PHASE1,digestive_system_disease
2680,Primary Peritoneal Cancer|Advanced Epithelial Ovarian Cancer,Iniparib,C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I,PHASE2,digestive_system_disease
2681,Acquired Hyperinsulinemic Hypoglycemia,Avexitide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)N,PHASE2,digestive_system_disease
2682,Graft-versus-host Disease Prevention,Nystatin,CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,PHASE2,digestive_system_disease
2683,Digestive Oncology|Supportive Care,Donepezil,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,PHASE2,digestive_system_disease
2684,Nonalcoholic Fatty Liver Disease (NAFLD)|Type 2 Diabetes (T2DM),Lanifibranor,C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2,PHASE2,digestive_system_disease
2685,Moderate Hepatic Impairment|Severe Hepatic Impairment|Healthy Volunteers,Lorlatinib,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PHASE1,digestive_system_disease
2686,Crohn's Disease,Thiotepa,C1CN1P(=S)(N2CC2)N3CC3,PHASE1|PHASE2,digestive_system_disease
2687,Liver Diseases,Macrogol,C(CO)O,APPROVED,digestive_system_disease
2688,Irritable Bowel Syndrome (IBS),Solabegron,C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNCC(C3=CC(=CC=C3)Cl)O,PHASE1,digestive_system_disease
2689,Hepatic Impairment,Deflazacort,CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C,PHASE1,digestive_system_disease
2690,Irritable Bowel Syndrome,Milnacipran,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,PHASE2,digestive_system_disease
2691,Colorectal Cancer|Colorectal Cancer Metastatic|Colorectal Cancer Recurrent,Famitinib,CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)C=C3C4=C(C=CC(=C4)F)NC3=O)C,PHASE2,digestive_system_disease
2692,Colorectal Cancer,Pacritinib,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,PHASE2,digestive_system_disease
2693,Hepatocellular Carcinoma,Norepinephrine,C1=CC(=C(C=C1C(CN)O)O)O,APPROVED,digestive_system_disease
2695,Gastric Cancer,Cabazitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC,PHASE2,digestive_system_disease
2696,Pancreatic Neoplasms,Aroplatin,CC(C)(C)CCCCCC(=O)[O-].CC(C)(C)CCCCCC(=O)[O-].C1CCC(C(C1)N)N.[Pt+2],PHASE1|PHASE2,digestive_system_disease
2697,Nalbuphine|Hepatic Impairment,Nalbuphine,C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O,PHASE1,digestive_system_disease
2698,Non Alcoholic Steatohepatitis (NASH),Icosabutate,CCC=CCC=CCC=CCC=CCC=CCCCCOC(CC)C(=O)O,PHASE2,digestive_system_disease
2699,Erythropoietic Protoporphyria,Colestipol,C1C(O1)CCl.C(CNCCNCCNCCN)N,PHASE2|PHASE3,digestive_system_disease
2700,Post Operative Ileus,Alvimopan,CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(CC3=CC=CC=C3)C(=O)NCC(=O)O,APPROVED,digestive_system_disease
2701,"Liver Cirrhosis|Hypertension, Portal",Serelaxin,CCC(C)C1C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C)C(C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O)C(CC(=O)O)N)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(C)C)NC(=O)C7CCC(=O)N7)C(C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CO)C(=O)O,PHASE2,digestive_system_disease
2702,Hemorrhoid|Peri Anal Fistula,Prilocaine,CCCNC(C)C(=O)NC1=CC=CC=C1C,APPROVED,digestive_system_disease
2703,Chronic Hepatitis C Infection,Valaciclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE1,digestive_system_disease
2704,Chronic Hepatitis C Infection,Valacyclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE1,digestive_system_disease
2705,Hepatocellular Carcinoma|Hepatoma|Cholangiocarcinoma|Gallbladder Neoplasms,Sevoflurane,C(OC(C(F)(F)F)C(F)(F)F)F,APPROVED,digestive_system_disease
2706,Crohn's Disease|Abdominal Pain,Olorinab,CC(C)(C)C(CO)NC(=O)C1=NN(C2=C1CC3C2C3)C4=NC=C[N+](=C4)[O-],PHASE2,digestive_system_disease
2707,Amoebic Dysentery|Giardiasis,Auranofin,CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+],PHASE2,digestive_system_disease
2708,Hepatic Impairment|Healthy Volunteers,Mobocertinib,CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE1,digestive_system_disease
2709,NASH - Nonalcoholic Steatohepatitis,Quinidine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE1,digestive_system_disease
2710,Carcinoid Syndrome|Carcinoid|Carcinoid Tumor|Carcinoid Tumor of Ileum|Carcinoid Tumor of Cecum|Carcinoid Syndrome Diarrhea|Carcinoid Intestine Tumor|Carcinoid Tumor of Liver|Carcinoid Tumor of Pancreas,Paltusotine,C1CN(CCC1N)C2=C3C=C(C=CC3=NC=C2C4=CC(=CC(=C4)F)F)C5=CC=CC(=C5O)C#N,PHASE2,digestive_system_disease
2712,Oral Mucositis,Cobiprostone,CCC(C)CC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F,PHASE2,digestive_system_disease
2713,Metastatic Colorectal Cancer,Perindopril,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O,PHASE2,digestive_system_disease
2715,Solid Tumors|Hematologic Malignancies|Hepatic Impairment,Carfilzomib,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,PHASE1,digestive_system_disease
2716,Hepatocellular Carcinoma|Metastatic Cancer,Thymidine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,PHASE1,digestive_system_disease
2717,Acetaminophen|Drug Overdose|Acetaminophen Overdose|Acetaminophen Poisoning|Drug-induced Liver Injury|Liver Failure|Liver Toxicity,Fomepizole,CC1=CNN=C1,PHASE2,digestive_system_disease
2718,Primary Biliary Cholangitis,Bezafibrate,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,PHASE2,digestive_system_disease
2719,Gastroparesis,Tradipitant,C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl,PHASE2,digestive_system_disease
2720,"Neoplasms|Colorectal Neoplasms|Melanoma|Pancreatic Neoplasms|Sarcoma|Ovarian Neoplasms|Brain Neoplasms|Thyroid Neoplasms|Neuroendocrine Tumors|Cholangiocarcinoma|Salivary Gland Neoplasms|Head and Neck Neoplasms|Thyroid Cancer, Papillary|Lymphoma, Large-Cell, Anaplastic|Neoplasms by Site|Respiratory Tract Neoplasms|Thoracic Neoplasms|Respiratory Tract Diseases|Carcinoma, Bronchogenic|Bronchial Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Digestive System Diseases|Gastrointestinal Diseases|Colonic Diseases|Intestinal Diseases|Central Nervous System",Alectinib,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,PHASE2,digestive_system_disease
2721,Cystic Fibrosis,Ataluren,C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F,APPROVED,digestive_system_disease
2722,Non-Resectable Cholangiocarcinoma|Recurrent Cholangiocarcinoma|Stage III Extrahepatic Bile Duct Cancer|Stage III Intrahepatic Cholangiocarcinoma|Stage IIIA Hilar Cholangiocarcinoma|Stage IIIB Hilar Cholangiocarcinoma|Stage IVA Extrahepatic Bile Duct Cancer|Stage IVA Hilar Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVB Extrahepatic Bile Duct Cancer|Stage IVB Hilar Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma|Unresectable Extrahepatic Bile Duct Carcinoma,Ricolinostat,C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO,PHASE1,digestive_system_disease
2724,Colorectal Neoplasms,Pelitrexol,CC1=C(SC(=C1)C(=O)NC(CCC(=O)O)C(=O)O)CCC2CC3=C(NC2)N=C(NC3=O)N,PHASE2,digestive_system_disease
2725,HIV-1 Infection,Doravirine,CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F,PHASE1,digestive_system_disease
2726,Platinum-Sensitive Biliary Tract Cancer,Pamiparib,CC12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F,PHASE2,digestive_system_disease
2727,Irritable Bowel Syndrome With Diarrhea,Mebeverine,CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)C(C)CC2=CC=C(C=C2)OC,APPROVED,digestive_system_disease
2729,Inflammatory Bowel Disease,Allopurinol,C1=NNC2=C1C(=O)NC=N2,PHASE1,digestive_system_disease
2730,"Urinary Incontinence, Stress|Fecal Incontinence",Imipramine,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE1,digestive_system_disease
2731,"Pancreatitis, Acute",Naldemedine,CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O,PHASE2|PHASE3,digestive_system_disease
2732,Gastrointestinal Stromal Tumors,Perifosine,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C,PHASE2,digestive_system_disease
2735,Cystic Fibrosis,Linezolid,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,PHASE2,digestive_system_disease
2736,Sphincter of Oddi Dysfunction,Pinaverium,CC1(C2CCC(C1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C,APPROVED,digestive_system_disease
2737,"Pancreatitis, Acute",Indomethacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,APPROVED,digestive_system_disease
2738,Stomach Neoplasms,Edotecarin,C1=CC2=C(C=C1O)NC3=C4C(=C5C(=C23)C(=O)N(C5=O)NC(CO)CO)C6=C(N4C7C(C(C(C(O7)CO)O)O)O)C=C(C=C6)O,PHASE2,digestive_system_disease
2741,Hepatic Impairment,Delafloxacin,C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O,PHASE1,digestive_system_disease
2742,Lung Cancer|Gastro-intestinal Cancer,Adagrasib,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,PHASE1,digestive_system_disease
2743,Colorectal Cancer|GIST,Ripretinib,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC,PHASE1|PHASE2,digestive_system_disease
2744,Gastrointestinal Tumor|Effect of Drug,Pyrotinib,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CC5CCCN5C,PHASE2,digestive_system_disease
2745,Hepatocellular Carcinoma Non-resectable,Deferoxamine,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,PHASE1,digestive_system_disease
2747,"Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor",Entrectinib,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,PHASE2,digestive_system_disease
2748,Lobular Breast Carcinoma|Gastric Cancer|Triple Negative Breast Cancer|CDH1 Gene Mutation,Crizotinib,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,PHASE2,digestive_system_disease
2749,Ulcerative Colitis,Rivenprost,COCC1=CC=CC(=C1)CC(C=CC2C(CC(=O)C2CCSCCCC(=O)OC)O)O,PHASE2,digestive_system_disease
2750,Rectal Cancer,Tecemotide,CCCCCCCCCCCCCCCC(=O)NCCCCC(C(=O)NCC(=O)O)NC(=O)C1CCCN1C(=O)C2CCCN2C(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)CNC(=O)C3CCCN3C(=O)C(C)NC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C5CCCN5C(=O)C(C)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC6=CN=CN6)NC(=O)C(C)NC(=O)C7CCCN7C(=O)C8CCCN8C(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CO)N,PHASE2,digestive_system_disease
2751,Acute Diarrhea|Acute Gastroenteritis,Racecadotril,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2,APPROVED,digestive_system_disease
2752,Hepatic Insufficiency & Healthy Subjects,Zanubrutinib,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,PHASE1,digestive_system_disease
2753,Hepatic Impairment|Healthy Volunteers,Soticlestat,C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4,PHASE1,digestive_system_disease
2755,HEPATOCELLULAR CARCINOMA,Darinaparsin,C[As](C)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N,PHASE2,digestive_system_disease
2756,Colorectal Cancer|Rectal Bleeding,Desmopressin,C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N,PHASE2,digestive_system_disease
2757,Advanced Colorectal Carcinoma,Resminostat,CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)C=CC(=O)NO,PHASE1|PHASE2,digestive_system_disease
2759,Hepatitis C|Hepatitis C Virus,Fluvastatin,CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,PHASE2,digestive_system_disease
2760,Non Alcoholic Fatty Liver|Osteo Arthritis,Salsalate,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,APPROVED,digestive_system_disease
2761,"Cirrhosis|Splenectomy; Status|Venous Thrombosis|Hypertension, Portal",Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,APPROVED,digestive_system_disease
2762,Metastatic Malignant Neoplasm in the Liver|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,Vactosertib,CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4,PHASE2,digestive_system_disease
2763,Unresectable Hepatocellular Carcinoma,Bumetanide,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,PHASE1|PHASE2,digestive_system_disease
2765,Neoplasm Metastases|Hepatic Insufficiency,Trabectedin,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O,PHASE1,digestive_system_disease
2766,"Acute, Perforated Appendicitis",Povidone,C=CN1CCCC1=O,PHASE2,digestive_system_disease
2767,HepatoCellular Carcinoma|Portal Vein Tumor Thrombosis,Lipotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)OC(=O)C(C)ON=C6C7=C(C(=CC(=C7)[N+](=O)[O-])[N+](=O)[O-])C8=C6C=C(C=C8[N+](=O)[O-])[N+](=O)[O-],PHASE1|PHASE2,digestive_system_disease
2768,Advanced Biliary Tract Carcinoma|Advanced Colorectal Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Lung Adenocarcinoma|Advanced Malignant Solid Neoplasm|Advanced Ovarian Carcinoma|Advanced Pancreatic Carcinoma|Advanced Urothelial Carcinoma|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Metastatic Biliary Tract Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Lung Adenocarcinoma|Metastatic Ovarian Carcinoma|Metastatic Pancreatic Carcinoma|Metastatic Urothelial Carcinoma|Refractory Biliary Tract Carcinoma|Refractory Colorectal Carcinoma|Refractory Gastroesophageal Junction Adenocarcinoma|Refractory Lung Adenocarcinoma|Refractory Ovarian Carcinoma|Refractory Pancreatic Carcinoma|Refractory Urothelial Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8,Devimistat,C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2,PHASE2,digestive_system_disease
2769,Hepatic Failure,Icenticaftor,CC(CNC(=O)C1=C(C=C(C(=N1)OC)C(F)(F)F)N)(C(F)(F)F)O,PHASE1,digestive_system_disease
2770,Irritable Bowel Syndrome,Fenoverine,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)CC(=O)N4C5=CC=CC=C5SC6=CC=CC=C64,APPROVED,digestive_system_disease
2771,Gastroparesis,Camicinal,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,PHASE2,digestive_system_disease
2773,Liver Fat|Liver Fibrosis|Glycemic Control|Body Weight Changes|Waist Circumference|Tolerance,Ertugliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl,APPROVED,digestive_system_disease
2774,Hepatitis C|Hepatitis,Merimepodib,COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)OC3CCOC3)C4=CN=CO4,PHASE2,digestive_system_disease
2776,"Esophagus Cancer, Adenocarcinoma|Stomach Cancer, Adenocarcinoma",Rucaparib,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,PHASE1|PHASE2,digestive_system_disease
2778,Advanced Hepatocellular Carcinoma,Oprozomib,CC1=NC=C(S1)C(=O)NC(COC)C(=O)NC(COC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C,PHASE1|PHASE2,digestive_system_disease
2781,"Disorders of Gallbladder, Biliary Tract and Pancrease",Meperidine,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,APPROVED,digestive_system_disease
2782,Metastatic Colorectal Carcinoma|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,Riluzole,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,PHASE1,digestive_system_disease
2784,Solid Tumor|Hepatocellular Carcinoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma,Vorolanib,CC1=C(NC(=C1C(=O)NC2CCN(C2)C(=O)N(C)C)C)C=C3C4=C(C=CC(=C4)F)NC3=O,PHASE1,digestive_system_disease
2785,Ulcerative Colitis,Alicaforsen,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)([O-])OC3CC(OC3COP(=S)([O-])OC4CC(OC4COP(=S)([O-])OC5CC(OC5COP(=S)([O-])OC6CC(OC6COP(=S)([O-])OC7CC(OC7COP(=S)([O-])OC8CC(OC8COP(=S)([O-])OC9CC(OC9COP(=S)([O-])OC1CC(OC1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)O,PHASE2,digestive_system_disease
2786,Advanced Solid Tumors|Hematologic Malignancies,Ixazomib,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,PHASE1,digestive_system_disease
2787,Metastatic Colorectal Cancer,Idelalisib,CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,PHASE2,digestive_system_disease
2788,Metastatic Colorectal Cancer,Larotrectinib,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,PHASE2,digestive_system_disease
2789,Metastatic Colorectal Cancer,Panobinostat,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,PHASE2,digestive_system_disease
2790,Metastatic Colorectal Cancer,Venetoclax,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,PHASE2,digestive_system_disease
2791,Chronic Hepatitis C|Chronic Hepatitis B,Hymecromone,CC1=CC(=O)OC2=C1C=CC(=C2)O,PHASE2,digestive_system_disease
2792,"Cancer|Pancreatic Cancer|Sarcoma|Renal Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms|Acute T Cell Leukemia Lymphoma",Lomustine,C1CCC(CC1)NC(=O)N(CCCl)N=O,PHASE2,digestive_system_disease
2793,Hepatic Impairment,Midostaurin,CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC,PHASE1,digestive_system_disease
2794,Celiac Disease,Teriflunomide,CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O,PHASE1|PHASE2,digestive_system_disease
2795,Pruritus With Chronic Liver Disease,Nalfurafine,CN(C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)C=CC7=COC=C7,PHASE2,digestive_system_disease
2796,Peptic Ulcer,Lafutidine,C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3,PHASE1,digestive_system_disease
2797,Peptic Ulcer,Irsogladine,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl,PHASE1,digestive_system_disease
2802,Chronic Radiation Proctitis,Sucralfate,C(C1C(C(C(C(O1)OC2(C(C(C(O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al],APPROVED,digestive_system_disease
2803,Breast Cancer|Colon Cancer,Eniluracil,C#CC1=CNC(=O)NC1=O,PHASE1,digestive_system_disease
2804,Neoplasm Metastasis,Combretastatin,COC1=C(C=C(C=C1)CC(C2=CC(=C(C(=C2)OC)OC)OC)O)O,PHASE1,digestive_system_disease
2807,Liver Dysfunction,Nemonoxacin,CC1CC(CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N,PHASE1,digestive_system_disease
2808,"Hepatitis B|HBV|Hepatitis B, Chronic",Inarigivir,COC1C(C(OC1N2C=CC(=O)NC2=O)CO)OP(=S)(O)OCC3C(CC(O3)N4C=NC5=C(N=CN=C54)N)O,PHASE2,digestive_system_disease
2809,Cystic Fibrosis,Tedizolid,CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F,APPROVED,digestive_system_disease
2811,Ulcerative Colitis,Cobitolimod,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=O)(O)OC3CC(OC3COP(=O)(O)OC4CC(OC4COP(=O)(O)OC5CC(OC5COP(=O)(O)OC6CC(OC6COP(=O)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=O)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=O)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=O)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)O,PHASE1,digestive_system_disease
2812,Breast Cancer|Breast Neoplasms|Colon Cancer|Colonic Cancer|Colon Neoplasms|Lung Cancer|Melanoma|Kidney Cancer,Dacarbazine,CN(C)N=NC1=C(NC=N1)C(=O)N,PHASE1,digestive_system_disease
2813,"Alcoholism,|Alcoholic Liver Disease",Metadoxine,CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)NC1C(=O)O,PHASE2,digestive_system_disease
2814,Portal Vein Thrombosis|Liver Cirrhosis,Nadroparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,digestive_system_disease
2815,Hepatic Impairment|Healthy Subjects,Aprocitentan,C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br,PHASE1,digestive_system_disease
2816,Hepatitis C,Candesartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,PHASE2,digestive_system_disease
2818,NASH - Nonalcoholic Steatohepatitis,Ethinylestradiol,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O,PHASE1,digestive_system_disease
2819,Chemotherapy|Colon Cancer,Mangafodipir,[H+].[H+].[H+].[H+].CC1=NC=C(C(=C1O)CN(CCN(CC2=C(C(=NC=C2COP(=O)([O-])[O-])C)O)CC(=O)[O-])CC(=O)[O-])COP(=O)([O-])[O-].[Mn+2],PHASE2,digestive_system_disease
2821,Bacterial Infections and Mycoses|Liver Disease,Caspofungin,CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O,APPROVED,digestive_system_disease
2822,HIV Infections|Hepatitis C,Zalcitabine,C1CC(OC1CO)N2C=CC(=NC2=O)N,PHASE1,digestive_system_disease
2823,HIV Infections|Hepatitis C,Didanosine,C1CC(OC1CO)N2C=NC3=C2N=CNC3=O,PHASE1,digestive_system_disease
2824,MALT Lymphoma,Chlorambucil,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,PHASE2,digestive_system_disease
2825,Primary Sclerosing Cholangitis,Vidofludimus,COC1=CC=CC(=C1)C2=CC(=C(C=C2)NC(=O)C3=C(CCC3)C(=O)O)F,PHASE2,digestive_system_disease
2826,Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent,Aldoxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)CCCCCN6C(=O)C=CC6=O)CO)O)N)O,PHASE1|PHASE2,digestive_system_disease
2827,Recurrent and Metastatic Gastric Cancer,Fluzoparib,C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE1,digestive_system_disease
2828,Digestive System Diseases|Disorientation,Alfentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC,APPROVED,digestive_system_disease
2829,Stomach Cancer,Vinflunine,CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C,PHASE2|PHASE3,digestive_system_disease
2830,GIST - Gastrointestinal Stromal Tumor,Repaglinide,CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,PHASE1,digestive_system_disease
2832,Irritable Bowel Syndrome,Dextofisopam,CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C,PHASE2,digestive_system_disease
2833,Infection|Liver Dysfunction|Urinary Tract Infection,Temocillin,CC1(C(N2C(S1)C(C2=O)(NC(=O)C(C3=CSC=C3)C(=O)O)OC)C(=O)O)C,APPROVED,digestive_system_disease
2834,"Carcinoma, Hepatocellular",Refametinib,COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)CC(CO)O)NC3=C(C=C(C=C3)I)F)F)F,PHASE2,digestive_system_disease
2835,Primary Biliary Cirrhosis,Moexipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC,PHASE2,digestive_system_disease
2838,C. Difficile|Diarrhea|Enterocolitis,Fidaxomicin,CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C,APPROVED,digestive_system_disease
2839,Cancer of Stomach|Gastroesophageal Cancer,Pegamotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)OC(=O)C(C)NC(=O)COCCOCC(=O)NC(C)C(=O)OC6(C7=C(COC6=O)C(=O)N8CC9=CC1=CC=CC=C1N=C9C8=C7)CC,PHASE2,digestive_system_disease
2840,"Cirrhosis, Liver|Cytopenia",Danazol,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5,PHASE2,digestive_system_disease
2841,Thromboembolism of Vein VTE in Colorectal Cancer|Thromboembolism of Vein in Pancreatic Cancer|Thromboembolism of Vein in Non-small Cell Lung Cancer,Isoquercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O)O,PHASE2|PHASE3,digestive_system_disease
2843,"Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-Small Cell Lung Cancer|Carcinoma, Esophageal|Malignant Pleural Mesotheliomas",Tetrahydrouridine,C1CN(C(=O)NC1O)C2C(C(C(O2)CO)O)O,PHASE1|PHASE2,digestive_system_disease
2845,Pancreatic Cancer,Chlorphenesin,C1=CC(=CC=C1OCC(CO)O)Cl,PHASE1,digestive_system_disease
2846,Nonalcoholic Fatty Liver Disease (NAFLD),Telmisartan,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,APPROVED,digestive_system_disease
2849,Cholelithiasis,Granisetron,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,APPROVED,digestive_system_disease
2850,Hepatic Impairment,Tavapadon,CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C,PHASE1,digestive_system_disease
2851,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Pancreatic Carcinoma|Refractory T-Cell Non-Hodgkin Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,Molibresib,CCNC(=O)CC1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C,PHASE1,digestive_system_disease
2853,Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Breast Cancer|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Breast Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Breast Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Breast Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer,Folate,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,PHASE1,digestive_system_disease
2856,Fatty Liver,Cysteamine,C(CS)N,PHASE1|PHASE2,digestive_system_disease
2857,Gastric Adenocarcinoma|Stage II Gastric Cancer|Stage III Gastric Cancer|Stage IV Gastric Cancer,Fludeoxyglucose,C(C(C(C(C(C=O)F)O)O)O)O,PHASE2,digestive_system_disease
2858,Ileus,Ipamorelin,CC(C)(C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC3=CC=CC=C3C=C2)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CCCCN)C(=O)N)N,PHASE2,digestive_system_disease
2859,Hepatic Impairment,Apalutamide,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,PHASE1,digestive_system_disease
2860,Cystic Fibrosis,Fenretinide,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C,PHASE1,digestive_system_disease
2861,Healthy|Hepatic Impairment,Favipiravir,C1=C(N=C(C(=O)N1)C(=O)N)F,PHASE1,digestive_system_disease
2862,Hepatic Impairment,Lemborexant,CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C,PHASE1,digestive_system_disease
2863,Locally Advanced Rectal Carcinoma|Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8,Ropidoxuridine,C1C(C(OC1N2C=C(C=NC2=O)I)CO)O,PHASE1,digestive_system_disease
2864,Obesity,Quinine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE1,digestive_system_disease
2865,Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma,Linagliptin,CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,PHASE1|PHASE2,digestive_system_disease
2866,Gastroparesis,Aprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,PHASE2,digestive_system_disease
2867,Cystic Fibrosis,Ceftaroline,CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-],APPROVED,digestive_system_disease
2868,Hepatitis B,Resiquimod,CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N,PHASE1|PHASE2,digestive_system_disease
2869,Hepatic Impairment,Tozadenant,CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O,PHASE1,digestive_system_disease
2870,Alpha-1-antitrypsin Deficiency|Liver Cirrhosis,Carbamazepine,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,PHASE2,digestive_system_disease
2871,Chronic Intestinal Pseudo-obstruction,Velusetrag,CC(C)N1C2=CC=CC=C2C=C(C1=O)C(=O)NC3CC4CCC(C3)N4CC(CN(C)S(=O)(=O)C)O,PHASE2,digestive_system_disease
2872,IBS|IBS - Irritable Bowel Syndrome,Tenapanor,CN1CC(C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)C5CN(CC6=C5C=C(C=C6Cl)Cl)C,APPROVED,digestive_system_disease
2873,Hepatic Impairment,Vorasidenib,CC(C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)NC(C)C(F)(F)F,PHASE1,digestive_system_disease
2874,Metastatic Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer,Indoximod,CN1C=C(C2=CC=CC=C21)CC(C(=O)O)N,PHASE1|PHASE2,digestive_system_disease
2875,"Head and Neck Neoplasms|Pheochromocytoma|Colorectal Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell",Fostamatinib,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,PHASE2,digestive_system_disease
2876,Colorectal Cancer,Pyridoxine,CC1=NC=C(C(=C1O)CO)CO,PHASE2,digestive_system_disease
2878,Liver Dysfunction,Mivacurium,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C,PHASE2,digestive_system_disease
2879,Hepatopulmonary Syndrome,Letrozole,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,PHASE2,digestive_system_disease
2880,Hepatitis C|HIV,Abacavir,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,PHASE1,digestive_system_disease
2881,Hepatocellular Carcinoma,Tefinostat,C1CCC(C1)OC(=O)C(C2=CC=CC=C2)NCC3=CC=C(C=C3)NC(=O)CCCCCCC(=O)NO,PHASE1|PHASE2,digestive_system_disease
2883,Cryptosporidiosis|HIV Infections,Spiramycin,CC1CC=CC=CC(C(CC(C(C(C(CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C,PHASE1,digestive_system_disease
2884,Metastatic Pancreatic Cancer,Anamorelin,CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N,PHASE2,digestive_system_disease
2887,Moderate Hepatic Impairment|Normal Hepatic Function,Rivipansel,CC1C(C(C(C(O1)OC2C(CC(CC2OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)O)OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)O)C=C(C=C7S(=O)(=O)O)S(=O)(=O)O)NC(=O)C8=CC(=O)NC(=O)N8)O)O)O,PHASE1,digestive_system_disease
2888,Advanced Malignant Solid Neoplasm|ALK Positive|Metastatic Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,Ceritinib,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,PHASE1,digestive_system_disease
2889,Anus Neoplasms,Indigo,C1=CC=C2C(=C1)C(=C(N2)C3=NC4=CC=CC=C4C3=O)O,PHASE2,digestive_system_disease
2890,Hepatic Impairment,Olorofim,CC1=CC(=C(N1C)C(=O)C(=O)NC2=CC=C(C=C2)N3CCN(CC3)C4=NC=C(C=N4)F)C5=CC=CC=C5,PHASE1,digestive_system_disease
2891,Gastroparesis,Ketoconazole,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,PHASE1,digestive_system_disease
2892,Hepatic Impairment,Ivosidenib,C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N,PHASE1,digestive_system_disease
2893,Celiac Disease,Larazotide,CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)N1CCCC1C(=O)NCC(=O)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)CN,PHASE2,digestive_system_disease
2894,Pancreatic Cancer,Bosutinib,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,PHASE1,digestive_system_disease
2895,Non Small Cell Lung Cancer (NSCLC),Alclometasone,CC1CC2C3C(CC4=CC(=O)C=CC4(C3C(CC2(C1(C(=O)CO)O)C)O)C)Cl,PHASE2,digestive_system_disease
2896,Chronic Pain|Chronic Pain Syndrome|Chronic Pancreatitis|Hyperalgesia|Opioid Use Disorder|Opioid-Related Disorders|Opioid Dependence|Chronic Abdominal Pain|ERCP|Pancreatic Surgery,Lacosamide,CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1,PHASE1,digestive_system_disease
2897,Hepatitis C Infection,Sertraline,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,PHASE1,digestive_system_disease
2898,Cystic Fibrosis,Colistimethate,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+],APPROVED,digestive_system_disease
2900,Gastroesophageal Reflux Disease (GERD),Dexrabeprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,APPROVED,digestive_system_disease
2901,Colorectal Carcinoma,Dolcanatide,CC1C(=O)NC2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)CNC(=O)C(NC2=O)C(C)O)C(=O)NC(CC(C)C)C(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)C)CC(=O)N)C(C)C)CC(C)C)CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)N)N,PHASE1,digestive_system_disease
2902,Crohn's Disease,Calcitriol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,PHASE1|PHASE2,digestive_system_disease
2903,Gastroparesis,Naronapride,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCCCC(=O)OC3CN4CCC3CC4,PHASE2,digestive_system_disease
2904,Healthy Subjects|Hepatic Impairment,Selatogrel,CCCCOC(=O)N1CCN(CC1)C(=O)C(CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CCC(C4)OC,PHASE1,digestive_system_disease
2905,Hepatic Impairment|Advanced Malignant Solid Tumor,Tazemetostat,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,PHASE1,digestive_system_disease
2906,Ulcerative Colitis (UC),Upadacitinib,CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F,PHASE2|PHASE3,digestive_system_disease
2907,Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,Bosentan,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,PHASE1,digestive_system_disease
2908,Cancer of Pancreas,Bemcentinib,C1CCN(C1)C2CCC3=C(CC2)C=C(C=C3)NC4=NN(C(=N4)N)C5=NN=C6C(=C5)CCCC7=CC=CC=C76,PHASE1|PHASE2,digestive_system_disease
2909,Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer,Brigatinib,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC,PHASE2,digestive_system_disease
2910,Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer,Pralsetinib,CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC,PHASE2,digestive_system_disease
2911,Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer,Selpercatinib,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,PHASE2,digestive_system_disease
2912,Alcoholic Hepatitis (AH),Selonsertib,CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F,PHASE2,digestive_system_disease
2915,Hepatic Impairment,Imeglimin,CC1N=C(NC(=N1)N(C)C)N,PHASE1,digestive_system_disease
2916,Chronic Kidney Disease,Sevelamer,C=CCN.C1C(O1)CCl,APPROVED,digestive_system_disease
2917,Eosinophilic Esophagitis,Loratadine,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,PHASE2,digestive_system_disease
2918,Cirrhosis,Cianidanol,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,digestive_system_disease
2919,Cirrhosis,Catechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,digestive_system_disease
2920,Cystic Fibrosis,Riociguat,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,PHASE2,digestive_system_disease
2921,Hepatocellular Carcinoma,Patupilone,CC1CCCC2(C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C,PHASE2,digestive_system_disease
2923,Digestive System Disorders,Ulimorelin,CC1CNC(C(=O)N(C(C(=O)NC(C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4,PHASE1,digestive_system_disease
2924,Bladder Cancer|Breast Cancer|Colorectal Cancer|Gastrointestinal Neoplasm|Head and Neck Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer,Picoplatin,CC1=CC=CC=N1.N.[Cl-].[Cl-].[Pt+2],PHASE1,digestive_system_disease
2926,Chronic Hepatitis C,Chlorcyclizine,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,PHASE1|PHASE2,digestive_system_disease
2927,Hepatic Insufficiency,Tipranavir,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,PHASE1,digestive_system_disease
2928,"Carcinoma, Hepatocellular",Foretinib,COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,PHASE1,digestive_system_disease
2930,Pancreatic Cancer|Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer,Tosedostat,CC(C)CC(C(C(=O)NO)O)C(=O)NC(C1=CC=CC=C1)C(=O)OC2CCCC2,PHASE1|PHASE2,digestive_system_disease
2931,Cholecystitis,Nefopam,CN1CCOC(C2=CC=CC=C2C1)C3=CC=CC=C3,APPROVED,digestive_system_disease
2932,Hepatic Disease,Ketotifen,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,APPROVED,digestive_system_disease
2933,Infectious Peritonitis,Dalbavancin,CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O,APPROVED,digestive_system_disease
2934,Advanced Pancreatic Carcinoma|Locally Advanced Pancreatic Carcinoma|Metastatic Pancreatic Carcinoma|Pancreatic Neoplasm|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,Verteporfin,CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C,PHASE2,digestive_system_disease
2935,Hepatic Veno-Occlusive Disease,Defibrotide,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)OP(=O)(O)O,PHASE2|PHASE3,digestive_system_disease
2936,Acute-On-Chronic Liver Failure,Trimetazidine,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,PHASE1,digestive_system_disease
2937,Metastatic Pancreatic Cancer,Azeliragon,CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC,PHASE1|PHASE2,digestive_system_disease
2938,Clear Cell Renal Cell Carcinoma|Locally Advanced Pancreatic Cancer|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Metastatic Renal Cell Carcinoma|Metastatic Urothelial Carcinoma|Metastatic Pancreatic Cancer|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Endometrial Cancer|Metastatic Castration-resistant Prostate Cancer,Ceralasertib,CC1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=N)(=O)C)C4=C5C=CNC5=NC=C4,PHASE2,digestive_system_disease
2939,Antipsychotic Induced Weight Gain|Non-alcoholic Steatohepatitis (NASH),Fluvoxamine,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,PHASE1,digestive_system_disease
2940,Irritable Bowel Syndrome (IBS),Ebastine,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,APPROVED,digestive_system_disease
2941,Cystic Fibrosis,Amikacin,C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N,PHASE2,digestive_system_disease
2943,Alpha 1-Antitrypsin Deficiency|Emphysema|COPD,Alvelestat,CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC3=NC=C(C=C3)S(=O)(=O)C)C4=CC=NN4C,PHASE2,digestive_system_disease
2944,Chronic Erosive Gastritis,Teprenone,CC(=CCCC(=CCCC(=CCCC(=CCCC(=O)C)C)C)C)C,APPROVED,digestive_system_disease
2945,"Locally Advanced Gastrointestinal Stromal Tumor|Locally Advanced Sarcoma|Metastatic Gastrointestinal Stromal Tumor|Metastatic Sarcoma|Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8|Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8",Rogaratinib,CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N,PHASE2,digestive_system_disease
2946,Gastroenteritis,Dimenhydrinate,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,APPROVED,digestive_system_disease
2947,Metastatic Biliary Tract Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Digestive System Neoplasm|Metastatic Pancreatic Adenocarcinoma|Stage IV Colorectal Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7,Sucrosofate,C(C1C(C(C(C(O1)OC2(C(C(C(O2)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)COS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O,PHASE1|PHASE2,digestive_system_disease
2948,"Mycosis Fungoides|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",Ifosfamide,C1CN(P(=O)(OC1)NCCCl)CCCl,PHASE1,digestive_system_disease
2949,Ulcerative Colitis,Terbinafine,CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21,PHASE2,digestive_system_disease
2950,Nasopharyngeal Carcinoma|EBV-Related Gastric Carcinoma|EBV-Related Leiomyosarcoma|EBV Related Carcinoma|EBV-Related Sarcoma,Nanatinostat,C1C2C(C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO,PHASE1|PHASE2,digestive_system_disease
2951,Cystic Fibrosis,Ticarcillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CSC=C3)C(=O)O)C(=O)O)C,APPROVED,digestive_system_disease
2952,Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Solid Tumor,Infigratinib,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,PHASE2,digestive_system_disease
2953,Pancreatic Neoplasm,Antroquinonol,CC1C(C(C(=C(C1=O)OC)OC)O)CC=C(C)CCC=C(C)CCC=C(C)C,PHASE1|PHASE2,digestive_system_disease
2954,Hepatic Failure,Latrepirdine,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C,PHASE1,digestive_system_disease
2955,Colorectal Adenomatous Polyp|Colorectal Carcinoma|Familial Adenomatous Polyposis|Multiple Adenomatous Polyps,Dordaviprone,CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5,PHASE1,digestive_system_disease
2956,Solid Tumor|Pancreatic Cancer,Evofosfamide,CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr,PHASE1,digestive_system_disease
2957,"Cystic Fibrosis|Pneumonia, Bacterial",Cilastatin,CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)O)C,APPROVED,digestive_system_disease
2958,"Cystic Fibrosis|Pneumonia, Bacterial",Relebactam,C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3,APPROVED,digestive_system_disease
2959,Prostate Cancer|Metabolic Syndrome|Hypogonadism|Fatty Liver,Triptorelin,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,APPROVED,digestive_system_disease
2960,Hepatic Impairment|Moderate Impaired Hepatic Function,Quizartinib,CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3,PHASE1,digestive_system_disease
2961,Pancreas Cancer|Biliary Tract Cancer|Psychological Distress,Psilocybin,CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,PHASE1,digestive_system_disease
2962,Fontan Operation|Protein-Losing Enteropathy|Camostat Mesylate,Camostat,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N,PHASE2,digestive_system_disease
2963,"Cystic Fibrosis|Pneumonia, Bacterial",Cefiderocol,CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4(CCCC4)CCNC(=O)C5=C(C(=C(C=C5)O)O)Cl)C(=O)[O-],APPROVED,digestive_system_disease
2964,HIV Infections|Anus Neoplasms,Isotretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1,digestive_system_disease
2965,Advanced HCC,Ningetinib,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(=O)NC3=CC(=C(C=C3)OC4=C5C=CC(=CC5=NC=C4)OCC(C)(C)O)F,PHASE1|PHASE2,digestive_system_disease
2966,Bulimia Nervosa,Lisdexamfetamine,CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N,PHASE2,digestive_system_disease
2967,Onchocerciasis,Albendazole,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,PHASE2,digestive_system_disease
2968,Onchocerciasis,Ivermectin,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,PHASE2,digestive_system_disease
2969,Gastroesophageal Reflux Disease,Domperidone,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,APPROVED,digestive_system_disease
2970,D842-related Mutant GIST,Crenolanib,CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4,PHASE2,digestive_system_disease
2971,Peritonitis,Icodextrin,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,APPROVED,digestive_system_disease
2972,Non-Alcoholic Fatty Liver Disease|Hyperuricemia,Febuxostat,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,APPROVED,digestive_system_disease
2973,Biliary Tract Cancer|Metastatic Cancer|Advanced Cancer,Merestinib,CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F,PHASE2,digestive_system_disease
2974,Hepatic Impairment,Cenobamate,C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl,PHASE1,digestive_system_disease
2975,Esophageal Cancer|Endostatin,Endostatin,CN(CC(=O)C1=CC=CC=C1)N=O,PHASE2,digestive_system_disease
2977,Healthy Volunteers|Hepatic Impairment,Fedratinib,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4,PHASE1,digestive_system_disease
2978,"Acute Intermittent Porphyria (AIP)|Acute Hepatic Porphyria (AHP)|Porphyria, Acute Intermittent|Acute Porphyria",Givosiran,CC1CC(CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCOC4C(C(C(C(O4)CO)O)O)NC(=O)C)O,PHASE1,digestive_system_disease
2980,Hepatic Impairment,Orelabrutinib,C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4,PHASE1,digestive_system_disease
2981,"Hepatitis C, Chronic",Amantadine,C1C2CC3CC1CC(C2)(C3)N,APPROVED,digestive_system_disease
2982,Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma,Linsitinib,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,PHASE2,digestive_system_disease
2983,Advanced Hepatocellular Carcinoma,Capmatinib,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,PHASE1|PHASE2,digestive_system_disease
2984,Liver Cancer,Irofulven,CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CO,PHASE1|PHASE2,digestive_system_disease
2985,"Parathyroid Hormone|Tenofovir Disoproxil Fumarate|Chronic Hepatitis, B Virus Without Hepatitis Delta (Diagnosis)|Vitamin D",Ergocalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,APPROVED,digestive_system_disease
2986,Ulcerative Colitis,Dersalazine,CC1=NC2=C(N1CC3CCN(CC3)C(=O)C=C(C4=CC=CC=C4)C5=CC=C(C=C5)N=NC6=CC(=C(C=C6)O)C(=O)O)C=CN=C2,PHASE2,digestive_system_disease
2987,"Gastroesophageal Reflux Disease|Reflux, Gastroesophageal",Lavoltidine,CN1C(=NC(=N1)CO)NCCCOC2=CC=CC(=C2)CN3CCCCC3,PHASE1,digestive_system_disease
2988,Hepatic Impairment,Remibrutinib,CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C,PHASE1,digestive_system_disease
2990,Hepatocellular Carcinoma,Menatetrenone,CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,PHASE2|PHASE3,digestive_system_disease
2991,Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Adenocarcinoma AJCC v7|Stage II Esophageal Adenocarcinoma AJCC v7|Stage IIA Esophageal Adenocarcinoma AJCC v7|Stage IIB Esophageal Adenocarcinoma AJCC v7|Stage IIIA Esophageal Adenocarcinoma AJCC v7|Stage IIIB Esophageal Adenocarcinoma AJCC v7,Taladegib,CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F,PHASE1|PHASE2,digestive_system_disease
2992,Non-erosive Reflux Disease,Revaprazan,CC1C2=CC=CC=C2CCN1C3=NC(=NC(=C3C)C)NC4=CC=C(C=C4)F,PHASE2,digestive_system_disease
2993,Hepatitis|Hepatitis C,Filibuvir,CCC1=CC(=CC(=N1)CC)CCC2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5,PHASE2,digestive_system_disease
2994,Hepatic Impairment|Healthy,Bardoxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C,PHASE1,digestive_system_disease
2995,Irritable Bowel Syndrome,Ethosuximide,CCC1(CC(=O)NC1=O)C,PHASE2,digestive_system_disease
2996,Non-erosive Reflux Disease,Fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,PHASE2|PHASE3,digestive_system_disease
2998,Irritable Bowel Syndrome,Asimadoline,CN(C(CN1CCC(C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2,digestive_system_disease
2999,Cirrhosis|Refractory/Recurrent Ascites,Tolvaptan,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C,PHASE2|PHASE3,digestive_system_disease
3000,Hepatic Impairment,Molnupiravir,CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)NO)O)O,PHASE1,digestive_system_disease
3001,Healthy|Hepatic Impairment,Cenerimod,CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OCC(CO)O,PHASE1,digestive_system_disease
3002,Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis|Fatigue in Workers With Chronic C Hepatitis|Fatigue,Acetylcarnitine,CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C,APPROVED,digestive_system_disease
3003,Hepatocellular Carcinoma (HCC),Fisogatinib,COC1=CC(=C(C(=C1Cl)C2=CC3=CN=C(N=C3C=C2)NC4COCCC4NC(=O)C=C)Cl)OC,PHASE1,digestive_system_disease
3004,Herpes Simplex|HIV Infections|Hepatitis B,Fialuridine,C1=C(C(=O)NC(=O)N1C2C(C(C(O2)CO)O)F)I,PHASE2,digestive_system_disease
3005,Non-alcoholic Fatty Liver Disease,Oltipraz,CC1=C(SSC1=S)C2=NC=CN=C2,PHASE2,digestive_system_disease
3006,Hepatic Impairment,Glasdegib,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,PHASE1,digestive_system_disease
3007,"Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Neutropenia|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Phenobarbital,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,PHASE1,digestive_system_disease
3008,Gastric Cancer,Olanzapine,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,PHASE2,digestive_system_disease
3009,Rheumatoid Arthritis|Osteoarthritis|Ankylosing Spondylitis|Other Musculoskeletal Disorder|Gastric Ulcer|Enteritis|NSAID-Associated Gastropathy|NSAID (Non-Steroidal Anti-Inflammatory Drug) Induced Enteropathy,Eupatilin,COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)OC)O)OC,APPROVED,digestive_system_disease
3010,Fascioliasis,Triclabendazole,CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl,APPROVED,digestive_system_disease
3013,Chronic Hepatic Impairment,Preladenant,COCCOC1=CC=C(C=C1)N2CCN(CC2)CCN3C4=C(C=N3)C5=NC(=NN5C(=N4)N)C6=CC=CO6,PHASE1,digestive_system_disease
3014,Solid Tumors|Non-small Cell Lung Cancer|Castration Resistant Prostate Cancer|Microsatellite Stable Colorectal Cancer,Navarixin,CCC(C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C,PHASE2,digestive_system_disease
3015,Gastroesophageal Reflux Disease,Pumosetrag,C1CN2CCC1C(C2)NC(=O)C3=CNC4=C(C3=O)SC=C4,PHASE2,digestive_system_disease
3017,"Biliary Atresia, Kasai Portoenterostomy Status",Meloxicam,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,APPROVED,digestive_system_disease
3018,Hepatic Impairment,Omaveloxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C,PHASE1,digestive_system_disease
3021,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Darolutamide,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,PHASE1,digestive_system_disease
3022,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Tretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1,digestive_system_disease
3023,Ulcerative Colitis,Hydroxocobalamin,CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2],PHASE2,digestive_system_disease
3024,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Capivasertib,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,PHASE2,digestive_system_disease
3025,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Taselisib,CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C,PHASE2,digestive_system_disease
3026,Short Bowel Syndrome,Cholestyramine,CCC(C)C.CCC(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)C[N+](C)(C)C.N.[Cl-],PHASE2,digestive_system_disease
3027,Neoplasms,Streptozocin,CN(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O,PHASE2,digestive_system_disease
3028,Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm,Navitoclax,CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C,PHASE1,digestive_system_disease
3029,Alcohol-Related Disorders,Dihydromyricetin,C1=C(C=C(C(=C1O)O)O)C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O,PHASE1,digestive_system_disease
3030,Falciparum Malaria,Artemether,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC)C,PHASE2,digestive_system_disease
3032,Hepatic Impairment,Iptacopan,CCOC1CCN(C(C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC,PHASE1,digestive_system_disease
3033,Rectal Cancer,Hydralazine,C1=CC=C2C(=C1)C=NN=C2NN,PHASE1|PHASE2,digestive_system_disease
3036,Moderate Hepatic Impairment,Mitapivat,C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5,PHASE1,digestive_system_disease
3037,Type 2 Diabetes Mellitus|Liver Dysfunction,Mitiglinide,C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)O,APPROVED,digestive_system_disease
3038,Cancer Stem Cell,Fursultiamine,CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCO)SSCC2CCCO2)C,PHASE2,digestive_system_disease
3040,Choledocholithiasis|Cholangiocarcinoma|Pancreatitis|Pancreatic Cancer,Etomidate,CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2,APPROVED,digestive_system_disease
3041,Non-small Cell Lung Cancer,Almonertinib,CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC,PHASE2,digestive_system_disease
3042,Hepatitis C,Norethindrone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE1,digestive_system_disease
3043,Hepatitis C,Norethisterone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE1,digestive_system_disease
3044,Head and Neck Neoplasms|Mucositis,Brilacidin,C1CNCC1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4OC5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N,PHASE2,digestive_system_disease
3046,Hepatic Encephalopathy|Liver Cirrhosis,Flumazenil,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,PHASE1|PHASE2,digestive_system_disease
3047,Advanced or Metastatic Hepatocellular Cancer|Advanced or Metastatic Ovarian Cancer|Metastatic Renal Cell Cancer|Advanced or Metastatic Gastric Carcinoma,Tasquinimod,CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O,PHASE2,digestive_system_disease
3048,Irritable Colon,Alosetron,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,PHASE2,digestive_system_disease
3049,Anti-Psychotic|Management of Manifestations of Psychotic Disorders|Treatment of Schizophrenia|Control Nausea and Vomiting|Relief of Restlessness and Apprehension Before Surgery|Acute Intermittent Porphyria|Adjunct in the Treatment of Tetanus|Control Manifestations of the Manic Type of Mani-depressive Illness|Relief of Intractable Hiccups,Chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,PHASE1,digestive_system_disease
3050,"Long QT Syndrome|Abnormalities, Drug-Induced",Ibutilide,CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,APPROVED,cardiovascular_disease
3051,Multi Vessel Coronary Artery Disease,Ticagrelor,CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F,APPROVED,cardiovascular_disease
3052,Multi Vessel Coronary Artery Disease,Clopidogrel,COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,APPROVED,cardiovascular_disease
3053,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,PHASE1,cardiovascular_disease
3054,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE1,cardiovascular_disease
3055,Intracranial Aneurysms|Seizure,Levetiracetam,CCC(C(=O)N)N1CCCC1=O,APPROVED,cardiovascular_disease
3056,Multiple Myeloma|Lymphoma,Lenalidomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,PHASE1,cardiovascular_disease
3057,Atrial Fibrillation|Obesity|Overweight,Semaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,APPROVED,cardiovascular_disease
3058,Multiple Myeloma,Bortezomib,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,PHASE2,cardiovascular_disease
3059,Multiple Myeloma,Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE2,cardiovascular_disease
3060,Hypertension,Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O,APPROVED,cardiovascular_disease
3061,"Glaucoma, Open-Angle|Ocular Hypertension",Dorzolamide,CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C,APPROVED,cardiovascular_disease
3062,Genetics Disease|Type2 Diabetes|Heart Failure,Sitagliptin,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,APPROVED,cardiovascular_disease
3063,Type 2 Diabetes Mellitus|Hypertension,Acetylcysteine,CC(=O)NC(CS)C(=O)O,APPROVED,cardiovascular_disease
3064,Out-Of-Hospital Cardiac Arrest|Postcardiac Arrest Syndrome,Hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,PHASE2,cardiovascular_disease
3065,Anemia|Cardiovascular Disease,Ferumoxytol,O[Fe]=O.O[Fe]=O.[Fe],PHASE1|PHASE2,cardiovascular_disease
3066,Thromboembolism|Hemodialysis,Dalteparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2|PHASE3,cardiovascular_disease
3067,Thromboembolism|Hemodialysis,Tinzaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2|PHASE3,cardiovascular_disease
3068,Acute Coronary Syndrome,Rosuvastatin,CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,APPROVED,cardiovascular_disease
3069,HIV|Cardiovascular Disease,Abacavir,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,APPROVED,cardiovascular_disease
3073,Acute Ischemic Stroke,Tirofiban,CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,APPROVED,cardiovascular_disease
3074,Coronary Artery Disease|Coronary Stenosis,Sirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,APPROVED,cardiovascular_disease
3075,Coronary Artery Disease|Coronary Stenosis,Everolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,APPROVED,cardiovascular_disease
3077,Asthma|Heart Rate Fast,Albuterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,APPROVED,cardiovascular_disease
3078,Cardiovascular Disease,Efavirenz,C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,APPROVED,cardiovascular_disease
3079,Cardiovascular Disease,Rilpivirine,CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N,APPROVED,cardiovascular_disease
3080,"Dyslipidemias|Atherosclerosis|Diabetes Mellitus, Type 2",Atorvastatin,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,APPROVED,cardiovascular_disease
3081,"Dyslipidemias|Atherosclerosis|Diabetes Mellitus, Type 2",Ezetimibe,C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O,APPROVED,cardiovascular_disease
3082,Percutaneous Transluminal Coronary Angioplasty|Coronary Disease,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,APPROVED,cardiovascular_disease
3083,Type 1 Diabetes|Diabetic Kidney Disease|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Sensitivity,Metformin,CN(C)C(=N)N=C(N)N,PHASE1,cardiovascular_disease
3084,Type 1 Diabetes|Diabetic Kidney Disease|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Sensitivity,Iohexol,CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,PHASE1,cardiovascular_disease
3085,Essential Hypertension,Fimasartan,CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C,PHASE1,cardiovascular_disease
3086,Essential Hypertension,Ketoconazole,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,PHASE1,cardiovascular_disease
3087,Essential Hypertension,Rifampin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE1,cardiovascular_disease
3088,Essential Hypertension,Rifampicin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE1,cardiovascular_disease
3089,Coronary Artery Disease|Pain|Peripheral Nervous System Diseases|Polyneuropathy,Ranolazine,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,APPROVED,cardiovascular_disease
3090,Liver Transplant With Clinically Significant Portal Hypertension,Somatostatin,CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)C(C)N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O,PHASE1,cardiovascular_disease
3091,Multiple Myeloma,Cyclophosphamide,C1CNP(=O)(OC1)N(CCCl)CCCl,PHASE2,cardiovascular_disease
3093,Multiple Myeloma,Melphalan,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,PHASE2,cardiovascular_disease
3095,Primary Open Angle Glaucoma|Ocular Hypertension,Epigallocatechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O,PHASE1|PHASE2,cardiovascular_disease
3096,Waldenstrom's Macroglobulinemia,Ibrutinib,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE1,cardiovascular_disease
3097,Obesity|Prehypertension|Hypertension,Clonidine,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,PHASE2,cardiovascular_disease
3098,Obesity|Prehypertension|Hypertension,Hydrochlorothiazide,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,PHASE2,cardiovascular_disease
3099,Anaphylaxis|Hypotension|Bronchospasm|Angioedema,Epinephrine,CNCC(C1=CC(=C(C=C1)O)O)O,PHASE2,cardiovascular_disease
3101,"Ocular Hypertension|Glaucoma, Open-Angle",Latanoprost,CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O,APPROVED,cardiovascular_disease
3103,DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Romidepsin,CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,PHASE2,cardiovascular_disease
3104,Hypertension,Minocycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,APPROVED,cardiovascular_disease
3105,Postpartum Pregnancy-Induced Hypertension|Postpartum Preeclampsia|Pregnancy-Induced Hypertension in Postpartum|Hypertensive Emergency,Labetalol,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,APPROVED,cardiovascular_disease
3106,Postpartum Pregnancy-Induced Hypertension|Postpartum Preeclampsia|Pregnancy-Induced Hypertension in Postpartum|Hypertensive Emergency,Nifedipine,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,APPROVED,cardiovascular_disease
3107,Stroke|Inflammation,Fingolimod,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,PHASE2,cardiovascular_disease
3108,Ischemic Optic Neuropathy,Alprostadil,CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O,PHASE2,cardiovascular_disease
3109,Hypertension,Atenolol,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,APPROVED,cardiovascular_disease
3110,Atherosclerosis,Gemfibrozil,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,APPROVED,cardiovascular_disease
3111,Coronary Artery Disease,Prasugrel,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,APPROVED,cardiovascular_disease
3112,Transfusional Iron Overload|Transfusional Hemosiderosis,Deferasirox,C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O,PHASE2,cardiovascular_disease
3113,Transfusional Iron Overload|Transfusional Hemosiderosis,Deferoxamine,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,PHASE2,cardiovascular_disease
3114,Heart Failure With Reduced Ejection Fraction,Vericiguat,COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N,APPROVED,cardiovascular_disease
3115,Coronary Heart Disease,Varenicline,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,APPROVED,cardiovascular_disease
3116,Endothelial Dysfunction,Telmisartan,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,PHASE2,cardiovascular_disease
3117,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes|Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease|Peripheral T-cell Lymphoma,Cyclosporine,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,cardiovascular_disease
3118,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes|Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease|Peripheral T-cell Lymphoma,Pentostatin,C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O,PHASE2,cardiovascular_disease
3119,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes|Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease|Peripheral T-cell Lymphoma,Mycophenolate,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,PHASE2,cardiovascular_disease
3120,Diabetic Macular Edema,Pegaptanib,COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC,APPROVED,cardiovascular_disease
3122,Acute Coronary Syndrome,Bivalirudin,CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C5CCCN5C(=O)C(CC6=CC=CC=C6)N,APPROVED,cardiovascular_disease
3123,Atherosclerosis|Coronary Artery Disease|Inflammation,Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2|PHASE3,cardiovascular_disease
3124,Hypertension,Amlodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,APPROVED,cardiovascular_disease
3126,Hypertrophic Cardiomyopathy|Non-ischemic Dilated Cardiomyopathy|Microvascular Ischaemia of Myocardium,Regadenoson,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N,APPROVED,cardiovascular_disease
3127,Waldenstrom Macroglobulinemia,Zanubrutinib,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,PHASE2,cardiovascular_disease
3128,Waldenstrom Macroglobulinemia,Bendamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,PHASE2,cardiovascular_disease
3132,Atrial Fibrillation,Antazoline,C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3,APPROVED,cardiovascular_disease
3133,Atrial Fibrillation,Propafenone,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,APPROVED,cardiovascular_disease
3134,Deep Vein Thrombosis (DVT)|Blood Clots,Enoxaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,cardiovascular_disease
3135,"Lymphoma, Non-Hodgkin|Multiple Myeloma",Plerixafor,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3,PHASE2,cardiovascular_disease
3136,Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Fludarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,PHASE1,cardiovascular_disease
3137,Cerebral Vasospasm|Subarachnoid Hemorrhage,Sildenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,PHASE2,cardiovascular_disease
3138,Atherosclerosis,Spironolactone,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,APPROVED,cardiovascular_disease
3139,"Heart Failure, Congestive",Eplerenone,CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC,APPROVED,cardiovascular_disease
3140,Multiple Myeloma,Thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,PHASE2,cardiovascular_disease
3141,Coronary Artery Disease|Angiotensin Converting Enzyme|Angiotensin Receptor Blockers|Cardiopulmonary Bypass|Fibrinolysis|Inflammation,Ramipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O,APPROVED,cardiovascular_disease
3142,Coronary Artery Disease|Angiotensin Converting Enzyme|Angiotensin Receptor Blockers|Cardiopulmonary Bypass|Fibrinolysis|Inflammation,Candesartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,APPROVED,cardiovascular_disease
3143,Multiple Myeloma,Pomalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,PHASE1|PHASE2,cardiovascular_disease
3144,Aortic Valve Insufficiency,Metoprolol,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,APPROVED,cardiovascular_disease
3145,Multiple Myeloma,Carfilzomib,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,PHASE2,cardiovascular_disease
3146,Relapsed or Refractory Multiple Myeloma,Vorinostat,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,PHASE2,cardiovascular_disease
3147,Hypertension,Cannabidiol,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,PHASE1,cardiovascular_disease
3148,Polymyalgia Rheumatica|Effect of Drug|Safety Issues,Tofacitinib,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,PHASE2,cardiovascular_disease
3149,Heart Failure,Levosimendan,CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,APPROVED,cardiovascular_disease
3150,Heart Failure,Simendan,CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,APPROVED,cardiovascular_disease
3151,Pulmonary Arterial Hypertension,Macitentan,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,APPROVED,cardiovascular_disease
3152,Pulmonary Arterial Hypertension,Tadalafil,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,APPROVED,cardiovascular_disease
3153,Pulmonary Arterial Hypertension,Vardenafil,CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C,APPROVED,cardiovascular_disease
3155,Carotid Artery Stenosis,Remifentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC,APPROVED,cardiovascular_disease
3156,Carotid Artery Stenosis,Dexmedetomidine,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,APPROVED,cardiovascular_disease
3157,Peripheral Vascular Disease|Intermittent Claudication|Peripheral Arterial Disease,Levocarnitine,C[N+](C)(C)CC(CC(=O)[O-])O,APPROVED,cardiovascular_disease
3158,Peripheral Vascular Disease|Intermittent Claudication|Peripheral Arterial Disease,Carnitine,C[N+](C)(C)CC(CC(=O)[O-])O,APPROVED,cardiovascular_disease
3159,Single-ventricle|Heart Diseases,Colchicine,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,PHASE2|PHASE3,cardiovascular_disease
3162,Hypotension,Ivabradine,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC,PHASE2,cardiovascular_disease
3163,Hypotension,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,PHASE2,cardiovascular_disease
3164,"Diabetes Mellitus, Type 2|Essential Hypertension",Lacidipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C,APPROVED,cardiovascular_disease
3165,Myocardial Ischemic Reperfusion Injury,Sevoflurane,C(OC(C(F)(F)F)C(F)(F)F)F,APPROVED,cardiovascular_disease
3166,"Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Small-Cell|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell, Marginal Zone",Vincristine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE1,cardiovascular_disease
3167,High Altitude Pulmonary Hypertension,Bambuterol,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,PHASE1,cardiovascular_disease
3168,Multiple Myeloma,Tacrolimus,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,PHASE1|PHASE2,cardiovascular_disease
3169,Multiple Myeloma,Panobinostat,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,PHASE1|PHASE2,cardiovascular_disease
3170,Hypertension,Losartan,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,APPROVED,cardiovascular_disease
3171,Permanent Atrial Fibrillation|Venous Thrombosis|Pulmonary Embolism|Anticoagulation Treatment at Least > or = to 12-month,Rivaroxaban,C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl,APPROVED,cardiovascular_disease
3172,Permanent Atrial Fibrillation|Venous Thrombosis|Pulmonary Embolism|Anticoagulation Treatment at Least > or = to 12-month,Fluindione,C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)F,APPROVED,cardiovascular_disease
3173,Permanent Atrial Fibrillation|Venous Thrombosis|Pulmonary Embolism|Anticoagulation Treatment at Least > or = to 12-month,Warfarin,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,APPROVED,cardiovascular_disease
3174,ST Segment Elevation Myocardial Infarction,Nicorandil,C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-],APPROVED,cardiovascular_disease
3175,Atrial Fibrillation|Atrial Flutter,Diltiazem,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,APPROVED,cardiovascular_disease
3176,Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer,Simvastatin,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE2,cardiovascular_disease
3177,Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer,Doxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,cardiovascular_disease
3178,Heart Arrest,Desflurane,C(C(F)(F)F)(OC(F)F)F,APPROVED,cardiovascular_disease
3179,Dilated Cardiomyopathy,Verapamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,APPROVED,cardiovascular_disease
3180,Dilated Cardiomyopathy,Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,APPROVED,cardiovascular_disease
3181,Pulmonary Hypertension,Bosentan,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,PHASE2|PHASE3,cardiovascular_disease
3182,Pulmonary Hypertension,Ambrisentan,CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,PHASE2|PHASE3,cardiovascular_disease
3183,Chest Pain Rule Out Myocardial Infarction,Citalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,cardiovascular_disease
3184,Atrial Fibrillation,Dabigatran,CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N,APPROVED,cardiovascular_disease
3185,Cardiovascular Disease,Evacetrapib,CC1=CC(=C2C(=C1)C(CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C,PHASE1,cardiovascular_disease
3186,Heart Failure,Dapagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,APPROVED,cardiovascular_disease
3190,Multiple Myeloma,Iberdomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5,PHASE1|PHASE2,cardiovascular_disease
3191,Coronary Heart Disease,Amiloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,PHASE2|PHASE3,cardiovascular_disease
3192,Pulmonary Arterial Hypertension,Treprostinil,CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,APPROVED,cardiovascular_disease
3193,Multiple Myeloma in Relapse,Clarithromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,PHASE2,cardiovascular_disease
3194,Venous Thromboembolism|Cancer,Apixaban,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,PHASE2,cardiovascular_disease
3195,Multiple Myeloma,Ibritumomab,CC(CN(CC(CC1=CC=C(C=C1)NC(=O)NC)N(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,PHASE2,cardiovascular_disease
3196,Polymyalgia Rheumatica|Inflammatory Diseases,Prednisone,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,PHASE2,cardiovascular_disease
3197,Stroke,Serotonin,C1=CC2=C(C=C1O)C(=CN2)CCN,PHASE2,cardiovascular_disease
3198,Chronic Heart Failure|Hyperuricemia,Allopurinol,C1=NNC2=C1C(=O)NC=N2,APPROVED,cardiovascular_disease
3199,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Selinexor,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,PHASE1|PHASE2,cardiovascular_disease
3201,Multiple Myeloma,Oprozomib,CC1=NC=C(S1)C(=O)NC(COC)C(=O)NC(COC)C(=O)NC(CC2=CC=CC=C2)C(=O)C3(CO3)C,PHASE1|PHASE2,cardiovascular_disease
3203,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Ixazomib,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,PHASE2,cardiovascular_disease
3204,Chronic Thromboembolic Disease (CTED)|Exercise Intolerance Post PEA Surgery,Riociguat,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,PHASE2,cardiovascular_disease
3205,"Diabetes Mellitus, Non-Insulin-Dependent|Hypertensive Disease",Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,APPROVED,cardiovascular_disease
3206,Hypertension,Lisinopril,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,APPROVED,cardiovascular_disease
3207,Hypertension,Chlorthalidone,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,APPROVED,cardiovascular_disease
3208,Hypertension,Chlortalidone,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,APPROVED,cardiovascular_disease
3209,Subarachnoid Hemorrhage|Cerebral Vasospasm,Dantrolene,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],PHASE1|PHASE2,cardiovascular_disease
3210,Non-Valvular Atrial Fibrillation|Left Atrial Appendage Closure,Edoxaban,CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C,APPROVED,cardiovascular_disease
3211,Congenital Hypothyroidism,Levothyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,APPROVED,cardiovascular_disease
3212,Heart Failure,Empagliflozin,C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,PHASE1,cardiovascular_disease
3213,Pulmonary Artery Hypertension,Trimetazidine,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,PHASE2,cardiovascular_disease
3214,Hypertension,Acetaminophen,CC(=O)NC1=CC=C(C=C1)O,APPROVED,cardiovascular_disease
3215,Atrial Fibrillation,Vernakalant,COC1=C(C=C(C=C1)CCOC2CCCCC2N3CCC(C3)O)OC,APPROVED,cardiovascular_disease
3216,Multiple Myeloma,Etoposide,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,PHASE2,cardiovascular_disease
3217,Thrombosis,Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,PHASE1,cardiovascular_disease
3218,Arterial Hypertension|Dyslipidemias|Blood Pressure|Lipid Metabolism Disorders,Perindopril,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O,APPROVED,cardiovascular_disease
3219,Hypertension,Bisoprolol,CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O,APPROVED,cardiovascular_disease
3220,Right Hemisphere Stroke|Hemispatial Neglect|Motor Deficit,Rotigotine,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,PHASE2,cardiovascular_disease
3221,Diabetes,Gliclazide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,APPROVED,cardiovascular_disease
3222,"Hodgkin Disease|Lymphoma, Non-Hodgkin|Multiple Myeloma|Mantle Cell Lymphoma",Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,cardiovascular_disease
3223,Myocardial Bridging,Nebivolol,C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O,PHASE2,cardiovascular_disease
3224,Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Myeloproliferative Diseases|Non-Hodgkins Lymphoma|Hodgkins Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome,Busulfan,CS(=O)(=O)OCCCCOS(=O)(=O)C,PHASE2,cardiovascular_disease
3225,Stroke,Exenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N,PHASE2,cardiovascular_disease
3226,Ischemic Stroke,Argatroban,CC1CCN(C(C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C,PHASE2,cardiovascular_disease
3227,Low Cardiac Output Syndrome|Cardiogenic Shock|Acute Coronary Syndrome|Pulmonary Edema,Milrinone,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,APPROVED,cardiovascular_disease
3228,Low Cardiac Output Syndrome|Cardiogenic Shock|Acute Coronary Syndrome|Pulmonary Edema,Dobutamine,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,APPROVED,cardiovascular_disease
3229,Hyperemia,Brimonidine,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,PHASE1,cardiovascular_disease
3230,Lower Extremity Fracture,Atropine,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,APPROVED,cardiovascular_disease
3231,Lower Extremity Fracture,Glycopyrrolate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],APPROVED,cardiovascular_disease
3232,Atherosclerosis,Darapladib,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,PHASE1,cardiovascular_disease
3233,"Ischemic Reperfusion Injury|Insufficiency; Hepatic, Postoperative|Liver Tumour",Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,PHASE2,cardiovascular_disease
3234,"Rheumatoid Arthritis|Stiffness, Aortic|Endothelial Dysfunction|Cardiovascular Risk Factor",Sulfasalazine,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,APPROVED,cardiovascular_disease
3235,Contrast Induced Nephropathy|Acute Myocardial Infarction,Iodixanol,CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(=C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,APPROVED,cardiovascular_disease
3236,Contrast Induced Nephropathy|Acute Myocardial Infarction,Iopromide,CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I,APPROVED,cardiovascular_disease
3237,Acute Ischemic Stroke,Tromethamine,C(C(CO)(CO)N)O,PHASE1,cardiovascular_disease
3238,Essential Hypertension,Rostafuroxin,CC12CCC(CC1CCC3C2CCC4(C3(CCC4(C5=COC=C5)O)O)C)O,PHASE2,cardiovascular_disease
3239,ST Segment Elevation Myocardial Infarction|Percutaneous Coronary Intervention,Cangrelor,CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O,APPROVED,cardiovascular_disease
3240,Esophageal Varices,Octreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,APPROVED,cardiovascular_disease
3241,Refractory Hypertension,Reserpine,COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,PHASE2,cardiovascular_disease
3242,Acute Decompensated Heart Failure,Metolazone,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,APPROVED,cardiovascular_disease
3243,Acute Decompensated Heart Failure,Furosemide,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,APPROVED,cardiovascular_disease
3244,Venous Thromboembolism,Semuloparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2,cardiovascular_disease
3245,Vascular Diseases,Sevelamer,C=CCN.C1C(O1)CCl,APPROVED,cardiovascular_disease
3246,Deep Vein Thrombosis|Pulmonary Embolism,Nadroparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2|PHASE3,cardiovascular_disease
3247,Deep Vein Thrombosis|Pulmonary Embolism,Fondaparinux,COC1C(C(C(C(O1)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)COS(=O)(=O)O)OC4C(C(C(C(O4)C(=O)O)OC5C(C(C(C(O5)COS(=O)(=O)O)O)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O)NS(=O)(=O)O,PHASE2|PHASE3,cardiovascular_disease
3248,Age Related Macular Degeneration|Diabetic Retinopathy,Acetazolamide,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,PHASE2,cardiovascular_disease
3249,Heart Failure|Cardiovascular Disease|Acute Heart Failure|Diastolic Heart Failure|Congestive Heart Failure|Heart Disease,Nesiritide,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C3CCCN3C(=O)C(CO)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC4=CN=CN4)C(=O)O)CC(C)C)CO)CO)CO)CO,APPROVED,cardiovascular_disease
3251,"Non-Alcoholic Fatty Liver Disease|Obesity|Obesity, Abdominal|Liver Fat|Fatty Liver",Tesamorelin,CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N,PHASE2,cardiovascular_disease
3253,Ischemic Mitral Regurgitation,Cyproheptadine,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,PHASE2,cardiovascular_disease
3254,Arrhythmia,Quinidine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE2|PHASE3,cardiovascular_disease
3255,Postoperative Pain|Renal Insufficiency|Myocardial Infarction,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,APPROVED,cardiovascular_disease
3256,Postoperative Pain|Renal Insufficiency|Myocardial Infarction,Oxycodone,CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,APPROVED,cardiovascular_disease
3257,Descending Aortic Dissection|Postoperative Pain|Thoracoabdominal Aortic Aneurysm,Ketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE2,cardiovascular_disease
3259,Cardiovascular Diseases|Heart Diseases|Hypertension,Fosinopril,CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3,PHASE2,cardiovascular_disease
3260,HIV-1-infection|Antiviral Drug Adverse Reaction|Vascular Diseases|Cardiovascular Abnormalities|Abnormality of Adipose Tissue|Body Weight Changes|Body Fat Disorder|HIV-Associated Lipodystrophy Syndrome,Dolutegravir,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,APPROVED,cardiovascular_disease
3261,"Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Low Grade B-cell Lymphoma, Not Otherwise Specified|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large-cell Lymphoma",Clofarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,PHASE1|PHASE2,cardiovascular_disease
3262,Hypertension,Aliskiren,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,PHASE2,cardiovascular_disease
3263,"Pulmonary Disease, Chronic Obstructive",Tiotropium,C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C,APPROVED,cardiovascular_disease
3264,"Pulmonary Disease, Chronic Obstructive",Olodaterol,CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O,APPROVED,cardiovascular_disease
3265,"Pulmonary Disease, Chronic Obstructive",Fluticasone,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F,APPROVED,cardiovascular_disease
3266,"Pulmonary Disease, Chronic Obstructive",Salmeterol,C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O,APPROVED,cardiovascular_disease
3267,Peripheral Artery Disease With Intermittent Claudication,Olmesartan,CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O,APPROVED,cardiovascular_disease
3268,Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients,Vildagliptin,C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N,APPROVED,cardiovascular_disease
3269,Abdominal Obesity|Hypertension,Moxonidine,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,APPROVED,cardiovascular_disease
3270,Abdominal Obesity|Hypertension,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,APPROVED,cardiovascular_disease
3271,Polymyalgia Rheumatica,Prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,PHASE2|PHASE3,cardiovascular_disease
3272,Glaucoma,Bimatoprost,CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O,APPROVED,cardiovascular_disease
3273,"Atrial Fibrillation or Pulmonary Embolism|Need of Long Term Oral Anticoagulation Therapy (OAT)|Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location",Phenprocoumon,CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,APPROVED,cardiovascular_disease
3276,Heart Failure,Tolvaptan,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C,APPROVED,cardiovascular_disease
3277,Intermittent Claudication,Cilostazol,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,PHASE1,cardiovascular_disease
3278,Refractory Plasma Cell Myeloma,Paclitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,PHASE2,cardiovascular_disease
3279,Waldenström's Macroglobulinemia,Perifosine,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C,PHASE2,cardiovascular_disease
3280,Tachycardia|Hypertension|Myocardial Ischemia,Esmolol,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,APPROVED,cardiovascular_disease
3281,Hyperinsulinism|Insulin Resistance|Insulin Sensitivity|Glucose Intolerance|Hypertension,Vigabatrin,C=CC(CCC(=O)O)N,PHASE2,cardiovascular_disease
3282,Acute Heart Failure,Enalapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O,APPROVED,cardiovascular_disease
3286,Hemorrhoids,Iferanserin,CN1CCCCC1CCC2=CC=CC=C2NC(=O)C=CC3=CC=CC=C3,PHASE2,cardiovascular_disease
3287,Protamine Adverse Reaction,Chlorpheniramine,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,APPROVED,cardiovascular_disease
3288,Thrombosis,Lepirudin,CCC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC2C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C3CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)O)NC(=O)C(CC(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)NC(C(C)C)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)NC(CCCCN)C(=O)N6CCCC6C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC7=CNC=N7)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CC8=CC=CC=C8)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)N9CCCC9C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C,PHASE2,cardiovascular_disease
3289,Type 2 Diabetes|Overweight|Obesity|Masked Hypertension,Mitiglinide,C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)O,APPROVED,cardiovascular_disease
3290,Idiopathic Pulmonary Arterial Hypertension.,Salbutamol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,PHASE2,cardiovascular_disease
3291,"Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult Diffuse Large Cell Lymphoma|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Myeloid Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma",Treosulfan,CS(=O)(=O)OCC(C(COS(=O)(=O)C)O)O,PHASE2,cardiovascular_disease
3292,Subarachnoid Haemorrhage (SAH),Propofol,CC(C)C1=C(C(=CC=C1)C(C)C)O,PHASE2,cardiovascular_disease
3293,Subarachnoid Haemorrhage (SAH),Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,PHASE2,cardiovascular_disease
3294,Portal Hypertension,Alverine,CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2,PHASE2,cardiovascular_disease
3295,Endocarditis,Amoxicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,APPROVED,cardiovascular_disease
3296,Endocarditis,Cephalexin,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O,APPROVED,cardiovascular_disease
3297,Endocarditis,Dicloxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,cardiovascular_disease
3298,Endocarditis,Linezolid,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,APPROVED,cardiovascular_disease
3299,Endocarditis,Levofloxacin,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,APPROVED,cardiovascular_disease
3300,Endocarditis,Ampicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)C,APPROVED,cardiovascular_disease
3301,Endocarditis,Oxacillin,CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,cardiovascular_disease
3302,Endocarditis,Vancomycin,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,APPROVED,cardiovascular_disease
3303,Endocarditis,Daptomycin,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,APPROVED,cardiovascular_disease
3304,Endocarditis,Ceftriaxone,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,APPROVED,cardiovascular_disease
3305,Endocarditis,Cefepime,C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-],APPROVED,cardiovascular_disease
3306,Endocarditis,Ceftaroline,CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-],APPROVED,cardiovascular_disease
3307,Postpartum Hypertension,Methyldopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N,APPROVED,cardiovascular_disease
3308,Autonomic Failure|Pure Autonomic Failure|Parkinson Disease|Multiple System Atrophy|Dementia With Lewy Bodies,Carbidopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,PHASE1,cardiovascular_disease
3309,Autonomic Failure|Pure Autonomic Failure|Parkinson Disease|Multiple System Atrophy|Dementia With Lewy Bodies,Entacapone,CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N,PHASE1,cardiovascular_disease
3310,Ischemic Stroke,Meglumine,CNCC(C(C(C(CO)O)O)O)O,APPROVED,cardiovascular_disease
3311,Coronary Artery Disease,Gefarnate,CC(=CCCC(=CCCC(=CCCC(=O)OCC=C(C)CCC=C(C)C)C)C)C,PHASE2|PHASE3,cardiovascular_disease
3312,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Defactinib,CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F,PHASE2,cardiovascular_disease
3314,Heart Failure,Pyridostigmine,C[N+]1=CC=CC(=C1)OC(=O)N(C)C,PHASE2,cardiovascular_disease
3315,Carotid Atherosclerosis,Perflutren,C(C(F)(F)F)(C(F)(F)F)(F)F,APPROVED,cardiovascular_disease
3316,Chronic Myeloid Leukemia (CML),Ponatinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,PHASE2,cardiovascular_disease
3317,Single Ventricle Heart Disease After Fontan Surgery,Udenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C,PHASE1|PHASE2,cardiovascular_disease
3318,Hypertension,Azilsartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O,PHASE2,cardiovascular_disease
3319,"Ischemic Stroke, Acute|Sleep Disorders, Circadian Rhythm",Melatonin,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,APPROVED,cardiovascular_disease
3320,Obstructive Sleep Apnea,Guanfacine,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,APPROVED,cardiovascular_disease
3321,Myeloma,Topotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,PHASE2,cardiovascular_disease
3322,Rheumatic Heart Disease in Children|Latent Rheumatic Heart Disease|Rheumatic Heart Disease|Heart Diseases,Phenoxymethylpenicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,PHASE2,cardiovascular_disease
3323,Rheumatic Heart Disease in Children|Latent Rheumatic Heart Disease|Rheumatic Heart Disease|Heart Diseases,Penicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,PHASE2,cardiovascular_disease
3324,"Dyslipidemia|Atherosclerosis|Diabetes Mellitus, Type 2",Policosanol,CCCO,APPROVED,cardiovascular_disease
3325,Prehypertension|Gout|Pulse Wave Velocity|Hypertension|24 Hour Blood Pressure,Febuxostat,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,APPROVED,cardiovascular_disease
3326,Coronary Artery Disease,Iopamidol,CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O,PHASE2,cardiovascular_disease
3327,Diabetic Retinopathy,Ketorolac,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,PHASE1,cardiovascular_disease
3328,"Diabetes Mellitus, Type 2|Vascular Diseases",Rosiglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,APPROVED,cardiovascular_disease
3329,"Diabetes Mellitus, Type 2|Vascular Diseases",Pioglitazone,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,APPROVED,cardiovascular_disease
3330,Heart Failure,Cenderitide,CCC(C)C(C(=O)NCC(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NCC(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CS)C(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC(=O)O)C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)N3CCCC3C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C)C(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CS)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CN,PHASE2,cardiovascular_disease
3331,"Atrial Fibrillation, Paroxysmal",Canrenone,CC12CCC(=O)C=C1C=CC3C2CCC4(C3CCC45CCC(=O)O5)C,APPROVED,cardiovascular_disease
3333,Cesarean Section Complications|Spinal Anesthetic Toxicity,Norepinephrine,C1=CC(=C(C=C1C(CN)O)O)O,APPROVED,cardiovascular_disease
3334,Cesarean Section Complications|Spinal Anesthetic Toxicity,Bupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,cardiovascular_disease
3335,"Hypertension, Pulmonary|Pulmonary Arterial Hypertension",Esomeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE1,cardiovascular_disease
3336,"Diabetes|Macular Edema|Diabetic Retinopathy|Retinal Disease|Uveitis, Posterior",Dextromethorphan,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,PHASE2,cardiovascular_disease
3337,Macular Degeneration|Retinal Vein Occlusion,Triamcinolone,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,PHASE1,cardiovascular_disease
3338,Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction,Phenylephrine,CNCC(C1=CC(=CC=C1)O)O,PHASE1,cardiovascular_disease
3339,Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction,Apocynin,CC(=O)C1=CC(=C(C=C1)O)OC,PHASE1,cardiovascular_disease
3340,Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction,Tempol,CC1(CC(CC(N1[O])(C)C)O)C,PHASE1,cardiovascular_disease
3341,Hereditary Hemorrhagic Telangiectasia (HHT),Doxycycline,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,PHASE2,cardiovascular_disease
3342,Cardiovascular Disease|Ischemic Heart Disease,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,APPROVED,cardiovascular_disease
3343,Open-Angle Glaucoma|Ocular Hypertension,Brinzolamide,CCNC1CN(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)CCCOC,PHASE2,cardiovascular_disease
3344,Multiple Myeloma,Tasquinimod,CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O,PHASE1,cardiovascular_disease
3345,Myocardial Infarction,Fulacimstat,CN1C2=C(C=C(C=C2)N3C=C(C(=O)N(C3=O)C4CCC5=C4C=CC=C5C(F)(F)F)C(=O)O)OC1=O,PHASE2,cardiovascular_disease
3346,Paroxysmal Atrial Fibrillation,Dronedarone,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC,APPROVED,cardiovascular_disease
3347,Heart Disease,Pentobarbital,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC,PHASE1,cardiovascular_disease
3348,Unresectable Hepatocellular Carcinoma|Pembrolizumab|Lenvatinib|Stereotactic Body Radiotherapy,Lenvatinib,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,PHASE1|PHASE2,cardiovascular_disease
3351,Clinically Significant Portal Hypertension,Sorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,PHASE2,cardiovascular_disease
3352,Heart Failure With Normal Ejection Fraction,Iloprost,CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O,APPROVED,cardiovascular_disease
3353,Ischemic Heart Disease,Quinapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O,APPROVED,cardiovascular_disease
3356,Heart Failure With Reduced Ejection Fraction NYHA Class III-IV,Mirabegron,C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,PHASE2|PHASE3,cardiovascular_disease
3357,Heart Failure|Cardiac Failure|Congestive Heart Failure,Hydralazine,C1=CC=C2C(=C1)C=NN=C2NN,PHASE2|PHASE3,cardiovascular_disease
3358,Retinal Vein Occlusion,Anecortave,CC12CCC(=O)C=C1CCC3C2=CCC4(C3CCC4(C(=O)CO)O)C,PHASE2,cardiovascular_disease
3359,Patent Ductus Arteriosus,Paracetamol,CC(=O)NC1=CC=C(C=C1)O,PHASE2,cardiovascular_disease
3361,Systolic Heart Failure,Rifaximin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,PHASE2,cardiovascular_disease
3362,Atrial Fibrillation,Liothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,PHASE1,cardiovascular_disease
3363,Atrial Fibrillation,Triiodothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,PHASE1,cardiovascular_disease
3364,"Diabetes Mellitus, Type 2|Hypertension",Ertugliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl,PHASE2,cardiovascular_disease
3365,Cardiovascular Diseases|Hypertension,Torasemide,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,APPROVED,cardiovascular_disease
3366,Cardiovascular Diseases|Hypertension,Torsemide,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,APPROVED,cardiovascular_disease
3367,"Heart Failure, Systolic",Sacubitril,CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O,APPROVED,cardiovascular_disease
3368,Oral Nimodipine|Milrinone|Vascular Spasm After Traumatic Subarachnoidhaemorrhage,Nimodipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,PHASE2,cardiovascular_disease
3369,Breast Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Sarcoma,Pravastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O,PHASE2,cardiovascular_disease
3370,"Hypertension|Diabetes Mellitus, Type 2|Blood Pressure|Obesity|Cardiac Hypertrophy|Microalbuminuria|Vascular Stiffness",Glyburide,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,APPROVED,cardiovascular_disease
3371,Essential Hypertension,Lercanidipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,PHASE2,cardiovascular_disease
3372,Peripheral Artery Disease,Vorapaxar,CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C,APPROVED,cardiovascular_disease
3373,Glaucoma|Ocular Hypertension,Travoprost,CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O,APPROVED,cardiovascular_disease
3374,Peripheral Arterial Disease,Cholecalciferol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,APPROVED,cardiovascular_disease
3375,Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma,Azacitidine,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,PHASE1,cardiovascular_disease
3376,Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma,Venetoclax,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,PHASE1,cardiovascular_disease
3377,Multiple Myeloma,Palbociclib,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,PHASE1,cardiovascular_disease
3379,Pulmonary Arterial Hypertension,Selexipag,CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3,APPROVED,cardiovascular_disease
3380,Other Specified Hypotension|Syncope,Acarbose,CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO,PHASE2,cardiovascular_disease
3382,Open-angle Glaucoma|Ocular Hypertension,Timolol,CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O,PHASE1|PHASE2,cardiovascular_disease
3383,Deep Venous Thrombosis,Desirudin,CCC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC2C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C3CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3)CC(C)C)CC(=O)N)CCC(=O)N)CO)CCC(=O)O)C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)NC(C(C)C)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)NC(CCCCN)C(=O)N6CCCC6C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC7=CN=CN7)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CC8=CC=CC=C8)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)N9CCCC9C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN)CCC(=O)O)CC(=O)O)CO)CC(C)C,PHASE2|PHASE3,cardiovascular_disease
3384,"Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases",Ranitidine,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,PHASE2,cardiovascular_disease
3385,"Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases",Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,PHASE2,cardiovascular_disease
3386,Venous Thromboembolic Disease|Respiratory Disease|Pulmonary Disease|Deep Venous Thrombosis|Pulmonary Embolism|Screening|Undefined,Fludeoxyglucose,C(C(C(C(C(C=O)F)O)O)O)O,APPROVED,cardiovascular_disease
3387,Heart Failure|Heart Decompensation,Cinaciguat,C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O,PHASE2,cardiovascular_disease
3389,Vascular Dementia,Donepezil,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,APPROVED,cardiovascular_disease
3390,"Relapsed, Refractory or Plateau Phase Multiple Myeloma",Dasatinib,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,PHASE2,cardiovascular_disease
3391,Hypertension,Doxazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,PHASE2|PHASE3,cardiovascular_disease
3392,"Hypertension,Essential",Captopril,CC(CS)C(=O)N1CCCC1C(=O)O,PHASE1|PHASE2,cardiovascular_disease
3393,"Multiple Myeloma|Multiple Myeloma in Relapse|Multiple Myeloma, Refractory",Marizomib,CC12C(C(=O)NC1(C(=O)O2)C(C3CCCC=C3)O)CCCl,PHASE2,cardiovascular_disease
3396,"Hemorrhoids, Internal",Polidocanol,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,PHASE2,cardiovascular_disease
3398,Pulmonary Hypertension|Sickle Cell Disease|Thalassemia,Glutamine,C(CC(=O)N)C(C(=O)O)N,PHASE2,cardiovascular_disease
3399,Sleep Disturbance|Heart Failure,Zolpidem,CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,APPROVED,cardiovascular_disease
3400,Schizophrenia|Schizoaffective Disorder,Paliperidone,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,PHASE1,cardiovascular_disease
3401,Hypertension|Sexual Dysfunction,Felodipine,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,APPROVED,cardiovascular_disease
3402,Pediatric Pulmonary Hypertension,Beraprost,CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O,APPROVED,cardiovascular_disease
3403,Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans,Probucol,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,APPROVED,cardiovascular_disease
3404,"Arteritis, Giant Cell",Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,cardiovascular_disease
3405,Cirrhosis|Portal Hypertension|Non-alcoholic Steatohepatitis,Emricasan,CC(C(=O)NC(CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C,PHASE2,cardiovascular_disease
3406,Diseases of Mitral Valve|Aortic Valve Disorder|Atrial Septal Defects|Intracardiac Myxoma,Articaine,CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC,APPROVED,cardiovascular_disease
3407,Young Healthy Adults|Ventricular Dysfunction,Isoflurane,C(C(F)(F)F)(OC(F)F)Cl,APPROVED,cardiovascular_disease
3408,Cardiovascular Disease|Diabetic Nephropathy,Paricalcitol,CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C,APPROVED,cardiovascular_disease
3409,Hypertension,Desmopressin,C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N,PHASE1,cardiovascular_disease
3410,Ventricular Tachycardia|Ventricular Fibrillation,Nifekalant,CN1C(=CC(=O)N(C1=O)C)NCCN(CCCC2=CC=C(C=C2)[N+](=O)[O-])CCO,APPROVED,cardiovascular_disease
3411,Ventricular Tachycardia|Ventricular Fibrillation,Amiodarone,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,APPROVED,cardiovascular_disease
3412,Coagulation Defect; Bleeding,Morphine,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,PHASE2,cardiovascular_disease
3413,Coronary Artery Disease,Omeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,APPROVED,cardiovascular_disease
3414,Coronary Artery Disease,Pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,APPROVED,cardiovascular_disease
3415,Spinal Cord Injury|Autonomic Dysreflexia|Orthostatic Hypotension|Baroreceptor Integrity|Sympathetic Integrity|Vagal Integrity|Hypotension|Cerebral Blood Flow|Blood Pressure|Venous Occlusion Plethysmography,Midodrine,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,PHASE2|PHASE3,cardiovascular_disease
3416,Stroke,Maraviroc,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,PHASE2|PHASE3,cardiovascular_disease
3417,Primary Open-Angle Glaucoma (POAG)|Ocular Hypertension (OHT),Trabodenoson,C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO[N+](=O)[O-])O)O,PHASE2,cardiovascular_disease
3418,Retinal Neovascularization,Squalamine,CC(C)C(CCC(C)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)NCCCNCCCCN)C)O)C)OS(=O)(=O)O,PHASE2,cardiovascular_disease
3420,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Nodal Marginal Zone Lymphoma|Recurrent Splenic Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Refractory Follicular Lymphoma|Refractory Grade 1 Follicular Lymphoma|Refractory Grade 2 Follicular Lymphoma|Refractory Grade 3a Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Nodal Marginal Zone Lymphoma|Refractory Splenic Marginal Zone Lymphoma|Refractory Waldenstrom Macroglobulinemia,Umbralisib,CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F,PHASE1,cardiovascular_disease
3421,Neurogenic Orthostatic Hypotension,Fludrocortisone,CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F,APPROVED,cardiovascular_disease
3422,Obesity|Hypertension,Trimethaphan,C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5,PHASE1,cardiovascular_disease
3423,"Arrhythmias, Cardiac|Atrial Fibrillation",Sotalol,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,APPROVED,cardiovascular_disease
3425,Anemia|Fatigue|Fever|Lymphadenopathy|Lymphocytosis|Night Sweats|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Refractory Chronic Lymphocytic Leukemia|Refractory Plasma Cell Myeloma|Splenomegaly|Thrombocytopenia|Weight Loss,Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,PHASE1,cardiovascular_disease
3426,Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy,Droxidopa,C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O,PHASE2,cardiovascular_disease
3427,Atherosclerosis|Cardiovascular Disease|Inflammation|Insulin Resistance|Noninsulin-dependent Diabetes Mellitus,Salsalate,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,PHASE2|PHASE3,cardiovascular_disease
3428,Acute Heart Failure,Serelaxin,CCC(C)C1C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C)C(C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O)C(CC(=O)O)N)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(C)C)NC(=O)C7CCC(=O)N7)C(C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CO)C(=O)O,PHASE2,cardiovascular_disease
3429,Depressive Syndrome,Escitalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,cardiovascular_disease
3430,Multiple Myeloma,Ruxolitinib,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE1|PHASE2,cardiovascular_disease
3431,Cardiovascular Disease,Epoprostenol,CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O,APPROVED,cardiovascular_disease
3432,Cardiovascular Disease,Prostacyclin,CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O,APPROVED,cardiovascular_disease
3433,Overweight|Hyperlipidemia|Cardiovascular Diseases,Aripiprazole,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,APPROVED,cardiovascular_disease
3434,Subacute/Chronic Myocardial Infarction,Gadobutrol,C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Gd+3],PHASE2,cardiovascular_disease
3435,Pulmonary Arterial Hypertension,Tezosentan,CC(C)C1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC,PHASE2,cardiovascular_disease
3436,DIABETES|DIABETIC RETINOPATHY|DIABETIC NEUROPATHY,Cholestyramine,CCC(C)C.CCC(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)C[N+](C)(C)C.N.[Cl-],APPROVED,cardiovascular_disease
3437,Cerebrovascular Accident|Hemiparesis,Ropinirole,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,PHASE2,cardiovascular_disease
3438,"Myeloma-Multiple|Myeloma, Plasma-Cell",Rimiducid,CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)C(CCC6=CC(=C(C=C6)OC)OC)OC(=O)C7CCCCN7C(=O)C(CC)C8=CC(=C(C(=C8)OC)OC)OC,PHASE1,cardiovascular_disease
3439,Acute Cerebrovascular Accident|Cerebral Edema,Conivaptan,CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,PHASE2,cardiovascular_disease
3440,Solid Tumors|Lymphoma|Multiple Myeloma,Bexarotene,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C,PHASE1,cardiovascular_disease
3441,Hypertension,Manidipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,APPROVED,cardiovascular_disease
3443,Chronic Obstructive Pulmonary Disease,Indacaterol,CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC,APPROVED,cardiovascular_disease
3444,Chronic Obstructive Pulmonary Disease,Glycopyrronium,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,APPROVED,cardiovascular_disease
3445,Hemorrhoids|Anal Fissures,Lactulose,C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O,APPROVED,cardiovascular_disease
3447,Congestive Heart Failure|Renal Impairment,Pecavaptan,CC(C1=NC(=NN1C2=CC(=CC=C2)Cl)CN3C(=O)N(C(=N3)C4=CC=C(C=C4)Cl)CC(C(F)(F)F)O)O,PHASE1,cardiovascular_disease
3448,Coronary Artery Disease|Valvular Heart Disease|Aorta Disease|Heart Failure,Sugammadex,C(CSCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(O2)C(C9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O,APPROVED,cardiovascular_disease
3449,Barth Syndrome,Elamipretide,CC1=CC(=CC(=C1CC(C(=O)NC(CCCCN)C(=O)NC(CC2=CC=CC=C2)C(=O)N)NC(=O)C(CCCN=C(N)N)N)C)O,PHASE2|PHASE3,cardiovascular_disease
3450,High Blood Pressure,Bunazosin,CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC,APPROVED,cardiovascular_disease
3451,Chronic Kidney Disease,Benidipine,CC1=C(C(C(=C(N1)C)C(=O)OC2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,APPROVED,cardiovascular_disease
3453,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Leflunomide,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,PHASE2,cardiovascular_disease
3454,Hypoplastic Left Heart|Congenital Heart Disease,Oxandrolone,CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C,PHASE1|PHASE2,cardiovascular_disease
3455,Paroxysmal Supraventricular Tachycardia (PSVT),Etripamil,CC(C)C(CCCN(C)CCC1=CC(=CC=C1)C(=O)OC)(C#N)C2=CC(=C(C=C2)OC)OC,PHASE2,cardiovascular_disease
3456,Multiple Myeloma,Pirarubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6,APPROVED,cardiovascular_disease
3457,Ataxia Telangiectasia,Betamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE1,cardiovascular_disease
3458,Acute Stroke|Aspiration Pneumonia,Metoclopramide,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,APPROVED,cardiovascular_disease
3460,Parkinson's Disease|Multiple System Atrophy|Orthostatic Hypotension,Domperidone,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,PHASE1,cardiovascular_disease
3461,Labor Pain|Obstetric Pain,Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,APPROVED,cardiovascular_disease
3462,Endocarditis|Bacteremia,Dalbavancin,CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O,PHASE2,cardiovascular_disease
3463,"Hypertension, Portal",Perflubutane,C(C(C(F)(F)F)(F)F)(C(F)(F)F)(F)F,PHASE2,cardiovascular_disease
3464,"Diabetes Mellitus, Type 2|Cardiovascular Diseases",Saxagliptin,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,APPROVED,cardiovascular_disease
3465,Multiple Myeloma,Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,PHASE1,cardiovascular_disease
3466,Hypertension,Zofenopril,CC(CSC(=O)C1=CC=CC=C1)C(=O)N2CC(CC2C(=O)O)SC3=CC=CC=C3,APPROVED,cardiovascular_disease
3467,Pulmonary Arterial Hypertension,Cicletanine,CC1=NC=C2C(OCC2=C1O)C3=CC=C(C=C3)Cl,PHASE2,cardiovascular_disease
3468,Hypotension,Levobupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,cardiovascular_disease
3469,Postinduction Hypotension|Elderly,Lidocaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,APPROVED,cardiovascular_disease
3470,Multiple Myeloma,Filanesib,CN(C(=O)N1C(SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC,PHASE1|PHASE2,cardiovascular_disease
3471,Essential Hypertension,Digoxin,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,PHASE1,cardiovascular_disease
3472,Heart Failure,Bumetanide,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,PHASE1,cardiovascular_disease
3473,Heart Failure,Chlorothiazide,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2,PHASE1,cardiovascular_disease
3474,Ventricular Arrhythmia,Eleclazine,C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4,PHASE2,cardiovascular_disease
3476,Renal Cell Carcinoma|Soft Tissue Sarcoma|Glioblastoma|Ovarian Cancer|Cervical Cancer|Breast Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Pancreatic Cancer|Melanoma|Gastrointestinal Cancer,Pazopanib,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,PHASE2,cardiovascular_disease
3477,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Sonidegib,CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F,PHASE2,cardiovascular_disease
3479,Cardiovascular Disease|Pulmonary Arterial Hypertension|Heart Failure,Moxifloxacin,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,PHASE1,cardiovascular_disease
3480,Hypertrophic Cardiomyopathy,Perhexiline,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,PHASE2,cardiovascular_disease
3481,Hypertension,Nitrendipine,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,APPROVED,cardiovascular_disease
3482,Healthy Participants,Mavacamten,CC(C)N1C(=O)C=C(NC1=O)NC(C)C2=CC=CC=C2,PHASE1,cardiovascular_disease
3483,Congenital Heart Disease,Phenoxybenzamine,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2,PHASE2,cardiovascular_disease
3484,"Cardiac; Dysrhythmia, Postoperative|Congenital Heart Surgery",Procainamide,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,APPROVED,cardiovascular_disease
3485,Pulmonary Arterial Hypertension,Fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,PHASE2,cardiovascular_disease
3486,Multiple System Atrophy,Inosine,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O,PHASE2,cardiovascular_disease
3487,Essential Hypertension,Aprocitentan,C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br,PHASE2,cardiovascular_disease
3489,Angiodysplasia,Pasireotide,C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,PHASE2,cardiovascular_disease
3490,Hypertension,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,PHASE2,cardiovascular_disease
3491,Waldenstrom Macroglobulinemia,Acalabrutinib,CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5,PHASE2,cardiovascular_disease
3492,Heart Failure,Icatibant,C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O,APPROVED,cardiovascular_disease
3493,Mantle Cell Lymphoma|B Cell Lymphoma|Multiple Myeloma,Canfosfamide,C1=CC=C(C=C1)C(C(=O)O)NC(=O)C(CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CCC(C(=O)O)N,PHASE2,cardiovascular_disease
3496,Thromboembolism,Betrixaban,CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl,PHASE2,cardiovascular_disease
3497,"Heart Failure, Diastolic",Dopamine,C1=CC(=C(C=C1CCN)O)O,APPROVED,cardiovascular_disease
3498,Coronary Artery Disease|Gastroesophageal Reflux Disease,Indobufen,CCC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,APPROVED,cardiovascular_disease
3501,"Cerebral Small Vessel Diseases|Stroke, Lacunar",Isosorbide,C1C(C2C(O1)C(CO2)O)O,PHASE2|PHASE3,cardiovascular_disease
3503,Multiple Myeloma,Amrubicin,CC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)OC5CC(C(CO5)O)O)N,PHASE1|PHASE2,cardiovascular_disease
3504,Multiple Myeloma,Pegfilgrastim,CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C,PHASE1|PHASE2,cardiovascular_disease
3505,Heart Failure With Preserved Ejection Fraction,Sotagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl,APPROVED,cardiovascular_disease
3506,"Diabetes Mellitus, Type 2",Repaglinide,CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,APPROVED,cardiovascular_disease
3507,Multiple Myeloma,Uproleselan,CCC1CC(CC(C1OC2C(C(C(C(O2)C)O)O)O)OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC,PHASE2,cardiovascular_disease
3508,Dilated Cardiomyopathy,Benazepril,CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O,APPROVED,cardiovascular_disease
3510,Adult B Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia,Alisertib,COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC,PHASE1,cardiovascular_disease
3511,Multiple Myeloma,Fosaprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F,PHASE1|PHASE2,cardiovascular_disease
3512,Multiple Myeloma,Pamidronate,C(CN)C(O)(P(=O)(O)O)P(=O)(O)O,PHASE2,cardiovascular_disease
3513,Diabetic Retinopathy,Runcaciguat,CC(C(C1=CC=C(C=C1)Cl)C(=O)NC2=C(C=CC(=C2)C(CC(=O)O)C3CC3)Cl)C(F)(F)F,PHASE2,cardiovascular_disease
3514,Atrial Fibrillation Paroxysmal,Riluzole,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,PHASE2,cardiovascular_disease
3515,Coronary Heart Disease|Chlamydophila Pneumoniae Infections,Azithromycin,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,PHASE2,cardiovascular_disease
3516,Coronary Heart Disease|Chlamydophila Pneumoniae Infections,Rifabutin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)C,PHASE2,cardiovascular_disease
3517,Multiple Myeloma,Atiprimod,CCCC1(CCC2(CC1)CCN(C2)CCCN(CC)CC)CCC,PHASE1|PHASE2,cardiovascular_disease
3518,Acute Myeloid Leukemia|Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Multiple Myeloma,Birabresib,CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C,PHASE1,cardiovascular_disease
3519,Coronary Artery Disease|Acute Coronary Syndrome,Trapidil,CCN(CC)C1=CC(=NC2=NC=NN12)C,APPROVED,cardiovascular_disease
3521,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Nelfinavir,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,PHASE1,cardiovascular_disease
3522,Relapsed/Refractory Multiple Myeloma,Mitoxantrone,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,PHASE1|PHASE2,cardiovascular_disease
3523,Arrhythmia Prophylaxis|Ventricular Arrhythmia,Celivarone,CCCCC1=C(C2=C(O1)C=CC(=C2)C(=O)OC(C)C)C(=O)C3=CC=C(C=C3)CCCN(CCCC)CCCC,PHASE2,cardiovascular_disease
3524,Von Hippel-Lindau Syndrome,Sunitinib,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,PHASE1|PHASE2,cardiovascular_disease
3525,Anemia,Erythropoietin,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],PHASE2,cardiovascular_disease
3526,HIV|Vascular Diseases|Cardiovascular Diseases|Atherosclerosis|HIV Infections,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,PHASE2,cardiovascular_disease
3527,Renal Insufficiency|Heart Failure,Tonapofylline,CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CCC(CC3)(CC4)CCC(=O)O,PHASE2,cardiovascular_disease
3528,Prediabetic State|Hypertension|Dyslipidemias,Pitavastatin,C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F,APPROVED,cardiovascular_disease
3529,Hypercholesterolemia|Acute Coronary Syndrome,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,APPROVED,cardiovascular_disease
3530,Hypercholesterolemia|Acute Coronary Syndrome,Bezafibrate,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,APPROVED,cardiovascular_disease
3532,Alagille Syndrome,Maralixibat,CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC,PHASE2,cardiovascular_disease
3533,HIV Infections,Tenofovir,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,APPROVED,cardiovascular_disease
3534,Congenital Heart Diseases|Aortic Valve Disorder,Cefazolin,CC1=NN=C(S1)SCC2=C(N3C(C(C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O,APPROVED,cardiovascular_disease
3535,"Aortic Aneurysm, Thoracic",Pimonidazole,C1CCN(CC1)CC(CN2C=CN=C2[N+](=O)[O-])O,PHASE1,cardiovascular_disease
3536,Pulmonary Hypertension|Heart Failure With Normal Ejection Fraction|Pulmonary Heart Disease and Diseases of Pulmonary Circulation,Chlorhexidine,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,PHASE1,cardiovascular_disease
3537,Prevention of Subclinical Atherosclerosis Progression|Prevention of Cognitive Decline,Nattokinase,B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl,PHASE2,cardiovascular_disease
3538,Myocardial Stunning,Diazoxide,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,PHASE1,cardiovascular_disease
3539,"Neoplasms, Haematologic",Afuresertib,CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl,PHASE1,cardiovascular_disease
3542,Medical Oncology,Copanlisib,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5,PHASE1,cardiovascular_disease
3543,Venous Thromboembolism|Anticoagulant-induced Bleeding|Venous Thromboses|Pulmonary Embolism,Acenocoumarol,CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O,PHASE2|PHASE3,cardiovascular_disease
3544,Acute Coronary Syndrome,Tryptophan,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N,APPROVED,cardiovascular_disease
3545,Vascular Calcification|Arteriosclerosis,Alendronate,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,APPROVED,cardiovascular_disease
3546,Non-arteritic Anterior Ischemic Optic Neuropathy,Citicoline,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O,APPROVED,cardiovascular_disease
3547,Stroke,Urokinase,CC(C)OC(=O)NC1=CC2=C(C=C1)N=C(N2)C3=CSC=N3,PHASE2,cardiovascular_disease
3548,Premature Ovarian Failure,Ethinylestradiol,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O,APPROVED,cardiovascular_disease
3549,Premature Ovarian Failure,Norethindrone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,cardiovascular_disease
3550,Premature Ovarian Failure,Norethisterone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,cardiovascular_disease
3551,"Kidney, Polycystic, Autosomal Dominant",Cilnidipine,CC1=C(C(C(=C(N1)C)C(=O)OCC=CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC,PHASE2,cardiovascular_disease
3552,"Kidney, Polycystic, Autosomal Dominant",Imidapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C(CN(C2=O)C)C(=O)O,PHASE2,cardiovascular_disease
3553,"Aortic Aneurysm, Abdominal",Ropivacaine,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,cardiovascular_disease
3554,Acute Coronary Syndrome|Sleep Disorder,Eszopiclone,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,APPROVED,cardiovascular_disease
3555,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Trametinib,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,PHASE2,cardiovascular_disease
3556,Systolic Heart Failure,Probenecid,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,PHASE2,cardiovascular_disease
3557,Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications,Glimepiride,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,APPROVED,cardiovascular_disease
3558,Complete Heart Block|Inferior Wall Myocardial Infarction,Aminophylline,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,APPROVED,cardiovascular_disease
3559,Multiple Myeloma,Mesna,C(CS(=O)(=O)[O-])S.[Na+],APPROVED,cardiovascular_disease
3562,Cardiac Failure,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,PHASE2,cardiovascular_disease
3563,Retinal Vein Occlusion,Fasudil,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3,PHASE2|PHASE3,cardiovascular_disease
3564,Coronary Artery Disease|Cerebrovascular Disease|Peripheral Vascular Disease,Rifalazil,CC1C=CC=C(C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C(C(O5)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)C,PHASE2,cardiovascular_disease
3565,Focal Segmental Glomerulosclerosis|Minimal Change Disease|Immunoglobulin A Nephropathy|IgA Vasculitis|Alport Syndrome,Sparsentan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC,PHASE2,cardiovascular_disease
3566,Intraventricular Hemorrhage|Periventricular Leukomalacia|Brain Injury|Renal Injury,Indomethacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,PHASE1|PHASE2,cardiovascular_disease
3567,Transthyretin Amyloid Cardiomyopathy,Tafamidis,C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl,APPROVED,cardiovascular_disease
3568,Multiple Myeloma,Vactosertib,CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4,PHASE1,cardiovascular_disease
3569,Multiple Myeloma,Cisplatin,N.N.Cl[Pt]Cl,PHASE2,cardiovascular_disease
3570,Aneurysmal Subarachnoid Hemorrhage,Clazosentan,CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC,PHASE2,cardiovascular_disease
3571,"Heart Failure, Congestive|Chronic Heart Failure|Depression",Sertraline,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,PHASE2|PHASE3,cardiovascular_disease
3572,Variant Angina,Sarpogrelate,CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O,APPROVED,cardiovascular_disease
3573,Waldenstrom's Macroglobulinemia|Multiple Myeloma,Enzastaurin,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7,PHASE2,cardiovascular_disease
3574,"Glaucoma, Open-Angle|Ocular Hypertension",Tafluprost,CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC=C2)(F)F)O)O,APPROVED,cardiovascular_disease
3575,"Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Chronic Lymphocytic Leukemia|Lymphoproliferative Disorders|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma",Pacritinib,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,PHASE1,cardiovascular_disease
3576,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma,Crizotinib,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,PHASE2,cardiovascular_disease
3577,Open Angle Glaucoma|Ocular Hypertension,Phentolamine,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,PHASE2,cardiovascular_disease
3578,Stable Coronary Artery Disease,Selatogrel,CCCCOC(=O)N1CCN(CC1)C(=O)C(CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CCC(C4)OC,PHASE2,cardiovascular_disease
3579,Multiple Myeloma,Budesonide,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,PHASE2,cardiovascular_disease
3582,Hypertension|Hypertriglyceridemia,Ciprofibrate,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,APPROVED,cardiovascular_disease
3584,"Renal Insufficiency, Chronic|Angioplasty, Transluminal, Percutaneous Coronary|Coronary Arteriosclerosis",Iomeprol,CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO,APPROVED,cardiovascular_disease
3585,Neuroendocrine Tumors|Von Hippel-Lindau Syndrome|Hippel-Lindau Disease,Dotatate,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O,PHASE2,cardiovascular_disease
3586,Refractory Multiple Myeloma,Tivantinib,C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,PHASE2,cardiovascular_disease
3587,Thrombocytopenia|Multiple Myeloma,Eltrombopag,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,PHASE2,cardiovascular_disease
3588,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Selumetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,PHASE2,cardiovascular_disease
3589,Hypertension|Type 2 Diabetes Mellitus,Indapamide,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,APPROVED,cardiovascular_disease
3590,Congestive Heart Failure,Oxypurinol,C1=NNC2=C1C(=O)NC(=O)N2,PHASE2|PHASE3,cardiovascular_disease
3591,Neonatal Seizure|Neonatal Encephalopathy|Hypoxic-Ischemic Encephalopathy|Seizure Newborn,Phenobarbital,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,PHASE2,cardiovascular_disease
3592,Aortic Valve Stenosis,Fluvastatin,CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,APPROVED,cardiovascular_disease
3593,Staphylococcal Infections|Osteomyelitis|CNS Infection|Septic Arthritis|Diabetic Foot Infection|Vertebral Osteomyelitis|Abscess|Coagulase Negative Staphylococcal Infection,Cloxacillin,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,cardiovascular_disease
3594,Multiple Myeloma,Acetylcarnitine,CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C,PHASE2,cardiovascular_disease
3595,Pulmonary Arterial Hypertension,Epicatechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,cardiovascular_disease
3596,Pulmonary Arterial Hypertension,Catechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,cardiovascular_disease
3597,Multiple Myeloma,Nirogacestat,CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F,PHASE2,cardiovascular_disease
3598,Autoimmune Disease|Neurologic Autoimmune Disease|Autologous Transplant Autoimmune|Multiple Sclerosis Transplant|MS Stem Cell Transplant|Multiple Sclerosis Stem Cell Transplant|Stiff Person Syndrome|HCT for Neurologic Autoimmune Disorders|CIDP Transplant|Myasthenia Gravis Transplant|Autoimmune Nervous System Disorder|Central Nervous System Vasculitis|Cerebellar Degeneration|Chronic Inflammatory Demyelinating Polyneuropathy|Lambert Eaton Myasthenic Syndrome|Myasthenia Gravis|Neuromyelitis Optica|Opsoclonus Myoclonus Syndrome|Rasmussen Subacute Encephalitis,Carmustine,C(CCl)NC(=O)N(CCCl)N=O,PHASE2,cardiovascular_disease
3599,Autoimmune Disease|Neurologic Autoimmune Disease|Autologous Transplant Autoimmune|Multiple Sclerosis Transplant|MS Stem Cell Transplant|Multiple Sclerosis Stem Cell Transplant|Stiff Person Syndrome|HCT for Neurologic Autoimmune Disorders|CIDP Transplant|Myasthenia Gravis Transplant|Autoimmune Nervous System Disorder|Central Nervous System Vasculitis|Cerebellar Degeneration|Chronic Inflammatory Demyelinating Polyneuropathy|Lambert Eaton Myasthenic Syndrome|Myasthenia Gravis|Neuromyelitis Optica|Opsoclonus Myoclonus Syndrome|Rasmussen Subacute Encephalitis,Cytarabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,PHASE2,cardiovascular_disease
3600,"Stroke, Ischemic|Stroke Hemorrhagic",Amantadine,C1C2CC3CC1CC(C2)(C3)N,PHASE2,cardiovascular_disease
3601,Hypoxic Ischemic Encephalopathy,Topiramate,CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,PHASE2,cardiovascular_disease
3602,Atrial Fibrillation,Flecainide,C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,APPROVED,cardiovascular_disease
3605,Hypothermia|Cardiac Arrest,Lorazepam,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,APPROVED,cardiovascular_disease
3606,Cardiac Arrest,Ubiquinol,CC1=C(C(=C(C(=C1O)OC)OC)O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,PHASE2,cardiovascular_disease
3607,Attention Deficit Hyperactivity Disorder (ADHD),Lisdexamfetamine,CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N,APPROVED,cardiovascular_disease
3608,"Chronic Myeloproliferative Disorders|Infection|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific",Trimethoprim,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,PHASE1|PHASE2,cardiovascular_disease
3611,Obesity|Hypoandrogenism,Clomiphene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE2,cardiovascular_disease
3612,Obesity|Hypoandrogenism,Clomifene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE2,cardiovascular_disease
3613,"Stroke, Acute",Naloxone,C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,APPROVED,cardiovascular_disease
3614,Multiple Myeloma,Tipifarnib,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,PHASE1,cardiovascular_disease
3615,Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN,Pemigatinib,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,PHASE1|PHASE2,cardiovascular_disease
3616,Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN,Gemcitabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,PHASE1|PHASE2,cardiovascular_disease
3617,Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN,Docetaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,PHASE1|PHASE2,cardiovascular_disease
3619,Hypertension,Daglutril,CCOC(=O)C(CCC1=CC=CC=C1)CC2(CCCC2)C(=O)NC3CCC4=CC=CC=C4N(C3=O)CC(=O)O,PHASE2,cardiovascular_disease
3620,Surgery|Coronary Artery Disease,Rocuronium,CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C,APPROVED,cardiovascular_disease
3621,Surgery|Coronary Artery Disease,Neostigmine,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,APPROVED,cardiovascular_disease
3623,Staphylococcus Aureus Bacteremia|Staphylococcus Aureus Septicemia|Staphylococcal Sepsis|Staphylococcus Aureus Endocarditis,Ertapenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O,PHASE2,cardiovascular_disease
3624,Refractory Multiple Myeloma|Relapsed Multiple Myeloma,Montelukast,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,PHASE2,cardiovascular_disease
3627,Recurrent Plasma Cell Myeloma,Dinaciclib,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO,PHASE1,cardiovascular_disease
3628,Diabetic Foot Ulcers,Gentamicin,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,PHASE1|PHASE2,cardiovascular_disease
3629,Diabetic Foot Ulcers,Ciprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,PHASE1|PHASE2,cardiovascular_disease
3630,Ectopic Pregnancy,Letrozole,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,APPROVED,cardiovascular_disease
3631,"Hypertension, Pulmonary",Clevidipine,CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,APPROVED,cardiovascular_disease
3632,Anemia|B-Cell Prolymphocytic Leukemia|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma|Hairy Cell Leukemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Richter Syndrome,Entospletinib,C1COCCN1C2=CC=C(C=C2)NC3=NC(=CN4C3=NC=C4)C5=CC6=C(C=C5)C=NN6,PHASE1|PHASE2,cardiovascular_disease
3633,Neurosensory Disorder,Huperzine A,CC=C1C2CC3=C(C1(CC(=C2)C)N)C=CC(=O)N3,APPROVED,cardiovascular_disease
3634,Diabetes Type 2|Coronary Artery Disease,Canagliflozin,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,PHASE2|PHASE3,cardiovascular_disease
3636,Coronary Artery Disease,Paroxetine,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,APPROVED,cardiovascular_disease
3637,Gastrointestinal Hemorrhage|Portal Hypertension|Cirrhosis,Nadolol,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,APPROVED,cardiovascular_disease
3638,Gastrointestinal Hemorrhage|Portal Hypertension|Cirrhosis,Prazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,APPROVED,cardiovascular_disease
3639,Patent Ductus Arteriosus (PDA)|Acute Kidney Injury (AKI),Fenoldopam,C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O,PHASE2|PHASE3,cardiovascular_disease
3640,Hypertension,Norfloxacin,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,PHASE1,cardiovascular_disease
3641,"Diabetes Mellitus, Type 2",Linagliptin,CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,APPROVED,cardiovascular_disease
3642,Hypertension Secondary to Kidney Transplant,Isradipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,PHASE2|PHASE3,cardiovascular_disease
3643,Hemorrhage|Esophageal Varices|Portal Hypertension,Terlipressin,C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N,APPROVED,cardiovascular_disease
3644,Heart Failure|Hyperuricemia,Benzbromarone,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,APPROVED,cardiovascular_disease
3645,Cerebrovascular Accident,Galantamine,CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O,APPROVED,cardiovascular_disease
3646,"Hypertension, Pulmonary",Terbogrel,CC(C)(C)N=C(NC#N)NC1=CC=CC(=C1)C(=CCCCC(=O)O)C2=CN=CC=C2,PHASE2,cardiovascular_disease
3647,Oral Cancer|Head and Neck Cancer|Free Flap|Hypotension,Dopexamine,C1=CC=C(C=C1)CCNCCCCCCNCCC2=CC(=C(C=C2)O)O,APPROVED,cardiovascular_disease
3648,Multiple Myeloma|Non-Hodgkin's Lymphoma,Meloxicam,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,PHASE2,cardiovascular_disease
3649,Arterial Calcification|CD73 Deficiency,Etidronate,CC(O)(P(=O)(O)O)P(=O)(O)O,PHASE2,cardiovascular_disease
3650,Aneurysmal Subarachnoid Hemorrhage,Gabapentin,C1CCC(CC1)(CC(=O)O)CN,APPROVED,cardiovascular_disease
3651,Obesity|Blood Pressure,Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,APPROVED,cardiovascular_disease
3652,Obesity|Blood Pressure,Bupropion,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,APPROVED,cardiovascular_disease
3653,Polycystic Ovary Syndrome,Drospirenone,CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,APPROVED,cardiovascular_disease
3654,Long QT Syndrome,Dofetilide,CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C,PHASE1|PHASE2,cardiovascular_disease
3656,"Ischemic Stroke, Acute",Propylthiouracil,CCCC1=CC(=O)NC(=S)N1,PHASE2,cardiovascular_disease
3657,"Ischemic Stroke, Acute",Perphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,PHASE2,cardiovascular_disease
3658,Atherosclerosis,Pactimibe,CCCCCCCCN1CCC2=C(C(=C(C(=C21)NC(=O)C(C)(C)C)C)CC(=O)O)C,PHASE2,cardiovascular_disease
3659,Carotid Artery Stenosis,Terazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,PHASE2,cardiovascular_disease
3660,Multiple Myeloma,Anlotinib,CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,PHASE1,cardiovascular_disease
3662,Intraluminal Pulmonary Vein Stenosis,Vinblastine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE2,cardiovascular_disease
3663,Symptomatic Neurogenic Orthostatic Hypertension|nOH,Ampreloxetine,C1CNCCC1C2=CC=CC=C2COC3=C(C=C(C=C3F)F)F,PHASE1,cardiovascular_disease
3664,Acute Leukemia|Chronic Myeloproliferative Disease|Chronic Lymphoproliferative Disease|Multiple Myeloma|Lymphoma|Poor-risk Myelodysplasia (MDS),Darinaparsin,C[As](C)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N,PHASE1,cardiovascular_disease
3665,Coronary Heart Disease,Dalcetrapib,CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C,PHASE2,cardiovascular_disease
3666,"Heart Failure|Ventricular Dysfunction, Left",Trandolapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCCC3CC2C(=O)O,APPROVED,cardiovascular_disease
3667,DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Vismodegib,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,PHASE1,cardiovascular_disease
3668,Endothelial Dysfunction|Inflammation|Thrombosis|COVID-19,Sulodexide,CNC1=C2C(=NC=N1)N(C=N2)C3C(C(C(O3)CO)O)OC,APPROVED,cardiovascular_disease
3669,Methamphetamine Use Disorder|Drug Interaction|Cardiovascular Abnormalities,Mirtazapine,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,PHASE1,cardiovascular_disease
3671,Methamphetamine Use Disorder|Drug Interaction|Cardiovascular Abnormalities,Methamphetamine,CC(CC1=CC=CC=C1)NC,PHASE1,cardiovascular_disease
3672,Sickle Cell Disease|Chronic Kidney Disease|Pulmonary Hypertension,Hydroxyurea,C(=O)(N)NO,PHASE1,cardiovascular_disease
3673,Cerebrovascular Accident,Methylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,APPROVED,cardiovascular_disease
3674,Acute Coronary Syndrome,Eptifibatide,C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N,PHASE2,cardiovascular_disease
3675,Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Plasma Cell Myeloma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Alvocidib,CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O,PHASE1,cardiovascular_disease
3676,Multiple Myeloma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|HDT-AHCT,Romiplostim,CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C,PHASE2,cardiovascular_disease
3677,Aortic Valve Stenosis,Ataciguat,C1COCCN1S(=O)(=O)C2=CC=C(C=C2)NC(=O)C3=C(C=CC(=C3)Cl)NS(=O)(=O)C4=CC=C(S4)Cl,PHASE2,cardiovascular_disease
3678,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Capivasertib,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,PHASE2,cardiovascular_disease
3679,Coronary Artery Disease|Percutaneous Coronary Intervention|Platelet Aggregation Inhibitors,Vicagrel,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3Cl)C(=O)OC,PHASE2,cardiovascular_disease
3680,Ischemic Stroke,Mepivacaine,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,PHASE2,cardiovascular_disease
3681,Hypertension and Coronary Artery Disease,Celecoxib,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,APPROVED,cardiovascular_disease
3682,Multiple Myeloma,Ciforadenant,CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5,PHASE1,cardiovascular_disease
3683,Congestive Heart Failure,Icodextrin,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,PHASE2,cardiovascular_disease
3684,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Afatinib,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,PHASE2,cardiovascular_disease
3685,Traumatic Brain Injury|Subarachnoid Hemorrhage,Phenytoin,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,APPROVED,cardiovascular_disease
3686,Heart Failure With Preserved Ejection Fraction,Teprenone,CC(=CCCC(=CCCC(=CCCC(=CCCC(=O)C)C)C)C)C,PHASE2,cardiovascular_disease
3687,Neurologic Claudication in Patients With Lumbar Spinal Stenosis,Limaprost,CCCCC(C)CC(C=CC1C(CC(=O)C1CCCCC=CC(=O)O)O)O,APPROVED,cardiovascular_disease
3688,Neurologic Claudication in Patients With Lumbar Spinal Stenosis,Pregabalin,CC(C)CC(CC(=O)O)CN,APPROVED,cardiovascular_disease
3689,Polypoidal Choroidal Vasculopathy,Verteporfin,CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C,APPROVED,cardiovascular_disease
3690,Autonomic Failure|Orthostatic Hypotension,Atomoxetine,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,PHASE1,cardiovascular_disease
3691,Autonomic Failure|Orthostatic Hypotension,Yohimbine,COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O,PHASE1,cardiovascular_disease
3692,Autonomic Failure|Orthostatic Hypotension,Modafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE1,cardiovascular_disease
3693,Autonomic Failure|Orthostatic Hypotension,Tranylcypromine,C1C(C1N)C2=CC=CC=C2,PHASE1,cardiovascular_disease
3694,Autonomic Failure|Orthostatic Hypotension,Oxymetazoline,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,PHASE1,cardiovascular_disease
3695,Autonomic Failure|Orthostatic Hypotension,Rivastigmine,CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C,PHASE1,cardiovascular_disease
3696,"Heart Defects, Congenital",Dexrazoxane,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,PHASE1,cardiovascular_disease
3697,Restless Legs Syndrome,Pramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,APPROVED,cardiovascular_disease
3698,Primary Open Angle Glaucoma or Ocular Hypertension,Netarsudil,CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)C(CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C,PHASE2,cardiovascular_disease
3699,Stroke,Dextroamphetamine,CC(CC1=CC=CC=C1)N,PHASE2,cardiovascular_disease
3700,Drug Overdose|Overdose of Beta-adrenergic Blocking Drug,Glucagon,CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CN=CN7)N,APPROVED,cardiovascular_disease
3701,Infective Endocarditis,Fosfomycin,CC1C(O1)P(=O)(O)O,APPROVED,cardiovascular_disease
3702,Contraception Desired|Obesity,Levonorgestrel,CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,APPROVED,cardiovascular_disease
3703,Williams Syndrome|Anxiety,Buspirone,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,APPROVED,cardiovascular_disease
3705,Arteriovenous Malformations (Extracranial),Cobimetinib,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,PHASE2,cardiovascular_disease
3706,Marijuana Dependence,Dronabinol,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,PHASE1,cardiovascular_disease
3708,"Leukemia, Acute|Myelodysplastic Syndromes|Myelomonocytic Leukemia, Chronic|T-cell Prolymphocytic Leukemia|CML|Myeloproliferative Disorders|Multiple Myeloma|Plasma Cell Leukemia",Itacitinib,C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F,PHASE1,cardiovascular_disease
3709,Coronary Artery Disease,Varespladib,CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)O)C(=O)C(=O)N,PHASE2,cardiovascular_disease
3710,HIV|Cardiovascular Disease,Darunavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,APPROVED,cardiovascular_disease
3712,Schizophrenia,Ziprasidone,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,APPROVED,cardiovascular_disease
3713,Schizophrenia,Olanzapine,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,APPROVED,cardiovascular_disease
3714,Atrial Fibrillation|Cardiac Surgery,Landiolol,CC1(OCC(O1)COC(=O)CCC2=CC=C(C=C2)OCC(CNCCNC(=O)N3CCOCC3)O)C,APPROVED,cardiovascular_disease
3715,Endometriosis,Bazedoxifene,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,APPROVED,cardiovascular_disease
3716,"Nontraumatic Intracerebral Hemorrhage, Multiple Localized",Urapidil,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC,APPROVED,cardiovascular_disease
3717,Congestive Heart Failure Chronic,Resveratrol,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,PHASE2,cardiovascular_disease
3718,Fabry Disease,Migalastat,C1C(C(C(C(N1)CO)O)O)O,PHASE2,cardiovascular_disease
3719,Non Hodgkin Lymphoma|Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Multiple Myeloma,Thiotepa,C1CN1P(=S)(N2CC2)N3CC3,PHASE2,cardiovascular_disease
3720,"Paroxysmal Nocturnal Hemoglobinuria|Hemoglobinuria|Hemoglobinuria, Paroxysmal|Proteinuria|Urination Disorders|Thrombosis|Bone Marrow Failure|Aplastic Anemia,|Anemia, Hemolytic",Levamisole,C1CSC2=NC(CN21)C3=CC=CC=C3,PHASE2,cardiovascular_disease
3721,Endocarditis Infective,Cefaclor,C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl,APPROVED,cardiovascular_disease
3722,Endocarditis Infective,Clindamycin,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,APPROVED,cardiovascular_disease
3723,Endocarditis Infective,Sulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,APPROVED,cardiovascular_disease
3724,Endocarditis Infective,Tedizolid,CN1N=C(N=N1)C2=NC=C(C=C2)C3=C(C=C(C=C3)N4CC(OC4=O)CO)F,APPROVED,cardiovascular_disease
3725,Vascular Anomalies,Marimastat,CC(C)CC(C(C(=O)NO)O)C(=O)NC(C(=O)NC)C(C)(C)C,PHASE1,cardiovascular_disease
3726,Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis|Churg-Strauss Syndrome|Polyarteritis Nodosa,Azathioprine,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],APPROVED,cardiovascular_disease
3727,Long QT Syndrome,Lumacaftor,CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O,PHASE2,cardiovascular_disease
3728,Long QT Syndrome,Ivacaftor,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,PHASE2,cardiovascular_disease
3730,Atherosclerosis,Flutemetamol,CNC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O)F,PHASE2|PHASE3,cardiovascular_disease
3731,Myocardial Infarction,Mangafodipir,[H+].[H+].[H+].[H+].CC1=NC=C(C(=C1O)CN(CCN(CC2=C(C(=NC=C2COP(=O)([O-])[O-])C)O)CC(=O)[O-])CC(=O)[O-])COP(=O)([O-])[O-].[Mn+2],PHASE2,cardiovascular_disease
3732,Relapsed or Refractory Multiple Myeloma,Cabozantinib,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,PHASE1|PHASE2,cardiovascular_disease
3733,Cardiovascular Diseases|Heart Diseases|Beta-Thalassemia,Deferiprone,CC1=C(C(=O)C=CN1C)O,PHASE2,cardiovascular_disease
3734,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Parkinson's Disease|Multiple System Atrophy,Fipamezole,CCC1(CC2=C(C1)C=C(C=C2)F)C3=CN=CN3,PHASE2,cardiovascular_disease
3735,Cushing Syndrome|Endocrine Disease,Pentetreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CO)C(C)O)O,PHASE2,cardiovascular_disease
3736,Stroke|Cerebral Infarction|Brain Infarction|Brain Ischemia|Nervous System Diseases|Central Nervous System Diseases|Vascular Diseases,Butylphthalide,CCCCC1C2=CC=CC=C2C(=O)O1,APPROVED,cardiovascular_disease
3737,"Heart Failure (HF)|Ventricular Dysfunction, Left",Iobenguane,C1=CC(=CC(=C1)I)CN=C(N)N,APPROVED,cardiovascular_disease
3739,Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,Leuprorelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,cardiovascular_disease
3740,Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,Degarelix,CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C,PHASE2,cardiovascular_disease
3741,Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Non-metastatic Renal Cell Carcinoma,Axitinib,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4,PHASE2,cardiovascular_disease
3742,"Telangiectasia, Hereditary Hemorrhagic|Rendu Osler Disease",Nintedanib,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,PHASE2,cardiovascular_disease
3743,Portal Hypertension,Entecavir,C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N,APPROVED,cardiovascular_disease
3745,Age-related Macular Degeneration|Diabetic Retinopathy|Diabetic Macular Edema,Povidone,C=CN1CCCC1=O,APPROVED,cardiovascular_disease
3746,Stroke|Acute Ischemic Stroke,Repinotan,C1CC2=CC=CC=C2OC1CNCCCCN3C(=O)C4=CC=CC=C4S3(=O)=O,PHASE2,cardiovascular_disease
3747,Heart Failure,Istaroxime,CC12CCC(=NOCCN)CC1C(=O)CC3C2CCC4(C3CCC4=O)C,PHASE1,cardiovascular_disease
3748,"Subarachnoid Hemorrhage|Intracerebral Hemorrhage|Ventriculitis, Cerebral|Hydrocephalus",Nafcillin,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,PHASE1,cardiovascular_disease
3749,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Taselisib,CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C,PHASE2,cardiovascular_disease
3750,Hemorrhoid|Peri Anal Fistula,Prilocaine,CCCNC(C)C(=O)NC1=CC=CC=C1C,APPROVED,cardiovascular_disease
3751,Pheochromocytoma/Paraganglioma|Pancreatic Neuroendocrine Tumor|Von Hippel-Lindau Disease|Advanced Gastrointestinal Stromal Tumor|HIF-2α Mutated Cancers,Belzutifan,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,PHASE2,cardiovascular_disease
3752,Cardiovascular Diseases,Lorcaserin,CC1CNCCC2=C1C=C(C=C2)Cl,PHASE1,cardiovascular_disease
3755,HIV Infections,Cenicriviroc,CCCCOCCOC1=CC=C(C=C1)C2=CC3=C(C=C2)N(CCCC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)CC5=CN=CN5CCC)CC(C)C,PHASE2,cardiovascular_disease
3756,Pulmonary Arterial Hypertension,Ralinepag,C1CC(CCC1COCC(=O)O)COC(=O)N(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,PHASE2,cardiovascular_disease
3757,Diabetes Mellitus,Albiglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N,APPROVED,cardiovascular_disease
3758,Renal Failure|ESRD|Cardiovascular Disease,Isoxaflutole,CS(=O)(=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C2=C(ON=C2)C3CC3,APPROVED,cardiovascular_disease
3759,Pulmonary Hypertension,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,cardiovascular_disease
3760,Hypertension,Levamlodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,PHASE1,cardiovascular_disease
3761,Essential Hypertension,Eprosartan,CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O,APPROVED,cardiovascular_disease
3762,Chronic Lymphocytic Leukemia|Indolent Non-Hodgkin Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)|Marginal Zone Lymphoma,Idelalisib,CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,PHASE1,cardiovascular_disease
3763,Atrial Fibrillation,Capadenoson,C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO,PHASE2,cardiovascular_disease
3764,Hypotension,Ondansetron,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,APPROVED,cardiovascular_disease
3766,Behcet Syndrome,Apremilast,CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,PHASE2,cardiovascular_disease
3767,Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics,Pimozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,PHASE1,cardiovascular_disease
3768,Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics,Cobicistat,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,PHASE1,cardiovascular_disease
3769,Heart Failure,Bendroflumethiazide,C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2,PHASE1,cardiovascular_disease
3770,Loss of Chromosome 17p|Recurrent Plasma Cell Myeloma,Idasanutlin,CC(C)(C)CC1C(C(C(N1)C(=O)NC2=C(C=C(C=C2)C(=O)O)OC)C3=C(C(=CC=C3)Cl)F)(C#N)C4=C(C=C(C=C4)Cl)F,PHASE1|PHASE2,cardiovascular_disease
3771,Arteriovenous Malformation,Sufentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC,APPROVED,cardiovascular_disease
3772,Prehypertension|Hypertension,Bradykinin,C1CC(N(C1)C(=O)C2CCCN2C(=O)C(CCCN=C(N)N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CO)C(=O)N4CCCC4C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCN=C(N)N)C(=O)O,APPROVED,cardiovascular_disease
3773,Coagulopathy|Cardiovascular Complication|COVID-19,Camostat,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N,PHASE1|PHASE2,cardiovascular_disease
3774,Cardiorenal Syndrome|Chronic Allograft Nephropathy,Calcitriol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,cardiovascular_disease
3775,Erythromelalgia,Carbamazepine,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,APPROVED,cardiovascular_disease
3777,Heart Failure With Reduced Ejection Fraction HFrEF,Lenomorelin,CCCCCCCC(=O)OCC(C(=O)NC(CO)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)N2CCCC2C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC=N3)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)N6CCCC6C(=O)NC(CCCNC(=N)N)C(=O)O)NC(=O)CN,PHASE1|PHASE2,cardiovascular_disease
3778,Hyperemia Eye,Naphazoline,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32,PHASE1,cardiovascular_disease
3779,Hyperemia Eye,Hypromellose,CC(COCC1C(C(C(C(O1)OC)OCC(C)O)OCC(C)O)OC2C(C(C(C(O2)COC)OC3C(C(C(C(O3)CO)OC)O)O)OC)OC)O,PHASE1,cardiovascular_disease
3780,Coronary Artery Bypass Graft Surgery|Myocardial Ischemia|Reperfusion Injury|Myocardial Revascularization,Pyridoxal,CC1=NC=C(C(=C1O)C=O)CO,PHASE2,cardiovascular_disease
3781,Kidney Failure|Secondary Hyperparathyroidism|Vascular Diseases,Cinacalcet,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,APPROVED,cardiovascular_disease
3782,Subarachnoid Hemorrhage|Subdural Hematoma|Traumatic Brain Injury|Ischemic Stroke|Fever|Intracerebral Hemorrhage,Bromocriptine,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,PHASE1|PHASE2,cardiovascular_disease
3783,B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|Richter Syndrome,Pevonedistat,C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N,PHASE1,cardiovascular_disease
3784,"Arthritis, Rheumatoid",Naproxen,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,APPROVED,cardiovascular_disease
3786,Type II Diabetes|Atherosclerosis,Tirzepatide,CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N,APPROVED,cardiovascular_disease
3787,Diastolic Dysfunction|Systolic Dysfunction|Diastolic Heart Failure,Sulforaphane,CS(=O)CCCCN=C=S,PHASE1|PHASE2,cardiovascular_disease
3788,Relapsed Refractory Multiple Myeloma,Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,PHASE1|PHASE2,cardiovascular_disease
3789,Relapsed Refractory Multiple Myeloma,Enasidenib,CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O,PHASE1|PHASE2,cardiovascular_disease
3790,Relapsed Refractory Multiple Myeloma,Erdafitinib,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,PHASE1|PHASE2,cardiovascular_disease
3792,Multiple Myeloma,Plitidepsin,CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(=O)C)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O,PHASE2,cardiovascular_disease
3793,Chronic Obstructive Pulmonary Disease,Formoterol,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O,PHASE2,cardiovascular_disease
3794,Congenital Heart Disease|Upper Gastrointestinal Bleeding|Stress Ulcer|Infection,Famotidine,C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N,APPROVED,cardiovascular_disease
3795,Velo-cardio-facial Syndrome|Psychosis,Metyrosine,CC(CC1=CC=C(C=C1)O)(C(=O)O)N,PHASE2,cardiovascular_disease
3796,Arterial Ischemic Stroke,Afamelanotide,CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C,PHASE2,cardiovascular_disease
3797,Cerebral Infarction,Edaravone,CC1=NN(C(=O)C1)C2=CC=CC=C2,APPROVED,cardiovascular_disease
3798,Cerebral Infarction,Ozagrel,C1=CC(=CC=C1CN2C=CN=C2)C=CC(=O)O,APPROVED,cardiovascular_disease
3799,Arteriovenous Malformations,Medroxyprogesterone,CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,APPROVED,cardiovascular_disease
3800,AIDS-Related Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Waldenstrom Macroglobulinemia,Temsirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,PHASE1|PHASE2,cardiovascular_disease
3801,Sleep Apnea Syndromes|Cerebral Infarction,Trazodone,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,APPROVED,cardiovascular_disease
3802,"Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer, Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme",Leucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1|PHASE2,cardiovascular_disease
3803,"Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer, Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme",Oxaliplatin,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],PHASE1|PHASE2,cardiovascular_disease
3804,"Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer, Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme",Irinotecan,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,PHASE1|PHASE2,cardiovascular_disease
3805,"Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer, Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme",Temozolomide,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,PHASE1|PHASE2,cardiovascular_disease
3806,Pulmonary Arterial Hypertension,Zamicastat,C1C(COC2=C1C=C(C=C2F)F)N3C(=CNC3=S)CCNCC4=CC=CC=C4,PHASE2,cardiovascular_disease
3808,"Cardiovascular Diseases|Cardiovascular Risk Factor|Triglycerides High|Diabetes Mellitus, Type 2",Icosapent,CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O,APPROVED,cardiovascular_disease
3810,COPD|Chronic Obstructive Pulmonary Disease|Moderate to Very Severe COPD,Aclidinium,C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5,APPROVED,cardiovascular_disease
3811,Vitamin D Deficiency|Diabetes,Ergocalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,APPROVED,cardiovascular_disease
3813,"Slow-Flow Vascular Malformation|Fast-Flow Vascular Malformation|Vascular Malformations|Venous Malformation|Lymphatic Malformation, Low Flow|Lymphatic Malformation|Lymphangioma|Arteriovenous Malformations|Venous Malformation, Low Flow|Cystic Hygroma|Vascular Anomaly|Vascular Anomalies|PI3K Gene Mutation|MAP2K1 Gene Mutation|PIK3CA-related Overgrowth Spectrum|Arteriovenous Malformation (AVM)|KRAS G12C|KRAS G12D",Alpelisib,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,PHASE2,cardiovascular_disease
3814,"Slow-Flow Vascular Malformation|Fast-Flow Vascular Malformation|Vascular Malformations|Venous Malformation|Lymphatic Malformation, Low Flow|Lymphatic Malformation|Lymphangioma|Arteriovenous Malformations|Venous Malformation, Low Flow|Cystic Hygroma|Vascular Anomaly|Vascular Anomalies|PI3K Gene Mutation|MAP2K1 Gene Mutation|PIK3CA-related Overgrowth Spectrum|Arteriovenous Malformation (AVM)|KRAS G12C|KRAS G12D",Mirdametinib,C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O,PHASE2,cardiovascular_disease
3815,Myeloma,Vinorelbine,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,PHASE2,cardiovascular_disease
3816,HIV Infections|Cardiovascular Diseases|Hypertension,Indinavir,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,PHASE1,cardiovascular_disease
3817,Multiple Myeloma,Opaganib,C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl,PHASE1|PHASE2,cardiovascular_disease
3818,"Abdominal Aorta Aneurysm|Abdominal Aorta Atheroma|Surgery|Pain, Postoperative",Metamizole,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O,APPROVED,cardiovascular_disease
3819,"Abdominal Aorta Aneurysm|Abdominal Aorta Atheroma|Surgery|Pain, Postoperative",Dipyrone,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],APPROVED,cardiovascular_disease
3820,Superficial Thrombophlebitis of the Upper Limb,Diclofenac,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,APPROVED,cardiovascular_disease
3821,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Olaparib,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE2,cardiovascular_disease
3822,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Bosutinib,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,PHASE2,cardiovascular_disease
3823,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Erlotinib,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,PHASE2,cardiovascular_disease
3824,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Vemurafenib,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,PHASE2,cardiovascular_disease
3825,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Tucatinib,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,PHASE2,cardiovascular_disease
3826,Multiple Myeloma,Imetelstat,CCCCCCCCCCCCCCCC(=O)NCC(COP(=S)(O)OCC1C(CC(O1)N2C=C(C(=O)NC2=O)C)NP(=S)(O)OCC3C(CC(O3)N4C=NC5=C(N=CN=C54)N)NP(=S)(O)OCC6C(CC(O6)N7C=NC8=C7N=C(NC8=O)N)NP(=S)(O)OCC9C(CC(O9)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)NP(=S)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)NP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)NP(=O)(OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)N)S)O,PHASE1,cardiovascular_disease
3828,"Cerebral Stroke|Cerebrovascular Accident, Acute|Cerebrovascular Stroke|Stroke, Acute|Stroke",Dapsone,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,PHASE2|PHASE3,cardiovascular_disease
3829,Waldenstrom's Macroglobulinemia,Valaciclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE2,cardiovascular_disease
3830,Waldenstrom's Macroglobulinemia,Valacyclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE2,cardiovascular_disease
3831,"Cardiac Valve Disease|Coronary Artery Disease|Organ Failure, Multiple",Valproate,CCCC(CCC)C(=O)O,PHASE1|PHASE2,cardiovascular_disease
3832,STEMI|Morphine|Ticagrelor|Methylnaltrexone,Methylnaltrexone,C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,APPROVED,cardiovascular_disease
3833,Acute Ischemic Stroke,Balovaptan,CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCC(CC4)OC5=CC=CC=N5)C1,PHASE2,cardiovascular_disease
3834,Multiple Myeloma,Tucidinostat,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,PHASE1|PHASE2,cardiovascular_disease
3835,Coronary Artery Disease,Tetrofosmin,CCOCCP(CCOCC)CCP(CCOCC)CCOCC,APPROVED,cardiovascular_disease
3837,Vasoplegic Syndrome,Hydroxocobalamin,CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.O.[Co+2],PHASE2,cardiovascular_disease
3838,Macular Edema|Central Retinal Vein Occlusion,Ecallantide,CCC(C)C1C(=O)NC(C(=O)NCC(=O)NCC(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4CCCC4C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N5CCCC5C(=O)N3)CC(=O)O)CC(=O)O)C)CCCCN)CC6=CC=CC=C6)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C(CCC(=O)O)N)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)O)CCSC)CCCCN)CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC2=O)CCC(=O)O)CC(=O)N)CCC(=O)N)CC(=O)N)CCCNC(=N)N)CC9=CC=CC=C9)CCC(=O)O)CO)CC(C)C)CCC(=O)O)CCC(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CC1=CC=CC=C1)CCC(=O)O)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)C(C)O)CC1=CC=CC=C1)C(C)CC)CC(=O)N)CC1=CC=CC=C1)CC1=CC=CC=C1)CC1=CNC2=CC=CC=C21)CCCNC(=N)N)CC1=CN=CN1)C)C)CCCNC(=N)N)CC1=CC=C(C=C1)O,PHASE1,cardiovascular_disease
3839,Acute Coronary Syndrome|Helicobacter Pylori Infection,Vonoprazan,CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3,APPROVED,cardiovascular_disease
3840,Stroke,Basmisanil,CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4,PHASE2,cardiovascular_disease
3841,Multiple System Atrophy,Safinamide,CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F,PHASE2,cardiovascular_disease
3842,Cerebral Infarction,Triflusal,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,APPROVED,cardiovascular_disease
3843,HepatoCellular Carcinoma|Portal Vein Tumor Thrombosis,Lipotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)OC(=O)C(C)ON=C6C7=C(C(=CC(=C7)[N+](=O)[O-])[N+](=O)[O-])C8=C6C=C(C=C8[N+](=O)[O-])[N+](=O)[O-],PHASE1|PHASE2,cardiovascular_disease
3844,Hemorrhoids|Postoperative Pain,Metronidazole,CC1=NC=C(N1CCO)[N+](=O)[O-],APPROVED,cardiovascular_disease
3848,Intraoperative Hypotension,Remimazolam,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=NC2CCC(=O)OC)C4=CC=CC=N4,APPROVED,cardiovascular_disease
3849,Chronic Obstructive Pulmonary Disease and Allied Conditions,Roflumilast,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,APPROVED,cardiovascular_disease
3850,Williams Beuren Syndrome,Minoxidil,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,PHASE2,cardiovascular_disease
3851,Kawasaki Disease,Defibrotide,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)OP(=O)(O)O,PHASE2,cardiovascular_disease
3852,Depression|Anxiety,Quetiapine,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,APPROVED,cardiovascular_disease
3853,Microvascular Angina,Zibotentan,CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4,PHASE2,cardiovascular_disease
3854,Depression|Acute Ischemic Stroke,Agomelatine,CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC,APPROVED,cardiovascular_disease
3855,Multiple Myeloma,Plinabulin,CC(C)(C)C1=C(N=CN1)C=C2C(=O)NC(=CC3=CC=CC=C3)C(=O)N2,PHASE2,cardiovascular_disease
3856,Macular Edema,Nepafenac,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N,PHASE2,cardiovascular_disease
3857,Dipeptidyl-Peptidase 4 Inhibitors|LDL Cholesterol|Glycosylated Hemoglobin|Diabetes Mellitus|Coronary Disease,Anagliptin,CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCCC3C#N,APPROVED,cardiovascular_disease
3858,"Hiv|HIV Infections|HIV Cardiomyopathy|Weight Change, Body|HIV Lipodystrophy|Cardiovascular Diseases",Lamivudine,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,APPROVED,cardiovascular_disease
3859,Adynamic Bone Disease|Chronic Kidney Diseases|Cardiac Disease|Chronic Kidney Disease-Mineral and Bone Disorder,Teriparatide,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N,APPROVED,cardiovascular_disease
3860,Atherosclerosis,Losmapimod,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C,PHASE2,cardiovascular_disease
3861,Hereditary Hemorrhagic Telangiectasia,Tamoxifen,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,PHASE2,cardiovascular_disease
3862,Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Lymphoplasmacytic Lymphoma|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma,Imexon,C1C2N1C(=O)N=C2N,PHASE2,cardiovascular_disease
3863,Pulmonary Arterial Hypertension,Apabetalone,CC1=CC(=CC(=C1OCCO)C)C2=NC3=C(C(=CC(=C3)OC)OC)C(=O)N2,PHASE2,cardiovascular_disease
3865,"Cardiovascular Diseases|Heart Diseases|Heart Defects, Congenital",Citrulline,C(CC(C(=O)O)N)CNC(=O)N,PHASE1|PHASE2,cardiovascular_disease
3866,Non-hodgkins Lymphoma|Hodgkins Lymphoma|Multiple Myeloma,Pegaspargase,CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C,PHASE2,cardiovascular_disease
3867,Gastrointestinal Cancer|Cancer of Unknown Primary Site|Pancreatic Cancer|Bile Duct Neoplasms,Gimeracil,C1=C(C(=CNC1=O)Cl)O,PHASE2,cardiovascular_disease
3868,Gastrointestinal Cancer|Cancer of Unknown Primary Site|Pancreatic Cancer|Bile Duct Neoplasms,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,PHASE2,cardiovascular_disease
3869,Coronary Disease,Otamixaban,CC(C(CC1=CC(=CC=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-],PHASE2,cardiovascular_disease
3870,Acute Myocardial Infarction|Acute Myocardial Ischemia|STEMI - ST Elevation Myocardial Infarction,Dutogliptin,B(C1CCCN1C(=O)CNC2CCNC2)(O)O,PHASE2,cardiovascular_disease
3871,Granisetron,Granisetron,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,PHASE2|PHASE3,cardiovascular_disease
3872,Heart Disease,Trichloroacetaldehyde,C(=O)C(Cl)(Cl)Cl,APPROVED,cardiovascular_disease
3873,Pulmonary Arterial Hypertension,Fulvestrant,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,PHASE2,cardiovascular_disease
3874,Cardiovascular Disease Risk Factors,Puerarin,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3C4C(C(C(C(O4)CO)O)O)O)O)O,PHASE2,cardiovascular_disease
3875,Renal Cancer|Von Hippel Lindau,Vandetanib,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,PHASE2,cardiovascular_disease
3876,Congestive Heart Failure,Azimilide,CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)N=CC3=CC=C(O3)C4=CC=C(C=C4)Cl,PHASE2,cardiovascular_disease
3877,Osteoarthritis With Controlled Hypertension,Lumiracoxib,CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O,APPROVED,cardiovascular_disease
3878,Atrial Fibrillation|Atrial Flutter,Methohexital,CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C,APPROVED,cardiovascular_disease
3879,"Post-COVID-19 Syndrome|Long COVID|Long Covid19|COVID-19|POTS - Postural Orthostatic Tachycardia Syndrome|Post COVID-19 Condition|Post-COVID Syndrome|Post COVID-19 Condition, Unspecified|Postinfectious Inflammation|Postinfectious Disorder",Nirmatrelvir,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C,PHASE2,cardiovascular_disease
3880,Diabetic Retinopathy,Pimagedine,C(=NN)(N)N,PHASE1,cardiovascular_disease
3881,Glaucoma|Ocular Hypertension,Benzalkonium,CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1,PHASE2,cardiovascular_disease
3882,Cardiac Arrythmias,Carbetocin,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSCCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,APPROVED,cardiovascular_disease
3883,Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Malignant Pericardial Effusion|Malignant Pleural Effusion|Minimally Invasive Lung Adenocarcinoma|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7,Carboplatin,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],PHASE2,cardiovascular_disease
3884,Pulmonary Arterial Hypertension,Anastrozole,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,PHASE2,cardiovascular_disease
3885,Adult B Acute Lymphoblastic Leukemia|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult Solid Neoplasm|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Plasma Cell Myeloma|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,Veliparib,CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N,PHASE1|PHASE2,cardiovascular_disease
3887,Vascular Dementia,Ergoloid,CCC(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.CC(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.CC(C)C1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C,PHASE2,cardiovascular_disease
3888,"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Leukemia|Lymphoma|Multiple Myeloma|MDS|Myelodysplastic/Myeloproliferative Diseases",Ganciclovir,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,PHASE2,cardiovascular_disease
3889,Diabetic Foot Infections,Nemonoxacin,CC1CC(CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N,PHASE2,cardiovascular_disease
3890,ST Elevation Myocardial Infarction|STEMI,Oseltamivir,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,APPROVED,cardiovascular_disease
3892,Thromboembolism of Vein VTE in Colorectal Cancer|Thromboembolism of Vein in Pancreatic Cancer|Thromboembolism of Vein in Non-small Cell Lung Cancer,Isoquercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O)O,PHASE2|PHASE3,cardiovascular_disease
3893,Hemodialysis Catheter Infection|Thrombosis; Dialysis Catheter,Taurolidine,C1CS(=O)(=O)NCN1CN2CCS(=O)(=O)NC2,APPROVED,cardiovascular_disease
3894,"Hepatitis C, Chronic|Heart Failure|Pulmonary Disease, Chronic Obstructive|Lung Diseases, Interstitial",Sofosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,APPROVED,cardiovascular_disease
3895,Pulmonary Hypertension,Hymecromone,CC1=CC(=O)OC2=C1C=CC(=C2)O,PHASE2,cardiovascular_disease
3897,Portal Hypertension|Liver Cirrhosis,Ifetroban,CCCCCNC(=O)C1=COC(=N1)C2C3CCC(C2CC4=CC=CC=C4CCC(=O)O)O3,PHASE2,cardiovascular_disease
3898,"Sleep Apnea, Central|Ventricular Dysfunction",Zopiclone,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,APPROVED,cardiovascular_disease
3899,Essential Hypertension,Bexagliflozin,C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,PHASE2|PHASE3,cardiovascular_disease
3900,Pulmonary Arterial Hypertension,Selonsertib,CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F,PHASE2,cardiovascular_disease
3901,Hypercholesterolemia,Inclisiran,CC(=O)NC1C(C(C(OC1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)NC(=O)CCCCCCCCCCC(=O)N4CC(CC4COP(=O)(O)O)O)CO)O)O,APPROVED,cardiovascular_disease
3902,Stroke|Cerebrovascular Accident|Hemiparesis,Armodafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE2,cardiovascular_disease
3903,Cerebral Small Vessel Diseases,Azelnidipine,CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C,APPROVED,cardiovascular_disease
3904,Myeloma,Pyridoxine,CC1=NC=C(C(=C1O)CO)CO,PHASE2,cardiovascular_disease
3908,Stroke|Rhabdomyolysis|Jaundice,Lovastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE2,cardiovascular_disease
3909,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Binimetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,PHASE2,cardiovascular_disease
3911,Arrhythmia,Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,APPROVED,cardiovascular_disease
3912,Ischemia-Reperfusion Injury|Kidney Diseases,Reparixin,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C,PHASE2,cardiovascular_disease
3913,Essential Hypertension,Arotinolol,CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O,APPROVED,cardiovascular_disease
3915,Healthy Subjects|Atherosclerosis,Rilapladib,COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C5=CC=CC=C5C(=O)C=C4SCC6=C(C(=CC=C6)F)F,PHASE1,cardiovascular_disease
3916,"Heart Failure, Congestive",Ularitide,CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C3CCCN3C(=O)C(C)NC(=O)C(C(C)O)N)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC5=CC=C(C=C5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C,PHASE1,cardiovascular_disease
3917,Multiple Myeloma,Palonosetron,C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5,PHASE2,cardiovascular_disease
3918,Acute Coronary Syndrome|Myocardial Infarction|ST Elevation Myocardial Infarction|Heart Diseases|Anxiety,Alprazolam,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,PHASE1|PHASE2,cardiovascular_disease
3920,Coronary Artery Disease|Mitral Valve Regurgitation,Etomidate,CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2,APPROVED,cardiovascular_disease
3921,Diastolic Heart Failure,Alagebrium,CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C,PHASE2,cardiovascular_disease
3922,EKG-QT Prolongation,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,APPROVED,cardiovascular_disease
3923,EKG-QT Prolongation,Hydromorphone,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4,APPROVED,cardiovascular_disease
3924,Vascular Depression,Desvenlafaxine,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,APPROVED,cardiovascular_disease
3926,Cushing's Syndrome,Mifepristone,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,PHASE2,cardiovascular_disease
3927,Hepatitis C,Elbasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC,APPROVED,cardiovascular_disease
3928,Systemic Lupus Erythematosus,Dehydroepiandrosterone,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C,PHASE2|PHASE3,cardiovascular_disease
3929,Systemic Lupus Erythematosus,Prasterone,CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C,PHASE2|PHASE3,cardiovascular_disease
3930,Tachycardia|Chronic Orthostatic Intolerance,Mecamylamine,CC1(C2CCC(C2)C1(C)NC)C,PHASE1|PHASE2,cardiovascular_disease
3932,Refractory Multiple Myeloma,Noscapine,CN1CCC2=CC3=C(C(=C2C1C4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,PHASE1,cardiovascular_disease
3934,Pulmonary Arterial Hypertension|Pulmonary Hypertension|Interstitial Lung Disease|Idiopathic Interstitial Pneumonia|Idiopathic Pulmonary Fibrosis|Sarcoidosis|Respiratory Bronchiolitis Associated Interstitial Lung Disease|Desquamative Interstitial Pneumonia|Cryptogenic Organizing Pneumonia|Acute Interstitial Pneumonitis|Idiopathic Lymphoid Interstitial Pneumonia|Idiopathic Pleuroparenchymal Fibroelastosis,Bardoxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C,PHASE2,cardiovascular_disease
3937,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Uprosertib,CN1C(=C(C=N1)Cl)C2=C(OC(=C2)C(=O)NC(CC3=CC(=C(C=C3)F)F)CN)Cl,PHASE2,cardiovascular_disease
3938,Multiple Myeloma|Diarrhea,Colesevelam,CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-],PHASE2,cardiovascular_disease
3939,Multiple Myeloma,Ricolinostat,C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO,PHASE1|PHASE2,cardiovascular_disease
3942,Symptomatic Atrial Fibrillation|Atrial Flutter,Vanoxerine,C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,PHASE2,cardiovascular_disease
3943,Acute Ischaemic Middle Cerebral Artery Stroke,Piracetam,C1CC(=O)N(C1)CC(=O)N,APPROVED,cardiovascular_disease
3944,Chagas Disease,Nifurtimox,CC1CS(=O)(=O)CCN1N=CC2=CC=C(O2)[N+](=O)[O-],PHASE2|PHASE3,cardiovascular_disease
3945,Chagas Disease,Benznidazole,C1=CC=C(C=C1)CNC(=O)CN2C=CN=C2[N+](=O)[O-],PHASE2|PHASE3,cardiovascular_disease
3946,Recurrent Multiple Myeloma|Refractory Multiple Myeloma,Telaglenastat,C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F,PHASE1,cardiovascular_disease
3947,Ataxia Telangiectasia,Triheptanoin,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,PHASE2,cardiovascular_disease
3948,Von Hippel-Lindau Syndrome,Dovitinib,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,PHASE2,cardiovascular_disease
3949,Primary Aldosteronism|Hypertension,Finerenone,CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C,APPROVED,cardiovascular_disease
3950,Hypotension,Metaraminol,CC(C(C1=CC(=CC=C1)O)O)N,PHASE2,cardiovascular_disease
3951,Macular Edema|Retinal Vein Occlusion,Fluocinolone,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CC(C4=CC(=O)C=CC43C)F)F)O,PHASE2,cardiovascular_disease
3952,Multiple Myeloma,Etodolac,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,PHASE2,cardiovascular_disease
3953,Copd|Heart Failure,Umeclidinium,C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5,APPROVED,cardiovascular_disease
3955,Heart Failure,Ruboxistaurin,CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O,PHASE1|PHASE2,cardiovascular_disease
3956,Cardiovascular Diseases|Hepatitis C|Hiv,Grazoprevir,CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1,APPROVED,cardiovascular_disease
3957,Coronary Artery Disease|Dyslipidemia,Laropiprant,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F,APPROVED,cardiovascular_disease
3958,Hematological Malignancies|Multiple Myeloma|Hodgkin's Lymphoma|Cutaneous T Cell Lymphoma,Tinostamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO,PHASE1,cardiovascular_disease
3960,"Claudication, Intermittent|Peripheral Artery Disease|Peripheral Vascular Diseases",Sapropterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE1,cardiovascular_disease
3961,"Claudication, Intermittent|Peripheral Artery Disease|Peripheral Vascular Diseases",Tetrahydrobiopterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE1,cardiovascular_disease
3963,Postoperative Cardiac Complication,Celiprolol,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C,PHASE2,cardiovascular_disease
3964,Stroke,Enecadin,CC1=NC(=CC(=N1)OCCCCCN2CCCCC2)C3=CC=C(C=C3)F,PHASE2,cardiovascular_disease
3965,"Altitude Sickness|Hypertension, Pulmonary",Methazolamide,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,APPROVED,cardiovascular_disease
3966,Congestive Heart Failure,Lixivaptan,CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl,PHASE2,cardiovascular_disease
3967,Type 2 Diabetes|Hypertension,Aprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,PHASE2,cardiovascular_disease
3968,Unstable Angina,Methoxyflurane,COC(C(Cl)Cl)(F)F,APPROVED,cardiovascular_disease
3969,Multiple Myeloma,Tecemotide,CCCCCCCCCCCCCCCC(=O)NCCCCC(C(=O)NCC(=O)O)NC(=O)C1CCCN1C(=O)C2CCCN2C(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)CNC(=O)C3CCCN3C(=O)C(C)NC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)C5CCCN5C(=O)C(C)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)C(CC6=CN=CN6)NC(=O)C(C)NC(=O)C7CCCN7C(=O)C8CCCN8C(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CO)N,PHASE2,cardiovascular_disease
3971,"Deep Vein Thrombosis|Fibrillation, Atrial|Venous Thromboembolism|Pulmonary Embolism",Odiparcil,CC1=CC(=O)OC2=C1C=CC(=C2)OC3C(C(C(CS3)O)O)O,PHASE2,cardiovascular_disease
3972,Ischemic Stroke|Post-stroke Cognitive Impairment,Cromolyn,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,PHASE2,cardiovascular_disease
3973,Fabry Disease,Lucerastat,CCCCN1CC(C(C(C1CO)O)O)O,PHASE1,cardiovascular_disease
3974,Aneurysmal Subarachnoid Hemorrhage,Tiopronin,CC(C(=O)NCC(=O)O)S,PHASE2,cardiovascular_disease
3975,Phlebitis,Clobetasol,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C,PHASE1|PHASE2,cardiovascular_disease
3976,ST-segment Elevation Myocardial Infarction (STEMI),Ketotifen,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,APPROVED,cardiovascular_disease
3977,Type 2 Diabetes|Coronary Artery Disease,Glipizide,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,APPROVED,cardiovascular_disease
3978,Plasmacytoma|Recurrent Multiple Myeloma|Refractory Multiple Myeloma,Navtemadlin,CC(C)C(CS(=O)(=O)C(C)C)N1C(C(CC(C1=O)(C)CC(=O)O)C2=CC(=CC=C2)Cl)C3=CC=C(C=C3)Cl,PHASE1,cardiovascular_disease
3979,Heart Failure,Terbutaline,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,APPROVED,cardiovascular_disease
3980,Stroke,Levodopa,C1=CC(=C(C=C1CC(C(=O)O)N)O)O,APPROVED,cardiovascular_disease
3981,Drug Toxicity|Platelet Dysfunction|Clotting Disorder,Tramadol,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,APPROVED,cardiovascular_disease
3982,"Diabetes Mellitus, Type 2",Teneligliptin,CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5,APPROVED,cardiovascular_disease
3983,Cardiovascular Disease|Sudden Cardiac Death,Alfacalcidol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,PHASE2,cardiovascular_disease
3984,Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics,Mexiletine,CC1=C(C(=CC=C1)C)OCC(C)N,PHASE1,cardiovascular_disease
3985,Atrial Fibrillation,Isoproterenol,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,PHASE2,cardiovascular_disease
3986,Atrial Fibrillation,Isoprenaline,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,PHASE2,cardiovascular_disease
3987,Chronic Obstructive Pulmonary Disease|Pulmonary Artery Hypertension|Heart Failure|Hypertension,Fexofenadine,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,PHASE1,cardiovascular_disease
3988,Coronary Artery Disease|Postoperative Shivering,Meperidine,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,APPROVED,cardiovascular_disease
3989,Smoldering Multiple Myeloma,Hiltonol,C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O.C(CCNC(=O)O)CN.C(C(=O)O)O,PHASE1,cardiovascular_disease
3990,Smoldering Multiple Myeloma,Citarinostat,C1=CC=C(C=C1)N(C2=CC=CC=C2Cl)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO,PHASE1,cardiovascular_disease
3991,Portal Hypertension,Cobiprostone,CCC(C)CC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F,PHASE2,cardiovascular_disease
3993,Multiple Myeloma,Osalmid,C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)O)O,PHASE1|PHASE2,cardiovascular_disease
3994,ST Elevation Myocardial Infarction,Roxadustat,CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,PHASE2,cardiovascular_disease
3995,Congestive Heart Failure,Piboserod,CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42,PHASE2,cardiovascular_disease
3996,Relapsed or Refractory Multiple Myeloma|Patients With BRAFV600 E or BRAFV600K Mutation,Encorafenib,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,PHASE2,cardiovascular_disease
3997,Diabetes Mellitus|Diabetic Foot,Piperacillin,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,cardiovascular_disease
3998,Diabetes Mellitus|Diabetic Foot,Tazobactam,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,APPROVED,cardiovascular_disease
3999,Coronary Artery Disease,Quercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,PHASE2,cardiovascular_disease
4000,Angioedema,Cortisone,CC12CCC(=O)C=C1CCC3C2C(=O)CC4(C3CCC4(C(=O)CO)O)C,PHASE2,cardiovascular_disease
4001,Staphylococcus Aureus Bacteremia|Staphylococcus Aureus Endocarditis,Oritavancin,CC1C(C(CC(O1)OC2C3C(=O)NC(C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)C(C(=O)N3)NC(=O)C6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)OC9C(C(C(C(O9)CO)O)O)OC1CC(C(C(O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)C(C(C(=O)NC(C(=O)N6)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O,APPROVED,cardiovascular_disease
4002,Heart Rate|Blood Pressure|Arrhythmias,Dimethindene,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C,PHASE1|PHASE2,cardiovascular_disease
4003,Heart Rate|Blood Pressure|Arrhythmias,Dimetindene,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C,PHASE1|PHASE2,cardiovascular_disease
4004,Obesity|Metabolic Syndrome X,Orlistat,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,PHASE2,cardiovascular_disease
4006,Hypertrophic Cardiomyopathy,Triethylenetetramine,C(CNCCNCCN)N,PHASE2,cardiovascular_disease
4007,Hypertrophic Cardiomyopathy,Trientine,C(CNCCNCCN)N,PHASE2,cardiovascular_disease
4008,Calcific Aortic Valve Disease,Evogliptin,CC(C)(C)OCC1C(=O)NCCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N,PHASE2|PHASE3,cardiovascular_disease
4009,Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma,Linsitinib,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,PHASE2,cardiovascular_disease
4010,Amyloidosis,Inotersen,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5C(OC(C5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)OC8C(OC(C8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(OC1C(OC(C1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)O,PHASE2,cardiovascular_disease
4011,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Stavudine,CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO,APPROVED,cardiovascular_disease
4012,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Didanosine,C1CC(OC1CO)N2C=NC3=C2N=CNC3=O,APPROVED,cardiovascular_disease
4013,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Zidovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],APPROVED,cardiovascular_disease
4014,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Nevirapine,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,APPROVED,cardiovascular_disease
4015,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Saquinavir,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,APPROVED,cardiovascular_disease
4016,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Amprenavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,APPROVED,cardiovascular_disease
4017,HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease,Tipranavir,CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4,APPROVED,cardiovascular_disease
4018,Diabetic Foot Ulcer,Ketanserin,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,PHASE1|PHASE2,cardiovascular_disease
4019,Hypertension|Anxiety,Tandospirone,C1CC2CC1C3C2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5,APPROVED,cardiovascular_disease
4020,Diabetic Retinopathy,Glatiramer,CC(C(=O)O)N.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N,APPROVED,cardiovascular_disease
4022,Immune Thrombocytopenia|Blood Coagulation Disorders|Thrombocytopenia|Physiological Effects of Drugs,Danazol,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5,PHASE2,cardiovascular_disease
4023,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,Dabrafenib,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,PHASE2,cardiovascular_disease
4024,Brugada Syndrome|Sudden Death,Ajmaline,CCC1C2CC3C4C5(CC(C2C5O)N3C1O)C6=CC=CC=C6N4C,PHASE2,cardiovascular_disease
4025,Pulmonary Arterial Hypertension,Nilotinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,cardiovascular_disease
4026,Ischaemic Heart Disease (IHD)|Benign Prostatic Hyperplasia (BPH)|Lower Urinary Tract Symptoms (LUTS),Tamsulosin,CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N,APPROVED,cardiovascular_disease
4027,Insomnia|Hypertension,Ramelteon,CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3,APPROVED,cardiovascular_disease
4030,Severe Acute Respiratory Syndrome-related Coronavirus|Renal Dialysis|Vaccines|Myocarditis Allergic|Infection Viral,Duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,APPROVED,cardiovascular_disease
4031,MELAS Syndrome,Idebenone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,PHASE2,cardiovascular_disease
4032,Multiple Myeloma,Tazemetostat,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,PHASE1|PHASE2,cardiovascular_disease
4035,Wegener's Granulomatosis,Gusperimus,C(CCCN=C(N)N)CCC(=O)NC(C(=O)NCCCCNCCCN)O,PHASE2,cardiovascular_disease
4036,Acute Coronary Syndrome,Lornoxicam,CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3,APPROVED,cardiovascular_disease
4037,Erythromelalgia,Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,cardiovascular_disease
4038,"Ischemic Stroke, Acute",Sarecycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC,PHASE2,cardiovascular_disease
4039,Cardiopulmonary Arrest|Fungal Infection,Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,PHASE1,cardiovascular_disease
4040,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Abiraterone,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,PHASE1,cardiovascular_disease
4041,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Bicalutamide,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,PHASE1,cardiovascular_disease
4042,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Cabazitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC,PHASE1,cardiovascular_disease
4043,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Dacomitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4,PHASE1,cardiovascular_disease
4044,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Darolutamide,CC(CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,PHASE1,cardiovascular_disease
4045,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Entrectinib,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,PHASE1,cardiovascular_disease
4046,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Enzalutamide,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,PHASE1,cardiovascular_disease
4047,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Fluorouracil,C1=C(C(=O)NC(=O)N1)F,PHASE1,cardiovascular_disease
4048,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Lorlatinib,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PHASE1,cardiovascular_disease
4049,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Neratinib,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,PHASE1,cardiovascular_disease
4050,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Regorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,PHASE1,cardiovascular_disease
4051,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic/Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic/Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma",Tretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1,cardiovascular_disease
4052,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Ipatasertib,CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,PHASE2,cardiovascular_disease
4053,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Larotrectinib,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,PHASE2,cardiovascular_disease
4054,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Osimertinib,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE2,cardiovascular_disease
4056,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Sapanisertib,CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,PHASE2,cardiovascular_disease
4057,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Ulixertinib,CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl,PHASE2,cardiovascular_disease
4058,Atherosclerosis|Cardiovascular Diseases,Rimonabant,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,APPROVED,cardiovascular_disease
4059,Heart Failure With Preserved Ejection Fraction (HFpEF),Verinurad,CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N,PHASE2,cardiovascular_disease
4060,Turner Syndrome|Short Stature,Vosoritide,CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CN=CN5)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO,PHASE2,cardiovascular_disease
4061,Adult Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Agatolimod,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1CC(OC1CO)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC(=C1C)C(=O)NC(=C)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=C(C(=O)NC1=O)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)O,PHASE1|PHASE2,cardiovascular_disease
4063,Multiple Myeloma,Fluphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,PHASE1,cardiovascular_disease
4064,Multiple Myeloma,Roneparstat,CC(=O)NC1C(C(C(OC1OC2C(C(C(OC2C(=O)O)OC3C(OC(C(C3O)NC(=O)C)OC(CO)C(C(=O)O)OC(CO)O)CO)OS(=O)(=O)O)O)CO)O)O,PHASE1,cardiovascular_disease
4065,Coronary Artery Disease (CAD)|Renal Impairment|Diabetes Mellitus,Ioversol,C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO,APPROVED,cardiovascular_disease
4066,Atrial Fibrillation,Tecadenoson,C1COCC1NC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO)O)O,PHASE2,cardiovascular_disease
4070,"Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Lymphoma, Non-Hodgkin|Hodgkin's Lymphoma|Multiple Myeloma",Clioquinol,C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1,PHASE1,cardiovascular_disease
4071,Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,PHASE1,cardiovascular_disease
4072,"End Stage Renal Disease|Hypertension, Renal",Folate,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,APPROVED,cardiovascular_disease
4073,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Talazoparib,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,PHASE2,cardiovascular_disease
4074,"Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors",Futibatinib,COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC,PHASE2,cardiovascular_disease
4075,"Abnormalities, Cardiovascular",Volanesorsen,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5C(OC(C5OCCOC)N6C=C(C(=O)NC6=O)C)COP(=S)(O)OC7C(OC(C7OCCOC)N8C=C(C(=O)NC8=O)C)COP(=S)(O)OC9C(OC(C9OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C(N=CN=C21)N)CO)N1C=C(C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)O,PHASE1,cardiovascular_disease
4076,Multiple Myeloma,Disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,PHASE1,cardiovascular_disease
4077,Congestive Heart Failure,Fenoterol,CC(CC1=CC=C(C=C1)O)NCC(C2=CC(=CC(=C2)O)O)O,PHASE1,cardiovascular_disease
4078,Multiple Myeloma,Ganetespib,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O,PHASE1,cardiovascular_disease
4079,Trichotillomania|Hair Pulling,Acetylcysteine,CC(=O)NC(CS)C(=O)O,PHASE2,mental_and_behavioural_disorder
4080,Low Risk Prostate Cancer,Padeliporfin,CCC1C(C2=CC3=NC(=C(C3=C(C)[O-])C)C=C4C(C(C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=NCCS(=O)(=O)O)[O-])CC(=O)OC)CCC(=O)O)C)C.[Pd+2],APPROVED,mental_and_behavioural_disorder
4081,Mild Cognitive Impairment,Methylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,APPROVED,mental_and_behavioural_disorder
4082,Major Depressive Disorder,Escitalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,mental_and_behavioural_disorder
4083,Major Depressive Disorder,Duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,APPROVED,mental_and_behavioural_disorder
4084,Attention Deficit Hyperactivity Disorder,Aripiprazole,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,APPROVED,mental_and_behavioural_disorder
4086,Bipolar Depression,Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,PHASE2,mental_and_behavioural_disorder
4087,Bipolar Depression,Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,mental_and_behavioural_disorder
4088,"Depressive Disorder, Major",Quetiapine,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,APPROVED,mental_and_behavioural_disorder
4089,Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder,Amphetamine,CC(CC1=CC=CC=C1)N,PHASE2,mental_and_behavioural_disorder
4090,"Depressive Disorder, Major",Cariprazine,CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,APPROVED,mental_and_behavioural_disorder
4091,"ADHD, Predominantly Inattentive Type",Metadoxine,CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)NC1C(=O)O,PHASE2,mental_and_behavioural_disorder
4092,Depression|Depression Severe|Depression Acute|Depression and Suicide|Suicidal Ideation,Ketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,APPROVED,mental_and_behavioural_disorder
4093,Attention Deficit Hyperactivity Disorder,Guanfacine,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,APPROVED,mental_and_behavioural_disorder
4094,Attention Deficit Hyperactivity Disorder,Atomoxetine,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,APPROVED,mental_and_behavioural_disorder
4095,Agitation|Psychosis|Alzheimer's Disease,Risperidone,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,APPROVED,mental_and_behavioural_disorder
4096,Gambling,Topiramate,CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,PHASE2,mental_and_behavioural_disorder
4097,Severe Depression,Psilocybin,CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,PHASE2,mental_and_behavioural_disorder
4098,Alcoholism|Alcohol Dependence|Post-Traumatic Stress Disorder,Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,APPROVED,mental_and_behavioural_disorder
4099,Urinary Incontinence,Tolterodine,CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2,APPROVED,mental_and_behavioural_disorder
4100,Autism Spectrum Disorders,Memantine,CC12CC3CC(C1)(CC(C3)(C2)N)C,APPROVED,mental_and_behavioural_disorder
4102,Urge Urinary Incontinence,Solifenacin,C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5,APPROVED,mental_and_behavioural_disorder
4103,Insomnia|Alcohol Use Disorder,Suvorexant,CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl,PHASE2,mental_and_behavioural_disorder
4104,Schizophrenia,Paliperidone,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,APPROVED,mental_and_behavioural_disorder
4105,REM Sleep Behavior Disorder|Parkinson Disease|Synucleinopathies,Rasagiline,C#CCNC1CCC2=CC=CC=C12,PHASE2|PHASE3,mental_and_behavioural_disorder
4106,HIV|Depression|Anhedonia,Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,mental_and_behavioural_disorder
4107,Attention Deficit Hyperactivity Disorder,Solriamfetol,C1=CC=C(C=C1)CC(COC(=O)N)N,PHASE2|PHASE3,mental_and_behavioural_disorder
4108,Major Depressive Disorder,Bupropion,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,APPROVED,mental_and_behavioural_disorder
4109,Bipolar Disorder|Bipolar Depression|Depression,Ziprasidone,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,PHASE2,mental_and_behavioural_disorder
4110,Major Depressive Disorder|Bipolar Disorder,Cycloserine,C1C(C(=O)NO1)N,PHASE2,mental_and_behavioural_disorder
4111,Stress Urinary Incontinence|Fecal Incontinence,Citalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,PHASE1,mental_and_behavioural_disorder
4112,Stress Urinary Incontinence|Fecal Incontinence,Reboxetine,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,PHASE1,mental_and_behavioural_disorder
4113,Attention Deficit Hyperactivity Disorder,Dasotraline,C1CC(C2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)N,PHASE2|PHASE3,mental_and_behavioural_disorder
4114,Unipolar Depression,Enoxolone,CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C,PHASE1|PHASE2,mental_and_behavioural_disorder
4115,Major Depressive Disorder,Sertraline,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,PHASE1,mental_and_behavioural_disorder
4116,Major Depressive Disorder,Ketoprofen,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,PHASE1,mental_and_behavioural_disorder
4117,Conduct Disorder,Oxcarbazepine,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,APPROVED,mental_and_behavioural_disorder
4118,Insomnia Chronic,Zopiclone,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,PHASE2,mental_and_behavioural_disorder
4119,Alcohol Abuse|Alcohol Addiction|Alcohol Dependence|Alcohol Use Disorder,Semaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,PHASE2,mental_and_behavioural_disorder
4120,Primary Monosymptomatic Nocturnal Enuresis,Desmopressin,C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N,APPROVED,mental_and_behavioural_disorder
4121,Attention Deficit Disorder With Hyperactivity,Valproate,CCCC(CCC)C(=O)O,APPROVED,mental_and_behavioural_disorder
4122,Alzheimer Disease,Seltorexant,CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C,PHASE2,mental_and_behavioural_disorder
4123,"Depressive Disorder, Major",Desvenlafaxine,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,PHASE1,mental_and_behavioural_disorder
4124,Depression|Bipolar Disorder|Bipolar Depression|Melancholia|Lamotrigine,Lamotrigine,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,APPROVED,mental_and_behavioural_disorder
4125,Type2 Diabetes|Major Depressive Disorder,Vortioxetine,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,APPROVED,mental_and_behavioural_disorder
4126,"Major Depressive Disorder, Healthy Volunteer",Basimglurant,CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl,PHASE1,mental_and_behavioural_disorder
4127,Insomnia Disorder,Melatonin,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,PHASE2|PHASE3,mental_and_behavioural_disorder
4128,Depression|Marijuana Abuse,Venlafaxine,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,PHASE2,mental_and_behavioural_disorder
4129,Alcoholism,Baclofen,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,PHASE2,mental_and_behavioural_disorder
4130,Alcoholism,Cyproheptadine,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,PHASE2,mental_and_behavioural_disorder
4131,Alzheimer Disease|Mild Cognitive Impairment,Donepezil,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,PHASE2,mental_and_behavioural_disorder
4132,Post Traumatic Stress Disorder|Suicidal Ideation|Nightmares,Prazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,APPROVED,mental_and_behavioural_disorder
4133,Alcohol Use Disorder|Bipolar Disorder,Citicoline,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O,APPROVED,mental_and_behavioural_disorder
4134,Alcohol Use Disorder|Bipolar Disorder,Pregnenolone,CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,APPROVED,mental_and_behavioural_disorder
4135,"Depression, Postpartum|Analgesia, Obstetrical|Anesthesia, Obstetrical",Meperidine,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,PHASE2|PHASE3,mental_and_behavioural_disorder
4136,"Depression, Postpartum|Analgesia, Obstetrical|Anesthesia, Obstetrical",Remifentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC,PHASE2|PHASE3,mental_and_behavioural_disorder
4137,"Depression, Postpartum|Analgesia, Obstetrical|Anesthesia, Obstetrical",Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,PHASE2|PHASE3,mental_and_behavioural_disorder
4138,"Depression, Postpartum|Analgesia, Obstetrical|Anesthesia, Obstetrical",Ropivacaine,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,PHASE2|PHASE3,mental_and_behavioural_disorder
4139,"Dental Pain and Sensation Disorder|Anesthesia, Local|Addiction, Opioid",Epinephrine,CNCC(C1=CC(=C(C=C1)O)O)O,APPROVED,mental_and_behavioural_disorder
4140,Depression,Nortriptyline,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,APPROVED,mental_and_behavioural_disorder
4141,Parkinsons Disease With Dementia|Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems,Rivastigmine,CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C,APPROVED,mental_and_behavioural_disorder
4142,"Depressive Disorder, Major",Radafaxine,CC1C(OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O,PHASE2,mental_and_behavioural_disorder
4143,Panic Disorder,Paroxetine,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,APPROVED,mental_and_behavioural_disorder
4144,Panic Disorder,Clozapine,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,APPROVED,mental_and_behavioural_disorder
4145,Heroin Addiction,Buprenorphine,CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,APPROVED,mental_and_behavioural_disorder
4146,REM Sleep Behavior Disorder|Pre-motor Parkinson's Disease|Symptomatic Parkinson Disease,Terazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,PHASE2,mental_and_behavioural_disorder
4147,"Depressive Disorder, Major",Serotonin,C1=CC2=C(C=C1O)C(=CN2)CCN,PHASE2,mental_and_behavioural_disorder
4148,"Depressive Disorder, Major",Norepinephrine,C1=CC(=C(C=C1C(CN)O)O)O,PHASE2,mental_and_behavioural_disorder
4149,Depression|Hemodialysis-Induced Symptom,Fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,APPROVED,mental_and_behavioural_disorder
4150,Bipolar Disorder|Depression|Depressive Disorder,Olanzapine,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,APPROVED,mental_and_behavioural_disorder
4151,Attention Deficit Hyperactivity Disorder (ADHD),Lisdexamfetamine,CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N,APPROVED,mental_and_behavioural_disorder
4152,"Depressive Disorder, Major|Alcoholism",Acamprosate,CC(=O)NCCCS(=O)(=O)O,PHASE2,mental_and_behavioural_disorder
4153,Cocaine Dependence,Modafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE2,mental_and_behavioural_disorder
4154,Tobacco Use Cessation|Psychiatric Disorders,Varenicline,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,APPROVED,mental_and_behavioural_disorder
4155,Urinary Incontinence|Urgency Urinary,Oxybutynin,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,APPROVED,mental_and_behavioural_disorder
4156,Urinary Incontinence|Urgency Urinary,Trospium,C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,APPROVED,mental_and_behavioural_disorder
4157,Urinary Incontinence|Urgency Urinary,Fesoterodine,CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2,APPROVED,mental_and_behavioural_disorder
4158,Depression,Esketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE1,mental_and_behavioural_disorder
4159,Depression,Trazodone,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,PHASE2|PHASE3,mental_and_behavioural_disorder
4160,Major Depressive Disorder,Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O,APPROVED,mental_and_behavioural_disorder
4161,"Depressive Disorder|Depression|Depression, Postpartum|Behavioral Symptoms|Mood Disorders|Mental Disorder|Pregnancy Complications|Postpartum Blues|PPD|Postpartum Disorder",Ganaxolone,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)(C)O)C)C,PHASE2,mental_and_behavioural_disorder
4162,Major Depressive Disorder,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,PHASE2|PHASE3,mental_and_behavioural_disorder
4164,Depression,Etomidate,CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2,APPROVED,mental_and_behavioural_disorder
4165,Major Depression,Pramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE2,mental_and_behavioural_disorder
4166,Depression,Metformin,CN(C)C(=N)N=C(N)N,APPROVED,mental_and_behavioural_disorder
4167,Major Depressive Disorder,Levomilnacipran,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,PHASE2,mental_and_behavioural_disorder
4168,Postpartum Depression,Sufentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC,APPROVED,mental_and_behavioural_disorder
4169,Cocaine Dependence|Alcohol Dependence,Aprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,PHASE2,mental_and_behavioural_disorder
4170,Attention-Deficit/Hyperactivity Disorder (ADHD),Dextromethorphan,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,APPROVED,mental_and_behavioural_disorder
4171,Attention-Deficit/Hyperactivity Disorder (ADHD),Dexmethylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,APPROVED,mental_and_behavioural_disorder
4172,Alcohol Use Disorder,Cannabidiol,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,PHASE2|PHASE3,mental_and_behavioural_disorder
4173,Insomnia|Depression|Suicidal Ideation,Zolpidem,CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,APPROVED,mental_and_behavioural_disorder
4174,Impotence|Depression,Sildenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,APPROVED,mental_and_behavioural_disorder
4175,Mood Disorders,Erythropoietin,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],PHASE2,mental_and_behavioural_disorder
4176,Binge Eating Behaviour,Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,APPROVED,mental_and_behavioural_disorder
4177,REM Sleep Behavior Disorder,Clonazepam,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,PHASE2,mental_and_behavioural_disorder
4178,Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Decreased Processing Speed|Decreased Gait Speed,Levodopa,C1=CC(=C(C=C1CC(C(=O)O)N)O)O,APPROVED,mental_and_behavioural_disorder
4179,Alcohol Use Disorder,Nalmefene,C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O,PHASE2,mental_and_behavioural_disorder
4180,Depressive Disorder,Fluvoxamine,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,APPROVED,mental_and_behavioural_disorder
4181,Depressive Disorder,Mirtazapine,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,APPROVED,mental_and_behavioural_disorder
4182,Insomnia|Major Depressive Disorder,Ramelteon,CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3,APPROVED,mental_and_behavioural_disorder
4183,Alcohol Abuse|Impulsive Behavior,Tolcapone,CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],PHASE2,mental_and_behavioural_disorder
4184,Treatment of Depression in Adults With Parkinson's Disease (PD),Pimavanserin,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,PHASE2,mental_and_behavioural_disorder
4185,Depression|Depressive Disorder,Folate,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,PHASE2,mental_and_behavioural_disorder
4186,Intellectual Disability|Developmental Disability|Aggression|Behavior Problem,Nabilone,CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O,PHASE1,mental_and_behavioural_disorder
4187,"Perinatal Depression|Post Partum Depression|Depression, Postpartum|Depression",Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,mental_and_behavioural_disorder
4188,Posttraumatic Stress Disorder|Anxiety Disorder,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,APPROVED,mental_and_behavioural_disorder
4189,Posttraumatic Stress Disorder|Anxiety Disorder,Mifepristone,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,APPROVED,mental_and_behavioural_disorder
4190,Bipolar Disorder,Riluzole,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,PHASE2,mental_and_behavioural_disorder
4191,Unipolar Depression|Bipolar Depression,Methohexital,CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C,APPROVED,mental_and_behavioural_disorder
4192,Major Depressive Disorder,Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,mental_and_behavioural_disorder
4193,Subclinical Hypothyroidism|Depression,Levothyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,APPROVED,mental_and_behavioural_disorder
4194,Major Depression,Tranylcypromine,C1C(C1N)C2=CC=CC=C2,APPROVED,mental_and_behavioural_disorder
4195,Major Depression,Dextroamphetamine,CC(CC1=CC=CC=C1)N,APPROVED,mental_and_behavioural_disorder
4196,Major Depression,Liothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,APPROVED,mental_and_behavioural_disorder
4197,Major Depression,Triiodothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,APPROVED,mental_and_behavioural_disorder
4198,Major Depressive Disorder Without Psychotic Features,Asenapine,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,APPROVED,mental_and_behavioural_disorder
4199,Feeding Behavior|Feeding Disorder of Infancy or Early Childhood,Megestrol,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,APPROVED,mental_and_behavioural_disorder
4200,Pathological Gambling,Haloperidol,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,PHASE2,mental_and_behavioural_disorder
4201,Pathological Gambling,Fluphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,PHASE2,mental_and_behavioural_disorder
4202,Major Depressive Disorder (MDD),Brexpiprazole,C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,APPROVED,mental_and_behavioural_disorder
4203,"Schizophrenia|Schizoaffective Disorder|Schizophreniform Disorder|Psychosis NOS|Autistic Disorder|Asperger Syndrome|Child Development Disorders, Pervasive|Bipolar I Disorder|Bipolar II Disorder|Mood Disorder NOS|Severe Major Depression With Psychotic Features|Single Episode Major Depression Without Psychotic Symptoms|Severe Mood Disorder With Psychotic Features",Lurasidone,C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,PHASE2,mental_and_behavioural_disorder
4204,Dementia,Roflumilast,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,PHASE2,mental_and_behavioural_disorder
4205,Obesity|Binge Eating,Orlistat,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,APPROVED,mental_and_behavioural_disorder
4207,Trichotillomania|Skin-Picking,Dronabinol,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,PHASE2|PHASE3,mental_and_behavioural_disorder
4208,Trichotillomania (Hair-Pulling Disorder),Valbenazine,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C(C(C)C)N)OC)OC,PHASE2,mental_and_behavioural_disorder
4209,PTSD|Depression,Vilazodone,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N,APPROVED,mental_and_behavioural_disorder
4210,Depressive Disorder|Major Depressive Disorder|Bipolar Disorder|Post Traumatic Stress Disorder|Suicidal Ideation,Perampanel,C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4,PHASE2,mental_and_behavioural_disorder
4211,Bipolar Disorder,Isradipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,PHASE2,mental_and_behavioural_disorder
4213,Attention Deficit Hyperactivity Disorder,Edivoxetine,COC1=C(C=C(C=C1)F)CC(C2CCOCC2)(C3CNCCO3)O,PHASE2|PHASE3,mental_and_behavioural_disorder
4214,Major Depressive Disorder,Gaboxadol,C1CNCC2=C1C(=O)NO2,PHASE2,mental_and_behavioural_disorder
4215,Opioid Dependence|Cocaine Abuse,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,PHASE1,mental_and_behavioural_disorder
4217,Attention Deficit/Hyperactivity Disorder,Serdexmethylphenidate,COC(=O)C(C1CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)NC(CO)C(=O)[O-])C3=CC=CC=C3,APPROVED,mental_and_behavioural_disorder
4218,Schizophrenia|Alcohol Use Disorder,Samidorphan,C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O,PHASE2,mental_and_behavioural_disorder
4219,Depression,Desipramine,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,APPROVED,mental_and_behavioural_disorder
4220,Opioid Induced Respiratory Depression|Chronic Opioid Use,Naloxone,C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,PHASE1,mental_and_behavioural_disorder
4222,Lesch-Nyhan Disease,Ecopipam,CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl,PHASE1,mental_and_behavioural_disorder
4223,Alcohol Use Disorder,Lacosamide,CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1,PHASE1,mental_and_behavioural_disorder
4224,Cocaine Addiction,Vigabatrin,C=CC(CCC(=O)O)N,PHASE1,mental_and_behavioural_disorder
4225,Attention Deficit Disorder With Hyperactivity Disease|Hyperkinesis|Attention Deficit and Disruptive Behavior Disorders,Tipepidine,CN1CCCC(=C(C2=CC=CS2)C3=CC=CS3)C1,PHASE1|PHASE2,mental_and_behavioural_disorder
4226,Major Depressive Disorder,Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,PHASE1,mental_and_behavioural_disorder
4227,Fragile X Syndrome,Minocycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,PHASE2,mental_and_behavioural_disorder
4228,Fragile X Syndrome,Lovastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE2,mental_and_behavioural_disorder
4230,Bipolar Disorder,Thyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,PHASE2|PHASE3,mental_and_behavioural_disorder
4231,Post Traumatic Stress Disorder|Alcohol Use Disorder,Zonisamide,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,PHASE2,mental_and_behavioural_disorder
4232,Treatment Resistant Depression,Liafensine,CN1CC(C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4,PHASE2,mental_and_behavioural_disorder
4233,"Frontotemporal Dementia|Dementia|Aphasia, Primary Progressive|Pick Disease of the Brain|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Neurocognitive Disorders|Mental Disorders|Neurodegenerative Diseases|Frontotemporal Lobar Degeneration|TDP-43 Proteinopathies|Proteostasis Deficiencies|Metabolic Disease|Aphasia|Speech Disorders|Language Disorders|Communication Disorders|Neurobehavioral Manifestations|Neurologic Manifestations",Rotigotine,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,PHASE2,mental_and_behavioural_disorder
4234,Postpartum Depression,Brexanolone,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C,APPROVED,mental_and_behavioural_disorder
4235,Bipolar Depression,Cytidine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,PHASE2,mental_and_behavioural_disorder
4236,Urinary Incontinence,Litoxetine,C1CNCCC1OCC2=CC3=CC=CC=C3C=C2,PHASE1|PHASE2,mental_and_behavioural_disorder
4237,Perimenopausal Disorder|Depression,Bazedoxifene,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,APPROVED,mental_and_behavioural_disorder
4238,Attention Deficit Hyperactivity Disorder,Centanafadine,C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3,PHASE2,mental_and_behavioural_disorder
4239,Alcohol Use Disorder,Ibudilast,CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C,PHASE2,mental_and_behavioural_disorder
4240,REM Sleep Behavior Disorder|Pre-motor Parkinson Disease|Symptomatic Parkinson Disease,Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,PHASE2,mental_and_behavioural_disorder
4241,Parkinson's Disease|Mpulse Control Disorders,Clonidine,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,PHASE2,mental_and_behavioural_disorder
4242,Enuresis|Obstructive Sleep Apnea|Sleep Disordered Breathing,Mometasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C,APPROVED,mental_and_behavioural_disorder
4243,Treatment Resistant Depression,Propofol,CC(C)C1=C(C(=CC=C1)C(C)C)O,APPROVED,mental_and_behavioural_disorder
4244,Dementia,Fasudil,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3,PHASE2,mental_and_behavioural_disorder
4245,Perimenopausal Depression,Tibolone,CC1CC2=C(CCC(=O)C2)C3C1C4CCC(C4(CC3)C)(C#C)O,APPROVED,mental_and_behavioural_disorder
4246,Major Depressive Disorder,Buspirone,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,PHASE2,mental_and_behavioural_disorder
4247,Premenstrual Syndrome|PMS|Healthy|Depression,Dutasteride,CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C,PHASE1,mental_and_behavioural_disorder
4248,Marijuana Abuse,Yohimbine,COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O,PHASE1,mental_and_behavioural_disorder
4249,Alcohol Use Disorder (AUD)|Post Traumatic Stress Disorder (PTSD),Dexmedetomidine,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,PHASE1,mental_and_behavioural_disorder
4250,Depression|Relapsing-remitting Multiple Sclerosis,Fingolimod,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,APPROVED,mental_and_behavioural_disorder
4251,Generalized Anxiety Disorder,Alprazolam,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,APPROVED,mental_and_behavioural_disorder
4252,Major Depressive Disorder|Depression|Depressive Symptoms|Cardiovascular Disease (CVD)|Coronary Artery Disease (CAD)|Heart Disease,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,PHASE2,mental_and_behavioural_disorder
4253,Respiratory Depression,Morphine,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,PHASE2,mental_and_behavioural_disorder
4254,Enuresis,Indomethacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,APPROVED,mental_and_behavioural_disorder
4255,Opioid Dependence|Addiction|HIV/AIDS|Tuberculosis|Hepatitis,Isoniazid,C1=CN=CC=C1C(=O)NN,APPROVED,mental_and_behavioural_disorder
4256,Opioid Dependence|Addiction|HIV/AIDS|Tuberculosis|Hepatitis,Rifapentine,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C,APPROVED,mental_and_behavioural_disorder
4257,Depression|Acute Ischemic Stroke,Agomelatine,CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC,APPROVED,mental_and_behavioural_disorder
4258,"Depression|Depressive Disorder, Major|Depressive Disorder|Unipolar Depression|Major Depressive Disorder",Lorazepam,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,APPROVED,mental_and_behavioural_disorder
4259,Depression|Inflammation,Tofacitinib,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,PHASE1|PHASE2,mental_and_behavioural_disorder
4260,Behavioural Disturbances|Pain|Dementia|Alzheimer's Dementia|Vascular Dementia,Acetaminophen,CC(=O)NC1=CC=C(C=C1)O,PHASE2,mental_and_behavioural_disorder
4261,Perimenopausal Depression|Depression,Raloxifene,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,APPROVED,mental_and_behavioural_disorder
4262,Attention Deficit Hyperactivity Disorder,Droxidopa,C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O,PHASE2,mental_and_behavioural_disorder
4263,Attention Deficit Hyperactivity Disorder,Carbidopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,PHASE2,mental_and_behavioural_disorder
4264,Primary Insomnia,Eszopiclone,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,APPROVED,mental_and_behavioural_disorder
4265,Bipolar I Depression,Armodafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE2,mental_and_behavioural_disorder
4266,Cocaine-Related Disorders,Tryptophan,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N,PHASE2,mental_and_behavioural_disorder
4267,Dementia|Pain|Agitation,Paracetamol,CC(=O)NC1=CC=C(C=C1)O,PHASE2|PHASE3,mental_and_behavioural_disorder
4268,Dementia|Pain|Agitation,Pregabalin,CC(C)CC(CC(=O)O)CN,PHASE2|PHASE3,mental_and_behavioural_disorder
4269,Attention Deficit Disorder With Hyperactivity,Betahistine,CNCCC1=CC=CC=N1,PHASE1,mental_and_behavioural_disorder
4270,Bipolar Disorder,Felbamate,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,PHASE2,mental_and_behavioural_disorder
4271,Depression,Resveratrol,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,APPROVED,mental_and_behavioural_disorder
4272,Disorder of Consciousness,Apomorphine,CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O,PHASE2,mental_and_behavioural_disorder
4273,Depressive Disorder,Dapagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,PHASE2,mental_and_behavioural_disorder
4274,Depressive Disorder,Atorvastatin,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,PHASE2,mental_and_behavioural_disorder
4275,Major Depressive Disorder,Sulforaphane,CS(=O)CCCCN=C=S,APPROVED,mental_and_behavioural_disorder
4276,"Major Depressive Disorder, Recurrent",Filorexant,CC1CCC(CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F,PHASE2,mental_and_behavioural_disorder
4277,Major Depressive Disorder,Tianeptine,CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O,APPROVED,mental_and_behavioural_disorder
4278,Dyslipidemias,Pravastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O,APPROVED,mental_and_behavioural_disorder
4279,Dyslipidemias,Simvastatin,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,APPROVED,mental_and_behavioural_disorder
4280,Cocaine Abuse,Disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,PHASE1,mental_and_behavioural_disorder
4281,Amphetamine-Related Disorders,Reserpine,COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,PHASE1,mental_and_behavioural_disorder
4282,Bipolar Disorder|Alcohol Use Disorder|Dual Diagnosis,Ondansetron,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,APPROVED,mental_and_behavioural_disorder
4283,"Depressive Disorder, Treatment-Resistant",Quinidine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE2,mental_and_behavioural_disorder
4284,Behavior and Mental Disorders|Methamphetamine Disorders,Metamfetamine,CC(CC1=CC=CC=C1)NC,PHASE1,mental_and_behavioural_disorder
4285,Behavior and Mental Disorders|Methamphetamine Disorders,Methamphetamine,CC(CC1=CC=CC=C1)NC,PHASE1,mental_and_behavioural_disorder
4286,Major Depressive Disorder,Pexacerfont,CCC(C)NC1=NC(=NC2=C(C(=NN21)C)C3=C(N=C(C=C3)OC)C)C,PHASE1|PHASE2,mental_and_behavioural_disorder
4287,Major Depression|Dysthymia|Depressive Disorder Not Otherwise Specified,Imipramine,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE1|PHASE2,mental_and_behavioural_disorder
4288,Depression,Milnacipran,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,PHASE2|PHASE3,mental_and_behavioural_disorder
4289,Post-Schizophrenic Depression,Amisulpride,CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC,APPROVED,mental_and_behavioural_disorder
4290,Depression|Hypertension,Candesartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,APPROVED,mental_and_behavioural_disorder
4291,REM Sleep Behavior Disorder|Parkinson Disease,Idebenone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,PHASE2|PHASE3,mental_and_behavioural_disorder
4292,"Post Operative Pain Control|Narcotic Use|Pelvic Organ Prolapse|Urinary Incontinence , Stress|Surgery",Ketorolac,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,APPROVED,mental_and_behavioural_disorder
4293,Depression|Inflammation,Celecoxib,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,APPROVED,mental_and_behavioural_disorder
4294,Delirium on Emergence,Sevoflurane,C(OC(C(F)(F)F)C(F)(F)F)F,APPROVED,mental_and_behavioural_disorder
4295,Delirium on Emergence,Isoflurane,C(C(F)(F)F)(OC(F)F)Cl,APPROVED,mental_and_behavioural_disorder
4296,Major Depression,Cimicoxib,COC1=C(C=C(C=C1)C2=C(N=CN2C3=CC=C(C=C3)S(=O)(=O)N)Cl)F,PHASE2,mental_and_behavioural_disorder
4297,Major Depressive Disorder,Selegiline,CC(CC1=CC=CC=C1)N(C)CC#C,APPROVED,mental_and_behavioural_disorder
4299,Depression,Citrulline,C(CC(C(=O)O)N)CNC(=O)N,APPROVED,mental_and_behavioural_disorder
4300,Bipolar Depression,Uridine,C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O,PHASE2,mental_and_behavioural_disorder
4301,"Depressive Disorder, Major",Rapastinel,CC(C(C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)N)N)O,PHASE2,mental_and_behavioural_disorder
4302,"Schizophrenia|Treatment Resistant Depression|Aging, Premature",Dasatinib,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,PHASE2,mental_and_behavioural_disorder
4303,"Schizophrenia|Treatment Resistant Depression|Aging, Premature",Quercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,PHASE2,mental_and_behavioural_disorder
4304,Major Depressive Disorder,Iloperidone,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,APPROVED,mental_and_behavioural_disorder
4305,Erectile Dysfunction,Vardenafil,CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C,APPROVED,mental_and_behavioural_disorder
4306,"Urinary Incontinence, Urge|Urinary Incontinence|Overactive Bladder|Incontinence, Urge|Incontinence, Urinary|Incontinence",Mirabegron,C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,APPROVED,mental_and_behavioural_disorder
4307,"Depressive Disorder, Treatment-Resistant",Ebselen,C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2,PHASE1,mental_and_behavioural_disorder
4308,Urgency Urinary Incontinence,Vibegron,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O,APPROVED,mental_and_behavioural_disorder
4309,Autism Spectrum Disorders,Arbaclofen,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,PHASE2,mental_and_behavioural_disorder
4310,Attention Deficit Hyperactivity Disorder,Amantadine,C1C2CC3CC1CC(C2)(C3)N,PHASE2,mental_and_behavioural_disorder
4311,Depressive Disorder|Hormone Disturbance,Metyrapone,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,APPROVED,mental_and_behavioural_disorder
4312,Post-Dural Puncture Headache,Pregabalin,CC(C)CC(CC(=O)O)CN,APPROVED,nervous_system_disease
4313,Post-Dural Puncture Headache,Hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,APPROVED,nervous_system_disease
4314,Post-Dural Puncture Headache,Acetaminophen,CC(=O)NC1=CC=C(C=C1)O,APPROVED,nervous_system_disease
4315,Post-Dural Puncture Headache,Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,APPROVED,nervous_system_disease
4316,Post-Dural Puncture Headache,Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,APPROVED,nervous_system_disease
4317,Post-Dural Puncture Headache,Diclofenac,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,APPROVED,nervous_system_disease
4318,Chemotherapy-Induced Peripheral Neuropathy,Olesoxime,CC(C)CCCC(C)C1CCC2C1(CCC3C2CCC4=CC(=NO)CCC34C)C,PHASE2,nervous_system_disease
4319,Intracranial Aneurysms|Seizure,Levetiracetam,CCC(C(=O)N)N1CCCC1=O,APPROVED,nervous_system_disease
4320,Sleep Disorder,Propofol,CC(C)C1=C(C(=CC=C1)C(C)C)O,APPROVED,nervous_system_disease
4321,Sleep Disorder,Dexmedetomidine,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,APPROVED,nervous_system_disease
4322,Parkinson Disease,Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,PHASE2,nervous_system_disease
4323,Prader-Willi Syndrome|Hyperphagia,Livoletide,CC(C)C1C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCC(=O)N)CC3=CN=CN3)CCC(=O)O)CO)CCC(=O)N,PHASE2|PHASE3,nervous_system_disease
4325,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Cyclophosphamide,C1CNP(=O)(OC1)N(CCCl)CCCl,PHASE2,nervous_system_disease
4326,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Etoposide,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,PHASE2,nervous_system_disease
4327,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Carboplatin,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],PHASE2,nervous_system_disease
4329,Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia,Cytarabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O,PHASE2,nervous_system_disease
4330,Back Pain|Acute Pain|Back Spasm Upper Back|Back Strain|Muscle Cramp|Muscle Spasm|Low Back Pain,Tolperisone,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,PHASE2,nervous_system_disease
4331,Dermatopolymyositis|Interstitial Lung Disease,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,APPROVED,nervous_system_disease
4332,"Lymphoma, Non-Hodgkin|HIV Infections",Bleomycin,CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,PHASE1,nervous_system_disease
4333,"Lymphoma, Non-Hodgkin|HIV Infections",Vincristine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE1,nervous_system_disease
4334,"Lymphoma, Non-Hodgkin|HIV Infections",Doxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE1,nervous_system_disease
4335,"Lymphoma, Non-Hodgkin|HIV Infections",Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,nervous_system_disease
4336,"Lymphoma, Non-Hodgkin|HIV Infections",Leucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,nervous_system_disease
4338,"Lymphoma, Non-Hodgkin|HIV Infections",Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE1,nervous_system_disease
4339,Emergence Delirium,Clonidine,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,PHASE2|PHASE3,nervous_system_disease
4341,Acromegaly,Octreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,APPROVED,nervous_system_disease
4342,Insomnia,Temazepam,CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3,APPROVED,nervous_system_disease
4343,Prader-Willi Syndrome,Guanfacine,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,APPROVED,nervous_system_disease
4344,Parkinson Disease|Movement Disorders|Neuro-Degenerative Disease|Nervous System Diseases|Brain Diseases,Dopamine,C1=CC(=C(C=C1CCN)O)O,PHASE1|PHASE2,nervous_system_disease
4347,Acute Ischemic Stroke,Tirofiban,CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,APPROVED,nervous_system_disease
4348,Chemotherapeutic Agent Toxicity|Cognitive/Functional Effects|Lymphoma|Neurotoxicity|Radiation Toxicity,Procarbazine,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,PHASE2,nervous_system_disease
4349,Alzheimer's Disease,Benfotiamine,CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOP(=O)(O)O)SC(=O)C2=CC=CC=C2)C,PHASE2,nervous_system_disease
4350,"Dyslipidemias|Atherosclerosis|Diabetes Mellitus, Type 2",Atorvastatin,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,APPROVED,nervous_system_disease
4351,"Dyslipidemias|Atherosclerosis|Diabetes Mellitus, Type 2",Ezetimibe,C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O,APPROVED,nervous_system_disease
4352,Myasthenia Gravis,Albuterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,PHASE2|PHASE3,nervous_system_disease
4353,Myasthenia Gravis,Salbutamol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,PHASE2|PHASE3,nervous_system_disease
4354,Parkinson Disease|Depression,Nortriptyline,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,nervous_system_disease
4355,Abdominal Pain|Inflammatory Bowel Diseases|Eosinophilic Gastroenteritis|Diarrhea|Hematochezia|Weight Loss,Ondansetron,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,APPROVED,nervous_system_disease
4356,Attention Deficit Hyperactivity Disorder,Aripiprazole,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,APPROVED,nervous_system_disease
4357,Cerebral Hypoxia|Postoperative Delirium,Sevoflurane,C(OC(C(F)(F)F)C(F)(F)F)F,APPROVED,nervous_system_disease
4358,Coronary Artery Disease|Pain|Peripheral Nervous System Diseases|Polyneuropathy,Ranolazine,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,APPROVED,nervous_system_disease
4359,Multiple Sclerosis,Tacrolimus,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,PHASE2,nervous_system_disease
4360,Tourette Syndrome,Valbenazine,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C(C(C)C)N)OC)OC,PHASE2,nervous_system_disease
4361,Stroke|Immunoregulation|Inflammation|Vinpocetine,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,PHASE2|PHASE3,nervous_system_disease
4362,Obesity|Prehypertension|Hypertension,Hydrochlorothiazide,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,PHASE2,nervous_system_disease
4363,Alzheimer Disease,Flortaucipir,C1=CC2=C(C=C1C3=CN=C(C=C3)F)NC4=C2C=NC=C4,PHASE2,nervous_system_disease
4364,Neurogenic Bladder|Catheter-Related Infections,Octenidine,CCCCCCCCN=C1C=CN(C=C1)CCCCCCCCCCN2C=CC(=NCCCCCCCC)C=C2,PHASE2|PHASE3,nervous_system_disease
4365,"Epilepsy, Partial",Ezogabine,CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N,PHASE1,nervous_system_disease
4366,Pompe Disease,Bortezomib,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,APPROVED,nervous_system_disease
4367,Attention Deficit Hyperactivity Disorder,Methylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,APPROVED,nervous_system_disease
4368,Alzheimer's Disease,Galantamine,CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O,APPROVED,nervous_system_disease
4369,Alzheimer's Disease,Memantine,CC12CC3CC(C1)(CC(C3)(C2)N)C,APPROVED,nervous_system_disease
4370,Hepatic Encephalopathy,Lactulose,C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O,APPROVED,nervous_system_disease
4371,Multiple Sclerosis,Dexrazoxane,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,PHASE2,nervous_system_disease
4372,Multiple Sclerosis,Mitoxantrone,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,PHASE2,nervous_system_disease
4374,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,Lenvatinib,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,PHASE1,nervous_system_disease
4375,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,PHASE1,nervous_system_disease
4376,Stroke|Inflammation,Fingolimod,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,PHASE2,nervous_system_disease
4377,Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm,Cediranib,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,PHASE1,nervous_system_disease
4378,Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm,Cilengitide,CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N,PHASE1,nervous_system_disease
4380,Ischemic Optic Neuropathy,Alprostadil,CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O,PHASE2,nervous_system_disease
4381,Memory Impairment Due to Corticosteroid Use|Hypomania Due to Corticosteroid Use|Hippocampal Atrophy Due to Corticosteroid,Lamotrigine,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,APPROVED,nervous_system_disease
4382,Schizophrenia,Risperidone,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,PHASE2|PHASE3,nervous_system_disease
4383,Breast Cancer,Paclitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,PHASE2,nervous_system_disease
4384,HIV Infections|Insomnia,Doxepin,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,APPROVED,nervous_system_disease
4385,Duchenne Muscular Dystrophy,Ezutromid,CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3,PHASE2,nervous_system_disease
4386,Parkinson's Disease|Dyskinesia,Sarizotan,C1CC2=CC=CC=C2OC1CNCC3=CC(=CN=C3)C4=CC=C(C=C4)F,PHASE2,nervous_system_disease
4387,Growing Vestibular Schwannomas,Nilotinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,nervous_system_disease
4388,Morbid Obesity|Postoperative Pain|Postoperative Bowel Function|Postoperative Ambulation,Morphine,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,PHASE2|PHASE3,nervous_system_disease
4389,Morbid Obesity|Postoperative Pain|Postoperative Bowel Function|Postoperative Ambulation,Levobupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,PHASE2|PHASE3,nervous_system_disease
4390,Epilepsy,Ganaxolone,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)(C)O)C)C,PHASE2,nervous_system_disease
4391,Neuromyelitis Optica Spectrum Disorder,Azathioprine,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],PHASE2|PHASE3,nervous_system_disease
4392,Diabetic Macular Edema,Pegaptanib,COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC,APPROVED,nervous_system_disease
4394,Amyotrophic Lateral Sclerosis (ALS),Olanzapine,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,PHASE2|PHASE3,nervous_system_disease
4395,Parkinson Disease,Selegiline,CC(CC1=CC=CC=C1)N(C)CC#C,APPROVED,nervous_system_disease
4396,Acute Pain,Lorazepam,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,PHASE2,nervous_system_disease
4397,Migraine,Lasmiditan,CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F,PHASE2,nervous_system_disease
4398,Parkinson Disease,Carbidopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,PHASE2,nervous_system_disease
4399,Parkinson Disease,Levodopa,C1=CC(=C(C=C1CC(C(=O)O)N)O)O,PHASE2,nervous_system_disease
4400,Relapsing-remitting Multiple Sclerosis,Glatiramer,CC(C(=O)O)N.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N,APPROVED,nervous_system_disease
4401,Myofacial Pain,Gabapentin,C1CCC(CC1)(CC(=O)O)CN,APPROVED,nervous_system_disease
4402,Myofacial Pain,Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,APPROVED,nervous_system_disease
4405,Cataract|Miosis,Ketorolac,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,PHASE2,nervous_system_disease
4406,Cataract|Miosis,Nepafenac,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N,PHASE2,nervous_system_disease
4407,Cataract|Miosis,Cyclopentolate,CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O,PHASE2,nervous_system_disease
4408,Parkinson's Disease,Varenicline,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,PHASE2,nervous_system_disease
4409,Intracerebral Hemorrhage,Deferoxamine,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,PHASE1,nervous_system_disease
4410,Hypogonadism|Diabetes|Sarcopenia|Osteoporosis|Depression,Anastrozole,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,PHASE2,nervous_system_disease
4412,CNS Tumor|Solid Tumor,Entinostat,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,PHASE1|PHASE2,nervous_system_disease
4413,Achalasia,Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,APPROVED,nervous_system_disease
4414,Achalasia,Oxycodone,CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,APPROVED,nervous_system_disease
4415,Cerebral Vasospasm|Subarachnoid Hemorrhage,Sildenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,PHASE2,nervous_system_disease
4416,Compliance|Chronic Pain,Quinine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE2,nervous_system_disease
4417,Multiple Sclerosis,Teriflunomide,CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O,PHASE2,nervous_system_disease
4418,Duchenne Muscular Dystrophy,Viltolarsen,CC1=CN(C(=O)NC1=O)C2CN(CC(O2)COP(=O)(N3CC(OC(C3)N4C=C(C(=O)NC4=O)C)COP(=O)(N5CC(OC(C5)N6C=NC7=C6N=C(NC7=O)N)COP(=O)(N8CC(OC(C8)N9C=C(C(=O)NC9=O)C)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C(N=CN=C21)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C(N=CN=C21)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=NC2=C1N=C(NC2=O)N)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=C(C(=O)NC1=O)C)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)COP(=O)(N1CC(OC(C1)N1C=CC(=NC1=O)N)CO)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)N(C)C)P(=O)(N(C)C)OCC1CNCC(O1)N1C=CC(=NC1=O)N,PHASE2,nervous_system_disease
4419,Alzheimer's Disease|Depression,Sertraline,CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,PHASE2|PHASE3,nervous_system_disease
4421,Attention Deficit Hyperactivity Disorder,Atomoxetine,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,APPROVED,nervous_system_disease
4422,Huntington's Disease,Pridopidine,CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C,PHASE2,nervous_system_disease
4423,"Leukemia, Juvenile Myelomonocytic|JMML|JCML|Neurofibromatosis 1|CBL Syndrome",Trametinib,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,PHASE1|PHASE2,nervous_system_disease
4424,"Leukemia, Juvenile Myelomonocytic|JMML|JCML|Neurofibromatosis 1|CBL Syndrome",Azacitidine,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,PHASE1|PHASE2,nervous_system_disease
4425,"Leukemia, Juvenile Myelomonocytic|JMML|JCML|Neurofibromatosis 1|CBL Syndrome",Fludarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,PHASE1|PHASE2,nervous_system_disease
4427,Diffuse Intrinsic Pontine Glioma,Imiquimod,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,PHASE1,nervous_system_disease
4428,Brain Tumor - Metastatic,Carmustine,C(CCl)NC(=O)N(CCCl)N=O,PHASE2,nervous_system_disease
4429,Epilepsy,Lacosamide,CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1,PHASE2,nervous_system_disease
4430,Polymyalgia Rheumatica|Effect of Drug|Safety Issues,Tofacitinib,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,PHASE2,nervous_system_disease
4431,Huntington Disease,Triheptanoin,CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC,PHASE2,nervous_system_disease
4432,Polyneuropathy,Imipramine,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,APPROVED,nervous_system_disease
4433,Agitation|Psychosis|Alzheimer's Disease,Escitalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,nervous_system_disease
4435,Acromegaly,Lanreotide,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,PHASE2|PHASE3,nervous_system_disease
4436,"Akathisia, Drug-Induced|Antipsychotic Agents|Movement Disorders",Preladenant,COCCOC1=CC=C(C=C1)N2CCN(CC2)CCN3C4=C(C=N3)C5=NC(=NN5C(=N4)N)C6=CC=CO6,PHASE2,nervous_system_disease
4437,"Akathisia, Drug-Induced|Antipsychotic Agents|Movement Disorders",Haloperidol,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,PHASE2,nervous_system_disease
4439,Carotid Artery Stenosis,Remifentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC,APPROVED,nervous_system_disease
4443,Multiple Sclerosis|Fatigue,Ketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE1|PHASE2,nervous_system_disease
4444,Multiple Sclerosis|Fatigue,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,PHASE1|PHASE2,nervous_system_disease
4445,Eye Pain,Loteprednol,CC12CC(C3C(C1CCC2(C(=O)OCCl)O)CCC4=CC(=O)C=CC34C)O,PHASE1,nervous_system_disease
4447,Peripheral Neuropathy|Antineoplastic Combined Chemotherapy Protocols,Nabilone,CCCCCCC(C)(C)C1=CC(=C2C3CC(=O)CCC3C(OC2=C1)(C)C)O,APPROVED,nervous_system_disease
4448,Muscle Weakness|Anterior Cruciate Ligament Rupture,Tramadol,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,PHASE2|PHASE3,nervous_system_disease
4449,Muscle Weakness|Anterior Cruciate Ligament Rupture,Paracetamol,CC(=O)NC1=CC=C(C=C1)O,PHASE2|PHASE3,nervous_system_disease
4450,Pelvic Pain|Interstitial Cystitis|Bladder Diseases,Lidocaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,PHASE2,nervous_system_disease
4451,Peripheral Nervous System Diseases,Ricolinostat,C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO,PHASE1,nervous_system_disease
4452,Brain Metastasis,Vorinostat,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,PHASE2,nervous_system_disease
4454,Overactive Bladder Syndrome|Urge Incontinence|Urinary Incontinence|Detrusor Hyperreflexia|Detrusor Instability,Phenazopyridine,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N,APPROVED,nervous_system_disease
4455,Postmenopausal Osteoporosis,Alendronate,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,APPROVED,nervous_system_disease
4456,Irritable Bowel Syndrome,Lubiprostone,CCCCC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F,PHASE1,nervous_system_disease
4457,Tuberculous Meningitis,Rifampin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE2,nervous_system_disease
4458,Tuberculous Meningitis,Rifampicin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE2,nervous_system_disease
4459,Tuberculous Meningitis,Isoniazid,C1=CN=CC=C1C(=O)NN,PHASE2,nervous_system_disease
4460,Tuberculous Meningitis,Linezolid,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,PHASE2,nervous_system_disease
4461,Tuberculous Meningitis,Pyrazinamide,C1=CN=C(C=N1)C(=O)N,PHASE2,nervous_system_disease
4462,Chest Pain Rule Out Myocardial Infarction,Citalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,APPROVED,nervous_system_disease
4463,Gastroparesis,Buspirone,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,PHASE2,nervous_system_disease
4464,Brain Neoplasms|Non Small Cell Lung Cancer,Gefitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,PHASE2,nervous_system_disease
4466,Bipolar Disorder|Bipolar Affective Psychosis|Mania|Manic Disorder|Manic State,Quetiapine,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,APPROVED,nervous_system_disease
4467,Sleep Initiation and Maintenance Disorders,Lemborexant,CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C,PHASE2,nervous_system_disease
4468,Neuropathic Pain|Chemotherapy Effect,Telmisartan,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,PHASE2,nervous_system_disease
4469,Migraine Headache,Psilocybin,CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O,PHASE1,nervous_system_disease
4470,Craniocerebral Injury,Oxiracetam,C1C(CN(C1=O)CC(=O)N)O,PHASE2,nervous_system_disease
4471,Parkinson Disease,Tavapadon,CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C,PHASE1,nervous_system_disease
4472,Brain Metastases|HR+ Metastatic Breast Cancer,Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,PHASE1|PHASE2,nervous_system_disease
4473,"Cerebral Palsy|Hip Dysplasia|Pain, Postoperative",Ropivacaine,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,nervous_system_disease
4474,"Trauma, Brain",Amantadine,C1C2CC3CC1CC(C2)(C3)N,APPROVED,nervous_system_disease
4475,"Spinal Cord Injured, Tetraplegia",Melatonin,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,PHASE1,nervous_system_disease
4476,Peripheral Nerve Sheath Tumor,Tazemetostat,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,PHASE2,nervous_system_disease
4477,Alzheimer's Disease,Bexarotene,CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C,PHASE2,nervous_system_disease
4479,Peripheral Neuropathy|Neuropathic Pain,Duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,PHASE2,nervous_system_disease
4480,Spinal Cord Injury|Pressure Ulcers,Pioglitazone,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,PHASE2,nervous_system_disease
4481,Alzheimer Disease|Healthy Volunteers,Donepezil,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,PHASE1,nervous_system_disease
4482,Polymyalgia Rheumatica|Inflammatory Diseases,Prednisone,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,PHASE2,nervous_system_disease
4483,Stroke,Serotonin,C1=CC2=C(C=C1O)C(=CN2)CCN,PHASE2,nervous_system_disease
4484,Fibromyalgia,Mecobalamin,[CH3-].CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=C(C7=NC(=CC8=NC(=C(C4=N5)C)C(C8(C)C)CCC(=O)N)C(C7(C)CC(=O)N)CCC(=O)N)C)[N-]6)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co+3],PHASE1|PHASE2,nervous_system_disease
4485,Alcohol-induced Brain Injury,Edaravone,CC1=NN(C(=O)C1)C2=CC=CC=C2,PHASE2,nervous_system_disease
4486,Clostridium Difficile|Spinal Cord Injury,Fidaxomicin,CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C,APPROVED,nervous_system_disease
4487,Clostridium Difficile|Spinal Cord Injury,Vancomycin,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,APPROVED,nervous_system_disease
4488,Subarachnoid Hemorrhage|Cerebral Vasospasm,Dantrolene,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],PHASE1|PHASE2,nervous_system_disease
4489,Multiple Sclerosis,Tricyclazole,CC1=C2C(=CC=C1)SC3=NN=CN23,PHASE1,nervous_system_disease
4490,Focal Epilepsy,Tiagabine,CC1=C(SC=C1)C(=CCCN2CCCC(C2)C(=O)O)C3=C(C=CS3)C,APPROVED,nervous_system_disease
4491,Focal Epilepsy,Topiramate,CC1(OC2COC3(C(C2O1)OC(O3)(C)C)COS(=O)(=O)N)C,APPROVED,nervous_system_disease
4492,Focal Epilepsy,Zonisamide,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,APPROVED,nervous_system_disease
4493,AIDS Dementia Complex|HIV Infections,Nimodipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,PHASE1,nervous_system_disease
4494,AIDS Dementia Complex|HIV Infections,Zidovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],PHASE1,nervous_system_disease
4495,"Aneurysm, Ruptured|Vasospasm, Intracranial|Delayed Cerebral Ischemia|Blood Brain Barrier Defect",Minocycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,PHASE2,nervous_system_disease
4496,Parkinson's Disease|Psychotic Disorders,Melperone,CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,PHASE2,nervous_system_disease
4497,Advanced Cancer|Anorexia|Weight Loss|Insomnia,Mirtazapine,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,PHASE2,nervous_system_disease
4498,Cancer|Head and Neck Cancer|Pelvic Cancer|Nervous System Neoplasms|Thoracic Neoplasms,Sunitinib,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,PHASE1,nervous_system_disease
4499,Idiopathic Parkinson Disease,Trimethobenzamide,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C(=C2)OC)OC)OC,PHASE1,nervous_system_disease
4500,Epilepsy,Perampanel,C1=CC=C(C=C1)N2C=C(C=C(C2=O)C3=CC=CC=C3C#N)C4=CC=CC=N4,PHASE2,nervous_system_disease
4501,Insomnia|Alcohol Use Disorder,Suvorexant,CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl,PHASE2,nervous_system_disease
4502,Surgical Wound Infection,Amoxicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,APPROVED,nervous_system_disease
4503,Non-functioning Pituitary Adenomas|Prolactinomas,Pasireotide,C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,PHASE2|PHASE3,nervous_system_disease
4504,Amyotrophic Lateral Sclerosis,Sirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,PHASE2,nervous_system_disease
4505,Osteoarthritis|Degenerative Joint Disease,Epinephrine,CNCC(C1=CC(=C(C=C1)O)O)O,APPROVED,nervous_system_disease
4506,Osteoarthritis|Degenerative Joint Disease,Bupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,nervous_system_disease
4507,Multiple Sclerosis|Overactive Detrusor,Darifenacin,C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5,PHASE2,nervous_system_disease
4508,Stroke,Lisinopril,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,PHASE1,nervous_system_disease
4509,REM Sleep Behavior Disorder|Parkinson Disease|Synucleinopathies,Rasagiline,C#CCNC1CCC2=CC=CC=C12,PHASE2|PHASE3,nervous_system_disease
4510,Knee Osteoarthritis,Etoricoxib,CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C,PHASE2,nervous_system_disease
4511,Acute Renal Colic,Tromethamine,C(C(CO)(CO)N)O,PHASE2|PHASE3,nervous_system_disease
4512,HIV|Depression|Anhedonia,Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,nervous_system_disease
4513,Sleep Apnea Syndrome|Hypertension,Amlodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,PHASE2|PHASE3,nervous_system_disease
4514,"Brain Injuries|Brain Injuries, Traumatic|Brain Injury, Chronic",Tolcapone,CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],PHASE2,nervous_system_disease
4515,Right Hemisphere Stroke|Hemispatial Neglect|Motor Deficit,Rotigotine,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,PHASE2,nervous_system_disease
4516,"Central Nervous System Tumor, Pediatric",Dactinomycin,CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C,PHASE2,nervous_system_disease
4517,Hyperalgesia|Opioid-Related Disorders,Acetazolamide,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,APPROVED,nervous_system_disease
4518,Dementia With Lewy Bodies,Armodafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,APPROVED,nervous_system_disease
4519,Dementia With Lewy Bodies,Modafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,APPROVED,nervous_system_disease
4520,Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer,Dianhydrogalactitol,C1C(O1)C(C(C2CO2)O)O,PHASE2,nervous_system_disease
4521,"Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Meningioma|Anaplastic Oligodendroglioma|Pleomorphic Xanthoastrocytoma, Anaplastic|Atypical Teratoid/Rhabdoid Tumor|Brain Cancer|Brain Tumor|Central Nervous System Neoplasms|Choroid Plexus Carcinoma|CNS Embryonal Tumor With Rhabdoid Features|Ganglioneuroblastoma of Central Nervous System|CNS Tumor|Embryonal Tumor of CNS|Ependymoma|Glioblastoma|Glioma|Glioma, Malignant|Medulloblastoma|Medulloblastoma; Unspecified Site|Medulloepithelioma|Neuroepithelial Tumor|Neoplasms|Neoplasms, Neuroepithelial|Papillary Tumor of the Pineal Region (High-grade Only)|Pediatric Brain Tumor|Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)|Pineoblastoma|Primitive Neuroectodermal Tumor|Recurrent Medulloblastoma|Refractory Brain Tumor|Neuroblastoma. CNS|Glioblastoma, IDH-mutant|Glioblastoma, IDH-wildtype|Medulloblastoma, Group 3|Medulloblastoma, Group 4|Glioma, High Grade|Neuroepithelial Tumor, High Grade|Medulloblastoma, SHH-activated and TP53 Mutant|Medulloblastoma, SHH-activated and TP53 Wildtype|Medulloblastoma, Chromosome 9q Loss|Medulloblastoma, Non-WNT Non-SHH, NOS|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, PTCH1 Mutation|Medulloblastoma, WNT-activated|Ependymoma, Recurrent|Glioma, Recurrent High Grade|Glioma, Recurrent Malignant|Embryonal Tumor, NOS|Glioma, Diffuse Midline, H3K27M-mutant|Embryonal Tumor With Multilayered Rosettes (ETMR)|Ependymoma, NOS, WHO Grade III|Ependymoma, NOS, WHO Grade II|Medulloblastoma, G3/G4|Ependymoma, RELA Fusion Positive",Gemcitabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,PHASE1,nervous_system_disease
4522,Attention Deficit Hyperactivity Disorder,Solriamfetol,C1=CC=C(C=C1)CC(COC(=O)N)N,PHASE2|PHASE3,nervous_system_disease
4523,Stroke,Clopidogrel,COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,APPROVED,nervous_system_disease
4524,Parkinson's Disease,Rivastigmine,CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C,APPROVED,nervous_system_disease
4525,Epilepsy,Diazepam,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,PHASE1|PHASE2,nervous_system_disease
4526,Restless Legs Syndrome,Moxifloxacin,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,PHASE1,nervous_system_disease
4527,Parkinson's Disease,Cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C,APPROVED,nervous_system_disease
4528,AIDS-related Dementia Complex,Darunavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,APPROVED,nervous_system_disease
4529,Lymphangioleiomyomatosis|Tuberous Sclerosis,Doxycycline,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,APPROVED,nervous_system_disease
4530,Tuberous Sclerosis Complex|Self-injury|Autism,Everolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,PHASE2,nervous_system_disease
4531,Migraine|Episodic Migraine|Phonophobia|Photophobia,Rimegepant,C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6,APPROVED,nervous_system_disease
4532,"Cancer|Metastasis|Metastatic Cancer|Brain Metastases|Brain Metastases, Adult",Azeliragon,CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC,PHASE1|PHASE2,nervous_system_disease
4533,Stroke,Exenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N,PHASE2,nervous_system_disease
4534,Ischemic Stroke,Argatroban,CC1CCN(C(C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C,PHASE2,nervous_system_disease
4535,Hypertension,Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,PHASE1,nervous_system_disease
4536,Parkinson Disease,Sulforaphane,CS(=O)CCCCN=C=S,PHASE2,nervous_system_disease
4537,Myopathy,Prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,APPROVED,nervous_system_disease
4538,Angina Pectoris,Rosuvastatin,CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,APPROVED,nervous_system_disease
4540,"Immune Reconstitution Inflammatory Syndrome|Leukoencephalopathy, Progressive Multifocal",Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,APPROVED,nervous_system_disease
4542,Spinal Muscular Atrophy,Nusinersen,CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)OP(=S)(O)OCC3C(C(C(O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OCC5C(C(C(O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OCC8C(C(C(O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)OCCOC,PHASE1|PHASE2,nervous_system_disease
4543,Multiple Sclerosis,Mirabegron,C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,APPROVED,nervous_system_disease
4544,Alzheimer Disease,Montelukast,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,PHASE2,nervous_system_disease
4545,Chronic Obstructive Pulmonary Disease,Fosinopril,CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3,APPROVED,nervous_system_disease
4546,Breast Cancer,Tesetaxel,CC1=C2C3C(C4(CCC5C(C4C(C(C2(C)C)(CC1OC(=O)C(C(C6=C(C=CC=N6)F)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)C)OC(O3)CN(C)C,PHASE2,nervous_system_disease
4547,Headache,Sumatriptan,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,APPROVED,nervous_system_disease
4548,Lung Cancer|Metastatic Cancer,Temozolomide,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,PHASE2,nervous_system_disease
4549,Advanced Solid Tumor|CNS Tumor|Recurrent WHO Grade II Glioma,Infigratinib,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,PHASE1|PHASE2,nervous_system_disease
4550,Ischemic Heart Disease,Eplerenone,CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC,APPROVED,nervous_system_disease
4551,Primary Central Nervous System Lymphoma,Lenalidomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,PHASE2,nervous_system_disease
4552,Epilepsy,Sulthiame,C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N,PHASE1,nervous_system_disease
4553,Epilepsy,Carbamazepine,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,APPROVED,nervous_system_disease
4554,Epilepsy,Valproate,CCCC(CCC)C(=O)O,APPROVED,nervous_system_disease
4555,Amyotrophic Lateral Sclerosis,Riluzole,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,PHASE2|PHASE3,nervous_system_disease
4556,Myoclonus,Etomidate,CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2,APPROVED,nervous_system_disease
4557,Delirium|Agitation,Trazodone,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,APPROVED,nervous_system_disease
4558,Attention Deficit Hyperactivity Disorder,Dasotraline,C1CC(C2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)N,PHASE2|PHASE3,nervous_system_disease
4561,Alzheimer's Disease,Perindopril,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O,PHASE2,nervous_system_disease
4562,Multiple Sclerosis,Simvastatin,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,APPROVED,nervous_system_disease
4563,Apathy|Huntington's Disease,Bupropion,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,PHASE2,nervous_system_disease
4564,Friedreich Ataxia,Etravirine,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,PHASE2,nervous_system_disease
4565,Neurofibromatosis Type 1|Plexiform Neurofibromas|Post-operative,Selumetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,PHASE2,nervous_system_disease
4566,Dravet Syndrome,Clemizole,C1CCN(C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl,PHASE1,nervous_system_disease
4567,"Stroke|Stroke, Acute|Stroke, Ischemic|Brain Diseases",Semaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,PHASE2,nervous_system_disease
4568,Breast Cancer,Pyrotinib,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CC5CCCN5C,PHASE2,nervous_system_disease
4570,Breast Cancer,Cisplatin,N.N.Cl[Pt]Cl,PHASE2,nervous_system_disease
4571,Optic Neuritis|Multiple Sclerosis,Amiloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,PHASE2,nervous_system_disease
4572,Myasthenia Gravis,Mesna,C(CS(=O)(=O)[O-])S.[Na+],PHASE1,nervous_system_disease
4573,"Muscular Atrophy, Spinal",Risdiplam,CC1=CC(=NN2C1=NC(=C2)C)C3=CC(=O)N4C=C(C=CC4=N3)N5CCNC6(C5)CC6,PHASE1,nervous_system_disease
4574,Migraine Headache,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,APPROVED,nervous_system_disease
4575,Menopausal Syndromes,Tibolone,CC1CC2=C(CCC(=O)C2)C3C1C4CCC(C4(CC3)C)(C#C)O,APPROVED,nervous_system_disease
4576,Brain and Central Nervous System Tumors,Pamiparib,CC12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F,PHASE1|PHASE2,nervous_system_disease
4577,Amyotrophic Lateral Sclerosis (ALS),Tamoxifen,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,PHASE2,nervous_system_disease
4580,Painful Myelopathy|Painful Neuropathy,Ziconotide,CC1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)NC(C(=O)NCC(=O)NC(C(=O)N3)CO)C(C)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN,APPROVED,nervous_system_disease
4581,Spinal Cord Injury|Neurogenic Detrusor Overactivity,Oxybutynin,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,APPROVED,nervous_system_disease
4582,Spinal Cord Injury|Neurogenic Detrusor Overactivity,Trospium,C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,APPROVED,nervous_system_disease
4583,Fibromyalgia Syndrome,Paroxetine,C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,APPROVED,nervous_system_disease
4584,Primary Central Nervous System Lymphoma,Pemetrexed,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2,nervous_system_disease
4585,Sarcoidosis,Corticotropin,CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N,APPROVED,nervous_system_disease
4586,Insomnia,Ramelteon,CCC(=O)NCCC1CCC2=C1C3=C(C=C2)OCC3,PHASE1,nervous_system_disease
4588,Migraine Without Aura|Migraine With Aura,Tonabersat,CC(=O)C1=CC2=C(C=C1)OC(C(C2NC(=O)C3=CC(=C(C=C3)F)Cl)O)(C)C,PHASE2,nervous_system_disease
4589,Musculoskeletal Pain,Codeine,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,PHASE2,nervous_system_disease
4590,Restless Legs Syndrome,Pramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE2,nervous_system_disease
4592,Migraine,Telcagepant,C1CC(C(=O)N(CC1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(NC4=O)N=CC=C5,PHASE2,nervous_system_disease
4593,Infantile Spasm,Fenfluramine,CCNC(C)CC1=CC(=CC=C1)C(F)(F)F,PHASE2,nervous_system_disease
4594,Familial Amyotrophic Lateral Sclerosis,Pyrimethamine,CCC1=C(C(=NC(=N1)N)N)C2=CC=C(C=C2)Cl,PHASE1|PHASE2,nervous_system_disease
4596,Post-operative Pain,Dronabinol,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,APPROVED,nervous_system_disease
4597,Epilepsy,Alprazolam,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,PHASE1,nervous_system_disease
4598,Insomnia Chronic,Zopiclone,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,PHASE2,nervous_system_disease
4599,Headache|Tension-Type Headache|Tension-Type Headache (Episodic),Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,APPROVED,nervous_system_disease
4600,Drug-resistant Epilepsy|Focal-Onset Seizures,Padsevonil,COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3CC(CC3=O)CC(F)(F)Cl,PHASE2,nervous_system_disease
4601,Brain Tumor,Demeclocycline,CN(C)C1C2CC3C(C4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O,PHASE1,nervous_system_disease
4602,Neonatal Seizures,Phenobarbital,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,PHASE1|PHASE2,nervous_system_disease
4603,Autonomic Failure|Pure Autonomic Failure|Parkinson Disease|Multiple System Atrophy|Dementia With Lewy Bodies,Entacapone,CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N,PHASE1,nervous_system_disease
4604,Ischemic Stroke,Meglumine,CNCC(C(C(C(CO)O)O)O)O,APPROVED,nervous_system_disease
4605,Polycystic Ovary Syndrome,Moxonidine,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,APPROVED,nervous_system_disease
4606,Brain and Central Nervous System Tumors,Erlotinib,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,PHASE1,nervous_system_disease
4607,Alzheimer's Disease|Disruptive Behavior,Prazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,PHASE2,nervous_system_disease
4608,Tinnitus,Acamprosate,CC(=O)NCCCS(=O)(=O)O,PHASE1,nervous_system_disease
4609,Carotid Atherosclerosis,Perflutren,C(C(F)(F)F)(C(F)(F)F)(F)F,APPROVED,nervous_system_disease
4610,Glioblastoma|Brain Metastases,Losartan,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,PHASE2,nervous_system_disease
4611,Diabetic Peripheral Neuropathy,Bicifadine,CC1=CC=C(C=C1)C23CC2CNC3,PHASE2,nervous_system_disease
4612,Refractory Cancer|Refractory Neoplasm|Cancer Pediatric|Refractory Tumor|Pediatric Cancer|Pediatric Brain Tumor|Neuroblastoma|Neuroblastoma Recurrent|Pediatric Lymphoma|Pediatric Meningioma|Diffuse Intrinsic Pontine Glioma,Irinotecan,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,PHASE1,nervous_system_disease
4613,Refractory Cancer|Refractory Neoplasm|Cancer Pediatric|Refractory Tumor|Pediatric Cancer|Pediatric Brain Tumor|Neuroblastoma|Neuroblastoma Recurrent|Pediatric Lymphoma|Pediatric Meningioma|Diffuse Intrinsic Pontine Glioma,Topotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,PHASE1,nervous_system_disease
4614,Dental Pain,Celecoxib,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,PHASE2,nervous_system_disease
4615,Dental Pain,Indomethacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,PHASE2,nervous_system_disease
4617,Becker's Muscular Dystrophy (BMD),Metformin,CN(C)C(=N)N=C(N)N,PHASE2,nervous_system_disease
4618,Becker's Muscular Dystrophy (BMD),Citrulline,C(CC(C(=O)O)N)CNC(=O)N,PHASE2,nervous_system_disease
4619,Wilson Disease,Tetrathiomolybdate,[SH-].[SH-].S=[Mo]=S,PHASE2,nervous_system_disease
4620,Parkinson's Disease|Peripheral Edema,Domperidone,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,PHASE2,nervous_system_disease
4621,"HIV Infections|Leukoencephalopathy, Progressive Multifocal",Zalcitabine,C1CC(OC1CO)N2C=CC(=NC2=O)N,PHASE2,nervous_system_disease
4622,"HIV Infections|Leukoencephalopathy, Progressive Multifocal",Didanosine,C1CC(OC1CO)N2C=NC3=C2N=CNC3=O,PHASE2,nervous_system_disease
4623,Duchenne Muscular Dystrophy,Deflazacort,CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C,PHASE1,nervous_system_disease
4624,Fibromyalgia,Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,PHASE2|PHASE3,nervous_system_disease
4625,Cerebral Palsy|GERD,Baclofen,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,APPROVED,nervous_system_disease
4626,Symptomatic Irreversible Pulpitis|Post Operative Pain,Naproxen,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,PHASE2|PHASE3,nervous_system_disease
4627,Amyotrophic Lateral Sclerosis (ALS),Pimozide,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,PHASE2,nervous_system_disease
4628,Insomnia Disorders,Zolpidem,CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C,PHASE1,nervous_system_disease
4629,"Pain, Postoperative|Back Pain|Opioid Use|Methadone|Degenerative Spondylolisthesis|Stenosis, Spinal",Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,APPROVED,nervous_system_disease
4630,Parkinson Disease|Cerebrospinal Fluid,Acetylcysteine,CC(=O)NC(CS)C(=O)O,PHASE1,nervous_system_disease
4631,Medication Overuse Headache,Ibudilast,CC(C)C1=NN2C=CC=CC2=C1C(=O)C(C)C,PHASE1|PHASE2,nervous_system_disease
4632,"Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma, H3 K27M-Mutant|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Diffuse Midline Glioma, H3 K27M-Mutant|Recurrent WHO Grade III Glioma|WHO Grade III Glioma",Paxalisib,CC1(C2=NC3=C(N2CCO1)N=C(N=C3N4CCOCC4)C5=CN=C(N=C5)N)C,PHASE2,nervous_system_disease
4633,Alzheimer Disease,Seltorexant,CC1=CC(=NC(=N1)N2CC3CN(CC3C2)C(=O)C4=C(C=CC=C4F)N5N=CC=N5)C,PHASE2,nervous_system_disease
4634,"Dyslipidemia|Atherosclerosis|Diabetes Mellitus, Type 2",Policosanol,CCCO,APPROVED,nervous_system_disease
4635,Chronic Prostatitis With Chronic Pelvic Pain Syndrome,Cycloserine,C1C(C(=O)NO1)N,APPROVED,nervous_system_disease
4636,Primary Central Nervous System Lymphoma|Autologous Hematopoietic Stem Cell Transplantation|Conditioning,Busulfan,CS(=O)(=O)OCCCCOS(=O)(=O)C,PHASE2|PHASE3,nervous_system_disease
4637,Preterm Labor|Cerebral Palsy,Nifedipine,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,PHASE2|PHASE3,nervous_system_disease
4638,Meningioma,Cabozantinib,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,PHASE2,nervous_system_disease
4639,Vestibular Migraine|Chronic Subjective Dizziness,Verapamil,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,PHASE1,nervous_system_disease
4640,"Sleep Disturbance|Insomnia|Insomnia Type; Sleep Disorder|Insomnia, Transient|Insomnia Due to Anxiety and Fear|Insomnia Due to Other Mental Disorder",Cannabidiol,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,PHASE2,nervous_system_disease
4641,Parkinson Disease,Opicapone,CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-],PHASE1,nervous_system_disease
4642,Vertigo,Levophencynonate,CN1CC2CCCC(C1)C2OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O,PHASE2,nervous_system_disease
4643,Renal Colic,Dexketoprofen,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,APPROVED,nervous_system_disease
4646,Multiple Sclerosis,Mycophenolate,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,PHASE2,nervous_system_disease
4647,Benzodiazepines|Bladder Cancer|Delirium|Surgery|Cancer Recurrence,Remimazolam,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=NC2CCC(=O)OC)C4=CC=CC=N4,APPROVED,nervous_system_disease
4648,Duchenne Muscular Dystrophy,Ataluren,C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F,PHASE2,nervous_system_disease
4649,Migraine,Prochlorperazine,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,PHASE1,nervous_system_disease
4650,"Prolonged First Stage of Labor|Failure of Cervical Dilation as Antepartum Condition|Labor Pain|Mild Birth Asphyxia, APGAR 4-7",Drotaverine,CCOC1=C(C=C(C=C1)C=C2C3=CC(=C(C=C3CCN2)OCC)OCC)OCC,PHASE2|PHASE3,nervous_system_disease
4651,Adult Anaplastic Oligodendroglioma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE1|PHASE2,nervous_system_disease
4652,Becker Muscular Dystrophy,Epicatechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,nervous_system_disease
4653,Becker Muscular Dystrophy,Catechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE1,nervous_system_disease
4654,Post-Dural Puncture Headache,Aminophylline,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,APPROVED,nervous_system_disease
4655,Post-Dural Puncture Headache,Neostigmine,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,APPROVED,nervous_system_disease
4656,Post-Dural Puncture Headache,Atropine,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,APPROVED,nervous_system_disease
4657,Parkinson's Disease,Nebicapone,C1=CC=C(C=C1)CC(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],PHASE1,nervous_system_disease
4658,DLBCL|Neurotoxicity Syndromes,Defibrotide,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)OP(=O)(O)O,PHASE2,nervous_system_disease
4659,Cardiac Complications|Signs and Symptoms|Muscle Weakness|Anemia|Hypotension,Levocarnitine,C[N+](C)(C)CC(CC(=O)[O-])O,APPROVED,nervous_system_disease
4660,Cardiac Complications|Signs and Symptoms|Muscle Weakness|Anemia|Hypotension,Carnitine,C[N+](C)(C)CC(CC(=O)[O-])O,APPROVED,nervous_system_disease
4661,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma|Low Grade Glioma|Malignant Glioma|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Ependymoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Childhood Malignant Germ Cell Tumor|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Rhabdoid Tumor|Wilms Tumor,Olaparib,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE2,nervous_system_disease
4662,Cancer|Peripheral Neuropathy,Ethosuximide,CCC1(CC(=O)NC1=O)C,PHASE2,nervous_system_disease
4663,Acute Migraine Headache,Zolmitriptan,CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3,APPROVED,nervous_system_disease
4664,Meniere's Disease,Acyclovir,C1=NC2=C(N1COCCO)N=C(NC2=O)N,PHASE2|PHASE3,nervous_system_disease
4665,Eye Injuries,Anecortave,CC12CCC(=O)C=C1CCC3C2=CCC4(C3CCC4(C(=O)CO)O)C,PHASE2,nervous_system_disease
4666,Non Dystrophic Myotonia,Mexiletine,CC1=C(C(=CC=C1)C)OCC(C)N,PHASE2,nervous_system_disease
4667,Amyotrophic Lateral Sclerosis,Zilucoplan,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCCC(C(=O)O)NC(=O)C(C1CCCCC1)NC(=O)C2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC4=CNC5=C4C=CC=N5)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(C(C)(C)C)NC(=O)C(CC(=O)O)N(C)C(=O)C7CC(=O)NCCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O,PHASE2|PHASE3,nervous_system_disease
4668,Autonomic Dysreflexia,Fesoterodine,CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2,PHASE2,nervous_system_disease
4669,Alzheimer's Disease,Resveratrol,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O,PHASE2,nervous_system_disease
4670,Estrogen Receptor Negative (ER-Negative) Breast Cancer|Progesterone Receptor Negative (PR-Negative) Breast Cancer|Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer|Brain Metastases,Iniparib,C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I,PHASE2,nervous_system_disease
4671,Parkinson's Disease,Safinamide,CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F,PHASE2,nervous_system_disease
4672,"Stroke, Acute",Labetalol,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,PHASE2,nervous_system_disease
4673,Sleep Apnea|Elderly Adults,Finasteride,CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C,APPROVED,nervous_system_disease
4674,"Headache, Migraine",Ubrogepant,CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6,APPROVED,nervous_system_disease
4675,Primary Fibromyalgia,Milnacipran,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2,PHASE2,nervous_system_disease
4676,Dementia With Lewy Bodies (DLB),Neflamapimod,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,PHASE2,nervous_system_disease
4677,Primary Central Nervous System Lymphoma,Isavuconazole,CC(C1=NC(=CS1)C2=CC=C(C=C2)C#N)C(CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O,PHASE1,nervous_system_disease
4678,Primary Central Nervous System Lymphoma,Ibrutinib,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE1,nervous_system_disease
4679,Ischemic Heart Disease,Quinapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O,APPROVED,nervous_system_disease
4680,Blood Pressure|Ischemic Stroke,Fimasartan,CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C,APPROVED,nervous_system_disease
4681,Blood Pressure|Ischemic Stroke,Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O,APPROVED,nervous_system_disease
4682,Blood Pressure|Ischemic Stroke,Atenolol,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,APPROVED,nervous_system_disease
4683,"Obstructive Sleep Apnea|Tonsillitis|Pain, Procedural",Hydromorphone,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4,PHASE2,nervous_system_disease
4684,AIDS Dementia Complex,Ferumoxytol,O[Fe]=O.O[Fe]=O.[Fe],PHASE2,nervous_system_disease
4685,Parkinson Disease,Apomorphine,CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O,APPROVED,nervous_system_disease
4686,Emotional Disorder|Neurologic Disorder,Flupenthixol,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,APPROVED,nervous_system_disease
4687,Emotional Disorder|Neurologic Disorder,Flupentixol,C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,APPROVED,nervous_system_disease
4688,Parkinson Disease,Talampanel,CC1CC2=CC3=C(C=C2C(=NN1C(=O)C)C4=CC=C(C=C4)N)OCO3,PHASE2,nervous_system_disease
4689,Multiple Sclerosis,Dalfampridine,C1=CN=CC=C1N,APPROVED,nervous_system_disease
4690,Intracranial Non-germinomatous Germ Cell Tumor,Thiotepa,C1CN1P(=S)(N2CC2)N3CC3,PHASE2,nervous_system_disease
4691,Intracranial Non-germinomatous Germ Cell Tumor,Melphalan,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,PHASE2,nervous_system_disease
4693,Anosmia,Budesonide,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,PHASE2,nervous_system_disease
4695,Major Depressive Disorder|Dementia,Vortioxetine,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,APPROVED,nervous_system_disease
4696,Diabetic Neuropathies,Carisbamate,C1=CC=C(C(=C1)C(COC(=O)N)O)Cl,PHASE2,nervous_system_disease
4697,"Leukoencephalopathy, Progressive Multifocal|HIV Infections",Enfuvirtide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(=O)N)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC7=CC=CC=C7)C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C,PHASE2,nervous_system_disease
4698,"Leukoencephalopathy, Progressive Multifocal|HIV Infections",Tenofovir,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,PHASE2,nervous_system_disease
4699,"Leukoencephalopathy, Progressive Multifocal|HIV Infections",Emtricitabine,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,PHASE2,nervous_system_disease
4700,Rett Syndrome,Trofinetide,CC1(CCCN1C(=O)CN)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2|PHASE3,nervous_system_disease
4701,"Meningitis, Cryptococcal|HIV Infections",Amphotericin B,CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,PHASE2,nervous_system_disease
4702,"Meningitis, Cryptococcal|HIV Infections",Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,PHASE2,nervous_system_disease
4703,"Meningitis, Cryptococcal|HIV Infections",Flucytosine,C1=NC(=O)NC(=C1F)N,PHASE2,nervous_system_disease
4704,"Meningitis, Cryptococcal|HIV Infections",Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,PHASE2,nervous_system_disease
4705,SIAD - Syndrome of Inappropriate Antidiuresis|Hyponatremia,Empagliflozin,C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,PHASE2|PHASE3,nervous_system_disease
4706,Traumatic Brain Injury,Erythropoietin,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],PHASE2,nervous_system_disease
4707,Amyotrophic Lateral Sclerosis,Fasudil,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3,PHASE2,nervous_system_disease
4708,Primary Mitochondrial Disease,Elamipretide,CC1=CC(=CC(=C1CC(C(=O)NC(CCCCN)C(=O)NC(CC2=CC=CC=C2)C(=O)N)NC(=O)C(CCCN=C(N)N)N)C)O,PHASE2,nervous_system_disease
4709,Childhood Cerebral Anaplastic Astrocytoma|Childhood Oligodendroglioma|Childhood Spinal Cord Neoplasm|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma,Fludeoxyglucose,C(C(C(C(C(C=O)F)O)O)O)O,PHASE2,nervous_system_disease
4710,General Anesthesia,Rocuronium,CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C,APPROVED,nervous_system_disease
4712,Tourette's Syndrome,Ecopipam,CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl,PHASE1|PHASE2,nervous_system_disease
4713,Multiple Sclerosis,Cholecalciferol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2,nervous_system_disease
4714,Chemotherapy-induced Neuropathic Pain|Chemotherapy-induced Peripheral Neuropathy,Tetrodotoxin,C(C1(C2C3C(N=C(NC34C(C1OC(C4O)(O2)O)O)N)O)O)O,PHASE2,nervous_system_disease
4715,Diabetic Neuropathies,Reboxetine,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,PHASE2,nervous_system_disease
4716,Parkinson's Disease,Istradefylline,CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C,PHASE2,nervous_system_disease
4717,Amyotrophic Lateral Sclerosis,Verdiperstat,CC(C)OCCN1C2=C(C(=O)NC1=S)NC=C2,PHASE2|PHASE3,nervous_system_disease
4718,Multiple Sclerosis,Isoxsuprine,CC(COC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O,PHASE1|PHASE2,nervous_system_disease
4719,Dementia|Alzheimer Disease,Dextroamphetamine,CC(CC1=CC=CC=C1)N,APPROVED,nervous_system_disease
4720,Other Specified Hypotension|Syncope,Acarbose,CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO,PHASE2,nervous_system_disease
4722,Unilateral Cerebral Palsy|Hemiplegic Cerebral Palsy|Remote Ischemic Conditioning,Isoxaflutole,CS(=O)(=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C2=C(ON=C2)C3CC3,PHASE2,nervous_system_disease
4723,Alzheimer Disease,Lecozotan,CC(CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5,PHASE1,nervous_system_disease
4724,Hypoxia|Altitude|Heart Failure,Nebivolol,C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O,APPROVED,nervous_system_disease
4725,Spinal Cord Injury|Neurogenic Bowel,Glycopyrrolate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],PHASE1,nervous_system_disease
4726,Advanced Malignant Solid Neoplasm|Malignant Solid Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Wilms Tumor,Ensartinib,CC1CN(CC(N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)OC(C)C4=C(C=CC(=C4Cl)F)Cl)N,PHASE2,nervous_system_disease
4727,Acromegaly,Somatostatin,CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)C(C)N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O,PHASE2,nervous_system_disease
4728,Fragile X Syndrome,Roflumilast,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,PHASE2,nervous_system_disease
4729,Muscular Dystrophies,Drisapersen,COC1C(C(OC1N2C=CC(=O)NC2=O)COP(=S)(O)OC3C(OC(C3OC)N4C=CC(=NC4=O)N)COP(=S)(O)OC5C(OC(C5OC)N6C=CC(=O)NC6=O)COP(=S)(O)OC7C(OC(C7OC)N8C=CC(=O)NC8=O)COP(=S)(O)OC9C(OC(C9OC)N1C=CC(=O)NC1=O)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1C(OC(C1OC)N1C=CC(=NC1=O)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OC)N1C=CC(=O)NC1=O)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1C(OC(C1OC)N1C=NC2=C(N=CN=C21)N)COP(=O)(OC1C(OC(C1OC)N1C=CC(=NC1=O)N)COP(=S)(O)OC1C(OC(C1OC)N1C=CC(=O)NC1=O)CO)S)O,PHASE2,nervous_system_disease
4730,Acute Ischemic Stroke,Enoxaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,nervous_system_disease
4731,Primary Non Hodgkin Lymphoma of the Central Nervous System,Lomustine,C1CCC(CC1)NC(=O)N(CCCl)N=O,PHASE2,nervous_system_disease
4732,Transient Ischemic Attack|Stroke,Levosimendan,CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,PHASE2,nervous_system_disease
4733,Transient Ischemic Attack|Stroke,Simendan,CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,PHASE2,nervous_system_disease
4734,"Multiple Myeloma|Multiple Myeloma in Relapse|Multiple Myeloma, Refractory",Marizomib,CC12C(C(=O)NC1(C(=O)O2)C(C3CCCC=C3)O)CCCl,PHASE2,nervous_system_disease
4735,"Multiple Myeloma|Multiple Myeloma in Relapse|Multiple Myeloma, Refractory",Pomalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,PHASE2,nervous_system_disease
4736,Complex Regional Pain Syndrome,Soticlestat,C1CN(CCC1(CC2=CC=CC=C2)O)C(=O)C3=C(N=CC=C3)C4=CC=NC=C4,PHASE2,nervous_system_disease
4737,Relapsing-remitting Multiple Sclerosis,Evobrutinib,C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N,PHASE2,nervous_system_disease
4738,"Hyperalgesia, Secondary",Parecoxib,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C,APPROVED,nervous_system_disease
4739,"Multiple Sclerosis, Secondary Progressive",Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,PHASE2,nervous_system_disease
4740,"Multiple Sclerosis, Secondary Progressive",Indapamide,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,PHASE2,nervous_system_disease
4741,Brain Cancer,Palonosetron,C1CC2CN(C(=O)C3=CC=CC(=C23)C1)C4CN5CCC4CC5,PHASE2,nervous_system_disease
4742,Attention Deficit Disorder With Hyperactivity,Amphetamine,CC(CC1=CC=CC=C1)N,PHASE2,nervous_system_disease
4743,Postoperative Cognitive Dysfunction|Postoperative Delirium,Tropisetron,CN1C2CCC1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,APPROVED,nervous_system_disease
4744,Down Syndrome,Ubiquinol,CC1=C(C(=C(C(=C1O)OC)OC)O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,PHASE2,nervous_system_disease
4745,"Multiple Sclerosis, Relapsing-Remitting",Inosine,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)CO)O)O,PHASE2,nervous_system_disease
4746,"Spinal Stenosis|Pain, Postoperative",Buprenorphine,CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,APPROVED,nervous_system_disease
4747,Parkinson Disease,Ropinirole,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,PHASE2,nervous_system_disease
4748,Multiple Sclerosis,Firategrast,CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)CC(C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC,PHASE2,nervous_system_disease
4749,Alzheimer Disease,Venlafaxine,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,PHASE1,nervous_system_disease
4750,Hypertension,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,PHASE1,nervous_system_disease
4751,Hypertension,Desmopressin,C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N,PHASE1,nervous_system_disease
4752,Hypertension,Hydralazine,C1=CC=C2C(=C1)C=NN=C2NN,PHASE1,nervous_system_disease
4753,Hypertension,Bosentan,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,PHASE1,nervous_system_disease
4754,Hypertension,Diltiazem,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,PHASE1,nervous_system_disease
4755,Brain Neoplasms,Temsirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,PHASE1,nervous_system_disease
4756,"Dysphonia, Spastic|Dysphonia|Laryngeal Dystonia",Pyridostigmine,C[N+]1=CC=CC(=C1)OC(=O)N(C)C,APPROVED,nervous_system_disease
4757,Intracerebral Hemorrhage|Spironolactone,Spironolactone,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,PHASE2,nervous_system_disease
4758,Advanced Malignant Solid Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma,Larotrectinib,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,PHASE2,nervous_system_disease
4759,Postural Orthostatic Tachycardia Syndrome,Metoprolol,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,PHASE2,nervous_system_disease
4760,REM Sleep Behavior Disorder|Pre-motor Parkinson's Disease|Symptomatic Parkinson Disease,Terazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,PHASE2,nervous_system_disease
4761,Toxoplasmosis,Spiramycin,CC1CC=CC=CC(C(CC(C(C(C(CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C,APPROVED,nervous_system_disease
4762,Toxoplasmosis,Sulfadiazine,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,APPROVED,nervous_system_disease
4763,Spinal Cord Injury|Autonomic Dysreflexia|Orthostatic Hypotension|Baroreceptor Integrity|Sympathetic Integrity|Vagal Integrity|Hypotension|Cerebral Blood Flow|Blood Pressure|Venous Occlusion Plethysmography,Midodrine,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,PHASE2|PHASE3,nervous_system_disease
4764,Stroke,Maraviroc,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,PHASE2|PHASE3,nervous_system_disease
4765,"Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis",Guanabenz,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,PHASE1,nervous_system_disease
4766,Hearing Loss Ototoxic,Azasetron,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,PHASE2,nervous_system_disease
4767,Neurogenic Orthostatic Hypotension,Fludrocortisone,CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F,APPROVED,nervous_system_disease
4768,Peripheral Neuropathy,Candesartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,PHASE2,nervous_system_disease
4769,Neurodegenerative Disease|Iron Overload,Deferiprone,CC1=C(C(=O)C=CN1C)O,PHASE2,nervous_system_disease
4770,Alzheimer's Disease,Nefiracetam,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,PHASE2,nervous_system_disease
4771,Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy,Droxidopa,C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O,PHASE2,nervous_system_disease
4772,Tonic-clonic Seizure,Fosphenytoin,C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3,APPROVED,nervous_system_disease
4773,Tonic-clonic Seizure,Phenytoin,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,APPROVED,nervous_system_disease
4774,Angina Pectoris,Lacidipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2C=CC(=O)OC(C)(C)C)C(=O)OCC)C)C,PHASE2,nervous_system_disease
4775,Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8,Binimetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,PHASE2,nervous_system_disease
4776,Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Melanoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8,Encorafenib,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,PHASE2,nervous_system_disease
4777,Leber Congenital Amaurosis|LCA|LCA1,Trimethoprim,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,PHASE1|PHASE2,nervous_system_disease
4778,Ischemic Stroke,Glyburide,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,PHASE1|PHASE2,nervous_system_disease
4779,Chronic Migraine,Betamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,APPROVED,nervous_system_disease
4780,Minimal Hepatic Encephalopathy,Rifaximin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,PHASE1|PHASE2,nervous_system_disease
4782,DIABETES|DIABETIC RETINOPATHY|DIABETIC NEUROPATHY,Cholestyramine,CCC(C)C.CCC(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)C[N+](C)(C)C.N.[Cl-],APPROVED,nervous_system_disease
4783,Acute Cerebrovascular Accident|Cerebral Edema,Conivaptan,CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,PHASE2,nervous_system_disease
4784,Urinary Incontinence|Parkinson's Disease,Solifenacin,C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5,APPROVED,nervous_system_disease
4786,Attention Deficit Hyperactivity Disorder (ADHD),Lisdexamfetamine,CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N,APPROVED,nervous_system_disease
4787,Blepharospasm|Dystonia,Dipraglurant,C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F,PHASE2,nervous_system_disease
4788,Sleep Apnea,Danavorexton,COC(=O)N1CCCC(C1COC2CCC(CC2)C3=CC=CC=C3)NS(=O)(=O)C,PHASE1,nervous_system_disease
4789,Obesity|Diabetes|Obstructive Sleep Apnea,Orlistat,CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O,PHASE2,nervous_system_disease
4790,Moderate to Severe Pain Due to Diabetic Polyneuropathy,Naloxone,C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O,PHASE2,nervous_system_disease
4791,Diabetic Polyneuropathy,Lidorestat,C1=CC=C2C(=C1)C(=CN2CC(=O)O)CC3=NC4=C(C(=CC(=C4S3)F)F)F,PHASE2,nervous_system_disease
4792,Chronic Obstructive Pulmonary Disease,Indacaterol,CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC,APPROVED,nervous_system_disease
4793,Chronic Obstructive Pulmonary Disease,Glycopyrronium,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C,APPROVED,nervous_system_disease
4794,Chronic Obstructive Pulmonary Disease,Tiotropium,C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C,APPROVED,nervous_system_disease
4795,Diabetic Peripheral Neuropathy,Dapagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,PHASE2|PHASE3,nervous_system_disease
4796,Pediatric Brain Tumor|Diffuse Intrinsic Pontine Glioma,Veledimex,CCCC(C(C)(C)C)N(C(=O)C1=CC(=CC(=C1)C)C)NC(=O)C2=C(C(=CC=C2)OC)CC,PHASE1|PHASE2,nervous_system_disease
4797,Endometriosis,Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,nervous_system_disease
4798,Endometriosis,Leuprorelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,nervous_system_disease
4799,Peripheral Neuropathy|Type 1 Diabetes,Salsalate,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,PHASE2,nervous_system_disease
4800,Pompe Disease,Duvoglustat,C1C(C(C(C(N1)CO)O)O)O,PHASE2,nervous_system_disease
4801,Bacterial Infection|Brain Injury,Metronidazole,CC1=NC=C(N1CCO)[N+](=O)[O-],PHASE1,nervous_system_disease
4802,Bacterial Infection|Brain Injury,Ciprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,PHASE1,nervous_system_disease
4803,Muscle Weakness|Sepsis,Lorcaserin,CC1CNCCC2=C1C=C(C=C2)Cl,PHASE1|PHASE2,nervous_system_disease
4806,Cochlear Hearing Loss,Triamcinolone,CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O,PHASE1,nervous_system_disease
4807,Migraine,Levonorgestrel,CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE2,nervous_system_disease
4808,Erectile Dysfunction,Vardenafil,CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C,APPROVED,nervous_system_disease
4809,Pompe Disease,Clenbuterol,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O,PHASE1|PHASE2,nervous_system_disease
4810,Renal Colic,Dipyrone,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],APPROVED,nervous_system_disease
4811,Dental Pain|Postoperative Pain,Benzocaine,CCOC(=O)C1=CC=C(C=C1)N,APPROVED,nervous_system_disease
4812,Postoperative Delirium|Major Noncardiac Surgery|Postoperative Cognitive Dysfunction,Desflurane,C(C(F)(F)F)(OC(F)F)F,APPROVED,nervous_system_disease
4813,Central Nervous System Lymphoma,Zanubrutinib,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,PHASE2,nervous_system_disease
4814,Brain Metastasis|Non-small Cell Lung Cancer,Patupilone,CC1CCCC2(C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C,PHASE2,nervous_system_disease
4815,Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm,Bendamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,PHASE2,nervous_system_disease
4817,Alzheimer's Disease,Avagacestat,C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)C(CCC(F)(F)F)C(=O)N)Cl,PHASE2,nervous_system_disease
4818,Brain and Nervous System|Cancer,Thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,PHASE1,nervous_system_disease
4819,Vestibular Schwannoma|Neurofibromatosis Type 2,Icotinib,C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4,PHASE2,nervous_system_disease
4821,Brain Cancer,Sugammadex,C(CSCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(O2)C(C9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O,APPROVED,nervous_system_disease
4823,Gastroparesis|Diabetes Mellitus,Cisapride,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,APPROVED,nervous_system_disease
4824,Alzheimer's Disease|Huntington's Disease,Latrepirdine,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C,PHASE1,nervous_system_disease
4825,"Alzheimer Disease, Early Onset|Mild Cognitive Impairment",Dasatinib,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,PHASE2,nervous_system_disease
4826,"Alzheimer Disease, Early Onset|Mild Cognitive Impairment",Quercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,PHASE2,nervous_system_disease
4827,Brain Cancer,Dexanabinol,CCCCCCC(C)(C)C1=CC(=C2C3CC(=CCC3C(OC2=C1)(C)C)CO)O,PHASE1,nervous_system_disease
4828,Acute Stroke|Aspiration Pneumonia,Metoclopramide,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,APPROVED,nervous_system_disease
4829,Hypoactive Delirium,Flumazenil,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,APPROVED,nervous_system_disease
4830,Alzheimer Disease,Huperzine A,CC=C1C2CC3=C(C1(CC(=C2)C)N)C=CC(=O)N3,PHASE2,nervous_system_disease
4831,Neurogenic Bladder,Methantheline,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13,PHASE1,nervous_system_disease
4833,"Alcohol Abuse, Nervous System",Pitolisant,C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl,PHASE2,nervous_system_disease
4834,Neurofibromatosis Type I|Plexiform Neurofibroma,Sorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,PHASE1,nervous_system_disease
4835,Medulloblastoma|Central Nervous System Tumors|Neuroblastoma|Osteosarcoma,Oxaliplatin,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],PHASE2,nervous_system_disease
4836,Strabismus,Thiopental,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,PHASE2,nervous_system_disease
4837,Sarcopenia,Allopurinol,C1=NNC2=C1C(=O)NC=N2,APPROVED,nervous_system_disease
4838,Cushing's Disease|Acromegaly,Sitagliptin,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,APPROVED,nervous_system_disease
4839,Brain and Central Nervous System Tumors,Cytochlor,C1C(C(OC1N2C=C(C(=NC2=O)N)Cl)CO)O,PHASE1,nervous_system_disease
4840,Brain and Central Nervous System Tumors,Tetrahydrouridine,C1CN(C(=O)NC1O)C2C(C(C(O2)CO)O)O,PHASE1,nervous_system_disease
4841,Renal Colic,Piroxicam,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,PHASE1|PHASE2,nervous_system_disease
4842,Multiple Sclerosis,Hydroxyurea,C(=O)(N)NO,PHASE2|PHASE3,nervous_system_disease
4843,Corneal Abrasions,Proparacaine,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,PHASE1,nervous_system_disease
4844,Alzheimer's Disease,Rosiglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,PHASE1,nervous_system_disease
4845,Pompe Disease,Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,PHASE1,nervous_system_disease
4846,Fragile X Syndrome,Sulindac,CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,PHASE2,nervous_system_disease
4847,Fragile X Syndrome,Gaboxadol,C1CNCC2=C1C(=O)NO2,PHASE2,nervous_system_disease
4849,Alzheimer's Disease,Tricaprylin,CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC,PHASE2,nervous_system_disease
4850,Lung Cancer,Almonertinib,CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC,PHASE2,nervous_system_disease
4851,Friedreich Ataxia,Vatiquinone,CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(CCC=C(C)CCC=C(C)CCC=C(C)C)O)C,PHASE2|PHASE3,nervous_system_disease
4853,Multiple Sclerosis,Cladribine,C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,APPROVED,nervous_system_disease
4854,Fibromyalgia,Esreboxetine,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,PHASE2,nervous_system_disease
4856,Epilepsy,Clobazam,CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,PHASE2,nervous_system_disease
4857,Leber's Hereditary Optic Neuropathy (LHON),Idebenone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,APPROVED,nervous_system_disease
4858,Alzheimer's Disease,Mifepristone,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,PHASE2,nervous_system_disease
4860,Intraocular Pressure,Fluorometholone,CC1CC2C3CCC(C3(CC(C2(C4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,APPROVED,nervous_system_disease
4861,Intraocular Pressure,Rimexolone,CCC(=O)C1(C(CC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)C)C,APPROVED,nervous_system_disease
4862,Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Oligodendroglioma|Gliosarcoma|Mixed Glioma|Recurrent Adult Brain Neoplasm|Recurrent Glioblastoma,Lapatinib,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,PHASE1,nervous_system_disease
4864,CNS Lymphoma,Orelabrutinib,C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4,PHASE2,nervous_system_disease
4868,Pneumococcal Meningitis,Daptomycin,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,PHASE2,nervous_system_disease
4869,"Muscular Dystrophy, Duchenne",Rimeporide,CC1=CC(=C(C=C1C(=O)N=C(N)N)S(=O)(=O)C)S(=O)(=O)C,PHASE1,nervous_system_disease
4871,Gastroparesis|Opioid Use,Naloxegol,COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O,PHASE2,nervous_system_disease
4872,Gastroparesis,Nizatidine,CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C,PHASE1,nervous_system_disease
4873,"Diffuse Intrinsic Pontine Glioma|Diffuse Pontine and Thalamic Gliomas|Diffuse Midline Glioma, H3 K27M-Mutant",Panobinostat,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,PHASE1,nervous_system_disease
4874,Gaucher Disease|HCV,Ledipasvir,CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,APPROVED,nervous_system_disease
4875,Gaucher Disease|HCV,Sofosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,APPROVED,nervous_system_disease
4876,Active Melanoma Brain Metastases,Cobimetinib,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,PHASE2,nervous_system_disease
4877,Active Melanoma Brain Metastases,Vemurafenib,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,PHASE2,nervous_system_disease
4879,Sarcopenia,Nandrolone,CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34,PHASE2,nervous_system_disease
4880,Attention-Deficit/Hyperactivity Disorder (ADHD),Dextromethorphan,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,APPROVED,nervous_system_disease
4881,Attention-Deficit/Hyperactivity Disorder (ADHD),Dexmethylphenidate,COC(=O)C(C1CCCCN1)C2=CC=CC=C2,APPROVED,nervous_system_disease
4882,Non Small Cell Lung Cancer|Brain Metastases,Dacomitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)C=CCN4CCCCC4,PHASE2,nervous_system_disease
4883,"Hereditary Tyrosinemia, Type I",Nitisinone,C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-],PHASE1,nervous_system_disease
4884,Malignant Solid Tumor - Malignant Nervous System Neoplasm,Cabazitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC,PHASE1|PHASE2,nervous_system_disease
4885,"Medulloblastoma|Astrocytoma, Grade III|Glioblastoma|Anaplastic Astrocytoma|Brain Stem Neoplasms, Malignant|Oligodendroblastoma|Anaplastic Oligodendroglioma|Malignant Glioma",Mebendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,PHASE1,nervous_system_disease
4886,Myotonic Dystrophy 1,Tideglusib,C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43,PHASE2,nervous_system_disease
4887,"Dental Pain|Anesthesia, Local",Articaine,CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC,APPROVED,nervous_system_disease
4888,Infant Bacterial Meningitis,Ceftriaxone,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,APPROVED,nervous_system_disease
4889,Infant Bacterial Meningitis,Phenoxymethylpenicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,APPROVED,nervous_system_disease
4890,Infant Bacterial Meningitis,Penicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,APPROVED,nervous_system_disease
4891,"Cerebral Small Vessel Diseases|Stroke, Lacunar",Isosorbide,C1C(C2C(O1)C(CO2)O)O,PHASE2|PHASE3,nervous_system_disease
4892,"Cerebral Small Vessel Diseases|Stroke, Lacunar",Cilostazol,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,PHASE2|PHASE3,nervous_system_disease
4893,Malignant Brain Stem Tumor|Glioma,Anlotinib,CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,PHASE2,nervous_system_disease
4894,Parkinson Disease|Movement Disorders,Altropane,COC(=O)C1C2CCC(N2CC=CI)CC1C3=CC=C(C=C3)F,PHASE2,nervous_system_disease
4896,Metastatic BRCA-Associated Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Metastatic Triple-Negative Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7,Veliparib,CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N,PHASE2,nervous_system_disease
4897,Neurofibromatosis Type 2|Vestibular Schwannoma|Non-vestibular Schwannoma|Meningioma|Ependymoma,Brigatinib,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC,PHASE2,nervous_system_disease
4898,Neurofibromatosis Type 2|Vestibular Schwannoma|Non-vestibular Schwannoma|Meningioma|Ependymoma,Neratinib,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,PHASE2,nervous_system_disease
4899,Amyotrophic Lateral Sclerosis,Dexpramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE1,nervous_system_disease
4900,Amyotrophic Lateral Sclerosis,Cimetidine,CC1=C(N=CN1)CSCCNC(=NC)NC#N,PHASE1,nervous_system_disease
4901,Hepatic Encephalopathy,Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],PHASE2,nervous_system_disease
4902,Diabetes,Epalrestat,CC(=CC1=CC=CC=C1)C=C2C(=O)N(C(=S)S2)CC(=O)O,APPROVED,nervous_system_disease
4903,Anovulatory Infertility|Abnormal Uterine Bleeding-Ovulatory Disorders|Polycystic Ovarian Syndrome|Hyperprolactinemia|Luteinized Unruptured Follicle Syndrome|Corpus Luteum Insufficiency|Ovarian Insufficiency,Clomiphene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE2,nervous_system_disease
4904,Anovulatory Infertility|Abnormal Uterine Bleeding-Ovulatory Disorders|Polycystic Ovarian Syndrome|Hyperprolactinemia|Luteinized Unruptured Follicle Syndrome|Corpus Luteum Insufficiency|Ovarian Insufficiency,Clomifene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE2,nervous_system_disease
4905,Muscle Relaxants,Succinylcholine,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,APPROVED,nervous_system_disease
4906,REM Sleep Behavior Disorder,Clonazepam,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,PHASE2,nervous_system_disease
4907,Orthostatic Hypertension,Norepinephrine,C1=CC(=C(C=C1C(CN)O)O)O,PHASE1|PHASE2,nervous_system_disease
4909,Aneurysmal Subarachnoid Hemorrhage,Nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,PHASE2,nervous_system_disease
4910,Becker Muscular Dystrophy,Vamorolone,CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1(C(=O)CO)O)C)C,PHASE2,nervous_system_disease
4911,Breast Neoplasms|Brain Neoplasms|Neoplasms by Site|Neoplasms|Breast Diseases|Central Nervous System Neoplasms|Brain Diseases|Central Nervous System Diseases,Elacestrant,CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O,PHASE1|PHASE2,nervous_system_disease
4913,Insomnia Disorder,Flurazepam,CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,PHASE1,nervous_system_disease
4914,Insomnia|Generalized Anxiety Disorder,Eszopiclone,CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl,APPROVED,nervous_system_disease
4915,Agitation,Loxapine,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,APPROVED,nervous_system_disease
4916,Delirium,Citicoline,C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)O)O,APPROVED,nervous_system_disease
4917,Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Primary CNS Tumor,Indoximod,CN1C=C(C2=CC=CC=C21)CC(C(=O)O)N,PHASE1,nervous_system_disease
4918,Meningitis|Ventriculitis,Ceftaroline,CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-],PHASE1,nervous_system_disease
4919,Dysphonia,Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,APPROVED,nervous_system_disease
4920,"CNS Embryonal Tumor, Not Otherwise Specified|Malignant Glioma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Childhood Ependymoma|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma|Refractory Diffuse Intrinsic Pontine Glioma",Ribociclib,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,PHASE1,nervous_system_disease
4921,Alzheimer Disease|Herpes Simplex 1|Herpes Simplex 2,Valaciclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE2,nervous_system_disease
4922,Alzheimer Disease|Herpes Simplex 1|Herpes Simplex 2,Valacyclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE2,nervous_system_disease
4923,Microvascular Angina,Udenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C,APPROVED,nervous_system_disease
4924,Perennial Allergic Rhinitis|Obstructive Sleep Apnea|Sleep Disorder,Mometasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C,APPROVED,nervous_system_disease
4925,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Erdafitinib,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,PHASE2,nervous_system_disease
4926,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Palbociclib,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,PHASE2,nervous_system_disease
4927,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Selpercatinib,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,PHASE2,nervous_system_disease
4928,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Tipifarnib,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,PHASE2,nervous_system_disease
4929,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Ulixertinib,CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl,PHASE2,nervous_system_disease
4930,Insomnia Disorder|Nocturia,Daridorexant,CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl,APPROVED,nervous_system_disease
4931,Chronic Obstructive Pulmonary Disease (COPD),Tesamorelin,CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)N,PHASE2,nervous_system_disease
4932,Alzheimer Disease|Cognitive Function,Tandospirone,C1CC2CC1C3C2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5,APPROVED,nervous_system_disease
4933,Treatment of Depression in Adults With Parkinson's Disease (PD),Pimavanserin,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,PHASE2,nervous_system_disease
4934,Grade 1 Meningioma|Grade 2 Meningioma|Grade 3 Meningioma|Recurrent Meningioma|Unresectable Meningioma,Dotatate,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(C(C)O)C(=O)O)O,PHASE2,nervous_system_disease
4935,Heart Failure|Sinus Rhythm|Cerebrovascular Disease,Apixaban,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,PHASE2,nervous_system_disease
4936,Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Primary Malignant Central Nervous System Neoplasm|Locally Advanced Sarcoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Primary Malignant Central Nervous System Neoplasm|Metastatic Sarcoma|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,Avapritinib,CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N,PHASE2,nervous_system_disease
4937,Erectile Dysfunction,Avanafil,COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl,APPROVED,nervous_system_disease
4938,Relapsing Remitting Multiple Sclerosis,Simethicone,CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,APPROVED,nervous_system_disease
4939,Relapsing Remitting Multiple Sclerosis,Loperamide,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,APPROVED,nervous_system_disease
4940,Breast Cancer|Brain Metastases,Vinorelbine,CCC1=CC2CC(C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,PHASE2,nervous_system_disease
4941,Gastroparesis,Erythromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,PHASE2,nervous_system_disease
4942,Gastroparesis,Azithromycin,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,PHASE2,nervous_system_disease
4943,Diabetes Mellitus|Diabetes Mellitus Complications|Gastroparesis,Relamorelin,C1CC(CNC1)C(=O)NC(CC2=CSC3=CC=CC=C32)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N,PHASE2,nervous_system_disease
4945,Patent Foramen Ovale|Migraine,Rivaroxaban,C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl,APPROVED,nervous_system_disease
4947,Phenylketonuria,Sapropterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,nervous_system_disease
4948,Analgesia|Sedation,Sufentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC,APPROVED,nervous_system_disease
4949,Progressive Supranuclear Palsy,Davunetide,CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(C)NC(=O)C(CC(=O)N)N,PHASE2|PHASE3,nervous_system_disease
4950,Brain Tumors,Vinblastine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE2|PHASE3,nervous_system_disease
4951,"NMO Spectrum Disorder|Spasticity, Muscle",Nabiximols,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,PHASE2,nervous_system_disease
4952,Huntington Disease,Deutetrabenazine,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC,PHASE2|PHASE3,nervous_system_disease
4953,Tardive Dyskinesia,Pyridoxal,CC1=NC=C(C(=C1O)C=O)CO,PHASE2,nervous_system_disease
4954,Huntington's Disease,Tetrabenazine,CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC,APPROVED,nervous_system_disease
4955,Spinocerebellar Ataxias|Spinocerebellar Ataxia Genotype Type 1|Spinocerebellar Ataxia Genotype Type 2|Spinocerebellar Ataxia Genotype Type 3|Spinocerebellar Ataxia Genotype Type 6|Spinocerebellar Ataxia Genotype Type 7|Spinocerebellar Ataxia Genotype Type 8|Spinocerebellar Ataxia Genotype Type 10,Troriluzole,CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN,PHASE2|PHASE3,nervous_system_disease
4956,"Diabetes Mellitus, Type 1|Hypoglycemia|Hypoglycemia Unawareness",Diazoxide,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,APPROVED,nervous_system_disease
4957,Stroke,Urokinase,CC(C)OC(=O)NC1=CC2=C(C=C1)N=C(N2)C3=CSC=N3,PHASE2,nervous_system_disease
4958,Brain and Central Nervous System Tumors,Mechlorethamine,CN(CCCl)CCCl,PHASE2,nervous_system_disease
4959,Tourette Syndrome,Palmidrol,CCCCCCCCCCCCCCCC(=O)NCCO,PHASE2,nervous_system_disease
4960,CADASIL,Dabigatran,CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N,PHASE2,nervous_system_disease
4961,Delirium|Cognition Disorders,Ziprasidone,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,PHASE2,nervous_system_disease
4962,Tuberous Sclerosis Complex,Vigabatrin,C=CC(CCC(=O)O)N,PHASE2|PHASE3,nervous_system_disease
4963,Methamphetamine Use Disorder,Metamfetamine,CC(CC1=CC=CC=C1)NC,PHASE1,nervous_system_disease
4964,Methamphetamine Use Disorder,Methamphetamine,CC(CC1=CC=CC=C1)NC,PHASE1,nervous_system_disease
4965,Down Syndrome|Depression,Fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,APPROVED,nervous_system_disease
4966,Musculoskeletal Pain,Ketoprofen,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,PHASE1,nervous_system_disease
4967,Spinal Cord Injury|Bone Loss|Osteoporosis,Teriparatide,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N,PHASE2,nervous_system_disease
4968,Pelvic Pain,Drospirenone,CC12CCC(=O)C=C1C3CC3C4C2CCC5(C4C6CC6C57CCC(=O)O7)C,APPROVED,nervous_system_disease
4969,Amyotrophic Lateral Sclerosis,Biotin,C1C2C(C(S1)CCCCC(=O)O)NC(=O)N2,PHASE2,nervous_system_disease
4970,Normal Tension Glaucoma,Netarsudil,CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)C(CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C,APPROVED,nervous_system_disease
4971,Normal Tension Glaucoma,Bimatoprost,CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O,APPROVED,nervous_system_disease
4972,Postural Tachycardia Syndrome,Ivabradine,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)CC3CC4=CC(=C(C=C34)OC)OC,PHASE2,nervous_system_disease
4974,Refractory Primary Central Nervous System Lymphoma|Primary CNS Lymphoma,Tirabrutinib,CC#CC(=O)N1CCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE2,nervous_system_disease
4975,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",Orphenadrine,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,APPROVED,nervous_system_disease
4976,"Colon Cancer|Colon Diverticulosis|Colonic Neoplasms|Colonic Diverticulitis|Pain, Postoperative|Ileus|Ileus Paralytic|Ileus; Mechanical|Constipation Drug Induced|Constipation|Rectum Cancer|Rectum Neoplasm",Hydrocodone,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,APPROVED,nervous_system_disease
4978,Deep Endometriosis|Pelvic Pain,Gestrinone,CCC12C=CC3=C4CCC(=O)C=C4CCC3C1CCC2(C#C)O,PHASE2,nervous_system_disease
4979,Neuropathic Pain,Tariquidar,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,PHASE1|PHASE2,nervous_system_disease
4980,Epilepsy,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,PHASE2,nervous_system_disease
4981,Dementia|Mild Cognitive Impairment,Nicorandil,C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-],PHASE2,nervous_system_disease
4982,Advanced Malignant Neoplasm|Delirium|Locally Advanced Malignant Neoplasm|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm,Chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,PHASE2|PHASE3,nervous_system_disease
4983,Attention Deficit Hyperactivity Disorder,Metadoxine,CC1=NC=C(C(=C1O)CO)CO.C1CC(=O)NC1C(=O)O,PHASE1,nervous_system_disease
4985,Impulse Control Disorders|Parkinson Disease,Nalmefene,C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O,PHASE2,nervous_system_disease
4986,Alzheimer's Disease,Isotretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1|PHASE2,nervous_system_disease
4987,Coronary Artery Disease|Cerebrovascular Disease|Peripheral Vascular Disease,Rifalazil,CC1C=CC=C(C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C(C(O5)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)C,PHASE2,nervous_system_disease
4988,Brain Tumor,Phenylephrine,CNCC(C1=CC(=CC=C1)O)O,APPROVED,nervous_system_disease
4990,Dementia With Lewy Bodies,Ambroxol,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,PHASE2,nervous_system_disease
4991,Pediatric ALL|Pediatric Anesthesia,Nalbuphine,C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O,APPROVED,nervous_system_disease
4992,"Angina, Unstable|Myocardial Infarction",Dalteparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,nervous_system_disease
4994,Aneurysmal Subarachnoid Hemorrhage,Clazosentan,CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC,PHASE2,nervous_system_disease
4995,Alzheimer's Disease|Hypertension,Ramipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O,APPROVED,nervous_system_disease
4996,Variant Angina,Sarpogrelate,CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O,APPROVED,nervous_system_disease
4997,Dementia With Lewy Bodies|REM Sleep Behavior Disorder|Parkinson's Disease Dementia,Nelotanserin,CN1C(=C(C=N1)Br)C2=C(C=CC(=C2)NC(=O)NC3=C(C=C(C=C3)F)F)OC,PHASE2,nervous_system_disease
4998,Constipation,Docusate,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,APPROVED,nervous_system_disease
4999,Constipation,Bisacodyl,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,APPROVED,nervous_system_disease
5000,Constipation,Methylnaltrexone,C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,APPROVED,nervous_system_disease
5001,"Pulmonary Disease, Chronic Obstructive",Salmeterol,C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O,APPROVED,nervous_system_disease
5003,Migraine,Tezampanel,C1CC2CNC(CC2CC1CCC3=NNN=N3)C(=O)O,PHASE2,nervous_system_disease
5004,Central Nervous System Infections,Meropenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O,APPROVED,nervous_system_disease
5005,Alzheimer´s Disease,Lornoxicam,CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3,PHASE2,nervous_system_disease
5006,Tinnitus,Neramexane,CC1(CC(CC(C1)(C)N)(C)C)C,PHASE2,nervous_system_disease
5007,Intracranial Hemorrhages,Colchicine,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,PHASE2,nervous_system_disease
5008,Congenital Cytomegalovirus (CMV),Valganciclovir,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,PHASE2|PHASE3,nervous_system_disease
5011,Hypertension,Trimethaphan,C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5,PHASE1,nervous_system_disease
5012,Multiple Sclerosis,Pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,PHASE1,nervous_system_disease
5014,Sleep Initiation and Maintenance Disorders|Primary Insomnia,Estazolam,C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4,APPROVED,nervous_system_disease
5017,"Carcinoma, Non-Small-Cell Lung|Surgery--Complications|Dexamethasone|Flubiprofen Axetil|Delirium",Flurbiprofen,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,APPROVED,nervous_system_disease
5018,Central Nervous System Lymphoma,Selinexor,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,PHASE1|PHASE2,nervous_system_disease
5019,Fibromyalgia,Desvenlafaxine,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,PHASE2,nervous_system_disease
5020,"Alzheimer Disease, Early Onset",Efavirenz,C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,PHASE1,nervous_system_disease
5021,"Coronary Microvascular Dysfunction|Microvascular Angina|Vasospasm, Coronary|Vasospastic Angina|Prinzmetal Angina|Coronary Artery Disease",Bisoprolol,CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O,APPROVED,nervous_system_disease
5022,Endometriosis|Pelvic Pain,Nafarelin,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8,PHASE1|PHASE2,nervous_system_disease
5023,Amyotrophic Lateral Sclerosis,Arimoclomol,C1CCN(CC1)CC(CON=C(C2=C[N+](=CC=C2)[O-])Cl)O,PHASE2|PHASE3,nervous_system_disease
5024,Desmoplastic Small Round Cell Tumor|Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Desmoplastic Small Round Cell Tumor|Recurrent Malignant Peripheral Nerve Sheath Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Recurrent Rhabdomyosarcoma|Refractory Desmoplastic Small Round Cell Tumor|Refractory Malignant Peripheral Nerve Sheath Tumor|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Rhabdomyosarcoma,Cyclosporine,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,nervous_system_disease
5025,Transthyretin Amyloidosis,Tafamidis,C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl,APPROVED,nervous_system_disease
5026,Traumatic Brain Injury (TBI),Brexanolone,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C,PHASE2,nervous_system_disease
5027,Traumatic Brain Injury (TBI),Allopregnanolone,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C,PHASE2,nervous_system_disease
5028,Traumatic Brain Injury (TBI),Pregnanolone,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C,PHASE2,nervous_system_disease
5029,Huntington Disease,Rolipram,COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3,PHASE1,nervous_system_disease
5031,Brain Metastases,Rivoceranib,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,PHASE2,nervous_system_disease
5032,Amyotrophic Lateral Sclerosis,Rabeprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,PHASE1,nervous_system_disease
5033,Relapsing-remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Primary-progressive Multiple Sclerosis,Norethindrone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE2,nervous_system_disease
5034,Relapsing-remitting Multiple Sclerosis|Secondary-progressive Multiple Sclerosis|Primary-progressive Multiple Sclerosis,Norethisterone,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE2,nervous_system_disease
5036,Prosthetic Cardiac Valve Thrombosis|Cerebrovascular Accident|Prosthetic Valve Malfunction,Acenocoumarol,CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O,APPROVED,nervous_system_disease
5037,Adult Alveolar Soft Part Sarcoma|Adult Angiosarcoma|Adult Desmoplastic Small Round Cell Tumor|Adult Epithelioid Hemangioendothelioma|Adult Epithelioid Sarcoma|Adult Extraskeletal Myxoid Chondrosarcoma|Adult Extraskeletal Osteosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Liposarcoma|Adult Malignant Peripheral Nerve Sheath Tumor|Adult Rhabdomyosarcoma|Adult Synovial Sarcoma|Adult Undifferentiated Pleomorphic Sarcoma|Malignant Adult Hemangiopericytoma|Recurrent Adult Soft Tissue Sarcoma|Sarcoma|Stage III Adult Soft Tissue Sarcoma AJCC v7|Stage IV Adult Soft Tissue Sarcoma AJCC v7,Pazopanib,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,PHASE2,nervous_system_disease
5038,Coronary Artery Disease|Myocardial Infarction|Heart Disease|Vascular Disease|Angina Pectoris|Cardiovascular Disease|Ischemia|Infarction|Embolism|Thrombosis|Chest Pain,Ticagrelor,CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F,APPROVED,nervous_system_disease
5039,Neurocysticercosis|Epilepsy,Praziquantel,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,PHASE2|PHASE3,nervous_system_disease
5040,Neurocysticercosis|Epilepsy,Albendazole,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,PHASE2|PHASE3,nervous_system_disease
5041,Staphylococcal Infections|Osteomyelitis|CNS Infection|Septic Arthritis|Diabetic Foot Infection|Vertebral Osteomyelitis|Abscess|Coagulase Negative Staphylococcal Infection,Cloxacillin,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,nervous_system_disease
5042,Staphylococcal Infections|Osteomyelitis|CNS Infection|Septic Arthritis|Diabetic Foot Infection|Vertebral Osteomyelitis|Abscess|Coagulase Negative Staphylococcal Infection,Cefazolin,CC1=NN=C(S1)SCC2=C(N3C(C(C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O,APPROVED,nervous_system_disease
5043,Migraine,Eletriptan,CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,APPROVED,nervous_system_disease
5044,Melanoma,Meprednisone,CC1CC2C3CCC4=CC(=O)C=CC4(C3C(=O)CC2(C1(C(=O)CO)O)C)C,PHASE2,nervous_system_disease
5045,"Inherited Mitochondrial Disease, Including Leigh Syndrome",Cysteamine,C(CS)N,PHASE2,nervous_system_disease
5046,"Lymphoma, B-Cell",Idarubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,PHASE2,nervous_system_disease
5047,Attention Deficit Hyperactivity Disorder,Edivoxetine,COC1=C(C=C(C=C1)F)CC(C2CCOCC2)(C3CNCCO3)O,PHASE2|PHASE3,nervous_system_disease
5048,Chronic Pain|Diabetic Neuropathies|Diabetes Mellitus,Cebranopadol,CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5,PHASE2,nervous_system_disease
5049,Adrenoleukodystrophy|Metachromatic Leukodystrophy|Globoid Cell Leukodystrophy|Tay Sachs Disease|Sandhoffs Disease|Wolman Disease|I-Cell Disease|Sanfilippo Syndrome|GM1 Gangliosidosis,Clofarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N,PHASE2,nervous_system_disease
5050,Multiple Sclerosis,Famciclovir,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,PHASE2,nervous_system_disease
5051,Migraine Disorders,Rizatriptan,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3,PHASE1,nervous_system_disease
5052,Breast Cancer,Eribulin,CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O,PHASE2,nervous_system_disease
5053,Endothelial Dysfunction|Vascular Diseases|Kidney Injury|Brain Disease|Vascular Inflammation,Vericiguat,COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N,APPROVED,nervous_system_disease
5055,Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor,Dacarbazine,CN(C)N=NC1=C(NC=N1)C(=O)N,PHASE2,nervous_system_disease
5056,Malignant Supratentorial Neoplasm|Recurrent Glioblastoma|Recurrent Gliosarcoma,Lonafarnib,C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N,PHASE1,nervous_system_disease
5057,Pompe Disease|Hypersensitivity Reaction,Miglustat,CCCCN1CC(C(C(C1CO)O)O)O,PHASE1,nervous_system_disease
5058,Amyotrophic Lateral Sclerosis,Tretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1|PHASE2,nervous_system_disease
5059,HTLV-I-Associated Myelopathy,Tamibarotene,CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C,PHASE2|PHASE3,nervous_system_disease
5060,"Epilepsy, Partial Seizures",Oxcarbazepine,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,APPROVED,nervous_system_disease
5061,Central Nervous System Lymphoma,Acalabrutinib,CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5,PHASE2,nervous_system_disease
5062,Non-small Cell Lung Cancer,Capmatinib,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,PHASE2,nervous_system_disease
5063,ADHD|Autism|Bipolar I Disorder|Conduct Disorder|Oppositional Defiant Disorder,Brexpiprazole,C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,PHASE1,nervous_system_disease
5064,Leukemia|Lymphoma|Meningeal Neoplasm,Mafosfamide,C1COP(=O)(NC1SCCS(=O)(=O)O)N(CCCl)CCCl,PHASE1,nervous_system_disease
5065,Medication Overuse Headache|Analgesic Overuse Headache,Frovatriptan,CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N,PHASE2,nervous_system_disease
5066,Hepatic Failure|Hepatic Impairment|Chronic Hepatitis C Infection With Hepatic Coma,Promethazine,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,APPROVED,nervous_system_disease
5067,Meningitis,Doripenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)CNS(=O)(=O)N)C(=O)O)C(C)O,PHASE1,nervous_system_disease
5068,Epilepsy,Eslicarbazepine,C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O,PHASE1,nervous_system_disease
5069,"Spasms, Infantile|Epilepsy",Pyridoxine,CC1=NC=C(C(=C1O)CO)CO,PHASE2,nervous_system_disease
5070,Glaucoma; Drugs|Normal Tension Glaucoma|Primary Open-angle Glaucoma,Timolol,CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O,APPROVED,nervous_system_disease
5071,Glaucoma; Drugs|Normal Tension Glaucoma|Primary Open-angle Glaucoma,Brimonidine,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,APPROVED,nervous_system_disease
5072,Mild Cognitive Impairment|Alzheimer Disease,Senicapoc,C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N,PHASE2,nervous_system_disease
5073,Painful Diabetic Neuropathy,Astaxanthin,CC1=C(C(CC(C1=O)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)C(CC2(C)C)O)C)C)C,PHASE2|PHASE3,nervous_system_disease
5074,Brain Neoplasm|Neoplasm Metastasis,Ganciclovir,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,PHASE1,nervous_system_disease
5075,Central Nervous System Diseases|Pediatric Disorder|Body Indication,Gadopiclenol,C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd+3],PHASE2,nervous_system_disease
5076,Mania|Bipolar I|Bipolar II|Bipolar Spectrum Disorder|Bipolar Disorder,Lurasidone,C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O,APPROVED,nervous_system_disease
5077,Trigeminal Neuralgia,Basimglurant,CC1=C(N=C(N1C2=CC=C(C=C2)F)C)C#CC3=CC(=NC=C3)Cl,PHASE2|PHASE3,nervous_system_disease
5078,Primary Central Nervous System Lymphoma,Glucarpidase,[Zn+2].[Zn+2].[Zn+2].[Zn+2],PHASE1,nervous_system_disease
5079,Infected Corneal Ulcers|Bacterial Keratitis|Corneal Ulcer|Childhood Blindness,Povidone,C=CN1CCCC1=O,PHASE2,nervous_system_disease
5080,Bipolar Disorder|Schizoaffective Disorder|Manic Disorder|Mania|Manic State,Pentazocine,CC1C2CC3=C(C1(CCN2CC=C(C)C)C)C=C(C=C3)O,PHASE2,nervous_system_disease
5081,Dementia of the Alzheimer Type|Age-related Cognitive Decline|Mild Cognitive Impairment Due to Alzheimer Disease,Probucol,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,PHASE1|PHASE2,nervous_system_disease
5084,Alzheimer's Disease,Equol,C1C(COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O,PHASE1,nervous_system_disease
5085,Gastroparesis,Itopride,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC,PHASE1|PHASE2,nervous_system_disease
5086,Parkinson's Disease,Muscimol,C1=C(ONC1=O)CN,PHASE1,nervous_system_disease
5087,"Toxoplasmosis, Cerebral|HIV Infections",Clarithromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,PHASE2,nervous_system_disease
5088,"Toxoplasmosis, Cerebral|HIV Infections",Atovaquone,C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O,PHASE2,nervous_system_disease
5089,Attention Deficit/Hyperactivity Disorder,Serdexmethylphenidate,COC(=O)C(C1CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)NC(CO)C(=O)[O-])C3=CC=CC=C3,APPROVED,nervous_system_disease
5090,Angina,Febuxostat,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,PHASE2,nervous_system_disease
5091,Myofascial Pain Syndromes,Thiocolchicoside,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC4C(C(C(C(O4)CO)O)O)O,APPROVED,nervous_system_disease
5093,Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization|Pain,Esketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,APPROVED,nervous_system_disease
5094,Epilepsy,Brivaracetam,CCCC1CC(=O)N(C1)C(CC)C(=O)N,PHASE1,nervous_system_disease
5095,Episodic Migraine,Quinidine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE2,nervous_system_disease
5097,Leptomeningeal Metastasis,Endostatin,CN(CC(=O)C1=CC=CC=C1)N=O,APPROVED,nervous_system_disease
5099,Migraine,Dihydroergotamine,CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C,APPROVED,nervous_system_disease
5100,Progressive Multiple Sclerosis,Loratadine,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,PHASE1,nervous_system_disease
5101,Progressive Multiple Sclerosis,Dexchlorpheniramine,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,PHASE1,nervous_system_disease
5102,Adult Solid Neoplasm|Childhood Solid Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Malignant Solid Neoplasm|Refractory Central Nervous System Neoplasm,Talazoparib,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,PHASE1|PHASE2,nervous_system_disease
5103,Malignant Melanoma|Metastases,Buparlisib,C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,PHASE2,nervous_system_disease
5104,Spinal Cord Injuries,Rimonabant,CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,PHASE2,nervous_system_disease
5105,Subarachnoid Hemorrhage|Aneurysmal Subarachnoid Hemorrhage,Isoflurane,C(C(F)(F)F)(OC(F)F)Cl,PHASE2,nervous_system_disease
5106,Bipolar Disorder,Cariprazine,CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl,PHASE2,nervous_system_disease
5107,Alzheimer's Disease,Flutemetamol,CNC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O)F,PHASE2,nervous_system_disease
5108,Parkinson Disease|Idiopathic Parkinson Disease,Fluorodopa,C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N,PHASE2,nervous_system_disease
5110,Amyotrophic Lateral Sclerosis (ALS),Masitinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,PHASE2|PHASE3,nervous_system_disease
5111,Phenylketonuria,Tetrahydrobiopterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,nervous_system_disease
5112,ALK Fusion-positive Solid or CNS Tumors,Alectinib,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,PHASE1|PHASE2,nervous_system_disease
5113,Restless Legs Syndrome,Aplindore,C1C(OC2=C(O1)C=CC3=C2CC(=O)N3)CNCC4=CC=CC=C4,PHASE2,nervous_system_disease
5115,Cancer,Dabrafenib,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,PHASE1|PHASE2,nervous_system_disease
5116,Diffuse Large B Cell Lymphoma|Relapse/Recurrence|Extranodal Extension|Central Nervous System Lymphoma,Decitabine,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,PHASE2,nervous_system_disease
5117,"Ischemic Stroke, Acute",Riociguat,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,PHASE2,nervous_system_disease
5118,"Ischemic Stroke, Acute",Propylthiouracil,CCCC1=CC(=O)NC(=S)N1,PHASE2,nervous_system_disease
5119,"Ischemic Stroke, Acute",Perphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,PHASE2,nervous_system_disease
5120,Tourette Syndrome|Tourette Syndrome in Adolescence,Sepranolone,CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C,PHASE2,nervous_system_disease
5121,Hereditary Angioedema (HAE),Icatibant,C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O,PHASE1,nervous_system_disease
5122,Alzheimer's Disease|Huntington's Disease,Ketoconazole,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,PHASE1,nervous_system_disease
5123,Alzheimer's Disease|Huntington's Disease,Omeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE1,nervous_system_disease
5124,Diffuse Intrinsic Pontine Glioma|High-grade Glioma,Crizotinib,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,PHASE1,nervous_system_disease
5125,Prader-Willi Syndrome,Setmelanotide,CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5,PHASE2,nervous_system_disease
5127,Postherpetic Neuralgia,Zucapsaicin,CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC,PHASE2,nervous_system_disease
5129,"Chronic Pain|Drug Dependence of Morphine Type|Symptom, Withdrawal",Probenecid,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,PHASE2,nervous_system_disease
5131,"Sleep Apnea, Obstructive",Desipramine,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,nervous_system_disease
5133,Cushing Disease,Fimepinostat,CN(CC1=CC2=C(S1)C(=NC(=N2)C3=CN=C(C=C3)OC)N4CCOCC4)C5=NC=C(C=N5)C(=O)NO,PHASE2,nervous_system_disease
5134,Advanced Non-Small Cell Lung Cancer With MET Mutations,Tepotinib,CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N,PHASE1|PHASE2,nervous_system_disease
5135,Alzheimer's Disease|Cognitive Dysfunction,Formoterol,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O,PHASE2,nervous_system_disease
5136,Amyotrophic Lateral Sclerosis,Enoxacin,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,PHASE1|PHASE2,nervous_system_disease
5137,Liposarcoma|Malignant Peripheral Nerve Sheath Tumors|Alveolar Soft Part Sarcoma|Ewing Sarcoma|Sarcoma,Ixazomib,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,PHASE1,nervous_system_disease
5139,Neurofibromatosis Type 1|Learning Disability|Reading Disability|NF1,Lovastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE2,nervous_system_disease
5140,Reflux Esophagitis,Vonoprazan,CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3,APPROVED,nervous_system_disease
5142,Ischemic Stroke,Mepivacaine,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,PHASE2,nervous_system_disease
5143,Low Back Pain|Neuropathic Pain,Tapentadol,CCC(C1=CC(=CC=C1)O)C(C)CN(C)C,APPROVED,nervous_system_disease
5144,Brain Tumor|Cancer,Zotiraciclib,CN1CC=CCCOC2=CC=CC(=C2)C3=NC(=NC=C3)NC4=CC=CC(=C4)C1,PHASE1|PHASE2,nervous_system_disease
5145,Agitation on Recovery From Sedation,Hydroxyzine,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,APPROVED,nervous_system_disease
5146,Acute Coronary Syndrome (ACS)|High On-treatment Platelet Reactivity (HTPR)|Microvascular Obstruction (MVO)|ST-segment Elevation Myocardial Infarction (STEMI)|Thrombolysis in Myocardial Infarction (TIMI)|Unstable Angina (UA),Cangrelor,CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O,APPROVED,nervous_system_disease
5147,Primary Insomnia,Adipiplon,CCCC1=C(N=CN2C1=NC(=N2)C)CN3C=CN=C3C4=C(C=CC=N4)F,PHASE2,nervous_system_disease
5148,Hypoactive Sexual Desire Disorder,Bremelanotide,CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C,APPROVED,nervous_system_disease
5149,Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Primary Central Nervous System Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm,Pevonedistat,C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N,PHASE1,nervous_system_disease
5150,Neurologic Claudication in Patients With Lumbar Spinal Stenosis,Limaprost,CCCCC(C)CC(C=CC1C(CC(=O)C1CCCCC=CC(=O)O)O)O,APPROVED,nervous_system_disease
5152,Percutaneous Coronary Intervention,Pitavastatin,C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F,APPROVED,nervous_system_disease
5153,Attention Deficit Disorder With Hyperactivity Disease|Hyperkinesis|Attention Deficit and Disruptive Behavior Disorders,Tipepidine,CN1CCCC(=C(C2=CC=CS2)C3=CC=CS3)C1,PHASE1|PHASE2,nervous_system_disease
5154,Alzheimer's Disease|Huntington's Disease,Warfarin,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,PHASE1,nervous_system_disease
5155,"Multiple Sclerosis|Multiple Sclerosis, Relapsing-Remitting",Bazedoxifene,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,PHASE2,nervous_system_disease
5156,"Acute Coronary Syndrome|Angina, Unstable",Eptifibatide,C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N,PHASE2,nervous_system_disease
5157,Parkinson Disease,Bromocriptine,CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,APPROVED,nervous_system_disease
5158,Nicotine Withdrawal|Marijuana Dependence|Cannabis Dependence|Nicotine Dependence|Cannabis Abuse,Aprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,PHASE1,nervous_system_disease
5159,Autonomic Failure|Orthostatic Hypotension,Yohimbine,COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O,PHASE1,nervous_system_disease
5160,Autonomic Failure|Orthostatic Hypotension,Ranitidine,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,PHASE1,nervous_system_disease
5161,Autonomic Failure|Orthostatic Hypotension,Tranylcypromine,C1C(C1N)C2=CC=CC=C2,PHASE1,nervous_system_disease
5162,Autonomic Failure|Orthostatic Hypotension,Oxymetazoline,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,PHASE1,nervous_system_disease
5163,Neurogenic Bladder|Spinal Cord Injuries,Gentamicin,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,PHASE2,nervous_system_disease
5165,End-stage Renal Disease (ESRD)|Kidney Disease,Icodextrin,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,APPROVED,nervous_system_disease
5166,Spasticity,Tizanidine,C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl,PHASE2,nervous_system_disease
5167,Fatigue|Musculoskeletal Pain|Cognitive Decline,Pregnenolone,CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,PHASE2,nervous_system_disease
5169,"Headache, Migraine",Norgestimate,CCC12CCC3C(C1CCC2(C#C)OC(=O)C)CCC4=CC(=NO)CCC34,PHASE1,nervous_system_disease
5170,Psychosis|Intellectual Disability,Clozapine,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,PHASE2,nervous_system_disease
5171,Relapsing Multiple Sclerosis,Laquinimod,CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O,PHASE2,nervous_system_disease
5172,Depression,Mianserin,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,APPROVED,nervous_system_disease
5173,Epilepsy,Gliclazide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,PHASE1,nervous_system_disease
5174,Morton's Neuroma,Resiniferatoxin,CC1CC2(C3C4C1(C5C=C(C(=O)C5(CC(=C4)COC(=O)CC6=CC(=C(C=C6)O)OC)O)C)OC(O3)(O2)CC7=CC=CC=C7)C(=C)C,PHASE1,nervous_system_disease
5175,Migraine,Flunarizine,C1CN(CCN1CC=CC2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,APPROVED,nervous_system_disease
5178,Chest Pain|Gastrointestinal Reflux Disease,Dexlansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,APPROVED,nervous_system_disease
5179,Epilepsy,Vinpocetine,CCC12CCCN3C1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC,PHASE1|PHASE2,nervous_system_disease
5180,"Pain, Postoperative|Irreversible Pulpitis",Nitrofurantoin,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-],APPROVED,nervous_system_disease
5181,Aicardi-Goutières Syndrome (AGS),Lamivudine,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,PHASE2,nervous_system_disease
5182,Aicardi-Goutières Syndrome (AGS),Abacavir,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,PHASE2,nervous_system_disease
5183,"Neurofibroma, Plexiform|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Promyelocytic, Acute|Sarcoma",Pexidartinib,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F,PHASE1,nervous_system_disease
5184,Adult Alveolar Soft Part Sarcoma|Adult Angiosarcoma|Adult Desmoplastic Small Round Cell Tumor|Adult Epithelioid Hemangioendothelioma|Adult Epithelioid Sarcoma|Adult Extraskeletal Myxoid Chondrosarcoma|Adult Extraskeletal Osteosarcoma|Adult Fibrosarcoma|Adult Leiomyosarcoma|Adult Liposarcoma|Adult Malignant Mesenchymoma|Adult Malignant Peripheral Nerve Sheath Tumor|Adult Rhabdomyosarcoma|Adult Synovial Sarcoma|Adult Unclassified Pleomorphic Sarcoma|Chondrosarcoma|Clear Cell Sarcoma of the Kidney|Conjunctival Kaposi Sarcoma|Dermatofibrosarcoma Protuberans|Gastrointestinal Stromal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Osteosarcoma|Ovarian Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Kaposi Sarcoma|Recurrent Osteosarcoma|Recurrent Uterine Corpus Sarcoma|Small Intestine Leiomyosarcoma|Stage III Adult Soft Tissue Sarcoma|Stage III Uterine Sarcoma|Stage IV Adult Soft Tissue Sarcoma|Stage IV Uterine Sarcoma|Unclassified Pleomorphic Sarcoma of Bone,Vismodegib,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,PHASE1|PHASE2,nervous_system_disease
5185,Cesarean Section|Pain Management|Neuropathic Pain,Metamizole,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O,APPROVED,nervous_system_disease
5186,"Migraine, With or Without Aura",Atogepant,CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F,PHASE2|PHASE3,nervous_system_disease
5188,"Nontraumatic Intracerebral Hemorrhage, Multiple Localized",Clevidipine,CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,APPROVED,nervous_system_disease
5189,"Nontraumatic Intracerebral Hemorrhage, Multiple Localized",Urapidil,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC,APPROVED,nervous_system_disease
5190,Fabry Disease,Migalastat,C1C(C(C(C(N1)CO)O)O)O,PHASE2,nervous_system_disease
5191,"Muscular Atrophy, Spinal",Amifampridine,C1=CN=CC(=C1N)N,PHASE2,nervous_system_disease
5193,Acute Myeloid Leukemia Post Cytotoxic Therapy|Down Syndrome|Myelodysplastic Syndrome Post Cytotoxic Therapy|Recurrent Acute Myeloid Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myelodysplastic Syndrome,Uproleselan,CCC1CC(CC(C1OC2C(C(C(C(O2)C)O)O)O)OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC,PHASE1,nervous_system_disease
5194,Solid Tumors|Brain Tumors|Brain Metastases,Satraplatin,CC(=O)O.CC(=O)O.C1CCC(CC1)N.N.Cl[Pt]Cl,PHASE1,nervous_system_disease
5196,Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome,Silodosin,CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F,PHASE2,nervous_system_disease
5197,"Colorectal Carcinoma|Neoplasms, Colorectal|Colorectal Cancer|Colorectal Tumors|Metastasis",Glutamine,C(CC(=O)N)C(C(=O)O)N,PHASE2,nervous_system_disease
5198,"Mycoses|Fungemia|Central Nervous System Fungal Infections|Lung Diseases, Fungal",Anidulafungin,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O,APPROVED,nervous_system_disease
5199,"Aneurysm, Cerebral|Endovascular Procedures",Prasugrel,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,APPROVED,nervous_system_disease
5200,Moderate to Severe Cyclic Mastalgia,Danazol,CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5,PHASE2,nervous_system_disease
5201,Attention Deficit Hyperactivity Disorder,Centanafadine,C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3,PHASE2,nervous_system_disease
5202,NSCLC|Non-small Cell Lung Cancer,Osimertinib,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE1,nervous_system_disease
5203,HIV Infections|Peripheral Nervous System Disease,Benzatropine,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2,nervous_system_disease
5204,HIV Infections|Peripheral Nervous System Disease,Benztropine,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,PHASE2,nervous_system_disease
5205,Inflamed Meninges|Suspected Meningitis|Ventriculitis,Ceftobiprole,C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O,PHASE2,nervous_system_disease
5206,Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Parkinson's Disease|Multiple System Atrophy,Fipamezole,CCC1(CC2=C(C1)C=C(C=C2)F)C3=CN=CN3,PHASE2,nervous_system_disease
5207,Relapsing Multiple Sclerosis,Ozanimod,CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N,PHASE2|PHASE3,nervous_system_disease
5208,Analgesic Rebound Headache,Almotriptan,CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3,APPROVED,nervous_system_disease
5209,Stroke|Cerebral Infarction|Brain Infarction|Brain Ischemia|Nervous System Diseases|Central Nervous System Diseases|Vascular Diseases,Butylphthalide,CCCCC1C2=CC=CC=C2C(=O)O1,APPROVED,nervous_system_disease
5210,Early Manifest Huntington Disease,Branaplam,CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C,PHASE2,nervous_system_disease
5211,Duchenne Muscular Dystrophy (DMD),Bocidelpar,CC1=CN=C(N1CC2=CC=CC=C2OCCCC(C)CC(=O)O)C3=CC=C(C=C3)C(F)(F)F,PHASE1,nervous_system_disease
5212,Brain and Central Nervous System Tumors,Laromustine,CNC(=O)N(N(CCCl)S(=O)(=O)C)S(=O)(=O)C,PHASE1,nervous_system_disease
5213,Alzheimer Disease,Talsaclidine,C#CCOC1CN2CCC1CC2,PHASE2|PHASE3,nervous_system_disease
5214,Brain Tumors With Ill-defined Margins,Indigo,C1=CC=C2C(=C1)C(=C(N2)C3=NC4=CC=CC=C4C3=O)O,PHASE1|PHASE2,nervous_system_disease
5215,Stroke|Acute Ischemic Stroke,Repinotan,C1CC2=CC=CC=C2OC1CNCCCCN3C(=O)C4=CC=CC=C4S3(=O)=O,PHASE2,nervous_system_disease
5216,"Subarachnoid Hemorrhage|Intracerebral Hemorrhage|Ventriculitis, Cerebral|Hydrocephalus",Nafcillin,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,PHASE1,nervous_system_disease
5217,Gastroparesis|Diabetes,Tegaserod,CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC,APPROVED,nervous_system_disease
5218,Memory Impairment,Vilazodone,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N,PHASE2,nervous_system_disease
5219,Essential Hypertension With Stable Angina and Dyslipidemia,Azilsartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)O,APPROVED,nervous_system_disease
5220,Pheochromocytoma/Paraganglioma|Pancreatic Neuroendocrine Tumor|Von Hippel-Lindau Disease|Advanced Gastrointestinal Stromal Tumor|HIF-2α Mutated Cancers,Belzutifan,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,PHASE2,nervous_system_disease
5221,Gram Negative Meningitis|Post Traumatic Bacterial Meningitis,Amikacin,C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N,APPROVED,nervous_system_disease
5222,High Blood Pressure|Migraine Headaches|Chest Pain,Nadolol,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,PHASE1,nervous_system_disease
5223,Brain Metastases|Non-small Cell Lung Cancer,Lucanthone,CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O,PHASE2,nervous_system_disease
5224,Japanese Encephalitis,Ribavirin,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,PHASE2,nervous_system_disease
5225,Wolfram Syndrome,Tirzepatide,CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N,PHASE2,nervous_system_disease
5226,Agitation,Levosulpiride,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,PHASE2|PHASE3,nervous_system_disease
5227,Crohn's Disease|Abdominal Pain,Olorinab,CC(C)(C)C(CO)NC(=O)C1=NN(C2=C1CC3C2C3)C4=NC=C[N+](=C4)[O-],PHASE2,nervous_system_disease
5228,Persistent Developmental Stuttering,Pagoclone,CC(C)CCC(=O)CC1C2=CC=CC=C2C(=O)N1C3=NC4=C(C=C3)C=CC(=N4)Cl,PHASE2,nervous_system_disease
5230,Non-small Cell Lung Cancer,Lazertinib,CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC,PHASE2,nervous_system_disease
5231,Alzheimer Disease,Acitretin,CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC,PHASE2,nervous_system_disease
5232,"Breast Cancer|Lung Cancer|Neurotoxicity|Ovarian Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Amifostine,C(CN)CNCCSP(=O)(O)O,PHASE2,nervous_system_disease
5233,Parkinson Disease,Isradipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,PHASE2,nervous_system_disease
5234,Central Nervous System Nongerminomatous Germ Cell Tumor|Choriocarcinoma|Embryonal Carcinoma|Immature Teratoma|Malignant Teratoma|Mixed Germ Cell Tumor|Pineal Region Germ Cell Tumor|Pineal Region Immature Teratoma|Pineal Region Yolk Sac Tumor|Suprasellar Germ Cell Tumor,Ifosfamide,C1CN(P(=O)(OC1)NCCCl)CCCl,PHASE2,nervous_system_disease
5235,Central Nervous System Nongerminomatous Germ Cell Tumor|Choriocarcinoma|Embryonal Carcinoma|Immature Teratoma|Malignant Teratoma|Mixed Germ Cell Tumor|Pineal Region Germ Cell Tumor|Pineal Region Immature Teratoma|Pineal Region Yolk Sac Tumor|Suprasellar Germ Cell Tumor,Pegfilgrastim,CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C,PHASE2,nervous_system_disease
5236,Adenomyosis|Heavy Uterine Bleeding|Dysmenorrhea,Ulipristal,CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,APPROVED,nervous_system_disease
5237,Overactive Bladder|Obstructive Sleep Apnea|Overactive Bladder Syndrome,Tolterodine,CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2,APPROVED,nervous_system_disease
5238,Essential Hypertension,Eprosartan,CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O,APPROVED,nervous_system_disease
5239,Confirmed Genetic Diagnosis of Prader-Willi Syndrome,Tesofensine,CCOCC1C2CCC(N2C)CC1C3=CC(=C(C=C3)Cl)Cl,PHASE2,nervous_system_disease
5240,Gastroparesis,Tradipitant,C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl,PHASE2,nervous_system_disease
5241,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Trimetazidine,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,PHASE2,nervous_system_disease
5242,Spinal Muscular Atrophy,Reldesemtiv,C1C(CC1(CNC2=NC=C(C=N2)N3C=CC(=C3)C(=O)N)C4=C(C=CC=N4)F)F,PHASE2,nervous_system_disease
5243,Early Alzheimer's Disease,Obicetrapib,CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O,PHASE2,nervous_system_disease
5244,Relapsing Remitting Multiple Sclerosis,Flupirtine,CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N,PHASE2,nervous_system_disease
5245,Malignant Gliomas|CNS|Brain Cancer|Cancer,Perifosine,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C,PHASE2,nervous_system_disease
5246,Coronary Disease|Angina Pectoris,Bivalirudin,CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C4CCCN4C(=O)C(CCCNC(=N)N)NC(=O)C5CCCN5C(=O)C(CC6=CC=CC=C6)N,APPROVED,nervous_system_disease
5247,Multiple Sclerosis,Mangafodipir,[H+].[H+].[H+].[H+].CC1=NC=C(C(=C1O)CN(CCN(CC2=C(C(=NC=C2COP(=O)([O-])[O-])C)O)CC(=O)[O-])CC(=O)[O-])COP(=O)([O-])[O-].[Mn+2],PHASE1,nervous_system_disease
5248,Cerebral Infarction,Vorapaxar,CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C,PHASE2,nervous_system_disease
5249,Childhood Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Primary Central Nervous System Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm,Prexasertib,COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N,PHASE1,nervous_system_disease
5250,Duchenne Muscular Dystrophy,Givinostat,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,PHASE2|PHASE3,nervous_system_disease
5251,Leptomeningeal Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Sapanisertib,CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,PHASE1,nervous_system_disease
5252,Leptomeningeal Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Telaglenastat,C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F,PHASE1,nervous_system_disease
5253,Intervertebral Disc Degeneration|Modic I Discopathy|Back Pain|Low Back Pain|Magnetic Resonance Imaging (MRI),Pamidronate,C(CN)C(O)(P(=O)(O)O)P(=O)(O)O,PHASE2,nervous_system_disease
5254,Alzheimer Disease,Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,PHASE2|PHASE3,nervous_system_disease
5257,Atrial Fibrillation|Coronary Artery Disease|Stable Angina|Stable Chronic Angina,Edoxaban,CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C,APPROVED,nervous_system_disease
5258,Brain Diseases|Spinal Cord Diseases,Gadobutrol,C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Gd+3],PHASE2,nervous_system_disease
5259,Friedreich Ataxia,Calcitriol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,nervous_system_disease
5260,Abnormal Uterine Bleeding|Dysmenorrhea,Etonogestrel,CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34,PHASE2,nervous_system_disease
5261,Encephalopathy|HIV Infections|Radiculitis,Foscarnet,C(=O)(O)P(=O)(O)O,PHASE1,nervous_system_disease
5262,Arterial Ischemic Stroke,Afamelanotide,CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C,PHASE2,nervous_system_disease
5264,Acromegaly,Paltusotine,C1CN(CCC1N)C2=C3C=C(C=CC3=NC=C2C4=CC(=CC(=C4)F)F)C5=CC=CC(=C5O)C#N,PHASE2,nervous_system_disease
5265,Cerebral Infarction,Ozagrel,C1=CC(=CC=C1CN2C=CN=C2)C=CC(=O)O,APPROVED,nervous_system_disease
5266,Multiple Sclerosis,Liothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,PHASE1,nervous_system_disease
5267,Hypotonia Cystinuria Syndrome|Isolated PREPL Deficiency,Sulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,PHASE2,nervous_system_disease
5268,Insomnia,Zaleplon,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C,PHASE2,nervous_system_disease
5271,Epilepsy Intractable,Clioquinol,C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1,PHASE2,nervous_system_disease
5272,"Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor",Entrectinib,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,PHASE2,nervous_system_disease
5273,"Epilepsy, Partial",Seletracetam,CCC(C(=O)N)N1CC(CC1=O)C=C(F)F,PHASE2,nervous_system_disease
5274,Opioid-induced Constipation,Naldemedine,CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O,PHASE2,nervous_system_disease
5276,Plexiform Neurofibroma|Neurofibromatosis Type 1 (NF1),Mirdametinib,C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O,PHASE2,nervous_system_disease
5277,Hepatitis C|Chronic Pain,Alisporivir,CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C,PHASE2,nervous_system_disease
5278,Neuromyelitis Optica Spectrum Disorder Relapse,Ruxolitinib,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE1|PHASE2,nervous_system_disease
5279,Parkinson Disease,Lixisenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N,PHASE2,nervous_system_disease
5280,Breast Cancer Metastatic|Leptomeningeal Metastasis,Tucatinib,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,PHASE2,nervous_system_disease
5282,Hypothyroidism|Trisomy 21,Levothyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,APPROVED,nervous_system_disease
5283,Osteomyelitis|Septic Arthritis|Pyomyositis,Cefadroxil,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O,PHASE1,nervous_system_disease
5284,Osteomyelitis|Septic Arthritis|Pyomyositis,Cephalexin,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O,PHASE1,nervous_system_disease
5285,"Acute Pain|Burns|Adverse Drug Event|Respiratory Depression|Nausea and Vomiting, Postoperative",Oliceridine,COC1=C(SC=C1)CNCCC2(CCOC3(C2)CCCC3)C4=CC=CC=N4,APPROVED,nervous_system_disease
5286,Fabry Disease,Iohexol,CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,PHASE1,nervous_system_disease
5287,Multiple Sclerosis,Ponesimod,CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C,PHASE2,nervous_system_disease
5289,Alzheimer's Disease,Velusetrag,CC(C)N1C2=CC=CC=C2C=C(C1=O)C(=O)NC3CC4CCC(C3)N4CC(CN(C)S(=O)(=O)C)O,PHASE1,nervous_system_disease
5290,Sarcopenia|Osteopenia,Anamorelin,CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N,PHASE1,nervous_system_disease
5291,Glioblastoma|Adult-type Diffuse Gliomas,Pemigatinib,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,PHASE2,nervous_system_disease
5292,"Cerebral Stroke|Cerebrovascular Accident, Acute|Cerebrovascular Stroke|Stroke, Acute|Stroke",Dapsone,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,PHASE2|PHASE3,nervous_system_disease
5293,Alzheimer's Disease,Posiphen,CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C,PHASE1|PHASE2,nervous_system_disease
5294,"Gaucher Disease, Type 1|Cerebroside Lipidosis Syndrome|Glucocerebrosidase Deficiency Disease|Glucosylceramide Beta-Glucosidase Deficiency Disease|Gaucher Disease, Non-Neuronopathic Form",Eliglustat,CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O,PHASE2,nervous_system_disease
5295,"Stroke, Acute|Vessels; Occlusion|Blood Pressure|Endovascular Thrombectomy|Mechanical Thrombectomy",Enalapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O,PHASE2,nervous_system_disease
5296,Recurrent High Grade Meningioma,Trabectedin,CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O,PHASE2,nervous_system_disease
5297,Acute Ischemic Stroke,Balovaptan,CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCC(CC4)OC5=CC=CC=N5)C1,PHASE2,nervous_system_disease
5298,Phrenic Nerve Paralysis|Diaphragm Sellae Meningioma|Complications|Respiratory Complication|Nerve Block|Brachial Plexus Block,Prilocaine,CCCNC(C)C(=O)NC1=CC=CC=C1C,APPROVED,nervous_system_disease
5299,Brain Tumors,Esmolol,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,PHASE1,nervous_system_disease
5300,Brain and Central Nervous System Tumors,Mibefradil,CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F,PHASE1,nervous_system_disease
5302,Dementia,Megestrol,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,PHASE2|PHASE3,nervous_system_disease
5303,Schizophrenia|Psychotic Disorders|Mood Disorders|Schizophrenia Spectrum|Mental Disorders|Antipsychotic Agents|Tranquilizing Agents|Central Nervous System Depressants|Physiological Effects of Drugs|Psychotropic Drugs|Neurotransmitter Agents|Molecular Mechanisms of Pharmacological Action,Paliperidone,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,PHASE1,nervous_system_disease
5304,Non-Small Cell Lung Cancer|Leptomeningeal Metastases|Brain Metastases,Tesevatinib,CN1CC2CC(CC2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC,PHASE2,nervous_system_disease
5305,Obstructive Sleep Apnea|Obesity|Hypertension,Sibutramine,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,APPROVED,nervous_system_disease
5306,Stroke,Basmisanil,CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4,PHASE2,nervous_system_disease
5307,Cerebral Infarction,Triflusal,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,APPROVED,nervous_system_disease
5308,Alzheimer's Disease,Idalopirdine,C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F,PHASE1,nervous_system_disease
5310,"Schizophrenia|Drug Induced Movement Disorder, Unspecified|Oxidative Stress",Cobalamin,CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co+2],PHASE2|PHASE3,nervous_system_disease
5311,Erosive Reflux Disease,Tegoprazan,CC1=NC2=C(N1)C=C(C=C2OC3CCOC4=C3C(=CC(=C4)F)F)C(=O)N(C)C,APPROVED,nervous_system_disease
5312,Erosive Reflux Disease,Esomeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,APPROVED,nervous_system_disease
5313,"Muscular Dystrophy, Duchenne",Edasalonexent,CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)NCCNC(=O)C1=CC=CC=C1O,PHASE1|PHASE2,nervous_system_disease
5314,Facial Bones Fracture,Ramosetron,CN1C=C(C2=CC=CC=C21)C(=O)C3CCC4=C(C3)NC=N4,APPROVED,nervous_system_disease
5316,Chronic Obstructive Pulmonary Disease,Olodaterol,CC(C)(CC1=CC=C(C=C1)OC)NCC(C2=C3C(=CC(=C2)O)NC(=O)CO3)O,APPROVED,nervous_system_disease
5317,Partial Epilepsy,Cenobamate,C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl,PHASE1,nervous_system_disease
5318,Williams Beuren Syndrome,Minoxidil,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,PHASE2,nervous_system_disease
5320,Gastroparesis,Camicinal,CC1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F,PHASE2,nervous_system_disease
5321,Microvascular Angina,Zibotentan,CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4,PHASE2,nervous_system_disease
5322,Intracranial Meningioma|Recurrent Meningioma|NF2 Gene Mutation,Capivasertib,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,PHASE2,nervous_system_disease
5324,Parkinson Disease|Healthy,Foliglurax,C1COCCN1CCCC2=CC3=C(C=C2)OC(=CC3=NO)C4=NC=C5C=CSC5=C4,PHASE1,nervous_system_disease
5325,Depression|Acute Ischemic Stroke,Agomelatine,CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC,APPROVED,nervous_system_disease
5326,Ischemic Stroke|Indobufen|Aspirin,Indobufen,CCC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,APPROVED,nervous_system_disease
5327,Infantile Spasms (IS),Radiprodil,C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4,PHASE2,nervous_system_disease
5328,Neuropathic Pain,Ergocalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2,nervous_system_disease
5329,Autism Spectrum Disorder|Language Disorders,Levoleucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2,nervous_system_disease
5331,COVID-19|Olfactory Disorder|Parosmia,Fluvoxamine,COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F,PHASE2,nervous_system_disease
5332,Dementia With Lewy Bodies,Bosutinib,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,PHASE2,nervous_system_disease
5333,Facioscapulohumeral Muscular Dystrophy 1,Losmapimod,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C,PHASE2,nervous_system_disease
5334,Metastatic Lung Neuroendocrine Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Berzosertib,CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N,PHASE1,nervous_system_disease
5335,Non-small Cell Lung Cancer|Leptomeningeal Disease|Central Nervous System Metastases,Afatinib,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,PHASE1,nervous_system_disease
5337,Vincristine Induced Neuropathy,Acetylcarnitine,CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C,PHASE2,nervous_system_disease
5338,Diabetic Gastroparesis,Mosapride,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,APPROVED,nervous_system_disease
5339,Neurofibromatosis Type 2|Vestibular Schwannomas,Axitinib,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4,PHASE2,nervous_system_disease
5340,Mild to Moderate Diabetic Sensorimotor Polyneuropathy,Ranirestat,C1C(=O)NC(=O)C12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F,PHASE2|PHASE3,nervous_system_disease
5341,Multiple Sclerosis|Fatigue,Mitoquinone,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4,PHASE1|PHASE2,nervous_system_disease
5343,Sleep Initiation and Maintenance Disorders,Eplivanserin,CN(C)CCON=C(C=CC1=CC=C(C=C1)O)C2=CC=CC=C2F,PHASE1,nervous_system_disease
5344,Anisocoria,Tropicamide,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2,APPROVED,nervous_system_disease
5345,Anisocoria,Pilocarpine,CCC1C(COC1=O)CC2=CN=CN2C,APPROVED,nervous_system_disease
5347,Parkinson Disease,Benserazide,C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O,APPROVED,nervous_system_disease
5348,Growth Hormone Disorder|Adult Growth Hormone Deficiency|Growth Hormone Deficiency in Children,Somapacitan,C(CCCCCCCC1=NNN=N1)CCCCCCCC(=O)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NC(CCCCNC(=O)CSCC(C(=O)O)N)C(=O)N)C(=O)O)C(=O)O,PHASE1,nervous_system_disease
5349,Subarachnoid Hemorrhage,Epoprostenol,CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O,PHASE2,nervous_system_disease
5350,Subarachnoid Hemorrhage,Prostacyclin,CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O,PHASE2,nervous_system_disease
5353,Hyperalgesia|Allodynia,Fenobam,CN1CC(=O)NC1=NC(=O)NC2=CC(=CC=C2)Cl,PHASE1,nervous_system_disease
5354,Renal Cancer|Von Hippel Lindau,Vandetanib,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,PHASE2,nervous_system_disease
5355,CDK Gene Mutation|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Solid Neoplasm|NTRK Family Gene Mutation|PI3K Gene Mutation|ROS1 Gene Mutation|KRAS G12C Mutation,Adagrasib,CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F,PHASE2,nervous_system_disease
5356,Fibromyalgia|Pain|Sleep|Fatigue,Cyclobenzaprine,CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31,APPROVED,nervous_system_disease
5357,Down Syndrome,Epigallocatechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O,PHASE2,nervous_system_disease
5358,Traumatic Brain Injury|Computed Tomography|Procedural Sedation,Trichloroacetaldehyde,C(=O)C(Cl)(Cl)Cl,PHASE2,nervous_system_disease
5359,"Post-COVID-19 Syndrome|Long COVID|Long Covid19|COVID-19|POTS - Postural Orthostatic Tachycardia Syndrome|Post COVID-19 Condition|Post-COVID Syndrome|Post COVID-19 Condition, Unspecified|Postinfectious Inflammation|Postinfectious Disorder",Nirmatrelvir,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C,PHASE2,nervous_system_disease
5360,Peripheral Nerve Injuries|Pain,Rufinamide,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,PHASE2,nervous_system_disease
5361,Neurocysticercosis,Oxfendazole,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3,PHASE1,nervous_system_disease
5362,Digestive System Diseases|Disorientation,Alfentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC,APPROVED,nervous_system_disease
5363,Orthostatic Intolerance,Ganirelix,CCNC(=NCCCCC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN=C(NCC)NCC)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC,PHASE2,nervous_system_disease
5364,Brain Tumor,Fluciclovine,C1C(CC1(C(=O)O)N)F,PHASE2,nervous_system_disease
5366,Attention Deficit Disorder With Hyperactivity,Betahistine,CNCCC1=CC=CC=N1,PHASE1,nervous_system_disease
5367,Secondary Hypothyroidism|Hypopituitarism|Hyperlipidemias,Thyroxine,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N,APPROVED,nervous_system_disease
5368,Secondary Hypothyroidism|Hypopituitarism|Hyperlipidemias,Triiodothyronine,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O,APPROVED,nervous_system_disease
5370,"Neuropathic Pain|Type 2 Diabetes Mellitus|Diabetic Neuropathy, Painful",Cetirizine,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,APPROVED,nervous_system_disease
5372,Vascular Dementia,Ergoloid,CCC(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.CC(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O.CC(C)C1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C,PHASE2,nervous_system_disease
5373,"Brain Neoplasms|Malignant Neoplasms, Brain|Brain Tumors",Cositecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O,PHASE2,nervous_system_disease
5374,Dyskinesia,Famotidine,C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N,PHASE2,nervous_system_disease
5375,ADHD|Attention Deficit Hyperactivity Disorder|Attention Deficit Disorder With Hyperactivity|Mental Disorders Diagnosed in Childhood|Attention Deficit and Disruptive Behavior Disorders,Cyproheptadine,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,APPROVED,nervous_system_disease
5376,"Multiple Sclerosis, Relapsing-Remitting",Clemastine,CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C,PHASE2,nervous_system_disease
5379,"Niemann-Pick Disease, Type C",Adrabetadex,CC(COCC1C2CC(C(O1)OC3C(OC(C(C3O)OCC(C)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(O2)C(C8O)O)COCC(C)O)CO)COCC(C)O)CO)CO)CO)O)O,PHASE2|PHASE3,nervous_system_disease
5380,Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Malignant Glioma|Recurrent Medulloblastoma|Recurrent Primary Central Nervous System Neoplasm|Refractory Diffuse Intrinsic Pontine Glioma|Refractory Malignant Glioma|Refractory Medulloblastoma|Refractory Primary Central Nervous System Neoplasm,Savolitinib,CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C,PHASE1,nervous_system_disease
5382,"Stroke, Lacunar|Cerebral Small Vessel Diseases",Tadalafil,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,PHASE2,nervous_system_disease
5384,"Stroke, Ischemic",Lenomorelin,CCCCCCCC(=O)OCC(C(=O)NC(CO)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)N2CCCC2C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC=N3)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(C)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)N6CCCC6C(=O)NC(CCCNC(=N)N)C(=O)O)NC(=O)CN,PHASE2,nervous_system_disease
5385,Alzheimer's Disease,Tryptophan,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N,APPROVED,nervous_system_disease
5386,Congenital Muscular Dystrophy,Omigapil,CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31,PHASE1,nervous_system_disease
5387,Parkinson Disease,Bumetanide,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,PHASE2,nervous_system_disease
5388,Jaw Fractures|Infection,Clindamycin,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,PHASE1,nervous_system_disease
5389,Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8,Docetaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,PHASE2,nervous_system_disease
5390,Synkinesis|Facial Nerve Palsy,Apraclonidine,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl,APPROVED,nervous_system_disease
5391,Spinal Cord Injuries,Mecamylamine,CC1(C2CCC(C2)C1(C)NC)C,APPROVED,nervous_system_disease
5392,Cataract Extraction,Besifloxacin,C1CCN(CC(C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F,APPROVED,nervous_system_disease
5393,Jet Lag Disorder,Tasimelteon,CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2,PHASE2,nervous_system_disease
5394,Cerebral Small Vessel Diseases,Azelnidipine,CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C,APPROVED,nervous_system_disease
5395,Aneurysmal Subarachnoid Hemorrhage|Delayed Cerebral Ischemia,Nadroparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE2,nervous_system_disease
5396,Primary Ciliary Dyskinesia,Ivacaftor,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,PHASE2,nervous_system_disease
5398,Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)|Aggressive B-cell Lymphoma With Secondary Involvement of the CNS,Venetoclax,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,PHASE1,nervous_system_disease
5399,"Pain, Acute",Methoxyflurane,COC(C(Cl)Cl)(F)F,APPROVED,nervous_system_disease
5400,Migraine,Naratriptan,CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C,PHASE1|PHASE2,nervous_system_disease
5401,Asymptomatic Amyloid-positive,Atabecestat,CC1(C=CSC(=N1)N)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F,PHASE2|PHASE3,nervous_system_disease
5402,FAP|Familial Amyloid Polyneuropathy|TTR|Transthyretin|Amyloidosis,Inotersen,CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5C(OC(C5OCCOC)N6C=NC7=C6N=C(NC7=O)N)COP(=S)(O)OC8C(OC(C8OCCOC)N9C=C(C(=O)NC9=O)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)COP(=O)(OC1C(OC(C1OCCOC)N1C=C(C(=NC1=O)N)C)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=C(C(=O)NC1=O)C)CO)S)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)O,PHASE2|PHASE3,nervous_system_disease
5403,Musculoskeletal Pain,Lumiracoxib,CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O,APPROVED,nervous_system_disease
5404,Alzheimer Disease,Medroxyprogesterone,CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,PHASE2|PHASE3,nervous_system_disease
5405,Brain Metastases,Endostar,CN(CC(=O)C1=CC=CC=C1)N=O,PHASE2,nervous_system_disease
5406,Microvascular Coronary Artery Disease,Regadenoson,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N,PHASE2,nervous_system_disease
5407,Huntington Disease,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,PHASE2,nervous_system_disease
5409,Alzheimer's Disease,Piromelatine,COC1=CC2=C(C=C1)NC=C2CCNC(=O)C3=CC(=O)C=CO3,PHASE2|PHASE3,nervous_system_disease
5410,"Chronic Migraine, Headache|Overuse Headache Medication",Cannabigerol,CCCCCC1=CC(=C(C(=C1)O)CC=C(C)CCC=C(C)C)O,APPROVED,nervous_system_disease
5411,"Muscular Dystrophy, Duchenne",Oxatomide,C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5,PHASE2,nervous_system_disease
5412,Patient-Controlled Analgesia,Dezocine,CC12CCCCCC(C1N)CC3=C2C=C(C=C3)O,APPROVED,nervous_system_disease
5413,Pain|Thermal Injury|Burns|Hyperalgesia,Voriconazole,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,PHASE2,nervous_system_disease
5416,Gastroparesis|Diabetes Mellitus,Prucalopride,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl,PHASE2|PHASE3,nervous_system_disease
5417,Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer,Daunorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,PHASE2,nervous_system_disease
5418,Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer,Epirubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,nervous_system_disease
5419,Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer,Mercaptopurine,C1=NC2=C(N1)C(=S)N=CN2,PHASE2,nervous_system_disease
5420,Relapsing Remitting Multiple Sclerosis,Raltegravir,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,PHASE2,nervous_system_disease
5421,Fragile X Syndrome,Arbaclofen,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,PHASE2,nervous_system_disease
5422,Mitochondrial Diseases|Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation|MELAS|Subacute Necrotizing Encephalomyelopathy,Sonlicromanol,CC1=C(C2=C(CCC(O2)(C)C(=O)NC3CCCNC3)C(=C1O)C)C,PHASE2,nervous_system_disease
5423,Knee Osteoarthritis|Arthroplasty Complications|Postoperative Pain,Meloxicam,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,APPROVED,nervous_system_disease
5424,Obstructive Sleep Apnea (OSA),Gefapixant,CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC,PHASE1,nervous_system_disease
5425,Narcolepsy With Cataplexy|Narcolepsy|Narcolepsy Without Cataplexy,Mazindol,C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O,PHASE2,nervous_system_disease
5427,Neuralgia,Carfentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CC=C3)C(=O)OC,PHASE2,nervous_system_disease
5428,"Tinnitus, Subjective",Sulodexide,CNC1=C2C(=NC=N1)N(C=N2)C3C(C(C(O3)CO)O)OC,PHASE2,nervous_system_disease
5429,Parkinson Disease,Mesdopetam,CCCNCCOC1=CC(=CC(=C1)S(=O)(=O)C)F,PHASE2,nervous_system_disease
5430,Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia,Pegaspargase,CC1=CC(=C(C=C1)C(=O)C(=C)CN(C)C)C,PHASE2,nervous_system_disease
5431,Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia,Tioguanine,C1=NC2=C(N1)C(=S)N=C(N2)N,PHASE2,nervous_system_disease
5432,Down Syndrome|Recurrent B Acute Lymphoblastic Leukemia,Thioguanine,C1=NC2=C(N1)C(=S)N=C(N2)N,PHASE2,nervous_system_disease
5434,Secondary-progressive Multiple Sclerosis,Siponimod,CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O,PHASE2|PHASE3,nervous_system_disease
5435,DYT-1|Dystonia,Ampicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)C,PHASE1,nervous_system_disease
5436,"Emergence Agitation|Remimazolam Besylate|Perioperative Sedation|Laparoscopic Abdominal Surgery|Anesthesia, General",Cisatracurium,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C,APPROVED,nervous_system_disease
5437,Non-Small Cell Lung Cancer (NSCLC),Lorlatinib,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PHASE2,nervous_system_disease
5441,Gastroparesis,Granisetron,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,PHASE2,nervous_system_disease
5442,Delirium,Zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,APPROVED,nervous_system_disease
5443,Metastatic Cancer|Central Nervous System Cancer,Niraparib,C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N,PHASE2,nervous_system_disease
5444,Acute Ischaemic Middle Cerebral Artery Stroke,Piracetam,C1CC(=O)N(C1)CC(=O)N,APPROVED,nervous_system_disease
5445,Multiple Sclerosis,Nerispirdine,CCCN(C1=C(C=NC=C1)F)N2C=C(C3=CC=CC=C32)C,PHASE2,nervous_system_disease
5446,"Candidiasis, Systemic|Candida Meningitis",Micafungin,CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O,PHASE2,nervous_system_disease
5447,X-Linked Adrenoleukodystrophy|Adrenomyeloneuropathy,Sobetirome,CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O,PHASE1,nervous_system_disease
5448,Von Hippel-Lindau Syndrome,Dovitinib,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,PHASE2,nervous_system_disease
5449,Diabetic Neuropathy,Ruboxistaurin,CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O,PHASE2,nervous_system_disease
5450,Atrial Remodeling|Myocardial Dysfunction|Left Ventricular Remodeling|Left Ventricular Diastolic Dysfunction|Hypertension|Cardiovascular Morbidity|Fibrosis Myocardial|Inflammatory Myopathy|Atrial Arrhythmia,Sacubitril,CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O,PHASE2,nervous_system_disease
5451,Insomnia Disorder,Cannabinol,CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O,PHASE1|PHASE2,nervous_system_disease
5452,Gastroparesis,Naronapride,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCCCC(=O)OC3CN4CCC3CC4,PHASE2,nervous_system_disease
5453,Breast Cancer|Chronic Pain Due to Malignancy (Finding),Sulfasalazine,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,PHASE2,nervous_system_disease
5454,Chronic Stable Angina,Capadenoson,C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO,PHASE2,nervous_system_disease
5456,Parosmia,Ivermectin,CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C,PHASE2,nervous_system_disease
5457,Post Acute Sequelae Covid-19 Hyposmia,Beclomethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)Cl)C,PHASE2,nervous_system_disease
5458,Creutzfeldt-Jakob Disease,Quinacrine,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,PHASE2,nervous_system_disease
5459,Post Operative Analgesia,Nefopam,CN1CCOC(C2=CC=CC=C2C1)C3=CC=CC=C3,APPROVED,nervous_system_disease
5460,Diffuse Intrinsic Pontine Glioma|Progressive or Refractory High-Grade Glioma,Crenolanib,CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4,PHASE1,nervous_system_disease
5462,Stroke,Enecadin,CC1=NC(=CC(=N1)OCCCCCN2CCCCC2)C3=CC=C(C=C3)F,PHASE2,nervous_system_disease
5463,"Influenza, Human|Arthralgia",Zanamivir,CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N,PHASE2,nervous_system_disease
5464,Metastatic Castration-resistant Prostate Cancer (mCRPC),Enzalutamide,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,APPROVED,nervous_system_disease
5465,"Dermatomyositis, Adult Type",Apremilast,CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,PHASE2,nervous_system_disease
5466,Endometriosis|Pelvic Pain,Raloxifene,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,PHASE2,nervous_system_disease
5468,Apnea|Snoring,Polidocanol,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,PHASE1|PHASE2,nervous_system_disease
5470,Myositis Associated Interstitial Lund Disease (MA-ILD),Nintedanib,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,APPROVED,nervous_system_disease
5472,Osteogenesis Imperfecta,Risedronate,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,APPROVED,nervous_system_disease
5473,Ischemic Stroke|Post-stroke Cognitive Impairment,Cromolyn,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,PHASE2,nervous_system_disease
5474,Fabry Disease,Lucerastat,CCCCN1CC(C(C(C1CO)O)O)O,PHASE1,nervous_system_disease
5475,Post-dural Puncture Headache,Tetracosactide,CC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC8=CNC=N8)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C(CO)N,PHASE2,nervous_system_disease
5476,Post-dural Puncture Headache,Cosyntropin,CC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC8=CNC=N8)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C(CO)N,PHASE2,nervous_system_disease
5477,Hearing Loss,Ofloxacin,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,PHASE1,nervous_system_disease
5478,Aneurysmal Subarachnoid Hemorrhage,Tiopronin,CC(C(=O)NCC(=O)O)S,PHASE2,nervous_system_disease
5479,Breast Cancer|Brain Metastases,Fulvestrant,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,PHASE2,nervous_system_disease
5480,Friedreich Ataxia,Artesunate,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C,PHASE1|PHASE2,nervous_system_disease
5481,ALS (Amyotrophic Lateral Sclerosis),Lunasine,CC(C)C1CC2=C(C3=C(C(=CC=C3)OC)[N+](=C2O1)C)OC,PHASE2,nervous_system_disease
5482,Alzheimer's Disease,Verubecestat,CC1(CS(=O)(=O)N(C(=N1)N)C)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)F)F,PHASE2|PHASE3,nervous_system_disease
5483,Familial Dysautonomia,Kinetin,C1=COC(=C1)CNC2=NC=NC3=C2NC=N3,PHASE1,nervous_system_disease
5484,Idiopathic Hypersomnia,Pentetrazol,C1CCC2=NN=NN2CC1,PHASE2,nervous_system_disease
5485,Temporomandibular Joint Disorders|Temporomandibular Joint Dysfunction Syndrome|Temporomandibular Joint Pain,Nimesulide,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,PHASE2,nervous_system_disease
5486,Parkinson Disease Psychosis,Iloperidone,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,PHASE2,nervous_system_disease
5487,MItochondrial Myopathies,Omaveloxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C,PHASE2,nervous_system_disease
5488,Parkinson Disease,Lisuride,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,PHASE2,nervous_system_disease
5490,Acute Migraine,Zavegepant,CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O,PHASE2|PHASE3,nervous_system_disease
5491,Parkinson Disease|Excessive Daytime Somnolence,Valiloxybate,CC(C)C(C(=O)OCCCC(=O)O)N,PHASE2,nervous_system_disease
5492,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Brain,Ropidoxuridine,C1C(C(OC1N2C=C(C=NC2=O)I)CO)O,PHASE1,nervous_system_disease
5493,Coronary Artery Disease|Carotid Artery Diseases|Atherosclerosis,Colesevelam,CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-],APPROVED,nervous_system_disease
5494,Kennedy's Disease|Spinal and Bulbar Muscular Atrophy,Dutasteride,CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C,PHASE2,nervous_system_disease
5495,Fibromyalgia|Chronic Fatigue Syndrome|Multiple Sclerosis|Healthy,Oxyquinoline,C1=CC2=C(C(=C1)O)N=CC=C2,PHASE1,nervous_system_disease
5496,Obsessive-Compulsive Disorder,Clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,PHASE2,nervous_system_disease
5497,Cushing Disease,Seliciclib,CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3,PHASE2,nervous_system_disease
5498,Amyotrophic Lateral Sclerosis,Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,PHASE1,nervous_system_disease
5499,Amyotrophic Lateral Sclerosis,Dolutegravir,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,PHASE1,nervous_system_disease
5500,Alzheimer's Disease,Rilapladib,COCCN1CCC(CC1)N(CC2=CC=C(C=C2)C3=CC=C(C=C3)C(F)(F)F)C(=O)CN4C5=CC=CC=C5C(=O)C=C4SCC6=C(C(=CC=C6)F)F,PHASE1,nervous_system_disease
5501,Delayed Onset Muscle Soreness,Loxoprofen,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O,PHASE2,nervous_system_disease
5502,Spinobulbar Muscular Atrophy|Kennedy's Disease,Goserelin,CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,APPROVED,nervous_system_disease
5503,Parkinson Disease,Radotinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=NC=CN=C5,PHASE2,nervous_system_disease
5505,Meningioma,Alpelisib,CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,PHASE1,nervous_system_disease
5506,Parkinson's Disease,Tozadenant,CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O,PHASE2,nervous_system_disease
5507,Hypertension|Pure Autonomic Failure|Multiple System Atrophy,Captopril,CC(CS)C(=O)N1CCCC1C(=O)O,PHASE1,nervous_system_disease
5508,Sleep Apnea,Ertugliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl,APPROVED,nervous_system_disease
5509,Insulin Resistance|Healthy|Obesity,Phentolamine,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,PHASE1,nervous_system_disease
5510,Depression|Psychosis|Anhedonia,Raclopride,CCN1CCCC1CNC(=O)C2=C(C(=CC(=C2OC)Cl)Cl)O,APPROVED,nervous_system_disease
5511,Movement Disorders|Parkinson Disease,Eliprodil,C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O,PHASE2,nervous_system_disease
5512,Aneurysmal Subarachnoid Hemorrhage,Milrinone,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,PHASE2,nervous_system_disease
5513,Postthoracotomy Pain|Postthoracoscopy Neuropathic Pain,Terbutaline,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,PHASE2,nervous_system_disease
5517,Alzheimer´s Disease,Lanabecestat,CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2,PHASE2|PHASE3,nervous_system_disease
5518,Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL),Copanlisib,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5,PHASE1|PHASE2,nervous_system_disease
5519,Epilepsy,Digoxin,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,PHASE1,nervous_system_disease
5520,"Stroke, Ischemic",Olmesartan,CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O,PHASE2,nervous_system_disease
5522,Asthma|Chronic Obstructive Pulmonary Disease|Obstructive Sleep Apnea,Fluticasone,CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)O)C)O)F)C)F,APPROVED,nervous_system_disease
5524,Corneal Abrasion,Tetracaine,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,PHASE2|PHASE3,nervous_system_disease
5525,Chronic Prostatitis With Chronic Pelvic Pain Syndrome,Tamsulosin,CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N,PHASE2,nervous_system_disease
5526,Severe Traumatic Brain Injury With High Cerebral Pressure,Dobutamine,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,PHASE2,nervous_system_disease
5527,Tinnitus,Vestipitant,CC1=C(C=CC(=C1)F)C2CNCCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,PHASE2,nervous_system_disease
5528,"Duchenne Muscular Dystrophy Cardiomyopathy|Cardiomyopathy, Dilated",Ifetroban,CCCCCNC(=O)C1=COC(=N1)C2C3CCC(C2CC4=CC=CC=C4CCC(=O)O)O3,PHASE2,nervous_system_disease
5531,Amyotrophic Lateral Sclerosis,Nitrofural,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)N,PHASE2,nervous_system_disease
5532,Amyotrophic Lateral Sclerosis,Nitrofurazone,C1=C(OC(=C1)[N+](=O)[O-])C=NNC(=O)N,PHASE2,nervous_system_disease
5533,"Gaucher Disease, Type 1|Type 1 Gaucher Disease|Gaucher Disease",Afegostat,C1C(C(C(CN1)O)O)CO,PHASE2,nervous_system_disease
5535,Acute Gout Flare|Gout Attack|Gout Flare|Gouty Arthritis|Gout|Arthritis|Joint Pain,Dapansutrile,CS(=O)(=O)CCC#N,PHASE2|PHASE3,nervous_system_disease
5536,Parkinson Disease,Repaglinide,CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,PHASE1,nervous_system_disease
5537,Parkinson's Disease|Dyskinesia,Eltoprazine,C1CN(CCN1)C2=C3C(=CC=C2)OCCO3,PHASE2,nervous_system_disease
5538,Multiple Sclerosis|Bladder Dysfunction,Alfuzosin,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC,PHASE2|PHASE3,nervous_system_disease
5541,Neuropathic Pain,Priralfinamide,CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F,PHASE2,nervous_system_disease
5542,"Ischemic Stroke, Acute",Sarecycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC,PHASE2,nervous_system_disease
5543,Normal Tension Glaucoma|Ocular Hypertension,Travoprost,CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O,APPROVED,nervous_system_disease
5545,Primary Insomnia|Chronic Insomnia,Chamomile,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,PHASE2,nervous_system_disease
5546,Hydromorphone|Analgesia|ICU,Butorphanol,C1CCC2(C3CC4=C(C2(C1)CCN3CC5CCC5)C=C(C=C4)O)O,APPROVED,nervous_system_disease
5547,"Stress Disorders, Post-Traumatic",Doxazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,PHASE2,nervous_system_disease
5548,Parkinson Disease,Gemfibrozil,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,PHASE2,nervous_system_disease
5549,"Hepatic Encephalopathy|Cirrhosis, Liver",Rifamycin,CC1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,PHASE2,nervous_system_disease
5550,Myxofibrosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Leiomyosarcoma|Recurrent Liposarcoma|Recurrent Malignant Peripheral Nerve Sheath Tumor|Recurrent Undifferentiated Pleomorphic Sarcoma|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7,Alisertib,COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC,PHASE2,nervous_system_disease
5551,Mitochondrial Diseases,Bezafibrate,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,PHASE2,nervous_system_disease
5552,Nausea|Vomiting|Vertigo,Dimenhydrinate,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,APPROVED,nervous_system_disease
5553,Pharmacoresistant Focal Epilepsies,Stiripentol,CC(C)(C)C(C=CC1=CC2=C(C=C1)OCO2)O,APPROVED,nervous_system_disease
5557,Relapsing Multiple Sclerosis,Fenebrutinib,CC1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8,PHASE2,nervous_system_disease
5558,Cerebral Palsy|Excessive Crying|Pain,Trihexyphenidyl,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,APPROVED,nervous_system_disease
5559,Agitation,Asenapine,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,APPROVED,nervous_system_disease
5561,Necrobiosis Lipoidica,Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,PHASE2,skin_and_connective_tissue_disease
5562,Necrobiosis Lipoidica,Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,skin_and_connective_tissue_disease
5563,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,Lenvatinib,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,PHASE1,skin_and_connective_tissue_disease
5564,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,PHASE1,skin_and_connective_tissue_disease
5566,Polymyalgia Rheumatica|Effect of Drug|Safety Issues,Tofacitinib,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,PHASE2,skin_and_connective_tissue_disease
5568,Polymyalgia Rheumatica|Inflammatory Diseases,Prednisone,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,PHASE2,skin_and_connective_tissue_disease
5569,Mastocytosis,Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,PHASE2|PHASE3,skin_and_connective_tissue_disease
5570,Skin Infection|Bacterial Infection,Daptomycin,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,PHASE2,skin_and_connective_tissue_disease
5571,Skin Infection|Bacterial Infection,Brilacidin,C1CNCC1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4OC5CCNC5)NC(=O)CCCCN=C(N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCN=C(N)N,PHASE2,skin_and_connective_tissue_disease
5573,"Arthritis, Rheumatoid",Cantharidin,CC12C3CCC(C1(C(=O)OC2=O)C)O3,PHASE1,skin_and_connective_tissue_disease
5574,"Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma",Tacrolimus,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,APPROVED,skin_and_connective_tissue_disease
5575,Polymyalgia Rheumatica,Prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,PHASE2|PHASE3,skin_and_connective_tissue_disease
5576,"Scleroderma, Systemic",Riociguat,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,PHASE2,skin_and_connective_tissue_disease
5577,Staphylococcal Skin Infections|Streptococcal Infections,Ceftobiprole,C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O,PHASE1,skin_and_connective_tissue_disease
5578,"Systemic Sclerosis|Scleroderma|Diffuse Systemic Sclerosis|Diffuse Scleroderma|Diffuse Cutaneous Systemic Sclerosis|Diffuse Cutaneous Scleroderma|Progressive Systemic Sclerosis|Progressive Scleroderma|Scleroderma, Systemic|Scleroderma, Diffuse|Scleroderma;Progressive|Systemic Sclerosis, Diffuse|Systemic; Sclerosis, Progressive|Scleroderma of Lung|Scleroderma With Pulmonary Involvement|Systemic Sclerosis Pulmonary|Systemic Sclerosis With Lung Involvement|Interstitial Lung Disease|Pulmonary Fibrosis Interstitial",Ixazomib,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,PHASE2,skin_and_connective_tissue_disease
5581,Systemic Sclerosis|Gastroesophageal Reflux|Proton Pubm Inhibitor,Omeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE1,skin_and_connective_tissue_disease
5583,Digital Ulcer of Scleroderma,Diltiazem,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,PHASE2,skin_and_connective_tissue_disease
5585,Scleroderma,Clobetasol,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)F)C,PHASE1,skin_and_connective_tissue_disease
5586,Scleroderma,Calcipotriol,CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C,PHASE1,skin_and_connective_tissue_disease
5587,Scleroderma,Calcipotriene,CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C,PHASE1,skin_and_connective_tissue_disease
5588,"Infections, Gram-Positive Bacterial|Abscess|Burns|Cellulitis|Ulcer|Wound Infections",Telavancin,CCCCCCCCCCNCCNC1(CC(OC(C1O)C)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)C,PHASE2,skin_and_connective_tissue_disease
5589,"Infections, Gram-Positive Bacterial|Abscess|Burns|Cellulitis|Ulcer|Wound Infections",Vancomycin,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,PHASE2,skin_and_connective_tissue_disease
5590,"Infections, Gram-Positive Bacterial|Abscess|Burns|Cellulitis|Ulcer|Wound Infections",Phenoxymethylpenicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,PHASE2,skin_and_connective_tissue_disease
5591,"Infections, Gram-Positive Bacterial|Abscess|Burns|Cellulitis|Ulcer|Wound Infections",Penicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,PHASE2,skin_and_connective_tissue_disease
5592,"Osteoarthritis|Arthritis, Rheumatoid|Arthritis, Psoriatic",Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,PHASE2,skin_and_connective_tissue_disease
5593,Systemic Sclerosis|Limited Cutaneous Systemic Sclerosis,Mycophenolate,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,PHASE2,skin_and_connective_tissue_disease
5594,"Pulmonary Fibrosis|Scleroderma, Systemic",Bosentan,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,PHASE2|PHASE3,skin_and_connective_tissue_disease
5595,Raynaud Phenomenon Secondary to Systemic Sclerosis,Iloprost,CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O,PHASE2,skin_and_connective_tissue_disease
5596,Liposarcoma|CRC|Prostate Cancer|Breast Neoplasms|Adenocarcinoma of Lung|Solid Tumors,Letrozole,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,PHASE1|PHASE2,skin_and_connective_tissue_disease
5597,Liposarcoma|CRC|Prostate Cancer|Breast Neoplasms|Adenocarcinoma of Lung|Solid Tumors,Fulvestrant,CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,PHASE1|PHASE2,skin_and_connective_tissue_disease
5598,Liposarcoma|CRC|Prostate Cancer|Breast Neoplasms|Adenocarcinoma of Lung|Solid Tumors,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,PHASE1|PHASE2,skin_and_connective_tissue_disease
5599,Liposarcoma|CRC|Prostate Cancer|Breast Neoplasms|Adenocarcinoma of Lung|Solid Tumors,Enzalutamide,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,PHASE1|PHASE2,skin_and_connective_tissue_disease
5601,Human Immunodeficiency Virus 1 Positive|Skin Kaposi Sarcoma,Pomalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,PHASE2,skin_and_connective_tissue_disease
5603,Scleroderma|Scleroderma Renal Crisis|Chronic Kidney Disease,Zibotentan,CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4,PHASE2,skin_and_connective_tissue_disease
5604,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Ensartinib,CC1CN(CC(N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)OC(C)C4=C(C=CC(=C4Cl)F)Cl)N,PHASE2,skin_and_connective_tissue_disease
5605,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Erdafitinib,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,PHASE2,skin_and_connective_tissue_disease
5606,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Larotrectinib,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,PHASE2,skin_and_connective_tissue_disease
5607,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Olaparib,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE2,skin_and_connective_tissue_disease
5608,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Palbociclib,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,PHASE2,skin_and_connective_tissue_disease
5609,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Selpercatinib,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,PHASE2,skin_and_connective_tissue_disease
5610,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Selumetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,PHASE2,skin_and_connective_tissue_disease
5611,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Tazemetostat,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,PHASE2,skin_and_connective_tissue_disease
5612,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Tipifarnib,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,PHASE2,skin_and_connective_tissue_disease
5613,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Ulixertinib,CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl,PHASE2,skin_and_connective_tissue_disease
5614,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Vemurafenib,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,PHASE2,skin_and_connective_tissue_disease
5615,Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Primary Malignant Central Nervous System Neoplasm|Locally Advanced Sarcoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Primary Malignant Central Nervous System Neoplasm|Metastatic Sarcoma|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8,Avapritinib,CC(C1=CC=C(C=C1)F)(C2=CN=C(N=C2)N3CCN(CC3)C4=NC=NN5C4=CC(=C5)C6=CN(N=C6)C)N,PHASE2,skin_and_connective_tissue_disease
5618,"Lupus Erythematosus, Cutaneous",Alitretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE2,skin_and_connective_tissue_disease
5619,Systemic Sclerosis,Tadalafil,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,PHASE2,skin_and_connective_tissue_disease
5620,Small-cell Lung Cancer|Soft Tissue Sarcoma|Triple-negative Breast Cancer|Ovarian Cancer|Endometrial Cancer,Tinostamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCCCCC(=O)NO,PHASE1|PHASE2,skin_and_connective_tissue_disease
5621,Cellulitis|Wound Infection|Abscess,Floxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,skin_and_connective_tissue_disease
5622,Cellulitis|Wound Infection|Abscess,Flucloxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,skin_and_connective_tissue_disease
5623,Cellulitis|Wound Infection|Abscess,Penicillin V,CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,APPROVED,skin_and_connective_tissue_disease
5624,Focal Segmental Glomerulosclerosis|Minimal Change Disease|Immunoglobulin A Nephropathy|IgA Vasculitis|Alport Syndrome,Sparsentan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC,PHASE2,skin_and_connective_tissue_disease
5625,Advanced Fallopian Tube Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Synovial Sarcoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Fallopian Tube Carcinoma|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Synovial Sarcoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Unresectable Melanoma|Unresectable Ovarian Carcinoma|Unresectable Synovial Sarcoma,Cyclophosphamide,C1CNP(=O)(OC1)N(CCCl)CCCl,PHASE1|PHASE2,skin_and_connective_tissue_disease
5626,Advanced Fallopian Tube Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Primary Peritoneal Carcinoma|Advanced Synovial Sarcoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Fallopian Tube Carcinoma|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Primary Peritoneal Carcinoma|Metastatic Synovial Sarcoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Unresectable Melanoma|Unresectable Ovarian Carcinoma|Unresectable Synovial Sarcoma,Decitabine,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,PHASE1|PHASE2,skin_and_connective_tissue_disease
5627,Scleroderma,Lidocaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,PHASE2|PHASE3,skin_and_connective_tissue_disease
5628,Immune Thrombocytopenia|Autoantibodies|Evan Syndrome|Connective Tissue Diseases,Avatrombopag,C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl,APPROVED,skin_and_connective_tissue_disease
5629,Epidermolysis Bullosa (EB)|Epidermolysis Bullosa Simplex|Dystrophic Epidermolysis Bullosa|Junctional Epidermolysis Bullosa,Diacerein,CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O,PHASE1,skin_and_connective_tissue_disease
5630,HLRCC|Sporadic Papillary Renal Cell Cancer,Erlotinib,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,PHASE2,skin_and_connective_tissue_disease
5631,"Sarcoma, Kaposi|HIV Infections",Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,PHASE2,skin_and_connective_tissue_disease
5633,"Sarcoma, Kaposi|HIV Infections",Nelfinavir,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,PHASE2,skin_and_connective_tissue_disease
5634,Breast Cancer|Soft Tissue Sarcoma,Temozolomide,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,PHASE2,skin_and_connective_tissue_disease
5635,Systemic Lupus Erythematosus|Systemic Sclerosis,Fludarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,PHASE1,skin_and_connective_tissue_disease
5636,Systemic Lupus Erythematosus|Systemic Sclerosis,Busulfan,CS(=O)(=O)OCCCCOS(=O)(=O)C,PHASE1,skin_and_connective_tissue_disease
5638,Discoid Lupus Erythematosus,Delgocitinib,CC1CN(C12CCN(C2)C3=NC=NC4=C3C=CN4)C(=O)CC#N,PHASE2,skin_and_connective_tissue_disease
5639,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Triple-Negative Breast Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,Cabozantinib,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,PHASE1,skin_and_connective_tissue_disease
5640,Skin Infection,Dalbavancin,CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)C(C6C(=O)NC(C7=C(C(=CC(=C7)O)OC8C(C(C(C(O8)CO)O)O)O)C9=C(C=CC(=C9)C(C(=O)N6)NC(=O)C4NC(=O)C1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)C(C(=O)NC(CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O,APPROVED,skin_and_connective_tissue_disease
5642,Rheumatoid Arthritis|Psoriatic Arthritis|Spondylarthritis,Upadacitinib,CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F,APPROVED,skin_and_connective_tissue_disease
5645,Rheumatoid Arthritis|Psoriatic Arthritis|Spondylarthritis,Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,APPROVED,skin_and_connective_tissue_disease
5647,Infectious Skin Diseases|Bacterial Skin Diseases|Staphylococcal Skin Infections|Streptococcal Infections|Abscess,Radezolid,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)C3=CC=C(C=C3)CNCC4=NNN=C4)F,PHASE2,skin_and_connective_tissue_disease
5648,Infectious Skin Diseases|Bacterial Skin Diseases|Staphylococcal Skin Infections|Streptococcal Infections|Abscess,Linezolid,CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,PHASE2,skin_and_connective_tissue_disease
5649,Dermatomyositis,Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2|PHASE3,skin_and_connective_tissue_disease
5651,Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage III Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IVC Pharyngeal Cancer|Thyroid Gland Neoplasm,Temsirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,PHASE1,skin_and_connective_tissue_disease
5652,Systemic Sclerosis,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,PHASE2,skin_and_connective_tissue_disease
5654,Community Acquired Pneumonia|Staphylococcal Skin Infections,Friulimicin B,CC1C(C(=O)N2CCCCC2C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N3CCCC3C(=O)N1)C(C)C)C(C)N)CC(=O)O)CC(=O)O)C(C)C(=O)O)NC(=O)C(CC(=O)N)NC(=O)CC=CCCCCCCCC(C)C,PHASE1,skin_and_connective_tissue_disease
5655,Systemic Sclerosis,Nilotinib,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE2,skin_and_connective_tissue_disease
5656,Advanced Malignant Solid Neoplasm|C-KIT Tyrosine Kinase Protein Overexpression|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Gastrointestinal Stromal Tumor|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Melanoma|Unresectable Solid Neoplasm,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE1,skin_and_connective_tissue_disease
5657,Hematological Neoplasms|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Leukemia|Myelodysplastic Syndromes|Neoplasms|Melanoma|Breast Cancer|Metastatic Breast Cancer|Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Renal Cell Carcinoma|Glioblastoma Multiforme|Osteosarcoma|Sarcoma|Thyroid Cancer|Genitourinary,Azacitidine,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,PHASE1,skin_and_connective_tissue_disease
5660,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Metformin,CN(C)C(=N)N=C(N)N,PHASE2,skin_and_connective_tissue_disease
5662,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Ganetespib,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O,PHASE2,skin_and_connective_tissue_disease
5663,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Neratinib,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C,PHASE2,skin_and_connective_tissue_disease
5664,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Talazoparib,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,PHASE2,skin_and_connective_tissue_disease
5665,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Irinotecan,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,PHASE2,skin_and_connective_tissue_disease
5668,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Tucatinib,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,PHASE2,skin_and_connective_tissue_disease
5670,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Trilaciclib,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6,PHASE2,skin_and_connective_tissue_disease
5671,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Paclitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,PHASE2,skin_and_connective_tissue_disease
5673,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Carboplatin,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],PHASE2,skin_and_connective_tissue_disease
5674,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,PHASE2,skin_and_connective_tissue_disease
5676,Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer,Lasofoxifene,C1CCN(C1)CCOC2=CC=C(C=C2)C3C(CCC4=C3C=CC(=C4)O)C5=CC=CC=C5,PHASE2,skin_and_connective_tissue_disease
5677,Skin and Connective Tissue Diseases,Betamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE1,skin_and_connective_tissue_disease
5678,"Lung Diseases, Interstitial|Systemic Sclerosis|Scleroderma",Bortezomib,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,PHASE2,skin_and_connective_tissue_disease
5679,Recurrent Cutaneous Melanoma|Recurrent Lip and Oral Cavity Carcinoma|Recurrent Malignant Endocrine Neoplasm|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Male Reproductive System Neoplasm|Recurrent Malignant Mesothelioma|Recurrent Malignant Neoplasm of Multiple Primary Sites|Recurrent Malignant Oral Neoplasm|Recurrent Malignant Pharyngeal Neoplasm|Recurrent Malignant Skin Neoplasm|Recurrent Malignant Soft Tissue Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Thyroid Gland Neoplasm|Recurrent Malignant Urinary System Neoplasm|Refractory Cutaneous Melanoma|Refractory Malignant Bone Neoplasm|Refractory Malignant Endocrine Neoplasm|Refractory Malignant Female Reproductive System Neoplasm|Refractory Malignant Male Reproductive System Neoplasm|Refractory Malignant Mesothelioma|Refractory Malignant Neoplasm of Multiple Primary Sites|Refractory Malignant Oral Neoplasm|Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Skin Neoplasm|Refractory Malignant Soft Tissue Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Malignant Thyroid Gland Neoplasm|Refractory Malignant Urinary System Neoplasm,Etoposide,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,PHASE1,skin_and_connective_tissue_disease
5680,"Skin Infections, Bacterial",Retapamulin,CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CC5CCC(C4)N5C)C,PHASE1,skin_and_connective_tissue_disease
5681,Skin Infections (Acne),Isotretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE1,skin_and_connective_tissue_disease
5687,Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Fibrosarcoma|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Liver Embryonal Sarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Cutaneous Granular Cell Tumor|Malignant Peripheral Nerve Sheath Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Skin Glomus Tumor|Stage IB Soft Tissue Sarcoma AJCC v7|Stage IIB Soft Tissue Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Synovial Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Doxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2|PHASE3,skin_and_connective_tissue_disease
5688,Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Fibrosarcoma|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Liver Embryonal Sarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Cutaneous Granular Cell Tumor|Malignant Peripheral Nerve Sheath Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Skin Glomus Tumor|Stage IB Soft Tissue Sarcoma AJCC v7|Stage IIB Soft Tissue Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Synovial Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Ifosfamide,C1CN(P(=O)(OC1)NCCCl)CCCl,PHASE2|PHASE3,skin_and_connective_tissue_disease
5689,Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Fibrosarcoma|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Liver Embryonal Sarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Cutaneous Granular Cell Tumor|Malignant Peripheral Nerve Sheath Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Skin Glomus Tumor|Stage IB Soft Tissue Sarcoma AJCC v7|Stage IIB Soft Tissue Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Synovial Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Pazopanib,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,PHASE2|PHASE3,skin_and_connective_tissue_disease
5690,Diffuse Cutaneous Systemic Sclerosis,Belumosudil,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,PHASE2,skin_and_connective_tissue_disease
5691,Systemic Sclerosis,Itacitinib,C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F,PHASE2,skin_and_connective_tissue_disease
5692,Raynaud's Phenomenon Secondary to Systemic Sclerosis,Alprostadil,CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O,PHASE2,skin_and_connective_tissue_disease
5693,Advanced Solid Tumors|HR+ Breast Cancer|CCNE1 Amplification|HER2-negative Breast Cancer|Ovarian Cancer|Endometrial Cancer|Gastric Cancer|Esophageal Adenocarcinoma|Carcinosarcoma,Ribociclib,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,PHASE1|PHASE2,skin_and_connective_tissue_disease
5696,Systemic Scleroderma,Plerixafor,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3,PHASE2,skin_and_connective_tissue_disease
5697,Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Solid Neoplasm,Romidepsin,CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,PHASE1,skin_and_connective_tissue_disease
5698,Epidermolysis Bullosa Dystrophica|Squamous Cell Carcinoma,Rigosertib,COC1=C(C=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)O,PHASE1|PHASE2,skin_and_connective_tissue_disease
5699,"Breast Cancer|Ovarian Epithelial Cancer Recurrent|Sarcoma|Non-small Cell Lung Cancer|Carcinoma, Transitional Cell|Prostate Cancer|Prostatic Neoplasms",Mifepristone,CC#CC1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,PHASE1,skin_and_connective_tissue_disease
5700,"Breast Cancer|Ovarian Epithelial Cancer Recurrent|Sarcoma|Non-small Cell Lung Cancer|Carcinoma, Transitional Cell|Prostate Cancer|Prostatic Neoplasms",Eribulin,CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O,PHASE1,skin_and_connective_tissue_disease
5701,Raynaud's Phenomenon Secondary to Systemic Sclerosis,Selexipag,CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3,PHASE2,skin_and_connective_tissue_disease
5702,"Scleroderma, Systemic",Nintedanib,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,PHASE1,skin_and_connective_tissue_disease
5705,Methicillin-Resistant Staphylococcus Aureus|Recurrence|Staphylococcal Skin Infections|Antibiotic Resistance,Chlorhexidine,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,APPROVED,skin_and_connective_tissue_disease
5706,Interstitial Lung Disease|Scleroderma|Pulmonary Hypertension,Macitentan,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,PHASE2|PHASE3,skin_and_connective_tissue_disease
5707,Raynaud's Disease,Cilostazol,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,APPROVED,skin_and_connective_tissue_disease
5710,"Lupus Erythematosus, Discoid|Lupus Erythematosus, Subacute Cutaneous",Deucravacitinib,CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4,PHASE2,skin_and_connective_tissue_disease
5712,Skin Infection|Staphylococcal Infections|Staphylococcus Aureus Infection,Clindamycin,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,APPROVED,skin_and_connective_tissue_disease
5713,"Scleroderma, Diffuse|Scleroderma, Systemic|Scleroderma, Limited|Sclerosis, Progressive Systemic|Skin Diseases|Connective Tissue Diseases|Pathologic Processes|Autoimmune Diseases",Ifetroban,CCCCCNC(=O)C1=COC(=N1)C2C3CCC(C2CC4=CC=CC=C4CCC(=O)O)O3,PHASE2,skin_and_connective_tissue_disease
5714,Systemic Sclerosis|Scleroderma,Mesna,C(CS(=O)(=O)[O-])S.[Na+],PHASE2|PHASE3,skin_and_connective_tissue_disease
5715,Systemic Sclerosis|Scleroderma,Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,PHASE2|PHASE3,skin_and_connective_tissue_disease
5717,Breast Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Uterine Corpus Cancer|Uterine Corpus Carcinosarcoma,Doxycycline,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,PHASE2,skin_and_connective_tissue_disease
5718,Benign Breast Disease|Fibrocystic Disease of Breast|Fibroadenoma|Mastalgia,Tamoxifen,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,APPROVED,skin_and_connective_tissue_disease
5719,Solid Tumors|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Colon Cancer|Rectal Cancer|Neoplasms|Endometrial Cancer|Soft Tissue Sarcoma|Triple Negative Breast Cancer|Pancreas Cancer|Pancreatic Cancer,Gemcitabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,PHASE1|PHASE2,skin_and_connective_tissue_disease
5720,Cutaneous Lupus Erythematosus,Lanraplenib,C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N,PHASE2,skin_and_connective_tissue_disease
5721,Cutaneous Lupus Erythematosus,Filgotinib,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,PHASE2,skin_and_connective_tissue_disease
5723,Systemic Sclerosis|Shortness of Breath|Pulmonary Hypertension,Ambrisentan,CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,APPROVED,skin_and_connective_tissue_disease
5725,"Colorectal Cancer Not MSI-H or MMR-deficient|GIST|Oesophageal or Gastric Carcinoma|Biliary Tract Cancer|Hepatocellular Carcinoma|Soft-tissue Sarcoma|Thyroid Cancer|Gastro-enteropancreatic Neuroendocrine Tumor|Non-small Cell Lung Cancer|Solid Tumor, Adult|Urothelial Carcinoma|HPV-Related Carcinoma|Triple Negative Breast Cancer|Renal Carcinoma|Mesotheliomas Pleural",Regorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,PHASE1|PHASE2,skin_and_connective_tissue_disease
5727,Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma,Linsitinib,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,PHASE2,skin_and_connective_tissue_disease
5731,Menkes Disease|Occipital Horn Syndrome,Droxidopa,C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O,PHASE1|PHASE2,skin_and_connective_tissue_disease
5732,"Skin Diseases, Infectious|Staphylococcal Skin Infections",Ceftaroline,CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-],APPROVED,skin_and_connective_tissue_disease
5733,"Anaplastic Large Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Subcutaneous Panniculitis-Like T-Cell Lymphoma",Pralatrexate,C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1|PHASE2,skin_and_connective_tissue_disease
5735,T-Cell Peripheral Lymphoma|Gamma Delta Hepatosplenic T-Cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|NK T-Cell Lymphoma,Vincristine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE1,skin_and_connective_tissue_disease
5736,"Advanced Solid Tumors|Solid Tumor|Solid Carcinoma|Solid Tumor, Adult|ccRCC|RCC, Clear Cell Adenocarcinoma|RCC|Kidney Cancer|Clear Cell Renal Cell Carcinoma|Renal Cell Carcinoma, Metastatic|Renal Cell Carcinoma Recurrent|Renal Cell Carcinoma, Clear Cell Adenocarcinoma|Glioblastoma|Glioblastoma, Adult|GBM|Glioblastoma Multiforme",Belzutifan,CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O,PHASE1,urinary_system_disease
5738,"Urinary Bladder Cancer|Bladder Tumors|Transitional Cell Carcinoma of the Bladder|Malignant Melanoma|Melanoma|Skin Cancer|Carcinoma, Non-Small-Cell Lung|Lung Cancer",Chloroquine,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,PHASE1,urinary_system_disease
5739,"Urinary Bladder Cancer|Bladder Tumors|Transitional Cell Carcinoma of the Bladder|Malignant Melanoma|Melanoma|Skin Cancer|Carcinoma, Non-Small-Cell Lung|Lung Cancer",Ciclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE1,urinary_system_disease
5740,Nephrolithiasis,Oxycodone,CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O,APPROVED,urinary_system_disease
5741,Nephrolithiasis,Ketorolac,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,APPROVED,urinary_system_disease
5742,Low Risk Prostate Cancer,Padeliporfin,CCC1C(C2=CC3=NC(=C(C3=C(C)[O-])C)C=C4C(C(C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=NCCS(=O)(=O)O)[O-])CC(=O)OC)CCC(=O)O)C)C.[Pd+2],APPROVED,urinary_system_disease
5743,"Urethral Neoplasms|Neoplasms, Urethral|Cancer of the Urethra|Urethral Cancer",Gemcitabine,C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F,PHASE1,urinary_system_disease
5744,"Urethral Neoplasms|Neoplasms, Urethral|Cancer of the Urethra|Urethral Cancer",Carboplatin,C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2],PHASE1,urinary_system_disease
5745,"Urethral Neoplasms|Neoplasms, Urethral|Cancer of the Urethra|Urethral Cancer",Lenalidomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,PHASE1,urinary_system_disease
5746,Type 1 Diabetes|Diabetic Kidney Disease|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Sensitivity,Metformin,CN(C)C(=N)N=C(N)N,PHASE1,urinary_system_disease
5747,Type 1 Diabetes|Diabetic Kidney Disease|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Sensitivity,Iohexol,CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,PHASE1,urinary_system_disease
5748,Chronic Kidney Disease,Paricalcitol,CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C,APPROVED,urinary_system_disease
5749,Bladder Pain Syndrome,Gefapixant,CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC,PHASE2,urinary_system_disease
5750,End-Stage Renal Disease,Levocarnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,urinary_system_disease
5751,End-Stage Renal Disease,Carnitine,C[N+](C)(C)CC(CC(=O)[O-])O,PHASE2,urinary_system_disease
5752,"Urinary Bladder, Overactive",Vibegron,C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O,PHASE2,urinary_system_disease
5753,"Urinary Bladder, Overactive",Tolterodine,CC1=CC(=C(C=C1)O)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2,PHASE2,urinary_system_disease
5754,Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis,Etelcalcetide,CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C,PHASE1,urinary_system_disease
5755,Neurogenic Bladder|Catheter-Related Infections,Octenidine,CCCCCCCCN=C1C=CN(C=C1)CCCCCCCCCCN2C=CC(=NCCCCCCCC)C=C2,PHASE2|PHASE3,urinary_system_disease
5756,Chronic Kidney Disease,Atorvastatin,CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,APPROVED,urinary_system_disease
5757,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,Lenvatinib,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,PHASE1,urinary_system_disease
5758,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,PHASE1,urinary_system_disease
5759,Renal Impairment,Gabapentin,C1CCC(CC1)(CC(=O)O)CN,APPROVED,urinary_system_disease
5760,IGA Nephropathy,Fostamatinib,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,PHASE2,urinary_system_disease
5761,Urinary Retention Postoperative,Tamsulosin,CCOC1=CC=CC=C1OCCNC(C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N,PHASE2,urinary_system_disease
5762,Metastatic Kidney Medullary Carcinoma|Metastatic Renal Cell Carcinoma|SMARCB1 Negative|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,Doxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,urinary_system_disease
5763,Metastatic Kidney Medullary Carcinoma|Metastatic Renal Cell Carcinoma|SMARCB1 Negative|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,Ixazomib,B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O,PHASE2,urinary_system_disease
5764,Acute Kidney Injury,Dexmedetomidine,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C,PHASE2|PHASE3,urinary_system_disease
5765,Complicated Urinary Tract Infection|Pyelonephritis,Ceftolozane,CC(C)(C(=O)O)ON=C(C1=NSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)[O-],PHASE2,urinary_system_disease
5766,Complicated Urinary Tract Infection|Pyelonephritis,Tazobactam,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,PHASE2,urinary_system_disease
5767,Complicated Urinary Tract Infection|Pyelonephritis,Meropenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O,PHASE2,urinary_system_disease
5768,Neurogenic Detrusor Overactivity,Fesoterodine,CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2,PHASE1,urinary_system_disease
5769,"Kidney Failure, Chronic|Disorder of Vitamin D",Calcifediol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,APPROVED,urinary_system_disease
5770,Kidney Cancer,Perflutren,C(C(F)(F)F)(C(F)(F)F)(F)F,PHASE2,urinary_system_disease
5773,Renal Cell Carcinoma,Axitinib,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4,PHASE1,urinary_system_disease
5774,Chronic Kidney Disease,Isoquercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O)O,PHASE2,urinary_system_disease
5775,Healthy|Renal Insufficiency,Rivaroxaban,C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl,PHASE1,urinary_system_disease
5776,Healthy|Renal Insufficiency,Erythromycin,CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O,PHASE1,urinary_system_disease
5777,Breast Cancer|Lung Cancer|Colon Cancer|Pancreatic Cancer|Head and Neck Cancer|Kidney Cancer|Sarcoma|Hepatocellular Cancer,Pazopanib,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,PHASE1,urinary_system_disease
5778,Breast Cancer|Lung Cancer|Colon Cancer|Pancreatic Cancer|Head and Neck Cancer|Kidney Cancer|Sarcoma|Hepatocellular Cancer,Ixabepilone,CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C,PHASE1,urinary_system_disease
5779,Secondary Hyperparathyroidism,Cinacalcet,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,PHASE2|PHASE3,urinary_system_disease
5780,Lower Urinary Tract Symptoms|Voiding Disorders|Pain|Quality of Life,Tadalafil,CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,APPROVED,urinary_system_disease
5781,Overactive Bladder,Solifenacin,C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5,APPROVED,urinary_system_disease
5782,Overactive Bladder,Oxybutynin,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,APPROVED,urinary_system_disease
5783,Cancer|Cisplatin Adverse Reaction,Gemigliptin,C1CC(CN(C1=O)CC(CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F,PHASE2|PHASE3,urinary_system_disease
5784,Cancer|Cisplatin Adverse Reaction,Cisplatin,N.N.Cl[Pt]Cl,PHASE2|PHASE3,urinary_system_disease
5785,"Infections, Bacterial",Gepotidacin,C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)CC4CN5C(=O)C=CC6=C5N4C(=O)C=N6,PHASE1,urinary_system_disease
5786,Lupus Nephritis,Cyclophosphamide,C1CNP(=O)(OC1)N(CCCl)CCCl,APPROVED,urinary_system_disease
5787,Lupus Nephritis,Azathioprine,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],APPROVED,urinary_system_disease
5788,Lupus Nephritis,Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,APPROVED,urinary_system_disease
5789,Metastatic Clear Cell Renal Cancer,Dovitinib,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,PHASE1,urinary_system_disease
5790,Metastatic Clear Cell Renal Cancer,Everolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC,PHASE1,urinary_system_disease
5791,Urinary Tract Infections,Methenamine,C1N2CN3CN1CN(C2)C3,APPROVED,urinary_system_disease
5792,Urinary Tract Infections,Methylthioninium,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2,APPROVED,urinary_system_disease
5793,Advanced Clear Cell Renal Cell Carcinoma,Palbociclib,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C,PHASE2,urinary_system_disease
5796,Pelvic Pain|Interstitial Cystitis|Bladder Diseases,Lidocaine,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,PHASE2,urinary_system_disease
5797,Overactive Bladder Syndrome|Urge Incontinence|Urinary Incontinence|Detrusor Hyperreflexia|Detrusor Instability,Phenazopyridine,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N,APPROVED,urinary_system_disease
5800,Renal Cell Carcinoma,Sunitinib,CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C,PHASE2,urinary_system_disease
5804,Kidney Transplantation|Primary Focal Segmental Glomerulosclerosis (FSGS),Mycophenolate,CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O,PHASE2,urinary_system_disease
5805,Kidney Transplantation|Primary Focal Segmental Glomerulosclerosis (FSGS),Tacrolimus,CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC,PHASE2,urinary_system_disease
5806,Kidney Transplantation|Primary Focal Segmental Glomerulosclerosis (FSGS),Methylprednisone,CC1CC2C3CCC4=CC(=O)C=CC4(C3C(=O)CC2(C1(C(=O)CO)O)C)C,PHASE2,urinary_system_disease
5807,Kidney Transplantation|Primary Focal Segmental Glomerulosclerosis (FSGS),Prednisone,CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,PHASE2,urinary_system_disease
5808,Bladder Cancer,Propranolol,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,PHASE2,urinary_system_disease
5809,"Urge Incontinence|Urinary Incontinence, Urge",Mirabegron,C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,APPROVED,urinary_system_disease
5811,Renal Disease,Ceftaroline,CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-],PHASE1,urinary_system_disease
5812,Bladder Cancer,Docetaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,PHASE2,urinary_system_disease
5813,Bladder Cancer,Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,PHASE2,urinary_system_disease
5815,"Clinical Trial, Phase I",Fulacimstat,CN1C2=C(C=C(C=C2)N3C=C(C(=O)N(C3=O)C4CCC5=C4C=CC=C5C(F)(F)F)C(=O)O)OC1=O,PHASE1,urinary_system_disease
5816,Chronic Kidney Disease,Eplerenone,CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC,PHASE2,urinary_system_disease
5817,Autosomal Dominant Polycystic Kidney Disease,Tolvaptan,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C,PHASE2,urinary_system_disease
5819,Migraine,Lasmiditan,CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F,PHASE1,urinary_system_disease
5821,Multiple Sclerosis|Overactive Detrusor,Darifenacin,C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5,PHASE2,urinary_system_disease
5822,"Urinary Tract Infections, Recurrent",Nitrofurantoin,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-],APPROVED,urinary_system_disease
5823,"Urinary Tract Infections, Recurrent",Trimethoprim,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,APPROVED,urinary_system_disease
5824,"Urinary Tract Infections, Recurrent",Cephalexin,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O,APPROVED,urinary_system_disease
5825,"Carcinoma, Renal Cell",Lapatinib,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,PHASE1,urinary_system_disease
5826,Renal Impairment,Lorcaserin,CC1CNCCC2=C1C=C(C=C2)Cl,PHASE1,urinary_system_disease
5827,"Hypertension, Renal",Bisoprolol,CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O,APPROVED,urinary_system_disease
5828,"Hypertension, Renal",Amlodipine,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,APPROVED,urinary_system_disease
5829,Chronic Kidney Diseases,Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,PHASE2,urinary_system_disease
5830,Inflammatory Disease,Lanraplenib,C1CN(CCN1C2COC2)C3=CC=C(C=C3)NC4=NC(=CN5C4=NC=C5)C6=CN=CC(=N6)N,PHASE1,urinary_system_disease
5831,IgA Nephropathy|Immunoglobulin A Nephropathy,Atrasentan,CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4,PHASE2,urinary_system_disease
5834,"Kidney Failure, Chronic",Iopromide,CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I,APPROVED,urinary_system_disease
5835,"Kidney Failure, Chronic",Iodixanol,CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(=C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I,APPROVED,urinary_system_disease
5836,Ureteral Stone,Silodosin,CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F,APPROVED,urinary_system_disease
5837,Renal Impairment,Tavapadon,CC1=C(C=CC(=C1)OC2=C(C=CC=N2)C(F)(F)F)C3=C(C(=O)NC(=O)N3C)C,PHASE1,urinary_system_disease
5838,Urinary Bladder Neoplasms,Paclitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,PHASE2,urinary_system_disease
5839,Benign Prostatic Hyperplasia|Urinary Tract Infections,Sulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,APPROVED,urinary_system_disease
5840,Benign Prostatic Hyperplasia|Urinary Tract Infections,Ciprofloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,APPROVED,urinary_system_disease
5841,Fecal Incontinence|Accidental Bowel Leakage|Anal Incontinence|Diarrhea|Urge Incontinence,Eluxadoline,CC1=CC(=CC(=C1CC(C(=O)N(CC2=CC(=C(C=C2)OC)C(=O)O)C(C)C3=NC=C(N3)C4=CC=CC=C4)N)C)C(=O)N,PHASE2,urinary_system_disease
5842,"Neoplasm, Ureter|Neoplasm, Bladder",Epirubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,PHASE2,urinary_system_disease
5843,Renal Cell Carcinoma|Metastatic Disease,Sorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,PHASE2,urinary_system_disease
5844,Diabetic Kidney Disease,Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O,APPROVED,urinary_system_disease
5845,Healthy|Renal Impairment,Lacosamide,CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1,PHASE1,urinary_system_disease
5846,"Low Birthweight|Preterm Birth|Maternal; Malnutrition, Affecting Fetus|Sexually Transmitted Diseases|Urinary Tract Infections|Pregnancy and Infectious Disease",Azithromycin,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,APPROVED,urinary_system_disease
5847,Hematopoietic and Lymphoid System Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Histiocytic and Dendritic Cell Neoplasm|Recurrent Langerhans Cell Histiocytosis|Recurrent Lymphoma|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent WHO Grade 2 Glioma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Histiocytic and Dendritic Cell Neoplasm|Refractory Langerhans Cell Histiocytosis|Refractory Lymphoma|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory WHO Grade 2 Glioma|Wilms Tumor,Selpercatinib,CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O,PHASE2,urinary_system_disease
5848,Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms,Talaporfin,CCC1=C(C2=CC3=C(C(=C(N3)C=C4C(C(C(=N4)C(=C5C(=C(C(=N5)C=C1N2)C)C(=O)O)CC(=O)NC(CC(=O)O)C(=O)O)CCC(=O)O)C)C)C=C)C,PHASE1,urinary_system_disease
5850,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Low Grade Glioma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Hodgkin Lymphoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Hodgkin Lymphoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Soft Tissue Sarcoma|Rhabdoid Tumor|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Wilms Tumor,Tazemetostat,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5,PHASE2,urinary_system_disease
5851,Chronic Kidney Disease|Type 2 Diabetes|Diabetic Nephropathy,Bardoxolone,CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C,PHASE2,urinary_system_disease
5852,Urethritis,Tinidazole,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,PHASE2,urinary_system_disease
5853,Urethritis,Doxycycline,CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,PHASE2,urinary_system_disease
5854,Stress Urinary Incontinence|Fecal Incontinence,Citalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,PHASE1,urinary_system_disease
5855,Stress Urinary Incontinence|Fecal Incontinence,Reboxetine,CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3,PHASE1,urinary_system_disease
5856,Renal Impairment,Surufatinib,CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C,PHASE1,urinary_system_disease
5857,Clear Cell Papillary Renal Neoplasm|Collecting Duct Carcinoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hereditary Papillary Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Unclassified Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8|Stage IV Renal Cell Cancer AJCC v8|Tubulocystic Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma,Pamiparib,CC12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F,PHASE2,urinary_system_disease
5858,Clear Cell Papillary Renal Neoplasm|Collecting Duct Carcinoma|Hereditary Leiomyomatosis and Renal Cell Carcinoma|Hereditary Papillary Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Unclassified Renal Cell Carcinoma|Papillary Renal Cell Carcinoma|Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8|Stage IV Renal Cell Cancer AJCC v8|Tubulocystic Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma,Temozolomide,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,PHASE2,urinary_system_disease
5859,"Kidney Failures, Acute",Fenoldopam,C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O,APPROVED,urinary_system_disease
5860,"Kidney Failures, Acute",Furosemide,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,APPROVED,urinary_system_disease
5861,Renal Cell Carcinoma Metastatic,Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,PHASE1,urinary_system_disease
5862,Chronic Kidney Disease|End Stage Renal Disease|Anemia,Roxadustat,CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3,PHASE2,urinary_system_disease
5863,SGLT2 INHIBITORS|Lupus Nephritis|BMD,Dapagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl,APPROVED,urinary_system_disease
5864,Chronic Kidney Diseases,Colchicine,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,PHASE2,urinary_system_disease
5865,Postoperative Pain|Renal Insufficiency|Myocardial Infarction,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,APPROVED,urinary_system_disease
5866,Non Small-cell Lung Cancer|Renal-cell Cancer|Gastrointestinal Stroma Tumor,Erlotinib,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,APPROVED,urinary_system_disease
5867,Non Small-cell Lung Cancer|Renal-cell Cancer|Gastrointestinal Stroma Tumor,Midazolam,CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F,APPROVED,urinary_system_disease
5868,Menopausal Syndromes,Tibolone,CC1CC2=C(CCC(=O)C2)C3C1C4CCC(C4(CC3)C)(C#C)O,APPROVED,urinary_system_disease
5869,Renal Insufficiency|Kidney Diseases|Urologic Diseases,Mirodenafil,CCCC1=CN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CCO)OCCC)CC,PHASE1,urinary_system_disease
5870,Proteinuria,Calcitriol,CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,urinary_system_disease
5871,Stage I Bladder Cancer|Stage II Bladder Cancer|Stage III Bladder Cancer,Cianidanol,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE2,urinary_system_disease
5872,Stage I Bladder Cancer|Stage II Bladder Cancer|Stage III Bladder Cancer,Catechin,C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O,PHASE2,urinary_system_disease
5874,Urinary Tract Infections,Doripenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)CNS(=O)(=O)N)C(=O)O)C(C)O,PHASE2,urinary_system_disease
5875,Spinal Cord Injury|Neurogenic Detrusor Overactivity,Trospium,C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,APPROVED,urinary_system_disease
5876,Radiocontrast Nephropathy,Acetylcysteine,CC(=O)NC(CS)C(=O)O,PHASE2,urinary_system_disease
5878,IGA Nephropathy,Enalapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O,APPROVED,urinary_system_disease
5879,IGA Nephropathy,Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O,APPROVED,urinary_system_disease
5882,"Bladder Cancer|Carcinoma, Transitional Cell|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer",Enzalutamide,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,PHASE1,urinary_system_disease
5883,Advanced Cancer|Clear Cell Renal Cell Carcinoma,Cabozantinib,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,PHASE2,urinary_system_disease
5884,Prostate Cancer|Bladder Cancer|Kidney Cancer,Ferumoxytol,O[Fe]=O.O[Fe]=O.[Fe],PHASE2,urinary_system_disease
5885,Complicated Urinary Tract Infection Including Acute Pyelonephritis,Ertapenem,CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)C(C)O,PHASE2|PHASE3,urinary_system_disease
5887,Venous Thromboembolism,Fondaparinux,COC1C(C(C(C(O1)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)COS(=O)(=O)O)OC4C(C(C(C(O4)C(=O)O)OC5C(C(C(C(O5)COS(=O)(=O)O)O)O)NS(=O)(=O)O)O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O)NS(=O)(=O)O,APPROVED,urinary_system_disease
5889,Kidney Diseases|Kidney Transplantation|Kidney Transplant|Renal Transplantation|Renal Transplant,Ganciclovir,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,PHASE1|PHASE2,urinary_system_disease
5890,Kidney Diseases|Kidney Transplantation|Kidney Transplant|Renal Transplantation|Renal Transplant,Valganciclovir,CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N,PHASE1|PHASE2,urinary_system_disease
5891,Diabetes Mellitus|Diabetic Nephropathy,Pirfenidone,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,PHASE1|PHASE2,urinary_system_disease
5892,Hematuria|Urinary Bladder Neoplasms,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,APPROVED,urinary_system_disease
5893,Postoperative Urinary Retention,Sugammadex,C(CSCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(C(C8O)O)OC9C(OC(O2)C(C9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O,PHASE1|PHASE2,urinary_system_disease
5894,Fibrosis|Renal Impairment,Gadobutrol,C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].[Gd+3],APPROVED,urinary_system_disease
5895,Benign Prostatic Hyperplasia,Dutasteride,CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C,APPROVED,urinary_system_disease
5896,Staphylococcal Skin Infections|Streptococcal Infections,Ceftobiprole,C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O,PHASE1,urinary_system_disease
5897,Primary Monosymptomatic Nocturnal Enuresis,Desmopressin,C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N,APPROVED,urinary_system_disease
5898,Advanced/Metastatic Clear Cell Renal Cell Carcinoma,Fludarabine,C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N,PHASE1,urinary_system_disease
5899,Heart Transplantation|Renal Failure,Cyclosporine,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,APPROVED,urinary_system_disease
5900,Heart Transplantation|Renal Failure,Sirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC,APPROVED,urinary_system_disease
5902,Bladder Neoplasms,Apaziquone,CN1C(=C(C2=C1C(=O)C=C(C2=O)N3CC3)CO)C=CCO,PHASE2,urinary_system_disease
5905,Hypercholesterolemia|CKD Stage 5|Chronic Kidney Disease Requiring Chronic Dialysis,Ezetimibe,C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O,APPROVED,urinary_system_disease
5906,"Anemia|Renal Insufficiency, Chronic|Renal Anemia",Daprodustat,C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O,APPROVED,urinary_system_disease
5907,Infections Joint Prosthetic|Overweight or Obesity|MSSA Colonization|MRSA|Chronic Kidney Diseases|Diabetes|Autoimmune Diseases|Inflammatory Disease|Tobacco Use,Cefadroxil,CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O,APPROVED,urinary_system_disease
5908,Contrast-Induced Acute Kidney Injury,Deferiprone,CC1=C(C(=O)C=CN1C)O,PHASE2,urinary_system_disease
5910,Fanconi Anemia,Plerixafor,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3,PHASE1|PHASE2,urinary_system_disease
5914,Inflammation|End-stage Renal Disease|Hemodialysis,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,APPROVED,urinary_system_disease
5915,Benzodiazepines|Bladder Cancer|Delirium|Surgery|Cancer Recurrence,Remimazolam,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=NC2CCC(=O)OC)C4=CC=CC=N4,APPROVED,urinary_system_disease
5916,Benzodiazepines|Bladder Cancer|Delirium|Surgery|Cancer Recurrence,Propofol,CC(C)C1=C(C(=CC=C1)C(C)C)O,APPROVED,urinary_system_disease
5917,Urinary Tract Infections,Cefoxitin,COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3,APPROVED,urinary_system_disease
5919,Uterine Cervical Neoplasms|Endometrial Neoplasms|Squamous Cell Carcinoma of Head and Neck|Gallbladder Neoplasms|Cholangiocarcinoma|Esophageal Neoplasms|Triple Negative Breast Neoplasms|Hepatocellular Carcinoma|Urinary Bladder Neoplasms|Ovarian Neoplasms|Stomach Neoplasms,Fluorouracil,C1=C(C(=O)NC(=O)N1)F,PHASE2,urinary_system_disease
5920,Uterine Cervical Neoplasms|Endometrial Neoplasms|Squamous Cell Carcinoma of Head and Neck|Gallbladder Neoplasms|Cholangiocarcinoma|Esophageal Neoplasms|Triple Negative Breast Neoplasms|Hepatocellular Carcinoma|Urinary Bladder Neoplasms|Ovarian Neoplasms|Stomach Neoplasms,Oxaliplatin,C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2],PHASE2,urinary_system_disease
5921,Chronic Kidney Disease Stage 3|Chronic Kidney Disease Stage 4,Sulforaphane,CS(=O)CCCCN=C=S,PHASE2,urinary_system_disease
5922,Type 2 Diabetes|Microalbuminuria,Sitagliptin,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N,APPROVED,urinary_system_disease
5923,Anemia|Dialysis-dependent Chronic Kidney Disease,Vadadustat,C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O,PHASE2,urinary_system_disease
5924,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma|Low Grade Glioma|Malignant Glioma|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Ependymoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Childhood Malignant Germ Cell Tumor|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Rhabdoid Tumor|Wilms Tumor,Olaparib,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE2,urinary_system_disease
5926,Acute Kidney Injury,Phenylephrine,CNCC(C1=CC(=CC=C1)O)O,APPROVED,urinary_system_disease
5928,Acute Kidney Injury|Melatonin|Polymyxin B Adverse Reaction,Melatonin,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,PHASE2,urinary_system_disease
5929,Cytomegalovirus Retinitis|Acute Renal Failure,Cidofovir,C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O,APPROVED,urinary_system_disease
5930,Chronic Kidney Disease,Sevelamer,C=CCN.C1C(O1)CCl,APPROVED,urinary_system_disease
5931,"Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Polycystic Kidney, Autosomal Dominant",Lanreotide,CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N,PHASE2|PHASE3,urinary_system_disease
5932,Uric Acid Nephropathy,Losartan,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,APPROVED,urinary_system_disease
5935,Postoperative Ileus|Bladder Cancer,Prucalopride,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl,PHASE2,urinary_system_disease
5936,Hyperkalemia|Resistant Hypertension,Spironolactone,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,PHASE2,urinary_system_disease
5937,Renal Failure|Anesthesia,Sevoflurane,C(OC(C(F)(F)F)C(F)(F)F)F,PHASE1,urinary_system_disease
5938,"Hepatitis B, Chronic|Chronic Kidney Diseases",Telbivudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O,APPROVED,urinary_system_disease
5939,Bladder Cancer,Tamoxifen,CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3,PHASE2,urinary_system_disease
5943,Advanced Malignant Solid Neoplasm|Stage III Cutaneous Melanoma AJCC v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7,Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,PHASE1,urinary_system_disease
5944,Chronic Kidney Diseases|Anemia of Chronic Kidney Disease,Desidustat,C1CC1CON2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O,APPROVED,urinary_system_disease
5945,Lupus Nephritis,Laquinimod,CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O,PHASE2,urinary_system_disease
5946,Lupus Nephritis,Prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,PHASE2,urinary_system_disease
5947,Bone Marrow Failure Syndrome|Congenital Amegakaryocytic Thrombocytopenia|Congenital Pure Red Cell Aplasia|Hereditary Sideroblastic Anemia|Myeloid Neoplasms With Germline GATA2 Mutation|Paroxysmal Nocturnal Hemoglobinuria|Shwachman-Diamond Syndrome,Treosulfan,CS(=O)(=O)OCC(C(COS(=O)(=O)C)O)O,PHASE2,urinary_system_disease
5948,Bone Marrow Failure Syndrome|Congenital Amegakaryocytic Thrombocytopenia|Congenital Pure Red Cell Aplasia|Hereditary Sideroblastic Anemia|Myeloid Neoplasms With Germline GATA2 Mutation|Paroxysmal Nocturnal Hemoglobinuria|Shwachman-Diamond Syndrome,Methotrexate,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2,urinary_system_disease
5950,Chronic Kidney Diseases|Hemodialysis Complication|Hyperphosphatemia,Cholestyramine,CCC(C)C.CCC(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)C[N+](C)(C)C.N.[Cl-],APPROVED,urinary_system_disease
5951,Benign Prostate Hyperplasia,Finasteride,CC12CCC3C(C1CCC2C(=O)NC(C)(C)C)CCC4C3(C=CC(=O)N4)C,APPROVED,urinary_system_disease
5954,"Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases",Pomalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N,PHASE2,urinary_system_disease
5955,"Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases",Acetaminophen,CC(=O)NC1=CC=C(C=C1)O,PHASE2,urinary_system_disease
5956,"Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases",Ranitidine,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,PHASE2,urinary_system_disease
5957,"Multiple Myeloma|Renal Impairment|Neoplasms, Plasma Cell|Neoplasms by Histologic Type|Neoplasms|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases",Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,PHASE2,urinary_system_disease
5958,"Urinary Tract Infections|Enterobacteriaceae Infections|Infection Due to ESBL Bacteria|Carbapenem|Escherichia Coli Infection|Klebsiella Pneumoniae Infection|Clinical Trial|Drug Resistance, Bacterial",Piperacillin,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,APPROVED,urinary_system_disease
5959,Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC),Selenomethionine,C[Se]CCC(C(=O)O)N,PHASE1|PHASE2,urinary_system_disease
5961,Advanced Malignant Solid Neoplasm|Malignant Solid Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Wilms Tumor,Ensartinib,CC1CN(CC(N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)OC(C)C4=C(C=CC(=C4Cl)F)Cl)N,PHASE2,urinary_system_disease
5962,Post-Op Complication,Bupivacaine,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,urinary_system_disease
5963,Post-Op Complication,Fentanyl,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,APPROVED,urinary_system_disease
5964,Renal Impairment,Lorlatinib,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PHASE1,urinary_system_disease
5966,Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer,Leucovorin,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,urinary_system_disease
5967,End-Stage Renal Disease|Hepatitis C,Ribavirin,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,APPROVED,urinary_system_disease
5968,End-Stage Renal Disease|Hepatitis C,Sofosbuvir,CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,APPROVED,urinary_system_disease
5969,Overactive Bladder|Constipation|Lower Urinary Tract Symptoms,Baclofen,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,APPROVED,urinary_system_disease
5970,Sickle Cell Disease,Hydroxycarbamide,C(=O)(N)NO,PHASE2,urinary_system_disease
5971,Sickle Cell Disease,Hydroxyurea,C(=O)(N)NO,PHASE2,urinary_system_disease
5972,"Diabetes Mellitus, Type 2|Diabetic Nephropathies",Gliclazide,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,APPROVED,urinary_system_disease
5973,Chronic Kidney Disease,Verinurad,CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N,PHASE2,urinary_system_disease
5974,Chronic Kidney Disease,Allopurinol,C1=NNC2=C1C(=O)NC=N2,PHASE2,urinary_system_disease
5975,"Transplant;Failure,Kidney|Pain, Postoperative",Ropivacaine,CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C,APPROVED,urinary_system_disease
5976,Uncomplicated Urinary Tract Infection|Antibiotic Resistant Infection,Cefixime,C=CC1=C(N2C(C(C2=O)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N)SC1)C(=O)O,APPROVED,urinary_system_disease
5977,Uncomplicated Urinary Tract Infection|Antibiotic Resistant Infection,Cefuroxime,CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O,APPROVED,urinary_system_disease
5978,Kidney Transplant Recipients|BK Virus,Mizoribine,C1=NC(=C(N1C2C(C(C(O2)CO)O)O)O)C(=O)N,APPROVED,urinary_system_disease
5979,"Anemia|Renal Insufficiency, Chronic",Molidustat,C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4,PHASE2,urinary_system_disease
5980,Overactive Bladder,Imidafenacin,CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N,APPROVED,urinary_system_disease
5981,Contrast-induced Acute Kidney Injury,Alprostadil,CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O,PHASE2,urinary_system_disease
5982,Advanced Malignant Solid Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Refractory Ependymoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma,Larotrectinib,C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F,PHASE2,urinary_system_disease
5983,Liver Cirrhosis|Renal Failure,Rifaximin,CC1C=CC=C(C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC(C4=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)C,APPROVED,urinary_system_disease
5984,Liver Cirrhosis|Renal Failure,Lactulose,C(C1C(C(C(C(O1)OC2C(OC(C2O)(CO)O)CO)O)O)O)O,APPROVED,urinary_system_disease
5985,Renal Cell Cancer,Melphalan,C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl,PHASE2,urinary_system_disease
5986,Chronic Kidney Disease,Minocycline,CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,APPROVED,urinary_system_disease
5987,IGA Glomerulonephritis,Ramipril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O,APPROVED,urinary_system_disease
5988,Chronic Kidney Diseases,Pioglitazone,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,APPROVED,urinary_system_disease
5990,Chronic Kidney Disease|Peritoneal Dialysis,Icodextrin,C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl,APPROVED,urinary_system_disease
5991,"Carcinoma, Renal Cell",Tivozanib,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,PHASE2,urinary_system_disease
5993,Paroxysmal Nocturnal Hemoglobinuria,Cemdisiran,CC(=O)NC1C(C(C(OC1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)NC(=O)CCCCCCCCCCC(=O)N4CC(CC4COP(=O)(O)O)O)CO)O)O,PHASE2,urinary_system_disease
5994,Renal Cell Carcinoma|Colorectal Adenocarcinoma|Non-squamous Non-small Cell Lung Cancer|Platinum-refractory Ovarian Carcinoma|Cervical Carcinoma,Nintedanib,CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,PHASE1,urinary_system_disease
5995,"Solid Tumor|Breast Tumor|Colon Tumor, Malignant|Lung Tumor|Urologic Cancer|Pancreatic Cancer|Melanoma|Metastatic Cancer|Locally Advanced Solid Tumor|Esophageal Cancer|Endometrial Cancer|Head and Neck Cancer",Niraparib,C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N,PHASE2,urinary_system_disease
5996,Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney,Leuprolide,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,urinary_system_disease
5997,Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney,Leuprorelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,PHASE2,urinary_system_disease
5998,"Alport Syndrome, X-Linked",Benazepril,CCOC(=O)C(CCC1=CC=CC=C1)NC2CCC3=CC=CC=C3N(C2=O)CC(=O)O,PHASE2,urinary_system_disease
5999,Soft Tissue Sarcoma|Lymphoma|Leukemia|Wilms' Tumor|Osteosarcoma,Vincristine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE2,urinary_system_disease
6000,Urinary Tract Infections|Acute Pyelonephritis,Finafloxacin,C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4CC5C(C4)OCCN5)F)C(=O)O,PHASE2,urinary_system_disease
6002,HIV,Bictegravir,C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F,PHASE1,urinary_system_disease
6003,End Stage Renal Disease,Empagliflozin,C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl,PHASE2,urinary_system_disease
6004,"Transplant; Failure, Kidney",Desflurane,C(C(F)(F)F)(OC(F)F)F,PHASE2,urinary_system_disease
6005,Renal Insufficiency|Kidney Diseases|Urologic Diseases,Udenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C,PHASE1,urinary_system_disease
6006,Chronic Kidney Disease Requiring Chronic Dialysis|Hyperphosphatemia,Tenapanor,CN1CC(C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)C5CN(CC6=C5C=C(C=C6Cl)Cl)C,APPROVED,urinary_system_disease
6007,Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor,Copanlisib,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5,PHASE2,urinary_system_disease
6008,Renal Transplantation|Uremia,Bortezomib,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,PHASE1|PHASE2,urinary_system_disease
6009,Renal Cancer|Non Small Cell Lung Cancer (NSCLC)|Soft Tissue Sarcoma,Panobinostat,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO,PHASE1,urinary_system_disease
6010,Congestive Heart Failure|Renal Impairment,Pecavaptan,CC(C1=NC(=NN1C2=CC(=CC=C2)Cl)CN3C(=O)N(C(=N3)C4=CC=C(C=C4)Cl)CC(C(F)(F)F)O)O,PHASE1,urinary_system_disease
6012,Atrial Fibrillation,Dabigatran,CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N,APPROVED,urinary_system_disease
6013,Gout|Moderate Renal Impairment,Febuxostat,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,PHASE2,urinary_system_disease
6014,Gout|Moderate Renal Impairment,Naproxen,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,PHASE2,urinary_system_disease
6015,Gout|Moderate Renal Impairment,Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,PHASE2,urinary_system_disease
6016,Chronic Kidney Disease,Fosinopril,CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3,APPROVED,urinary_system_disease
6017,Chronic Kidney Disease,Benidipine,CC1=C(C(C(=C(N1)C)C(=O)OC2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,APPROVED,urinary_system_disease
6018,Chronic Kidney Disease,Hydrochlorothiazide,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,APPROVED,urinary_system_disease
6019,Bladder Urothelial Carcinoma|Stage III Bladder Cancer AJCC v8,Mitomycin,CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N,PHASE2,urinary_system_disease
6020,"Renal Insufficiency, Chronic|Hepatic Insufficiency|Healthy",Itraconazole,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,PHASE1,urinary_system_disease
6021,"Renal Insufficiency, Chronic|Hepatic Insufficiency|Healthy",Diclofenac,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,PHASE1,urinary_system_disease
6022,Urinary Tract Infection|Asymptomatic Bacteriuria|Allograft Rejection|Microbiologic Resistance|Hospitalization,Fosfomycin,CC1C(O1)P(=O)(O)O,APPROVED,urinary_system_disease
6023,Urinary Tract Infection|Asymptomatic Bacteriuria|Allograft Rejection|Microbiologic Resistance|Hospitalization,Tromethamine,C(C(CO)(CO)N)O,APPROVED,urinary_system_disease
6024,Albuminuria,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,APPROVED,urinary_system_disease
6025,Diabetic Nephropathy,Probucol,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,APPROVED,urinary_system_disease
6026,Diabetic Nephropathy,Cilostazol,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,APPROVED,urinary_system_disease
6027,Wilms Tumor,Tricyclazole,CC1=C2C(=CC=C1)SC3=NN=CN23,PHASE2,urinary_system_disease
6028,Neurogenic Bladder,Methantheline,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13,PHASE1,urinary_system_disease
6029,"Hepatorenal Syndrome|Cirrhosis|Kidney Failure, Acute",Midodrine,COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O,PHASE2,urinary_system_disease
6030,"Hepatorenal Syndrome|Cirrhosis|Kidney Failure, Acute",Octreotide,CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O,PHASE2,urinary_system_disease
6031,Kidney Diseases|Coronary Artery Disease,Regadenoson,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N,APPROVED,urinary_system_disease
6032,Paroxysmal Nocturnal Hemoglobinuria (PNH),Zilucoplan,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCCC(C(=O)O)NC(=O)C(C1CCCCC1)NC(=O)C2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC4=CNC5=C4C=CC=N5)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(C(C)(C)C)NC(=O)C(CC(=O)O)N(C)C(=O)C7CC(=O)NCCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O,PHASE2,urinary_system_disease
6033,Renal Cell Carcinoma,Quinacrine,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,PHASE2,urinary_system_disease
6034,Microalbuminuria|Macroalbuminuric Diabetic Nephropathy|Diabetes|Proteinuria|Albuminuria,Aliskiren,CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,APPROVED,urinary_system_disease
6035,Diabetic Nephropathies,Exenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N,APPROVED,urinary_system_disease
6036,Renal Impairment,Saroglitazar,CCOC(CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O,PHASE1,urinary_system_disease
6037,Urinary Tract Infection,Levofloxacin,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,APPROVED,urinary_system_disease
6038,Cardiorenal Syndrome,Nesiritide,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C3CCCN3C(=O)C(CO)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC4=CN=CN4)C(=O)O)CC(C)C)CO)CO)CO)CO,PHASE1|PHASE2,urinary_system_disease
6039,"Kidney Failure|Hepatitis C|Kidney Disease, Chronic",Glecaprevir,CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C,APPROVED,urinary_system_disease
6040,"Kidney Failure|Hepatitis C|Kidney Disease, Chronic",Pibrentasvir,CC(C(C(=O)N1CCCC1C2=NC3=C(N2)C=C(C(=C3)F)C4CCC(N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)C1CCCN1C(=O)C(C(C)OC)NC(=O)OC)NC(=O)OC)OC,APPROVED,urinary_system_disease
6041,Kidney Cancer,Temsirolimus,CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC,PHASE2,urinary_system_disease
6042,Renal Cancer|GIST,Perifosine,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C,PHASE1,urinary_system_disease
6043,Type 2 Diabetes Mellitus|Chronic Kidney Diseases,Cotadutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CO)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)C)C(=O)NC(C)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)N)C(=O)O,PHASE2,urinary_system_disease
6044,Type 2 Diabetes Mellitus|Chronic Kidney Diseases,Semaglutide,CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N,PHASE2,urinary_system_disease
6045,Anemia of Chronic Kidney Disease,Cholecalciferol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,PHASE2,urinary_system_disease
6047,Subjects With Impaired Renal Function and Healthy Subjects,Rivoceranib,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,PHASE1,urinary_system_disease
6048,Platelet Aggregation|Adenosine|Coronary Artery Disease|Kidney Dysfunction|Antiplatelet Therapy,Clopidogrel,COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,PHASE2,urinary_system_disease
6049,Platelet Aggregation|Adenosine|Coronary Artery Disease|Kidney Dysfunction|Antiplatelet Therapy,Ticagrelor,CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F,PHASE2,urinary_system_disease
6050,Chronic Kidney Diseases,Zibotentan,CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4,PHASE2,urinary_system_disease
6051,Hypertension,Telmisartan,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,APPROVED,urinary_system_disease
6052,Renal Insufficiency|Hepatic Insufficiency,Nevirapine,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,PHASE1,urinary_system_disease
6053,End-Stage Renal Disease|Stage 5 Chronic Kidney Disease,Telavancin,CCCCCCCCCCNCCNC1(CC(OC(C1O)C)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)C,APPROVED,urinary_system_disease
6054,Chronic Hemodialysis (ESRD),Hydralazine,C1=CC=C2C(=C1)C=NN=C2NN,APPROVED,urinary_system_disease
6057,Wolfram Syndrome,Valproate,CCCC(CCC)C(=O)O,PHASE2,urinary_system_disease
6058,HCV Infection,Voxilaprevir,CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C,PHASE1,urinary_system_disease
6059,Kidney Failure,Terlipressin,C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N,PHASE2,urinary_system_disease
6060,Diabetic Nephropathy,Captopril,CC(CS)C(=O)N1CCCC1C(=O)O,PHASE2|PHASE3,urinary_system_disease
6061,Chronic Renal Disease,Beraprost,CC#CCC(C)C(C=CC1C(CC2C1C3=CC=CC(=C3O2)CCCC(=O)O)O)O,APPROVED,urinary_system_disease
6062,"Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute|Renal Insufficiency|Liver Disease|Neoplasms",Azacitidine,C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N,PHASE1,urinary_system_disease
6063,"Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute|Renal Insufficiency|Liver Disease|Neoplasms",Pevonedistat,C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N,PHASE1,urinary_system_disease
6064,"Polycystic Kidney, Autosomal Dominant",Tesevatinib,CN1CC2CC(CC2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC,PHASE1|PHASE2,urinary_system_disease
6065,Renal Calculus,Tramadol,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,APPROVED,urinary_system_disease
6066,Contrast Induced Nephropathy,Acetazolamide,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,PHASE2,urinary_system_disease
6067,Chronic Kidney Disease|Type 2 Diabetes Mellitus,Finerenone,CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C,PHASE2,urinary_system_disease
6068,Renal Insufficiency|Chronic Hypertension,Chlorthalidone,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,PHASE2,urinary_system_disease
6069,Malignant Solid Tumour|Renal Cell Carcinoma|Non Small Cell Lung Carcinoma,Vorinostat,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,PHASE1,urinary_system_disease
6070,Nephrolithiasis|Nephrocalcinosis|Hypercalciuria,Fluconazole,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,PHASE2,urinary_system_disease
6071,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Erdafitinib,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,PHASE2,urinary_system_disease
6072,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Selumetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,PHASE2,urinary_system_disease
6073,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Tipifarnib,CN1C=NC=C1C(C2=CC=C(C=C2)Cl)(C3=CC4=C(C=C3)N(C(=O)C=C4C5=CC(=CC=C5)Cl)C)N,PHASE2,urinary_system_disease
6074,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Ulixertinib,CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl,PHASE2,urinary_system_disease
6075,Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor,Vemurafenib,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,PHASE2,urinary_system_disease
6076,Insomnia Disorder|Nocturia,Daridorexant,CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl,APPROVED,urinary_system_disease
6077,Interstitial Cystitis/Painful Bladder Syndrome|Myofascial Pelvic Pain,Metoprolol,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,APPROVED,urinary_system_disease
6078,"Renal Disease, End-Stage|Renal Insufficiency, Chronic|Renal Insufficiency, Acute",Bosutinib,CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC,PHASE1,urinary_system_disease
6079,Bladder Cancer,Mitomycin C,CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N,PHASE2,urinary_system_disease
6081,"Collapsing Glomerulopathy|Glomerulosclerosis, Focal Segmental",Isotretinoin,CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C,PHASE2,urinary_system_disease
6082,Renal Insufficiency|Heart Failure,Tonapofylline,CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CCC(CC3)(CC4)CCC(=O)O,PHASE2,urinary_system_disease
6083,Cystinuria,Bucillamine,CC(C)(C(=O)NC(CS)C(=O)O)S,PHASE2,urinary_system_disease
6084,"Hepatitis C|Renal Insufficiency, Chronic|Disorder of Transplanted Kidney",Grazoprevir,CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1,APPROVED,urinary_system_disease
6085,"Hepatitis C|Renal Insufficiency, Chronic|Disorder of Transplanted Kidney",Elbasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC4=C(C=C3)N5C(OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)C8CCCN8C(=O)C(C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC,APPROVED,urinary_system_disease
6086,Renal Impairment,Ioversol,C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO,APPROVED,urinary_system_disease
6088,Renal Impairment,Cefepime,C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-],PHASE1,urinary_system_disease
6089,Vascular Calcification|Arteriosclerosis,Alendronate,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,APPROVED,urinary_system_disease
6092,Urinary Tract Infections,Hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,APPROVED,urinary_system_disease
6094,"Kidney, Polycystic, Autosomal Dominant",Cilnidipine,CC1=C(C(C(=C(N1)C)C(=O)OCC=CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC,PHASE2,urinary_system_disease
6095,"Kidney, Polycystic, Autosomal Dominant",Imidapril,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C(CN(C2=O)C)C(=O)O,PHASE2,urinary_system_disease
6097,Bladder Cancer|Muscle-invasive Bladder Cancer,Pegfilgrastim,CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C,PHASE2,urinary_system_disease
6098,Nephrolithiasis|Urolithiasis|Idiopathic Hypercalciuria|Vitamin D Deficiency|Disorder of Vitamin D,Ergocalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C,APPROVED,urinary_system_disease
6099,Diabetic Nephropathies,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,PHASE2,urinary_system_disease
6101,Contrast Induced Nephropathy,Iopamidol,CC(C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O,APPROVED,urinary_system_disease
6102,Overactive Bladder,Solabegron,C1=CC(=CC(=C1)C(=O)O)C2=CC(=CC=C2)NCCNCC(C3=CC(=CC=C3)Cl)O,PHASE2,urinary_system_disease
6103,Urologic Neoplasms,Afatinib,CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4,PHASE2,urinary_system_disease
6104,Renal Cell Cancer|Cancer,Nelfinavir,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,PHASE1,urinary_system_disease
6105,Urinary Tract Infections|Pyelonephritis Acute|Intraabdominal Infections,Sulopenem,CC(C1C2N(C1=O)C(=C(S2)SC3CCS(=O)C3)C(=O)O)O,PHASE1,urinary_system_disease
6107,"Carcinoma, Renal Cell",Lactoferrin,CCC(C)C(C(=NC(C(C)O)C(=NC(CS)C(=NC(C(C)C)C(=NC(CCCNC(=N)N)C(=NC(CCCNC(=N)N)C(=NC(C)C(=NC(CC1=CC=CC=C1)C(=O)O)O)O)O)O)O)O)O)N=C(C(CO)N=C(C2CCCN2C(=O)C(C)N=C(CN=C(C(CC(C)C)N=C(C(CCCCN)N=C(C(CCCCN)N=C(C(CCSC)N=C(C(CCCNC(=N)N)N=C(C(CC3=CNC4=CC=CC=C43)N=C(C(CCC(=N)O)N=C(C(CC5=CNC6=CC=CC=C65)N=C(C(CCCNC(=N)N)N=C(C(CCCNC(=N)N)N=C(C(CS)N=C(C(CCCCN)N=C(C(CC7=CC=CC=C7)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O,PHASE2,urinary_system_disease
6108,Renal Impairment|Type 2 Diabetes Mellitus,Ertugliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl,PHASE1,urinary_system_disease
6109,Benign Prostatic Hypertrophy,Ozarelix,CCCCC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCCNC(=O)N)NC(=O)C(CC2=CC=C(C=C2)O)N(C)C(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C,PHASE2,urinary_system_disease
6110,Diabetes,Acarbose,CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO,APPROVED,urinary_system_disease
6111,Type 2 Diabetes Mellitus,Perindopril,CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O,APPROVED,urinary_system_disease
6113,End Stage Renal Disease|Chronic Pain|Opioid Dependence,Buprenorphine,CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,PHASE2,urinary_system_disease
6114,Renal Impairment,Olorofim,CC1=CC(=C(N1C)C(=O)C(=O)NC2=CC=C(C=C2)N3CCN(CC3)C4=NC=C(C=N4)F)C5=CC=CC=C5,PHASE1,urinary_system_disease
6115,Hypertension|Hemodialysis,Digoxin,CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,APPROVED,urinary_system_disease
6116,Focal Segmental Glomerulosclerosis|Minimal Change Disease|Immunoglobulin A Nephropathy|IgA Vasculitis|Alport Syndrome,Sparsentan,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC,PHASE2,urinary_system_disease
6117,Fanconi Anemia,Eltrombopag,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,PHASE2,urinary_system_disease
6118,Renal Impairment,Buparlisib,C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4,PHASE1,urinary_system_disease
6120,Paroxysmal Nocturnal Hemoglobinuria (PNH),Danicopan,CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4CC(CC4C(=O)NC5=NC(=CC=C5)Br)F,PHASE2,urinary_system_disease
6121,HIV Infections|Kidney Disease,Zidovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],PHASE1,urinary_system_disease
6122,Cholecystitis|Endometriosis|Bowel Obstruction|Fibroids|Prostate Cancer|Chronic Kidney Disease|Uterine Prolapse,Rocuronium,CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C,APPROVED,urinary_system_disease
6123,Kidney Failure,Voriconazole,CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,PHASE1|PHASE2,urinary_system_disease
6124,Renal Impairment,Nalmefene,C=C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O,PHASE1,urinary_system_disease
6125,Urothelial Carcinoma Bladder|Androgen Receptor Positive,Degarelix,CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC(=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC=C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C,PHASE1,urinary_system_disease
6126,Diabetic Nephropathy Type 2,Linagliptin,CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C,APPROVED,urinary_system_disease
6127,Diabetic Nephropathy Type 2,Sulodexide,CNC1=C2C(=NC=N1)N(C=N2)C3C(C(C(O3)CO)O)OC,APPROVED,urinary_system_disease
6128,"Carcinoma, Renal Cell",Topotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,PHASE1,urinary_system_disease
6129,Chronic Kidney Disease,Amiloride,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,APPROVED,urinary_system_disease
6130,End Stage Renal Disease,Apixaban,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,PHASE1,urinary_system_disease
6131,Urinary Tract Infections,Gentamicin,CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC,APPROVED,urinary_system_disease
6132,Diabetic Kidney Disease,Selonsertib,CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F,PHASE2,urinary_system_disease
6133,Hepatorenal Syndrome,Ifetroban,CCCCCNC(=O)C1=COC(=N1)C2C3CCC(C2CC4=CC=CC=C4CCC(=O)O)O3,PHASE2,urinary_system_disease
6134,Primary Hyperoxaluria,Stiripentol,CC(C)(C)C(C=CC1=CC2=C(C=C1)OCO2)O,PHASE2,urinary_system_disease
6135,"Renal Insufficiency, Chronic|Angioplasty, Transluminal, Percutaneous Coronary|Coronary Arteriosclerosis",Iomeprol,CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO,APPROVED,urinary_system_disease
6136,Urinary Tract Infections,Cefiderocol,CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4(CCCC4)CCNC(=O)C5=C(C(=C(C=C5)O)O)Cl)C(=O)[O-],PHASE2,urinary_system_disease
6137,Urinary Tract Infections,Imipenem,CC(C1C2CC(=C(N2C1=O)C(=O)O)SCCN=CN)O,PHASE2,urinary_system_disease
6138,"Kidney Failure, Chronic|Disorders Associated With Peritoneal Dialysis",Isoxaflutole,CS(=O)(=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C2=C(ON=C2)C3CC3,APPROVED,urinary_system_disease
6139,"Kidney Failure, Chronic",Pimodivir,C1CC2CCC1C(C2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O,PHASE1,urinary_system_disease
6140,HIV-infected Participants With ESRD Undergoing Routine Hemodialysis,Doravirine,CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)(F)F,APPROVED,urinary_system_disease
6141,Non Muscle Invasive Bladder Cancer,Celecoxib,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,PHASE2,urinary_system_disease
6142,Healthy Volunteer|Renal Impairment,Probenecid,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,PHASE1,urinary_system_disease
6143,Heart Failure|Renal Insufficiency,Cenderitide,CCC(C)C(C(=O)NCC(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NCC(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CS)C(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC(=O)O)C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)N3CCCC3C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CO)C(=O)NC(C)C(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CS)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CN,PHASE1|PHASE2,urinary_system_disease
6144,"Kidney Failure, Chronic|Cardiovascular Diseases",Candesartan,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,APPROVED,urinary_system_disease
6145,Renal Cell Carcinoma,Fluzoparib,C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,PHASE2,urinary_system_disease
6146,Chronic Kidney Disease,Pitavastatin,C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F,APPROVED,urinary_system_disease
6147,"Leukemia|Lymphoma|Hodgkin's Disease|Hematologic Neoplasms|Multiple Myeloma|Carcinoma, Renal Cell",Pentostatin,C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O,PHASE2,urinary_system_disease
6149,Nephrogenic Fibrosing Dermopathy,Gadodiamide,CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3],APPROVED,urinary_system_disease
6150,Nephrogenic Fibrosing Dermopathy,Meglumine,CNCC(C(C(C(CO)O)O)O)O,APPROVED,urinary_system_disease
6151,Urolithiasis,Morphine,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O,APPROVED,urinary_system_disease
6152,Urolithiasis,Paracetamol,CC(=O)NC1=CC=C(C=C1)O,APPROVED,urinary_system_disease
6153,Urinary Tract Infection|Acute Pyelonephritis|Hospital Acquired Pneumonia|Ventilator-associated Pneumonia|Bacteremia|Intra-abdominal Infection,Ceftazidime,CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-],APPROVED,urinary_system_disease
6154,Urinary Tract Infection|Acute Pyelonephritis|Hospital Acquired Pneumonia|Ventilator-associated Pneumonia|Bacteremia|Intra-abdominal Infection,Avibactam,C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)N,APPROVED,urinary_system_disease
6155,Postural Tachycardia Syndrome|Orthostatic Intolerance,Carbidopa,CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,PHASE2|PHASE3,urinary_system_disease
6157,"Kidney Failure, Chronic",Sapropterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,urinary_system_disease
6158,"Kidney Failure, Chronic",Tetrahydrobiopterin,CC(C(C1CNC2=C(N1)C(=O)NC(=N2)N)O)O,PHASE2,urinary_system_disease
6159,"Kidney Failure, Chronic",Folate,C1=CC(=CC=C1C(=O)NC(CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N,PHASE2,urinary_system_disease
6161,Colorectal Carcinoma|Endometrial Carcinoma|Melanoma|Neuroblastoma|Ovarian Carcinoma|Pancreatic Ductal Adenocarcinoma|Recurrent Desmoid Fibromatosis|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Refractory Desmoid Fibromatosis|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Hepatocellular Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Solid Pseudopapillary Neoplasm of the Pancreas|Wilms Tumor,Tegavivint,CC1CC(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=C4C=CC(=CC4=C3N=O)S(=O)(=O)N5CC(CC(C5)C)C)NO)C,PHASE1|PHASE2,urinary_system_disease
6162,Vestibulodynia|Temporomandibular Disorder|Fibromyalgia Syndrome|Irritable Bowel Syndrome|Migraines|Tension Headache|Endometriosis|Interstitial Cystitis|Back Pain|Chronic Fatigue Syndrome,Nortriptyline,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE2,urinary_system_disease
6164,Kidney Failure|Renal Failure,Erythropoietin,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+],PHASE2,urinary_system_disease
6165,Multiple Myeloma|Chronic Kidney Disease,Thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,PHASE2,urinary_system_disease
6166,Multiple Myeloma|Chronic Kidney Disease,Bendamustine,CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O,PHASE2,urinary_system_disease
6167,Urinary Schistosomiasis,Mefloquine,C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,PHASE2,urinary_system_disease
6168,Insomnia,Suvorexant,CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl,PHASE1,urinary_system_disease
6169,Kidney Dysfunction,Nemonoxacin,CC1CC(CN(C1)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)OC)N,PHASE1,urinary_system_disease
6170,"Renal Insufficiency, Chronic|Proteinuria",Lisinopril,C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O,APPROVED,urinary_system_disease
6172,Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkin's Lymphoma,Merestinib,CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F,PHASE1,urinary_system_disease
6173,Kidney Stone|Unexplained Haematuria|Benignant Tumour Mass in the Upper Urinary Tract,Isoproterenol,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,PHASE2|PHASE3,urinary_system_disease
6174,Kidney Stone|Unexplained Haematuria|Benignant Tumour Mass in the Upper Urinary Tract,Isoprenaline,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,PHASE2|PHASE3,urinary_system_disease
6175,Renal Cell Cancer|Metastatic Renal Cell Cancer,Famitinib,CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)C=C3C4=C(C=CC(=C4)F)NC3=O)C,PHASE2,urinary_system_disease
6176,Nephrotic Syndrome|Hyperlipidemia,Pravastatin,CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O,PHASE1,urinary_system_disease
6177,"Glomerulonephritis, IGA|Renal Insufficiency, Chronic",Leflunomide,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,APPROVED,urinary_system_disease
6180,"Polycystic Kidney, Autosomal Dominant",Venglustat,CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)OC3CN4CCC3CC4,PHASE2|PHASE3,urinary_system_disease
6181,Atherosclerosis,Darapladib,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,PHASE1,urinary_system_disease
6182,Acute Renal Colic|Ureteric Stone,Parecoxib,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C,APPROVED,urinary_system_disease
6183,Ovarian Cancer|Renal Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Solid Tumors|Multiple Myeloma|Lymphoma,Carfilzomib,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,PHASE1|PHASE2,urinary_system_disease
6184,BRAF Gene Mutation|Hepatic Complication|Renal Failure|Solid Neoplasm,Dabrafenib,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F,PHASE1,urinary_system_disease
6185,Endstage Renal Disease,Nadroparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,urinary_system_disease
6186,Pyelonephritis Acute,Ceftriaxone,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,APPROVED,urinary_system_disease
6187,Chronic Kidney Disease,Rifampin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE1,urinary_system_disease
6188,Chronic Kidney Disease,Rifampicin,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C,PHASE1,urinary_system_disease
6189,Critical Illness|Acute Kidney Injury|End-stage Renal Disease|Renal Replacement Therapy|Proton Pump Inhibitor,Pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,APPROVED,urinary_system_disease
6190,Brain and Central Nervous System Tumors|Kidney Cancer|Liver Cancer|Retinoblastoma|Sarcoma,Mesna,C(CS(=O)(=O)[O-])S.[Na+],PHASE1,urinary_system_disease
6191,Renal Cell Carcinoma,Cediranib,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,PHASE2,urinary_system_disease
6192,Diabetic Nephropathy,Benfotiamine,CC1=NC=C(C(=N1)N)CN(C=O)C(=C(CCOP(=O)(O)O)SC(=O)C2=CC=CC=C2)C,APPROVED,urinary_system_disease
6193,"Diabetes Mellitus, Type 1|Diabetic Nephropathy",Alagebrium,CC1=C(SC=[N+]1CC(=O)C2=CC=CC=C2)C,PHASE2,urinary_system_disease
6194,Urinary Bladder Neoplasms|Ureteral Neoplasms|Urethral Neoplasms,Crizotinib,CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,PHASE2,urinary_system_disease
6195,Bladder Cancer,Simvastatin,CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C,PHASE2,urinary_system_disease
6196,Renal Impairment|Healthy Participants,Linzagolix,COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC,PHASE1,urinary_system_disease
6197,Lupus Nephritis,Voclosporin,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,PHASE2,urinary_system_disease
6198,Urothelial Carcinoma of the Urinary Bladder,Cabazitaxel,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC,PHASE1|PHASE2,urinary_system_disease
6199,Clear-Cell Renal Cell Carcinoma,Sitravatinib,COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,PHASE1,urinary_system_disease
6201,Advanced/Metastasis Renal Cell Carcinoma,Lipotecan,CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)OC(=O)C(C)ON=C6C7=C(C(=CC(=C7)[N+](=O)[O-])[N+](=O)[O-])C8=C6C=C(C=C8[N+](=O)[O-])[N+](=O)[O-],PHASE2,urinary_system_disease
6202,Renal Impairment|Healthy,Esketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE1,urinary_system_disease
6203,"Renal Failure, Chronic|End-Stage Renal Disease",Serelaxin,CCC(C)C1C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)C)C(C)CC)CCC(=O)N)C)CCCNC(=N)N)C(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O)C(CC(=O)O)N)C(=O)NC(C(=O)NC(C(=O)NCC(=O)N2)C(C)C)CC5=CN=CN5)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(C)C)NC(=O)C7CCC(=O)N7)C(C)O)CCCCN)CCCNC(=N)N)CO)CC(C)C)C)CCCNC(=N)N)CC8=CC=CC=C8)C(=O)O)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CO)C(=O)O,PHASE1,urinary_system_disease
6205,Benign Prostatic Hyperplasia|Lower Urinary Tract Symptoms,Alfuzosin,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC,APPROVED,urinary_system_disease
6207,AKI - Acute Kidney Injury,Trimetazidine,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,APPROVED,urinary_system_disease
6208,Acute Kidney Injury|Renal Replacement Therapy|Anticoagulants,Tinzaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,urinary_system_disease
6209,Metastatic Ureter Carcinoma|Metastatic Urethral Carcinoma|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage III Ureter Cancer AJCC v7|Stage III Urethral Cancer AJCC v7|Stage IV Bladder Urothelial Carcinoma AJCC v7|Stage IV Ureter Cancer AJCC v7|Stage IV Urethral Cancer AJCC v7|Ureter Urothelial Carcinoma|Urethral Urothelial Carcinoma,Eribulin,CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O,PHASE2,urinary_system_disease
6210,Healthy,Licarbazepine,C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O,PHASE1,urinary_system_disease
6211,Coronary Artery Disease|End Stage Renal Disease,Nicorandil,C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-],APPROVED,urinary_system_disease
6213,Analgesia|Urolithiasis,Meperidine,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,APPROVED,urinary_system_disease
6214,HIV Infections|Kidney Diseases,Maraviroc,CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,PHASE2,urinary_system_disease
6215,Renal Impairment,Molnupiravir,CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)NO)O)O,PHASE1,urinary_system_disease
6217,Clear Cell Renal Cell Carcinoma,Imatinib,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,PHASE1|PHASE2,urinary_system_disease
6218,Renal Impairment,Besifovir,C1CC1(CN2C=NC3=CN=C(N=C32)N)OCP(=O)(O)O,PHASE1,urinary_system_disease
6219,Fanconi Anemia|Myelodysplastic Syndrome (MDS)|Acute Myelogenous Leukemia (AML),Busulfan,CS(=O)(=O)OCCCCOS(=O)(=O)C,PHASE2,urinary_system_disease
6220,First-line Treatment of Non-clear Renal Cell Carcinoma,Fruquintinib,CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC,PHASE2,urinary_system_disease
6222,Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer,Suramin,CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C,PHASE1|PHASE2,urinary_system_disease
6223,"Carcinoma, Renal Cell",Regorafenib,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,PHASE2,urinary_system_disease
6224,Bladder Cancer,Vinblastine,CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,PHASE2,urinary_system_disease
6225,Nephrotic Syndrome in Children,Levamisole,C1CSC2=NC(CN21)C3=CC=CC=C3,APPROVED,urinary_system_disease
6226,Henoch-Schönlein Purpura Nephritis,Dipyridamole,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,PHASE1|PHASE2,urinary_system_disease
6227,Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer,Vinflunine,CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)C6(CC7CC(CN(C7)CC8=C6NC9=CC=CC=C89)C(C)(F)F)C(=O)OC)OC)C,PHASE2,urinary_system_disease
6228,Catheter; Infection (Indwelling Catheter)|Catheter Infection|Catheter-Related Infections|Catheter Bacteraemia|Urinary Tract Infections,Povidone,C=CN1CCCC1=O,APPROVED,urinary_system_disease
6229,Prostatic Hyperplasia,Lemuteporfin,CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OCCO)C(=C3C)CCC(=O)OCCO)C=C,PHASE2,urinary_system_disease
6231,Advanced Cancer|Advanced Malignancies|Bladder Cancer|Cervical Cancer|Esophageal Cancer|Gastric Cancer|Gastroesophageal-junction Cancer (GEJ)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Non-Small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Renal Cell Carcinoma (RCC)|Triple Negative Breast Cancer (TNBC),Pemetrexed,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)NC(CCC(=O)O)C(=O)O,PHASE1,urinary_system_disease
6232,End-stage Renal Disease|HCV Coinfection,Ombitasvir,CC(C)C(C(=O)N1CCCC1C(=O)NC2=CC=C(C=C2)C3CCC(N3C4=CC=C(C=C4)C(C)(C)C)C5=CC=C(C=C5)NC(=O)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,APPROVED,urinary_system_disease
6233,End-stage Renal Disease|HCV Coinfection,Paritaprevir,CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8,APPROVED,urinary_system_disease
6234,End-stage Renal Disease|HCV Coinfection,Ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,APPROVED,urinary_system_disease
6235,Small Cell Neuroendocrine Carcinoma of Bladder|Bladder Cancer|Urothelial Carcinoma Bladder,Etoposide,CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,PHASE2,urinary_system_disease
6236,BK Virus Infection|Nephropathy|Kidney Transplantation,Brincidofovir,CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(CN1C=CC(=NC1=O)N)CO)O,PHASE2,urinary_system_disease
6237,Urinary Tract Infections|Elderly Infection,Amikacin,C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N,APPROVED,urinary_system_disease
6241,Renal Impairment|Diabetes,Vildagliptin,C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N,PHASE1|PHASE2,urinary_system_disease
6242,Urinary Incontinence,Litoxetine,C1CNCCC1OCC2=CC3=CC=CC=C3C=C2,PHASE1|PHASE2,urinary_system_disease
6243,Renal Insufficiency|Tenofovir,Tenofovir,CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O,APPROVED,urinary_system_disease
6244,Renal Impairment,Methylnaltrexone,C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,PHASE1,urinary_system_disease
6245,Renal Insufficiency,Tiotropium,C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C,PHASE1,urinary_system_disease
6246,"Diabetes Mellitus, Type 2|Renal Disease|Diabetes Mellitus|Metabolic Disease|Endocrine System Diseases",Evogliptin,CC(C)(C)OCC1C(=O)NCCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N,APPROVED,urinary_system_disease
6247,Diabetic Nephropathy,Nidufexor,CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O,PHASE2,urinary_system_disease
6248,"Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors",Anlotinib,CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,PHASE2,urinary_system_disease
6249,Cardiorenal Syndrome,Chlortalidone,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,PHASE2,urinary_system_disease
6250,Renal Impairment,Lemborexant,CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C,PHASE1,urinary_system_disease
6251,End Stage Renal Disease on Hemodialysis,Difelikefalin,CC(C)CC(C(=O)NC(CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N,PHASE1,urinary_system_disease
6252,Neoplasms|Solid Tumors|Bone Cancer|Kidney Tumor|Neuroblastoma,Ifosfamide,C1CN(P(=O)(OC1)NCCCl)CCCl,PHASE1,urinary_system_disease
6253,Neoplasms|Solid Tumors|Bone Cancer|Kidney Tumor|Neuroblastoma,Irinotecan,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,PHASE1,urinary_system_disease
6256,"Anti-Infective Agents, Urinary|Escherichia Coli Infections|Klebsiella Infections|Kidney Transplantation|Urinary Tract Infections",Sitafloxacin,C1CC12CN(CC2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5F)F,PHASE2|PHASE3,urinary_system_disease
6257,Bladder Pain Syndrome|Interstitial Cystitis,Naltrexone,C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O,PHASE2,urinary_system_disease
6258,"Chronic Kidney Disease, Stage 5|Secondary Hyperparathyroidism",Doxercalciferol,CC(C)C(C)C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,urinary_system_disease
6259,"Cirrhosis, Liver|Upper Gastrointestinal Bleeding",Somatostatin,CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)C(C)N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O,APPROVED,urinary_system_disease
6260,Accidental Falls|Chronic Renal Insufficiency|Aged,Alfacalcidol,CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C,APPROVED,urinary_system_disease
6262,Kidney Cancer|Leukemia|Lymphoma|Neurotoxicity|Peripheral Neuropathy|Sarcoma,Glutamine,C(CC(=O)N)C(C(=O)O)N,PHASE2,urinary_system_disease
6263,Overactive Bladder,Propiverine,CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C,APPROVED,urinary_system_disease
6264,Nephrolithiasis,Fexofenadine,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,PHASE2,urinary_system_disease
6265,Wolfram Syndrome,Tirzepatide,CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N,PHASE2,urinary_system_disease
6266,Urinary Tract Infections,Norfloxacin,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,APPROVED,urinary_system_disease
6267,Stress Urinary Incontinence,Epinephrine,CNCC(C1=CC(=C(C=C1)O)O)O,APPROVED,urinary_system_disease
6268,Enuresis|Obstructive Sleep Apnea|Sleep Disordered Breathing,Mometasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C,APPROVED,urinary_system_disease
6269,Renal Impairment,Teduglutide,CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N,PHASE1,urinary_system_disease
6271,Chronic Kidney Disease|Proteinuria,Nifedipine,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,PHASE1,urinary_system_disease
6272,Renal Cell Carcinoma,Brivanib,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C,PHASE2,urinary_system_disease
6273,Heart Failure|Renal Insufficiency,Levosimendan,CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,APPROVED,urinary_system_disease
6274,Heart Failure|Renal Insufficiency,Simendan,CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,APPROVED,urinary_system_disease
6275,T2DM (Type 2 Diabetes Mellitus)|Metformin|SGLT2-Inhibitors,Tofogliflozin,CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2,PHASE2,urinary_system_disease
6276,Chronic Kidney Disease|Proteinuria,Rosuvastatin,CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C,APPROVED,urinary_system_disease
6277,Albuminuria,Montelukast,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,APPROVED,urinary_system_disease
6278,"Renal Disease, End Stage",Amisulpride,CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC,PHASE1,urinary_system_disease
6279,Proteinuria,Triamterene,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,APPROVED,urinary_system_disease
6280,"Urinary Incontinence, Stress|Fecal Incontinence",Imipramine,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,PHASE1,urinary_system_disease
6282,Renal Impairment,Inclisiran,CC(=O)NC1C(C(C(OC1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)NC(=O)CCCCCCCCCCC(=O)N4CC(CC4COP(=O)(O)O)O)CO)O)O,PHASE1,urinary_system_disease
6283,Kidney Transplantation|Kidney Disease,Acyclovir,C1=NC2=C(N1COCCO)N=C(NC2=O)N,PHASE1|PHASE2,urinary_system_disease
6284,Kidney Transplantation|Kidney Disease,Pentamidine,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,PHASE1|PHASE2,urinary_system_disease
6285,Kidney Transplantation|Kidney Disease,Clotrimazole,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,PHASE1|PHASE2,urinary_system_disease
6286,Kidney Transplantation|Kidney Disease,Nystatin,CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O,PHASE1|PHASE2,urinary_system_disease
6287,Stage III Cutaneous Melanoma|Stage IV Cutaneous Melanoma|Locally Advanced Melanoma|Locally Advanced Solid Neoplasm|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Urothelial Carcinoma|Non-Small Cell Lung Carcinoma|Stage IB Lung Cancer AJCC v7|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ureter Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ureter Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Abexinostat,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PHASE1,urinary_system_disease
6288,Acute Renal Failure|Infection,Anidulafungin,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O,PHASE2,urinary_system_disease
6290,Proteinuria|Idiopathic Membranous Nephropathy,Corticotropin,CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C2CCCN2C(=O)C(CC3=CC=CC=C3)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C6CCCN6C(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(C(C)C)NC(=O)C7CCCN7C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC8=CNC9=CC=CC=C98)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CO)N,APPROVED,urinary_system_disease
6291,Healthy,Megestrol,CC1=CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,PHASE1,urinary_system_disease
6294,Uremic Pruritus,Nalfurafine,CN(C1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC6CC6)O)C(=O)C=CC7=COC=C7,PHASE2,urinary_system_disease
6295,Diabetic Nephropathy,Topiroxostat,C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N,PHASE2,urinary_system_disease
6296,End Stage Renal Disease,Plazomicin,CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CNCCO)N)N)NC(=O)C(CCN)O)O,PHASE1,urinary_system_disease
6297,End Stage Renal Disease|Peritoneal Dialysis,Chlorhexidine,C1=CC(=CC=C1NC(=NC(=NCCCCCCN=C(N)N=C(N)NC2=CC=C(C=C2)Cl)N)N)Cl,APPROVED,urinary_system_disease
6298,Renal Impairment,Brensocatib,CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)CC(C#N)NC(=O)C4CNCCCO4)OC1=O,PHASE1,urinary_system_disease
6299,Renal Cell Carcinoma|Hereditary Leiomyomatosis|Renal Cell Cancer,Vandetanib,CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC,PHASE1|PHASE2,urinary_system_disease
6300,Childhood Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of the Kidney|Papillary Renal Cell Carcinoma|Rhabdoid Tumor of the Kidney|Stage I Renal Cell Cancer|Stage I Renal Wilms Tumor|Stage II Renal Cell Cancer|Stage II Renal Wilms Tumor|Stage III Renal Cell Cancer|Stage III Renal Wilms Tumor|Stage IV Renal Cell Cancer|Stage IV Renal Wilms Tumor,Dactinomycin,CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C,PHASE2,urinary_system_disease
6301,Renal Insufficiency,Tirofiban,CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O,PHASE1,urinary_system_disease
6302,Malignant Neoplasms of Urinary Tract|Bladder Cancer,Neostigmine,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,APPROVED,urinary_system_disease
6303,Malignant Neoplasms of Urinary Tract|Bladder Cancer,Glycopyrrolate,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],APPROVED,urinary_system_disease
6304,Breast Cancer|Ovarian Cancer|Non Small Cell Lung Cancer|Colorectal Cancer|Pancreatic Cancer|Renal Cell Carcinoma|Nasopharyngeal Cancer|Head and Neck Squamous Cell Carcinoma|Gastric Cancer,Rimiducid,CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)C(CCC6=CC(=C(C=C6)OC)OC)OC(=O)C7CCCCN7C(=O)C(CC)C8=CC(=C(C(=C8)OC)OC)OC,PHASE1,urinary_system_disease
6305,Prostate Cancer|Erectile Dysfunction|Lower Urinary Tract Symptoms,Bicalutamide,CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,PHASE2,urinary_system_disease
6306,Renal Disease|End Stage Renal Disease,Droxidopa,C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O,PHASE1,urinary_system_disease
6307,Renal Insufficiency,Abiraterone,CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O,PHASE1,urinary_system_disease
6308,Atrial Fibrillation and Flutter|Stroke|Major Bleed|End-stage Renal Disease,Warfarin,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,APPROVED,urinary_system_disease
6309,"Diabetes Mellitus, Type 2|Albuminuria",Canagliflozin,CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F,APPROVED,urinary_system_disease
6310,Renal Insufficiency,Setmelanotide,CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5,PHASE1,urinary_system_disease
6311,Lupus Nephritis,Iguratimod,CS(=O)(=O)NC1=C(C=C2C(=C1)OC=C(C2=O)NC=O)OC3=CC=CC=C3,PHASE2,urinary_system_disease
6312,"Neoplasms|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Bronchial Neoplasms|Lung Neoplasms|Respiratory Tract Neoplasms|Thoracic Neoplasms|Digestive System Neoplasms|Endocrine Gland Neoplasms|Carcinoma, Non-Small-Cell Lung|Lung Diseases|Breast Diseases|Renal Neoplasm|Solid Tumors",Entinostat,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,PHASE1,urinary_system_disease
6313,Chronic Kidney Diseases|Major Depressive Disorder,Bupropion,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,PHASE2,urinary_system_disease
6314,Acute Cystitis (Excl in Pregnancy),Amdinocillin,CC1(C(N2C(S1)C(C2=O)N=CN3CCCCCC3)C(=O)O)C,APPROVED,urinary_system_disease
6315,Urinary Stress Incontinence,Duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,PHASE2,urinary_system_disease
6316,HIV,Dolutegravir,CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,APPROVED,urinary_system_disease
6317,Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms,Tetrahydrouridine,C1CN(C(=O)NC1O)C2C(C(C(O2)CO)O)O,PHASE2,urinary_system_disease
6318,Neuromuscular Blockade|Renal Impairment,Cisatracurium,C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C,PHASE2,urinary_system_disease
6320,Hepatoblastoma|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Kidney Neoplasm|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Neuroblastoma|Recurrent Osteosarcoma,Alisertib,COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC,PHASE2,urinary_system_disease
6321,Kidney Disease,Eprosartan,CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O,PHASE1,urinary_system_disease
6322,"Beta-thalassemia|Myelodysplastic Syndromes|Fanconi Syndrome|Anemia, Diamond-Blackfan|Anemia, Aplastic",Deferasirox,C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O,PHASE2,urinary_system_disease
6323,Urinary Tract Infections,Temocillin,CC1(C(N2C(S1)C(C2=O)(NC(=O)C(C3=CSC=C3)C(=O)O)OC)C(=O)O)C,APPROVED,urinary_system_disease
6324,Respiratory Tract Infections|Urinary Tract Infections,Cefoperazone,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O,PHASE2,urinary_system_disease
6325,Respiratory Tract Infections|Urinary Tract Infections,Sulbactam,CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)C,PHASE2,urinary_system_disease
6327,Lupus Nephritis,Tamibarotene,CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C,PHASE2,urinary_system_disease
6328,Hiv|HIV Infections|HIV Lipodystrophy|Osteoporosis|Renal Insufficiency|Weight Gain|Obesity,Lamivudine,C1C(OC(S1)CO)N2C=CC(=NC2=O)N,APPROVED,urinary_system_disease
6329,Wilms' Tumor|Sarcoma|Adenaocortical Carcinoma|Refractory Cancer|Coldrhood Cancer,Tariquidar,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,PHASE1,urinary_system_disease
6331,"Kidney Failure, Chronic",Alisporivir,CCC1C(=O)N(C(C(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C,PHASE1,urinary_system_disease
6332,Enuresis,Indomethacin,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,APPROVED,urinary_system_disease
6336,Renal Impairment,Phentermine,CC(C)(CC1=CC=CC=C1)N,PHASE1,urinary_system_disease
6337,Chronic Kidney Disease|End Stage Renal Disease,Metolazone,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,PHASE2,urinary_system_disease
6338,Urinary Stone,Cannabidiol,CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O,PHASE2|PHASE3,urinary_system_disease
6339,Restless Legs Syndrome|End Stage Renal Disease,Ropinirole,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,PHASE2,urinary_system_disease
6340,Adynamic Bone Disease|Chronic Kidney Diseases|Cardiac Disease|Chronic Kidney Disease-Mineral and Bone Disorder,Teriparatide,CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N,APPROVED,urinary_system_disease
6342,Renal Impairment,Deflazacort,CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C,PHASE1,urinary_system_disease
6343,Renal Insufficiency,Iberdomide,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5,PHASE1,urinary_system_disease
6344,Solid Tumor|Colorectal Cancer|Cholangiocarcinoma|Bladder Cancer|Ovarian Cancer|Gastric Cancer|Palpable Subcutaneous Malignant Lesions|Renal Cell Carcinoma|Melanoma|Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer,Imiquimod,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,PHASE1,urinary_system_disease
6345,Depression,Fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,APPROVED,urinary_system_disease
6346,Gram-Positive Bacterial Infections|Nephrotoxicity|Sepsis,Vancomycin,CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,APPROVED,urinary_system_disease
6347,Renal Impairment,Otamixaban,CC(C(CC1=CC(=CC=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-],PHASE1,urinary_system_disease
6348,"Pain, Chronic|Urge Incontinence|Overactive Bladder Syndrome|Quality of Life",Valaciclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE1,urinary_system_disease
6349,"Pain, Chronic|Urge Incontinence|Overactive Bladder Syndrome|Quality of Life",Valacyclovir,CC(C)C(C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,PHASE1,urinary_system_disease
6351,"Cancer|Pancreatic Cancer|Sarcoma|Renal Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms|Acute T Cell Leukemia Lymphoma",Lomustine,C1CCC(CC1)NC(=O)N(CCCl)N=O,PHASE2,urinary_system_disease
6352,Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Solid Neoplasm,Romidepsin,CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C,PHASE1,urinary_system_disease
6353,"Renal Insufficiency, Chronic",Bumetanide,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,PHASE2,urinary_system_disease
6354,Chronic Kidney Disease|Proteinuria|Blood Pressure,Sitaxentan,CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2,PHASE2,urinary_system_disease
6355,Renal Function,Ulipristal,CC(=O)C1(CCC2C1(CC(C3=C4CCC(=O)C=C4CCC23)C5=CC=C(C=C5)N(C)C)C)O,PHASE1,urinary_system_disease
6356,Growth Hormone Disorder|Adult Growth Hormone Deficiency|Growth Hormone Deficiency in Children,Somapacitan,C(CCCCCCCC1=NNN=N1)CCCCCCCC(=O)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCOCC(=O)NC(CCCCNC(=O)CSCC(C(=O)O)N)C(=O)N)C(=O)O)C(=O)O,PHASE1,urinary_system_disease
6357,Bladder Carcinoma|Refractory Bladder Carcinoma|Urinary Tract Infection,Clindamycin,CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,APPROVED,urinary_system_disease
6358,Acute Pyelonephritis,Omadacycline,CC(C)(C)CNCC1=CC(=C2CC3CC4C(C(=O)C(=C(C4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C,PHASE2,urinary_system_disease
6360,Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson,Aminophylline,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,APPROVED,urinary_system_disease
6361,Kidney Cancer|Renal Cancer|Renal Neoplasm,Hydromorphone,CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(=O)CC4,PHASE2,urinary_system_disease
6362,Renal Impairment|Renal Disease,Venetoclax,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C,PHASE1,urinary_system_disease
6363,Breast Cancer|Breast Neoplasms|Colon Cancer|Colonic Cancer|Colon Neoplasms|Lung Cancer|Melanoma|Kidney Cancer,Dacarbazine,CN(C)N=NC1=C(NC=N1)C(=O)N,PHASE1,urinary_system_disease
6365,Metastatic Renal Cell Carcinoma,Enzastaurin,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7,PHASE2,urinary_system_disease
6366,End Stage Renal Disease,Mupirocin,CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)C(C)O,APPROVED,urinary_system_disease
6367,Advanced Malignant Solid Neoplasm|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Fallopian Tube Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Renal Cell Carcinoma|Ovarian Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Primary Peritoneal Carcinoma|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Melanoma|Unresectable Renal Cell Carcinoma,Selinexor,C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,PHASE1,urinary_system_disease
6368,"Kidney Stone|Pain, Postoperative|Addiction|Opioid Use",Pregabalin,CC(C)CC(CC(=O)O)CN,PHASE2|PHASE3,urinary_system_disease
6369,Renal Impairment|End-stage Renal Disease,Simeprevir,CC1=C(C=CC2=C1N=C(C=C2OC3CC4C(C3)C(=O)N(CCCCC=CC5CC5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC,PHASE2,urinary_system_disease
6370,Renal Impairment|End-stage Renal Disease,Daclatasvir,CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE2,urinary_system_disease
6372,Lupus Nephritis,Zanubrutinib,C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N,PHASE2,urinary_system_disease
6375,Chronic Renal Insufficiency|Type 2 Diabetes Mellitus,Omarigliptin,CS(=O)(=O)N1C=C2CN(CC2=N1)C3CC(C(OC3)C4=C(C=CC(=C4)F)F)N,PHASE1,urinary_system_disease
6376,Congenital Heart Defects,Milrinone,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,PHASE2,urinary_system_disease
6377,Renal Impairment|Heart Failure,Torasemide,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,PHASE1,urinary_system_disease
6378,Renal Impairment|Heart Failure,Torsemide,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,PHASE1,urinary_system_disease
6379,Nephrotic Syndrome|Thromboembolic Disease,Dalteparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE1|PHASE2,urinary_system_disease
6380,"Kidney Failure, Chronic|Renal Disease, End-Stage",Argatroban,CC1CCN(C(C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C,APPROVED,urinary_system_disease
6382,Metastatic Renal Cell Cancer|Stage IV Renal Cell Cancer,Ibrutinib,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,PHASE1|PHASE2,urinary_system_disease
6383,Clear Cell Renal Cell Carcinoma|Metastatic Kidney Carcinoma|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7,Fludeoxyglucose,C(C(C(C(C(C=O)F)O)O)O)O,PHASE1|PHASE2,urinary_system_disease
6384,Hemodialysis-Induced Symptom|Mitochondrial Diseases,Icatibant,C1CCC2C(C1)CC(N2C(=O)C3CC4=CC=CC=C4CN3C(=O)C(CO)NC(=O)C(CC5=CC=CS5)NC(=O)CNC(=O)C6CC(CN6C(=O)C7CCCN7C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N)O)C(=O)NC(CCCN=C(N)N)C(=O)O,PHASE2,urinary_system_disease
6385,"Cirrhosis, Liver|End Stage Liver DIsease|Acute Kidney Injury|Liver Transplant; Complications",Norepinephrine,C1=CC(=C(C=C1C(CN)O)O)O,APPROVED,urinary_system_disease
6386,Cough|Endometriosis|Overactive Bladder,Moxifloxacin,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,PHASE1,urinary_system_disease
6387,Renal Impairment|Healthy,Sotagliflozin,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl,PHASE1,urinary_system_disease
6389,Advanced Bladder Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Merkel Cell Carcinoma|Advanced Renal Cell Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Merkel Cell Carcinoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage III Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Pathologic Stage IV Merkel Cell Carcinoma AJCC v8|Stage III Bladder Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IIIA Bladder Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Bladder Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IVA Bladder Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,Plinabulin,CC(C)(C)C1=C(N=CN1)C=C2C(=O)NC(=CC3=CC=CC=C3)C(=O)N2,PHASE1|PHASE2,urinary_system_disease
6390,Cannabis|Chronic Kidney Diseases|Dialysis,Dronabinol,CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O,PHASE1,urinary_system_disease
6391,Myelofibrosis,Pacritinib,C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,PHASE1,urinary_system_disease
6393,Recurrent Solid Tumor|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Wilms Tumor|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma,Talazoparib,CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,PHASE1|PHASE2,urinary_system_disease
6394,Complicated Urinary Tract Infection,Cilastatin,CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)O)C,PHASE2,urinary_system_disease
6395,Hepatitis C,Asunaprevir,CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C,APPROVED,urinary_system_disease
6396,End-stage Renal Disease|Cardiovascular Disease,Ranolazine,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O,APPROVED,urinary_system_disease
6397,Ischemia-Reperfusion Injury|Kidney Diseases,Reparixin,CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C,PHASE2,urinary_system_disease
6398,Cardiorenal Syndrome,Dobutamine,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,PHASE2,urinary_system_disease
6399,Renal Impairment|Healthy,Rivipansel,CC1C(C(C(C(O1)OC2C(CC(CC2OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)O)OC(=O)C5=CC=CC=C5)C(=O)NCCNC(=O)COCCOCC(=O)NC6=C7C(=CC(=C6)S(=O)(=O)O)C=C(C=C7S(=O)(=O)O)S(=O)(=O)O)NC(=O)C8=CC(=O)NC(=O)N8)O)O)O,PHASE1,urinary_system_disease
6400,"Glomerulosclerosis, Focal Segmental",Losmapimod,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C,PHASE2,urinary_system_disease
6401,Urinary Tract Infections,Cefotaxime,CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O,APPROVED,urinary_system_disease
6402,"COVID-19|Renal Insufficiency, Chronic",Nirmatrelvir,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C,APPROVED,urinary_system_disease
6404,Acute Decompensated Heart Failure,Dopamine,C1=CC(=C(C=C1CCN)O)O,APPROVED,urinary_system_disease
6406,Diabetic Nephropathies,Moxonidine,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,APPROVED,urinary_system_disease
6407,Autosomal Dominant Polycystic Kidney Disease,Lixivaptan,CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl,PHASE2,urinary_system_disease
6408,Amyotrophic Lateral Sclerosis|Renal Insufficiency,Dexpramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE1,urinary_system_disease
6409,Amyotrophic Lateral Sclerosis|Renal Insufficiency,Pramipexole,CCCNC1CCC2=C(C1)SC(=N2)N,PHASE1,urinary_system_disease
6410,Overactive Bladder|Detrusor Overactivity,Vardenafil,CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C,PHASE2,urinary_system_disease
6411,"Renal Dialysis|Renal Failure, Chronic",Tobramycin,C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N,PHASE1,urinary_system_disease
6412,Urinary Tract Infections|Pyelonephritis,Relebactam,C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3,PHASE2,urinary_system_disease
6413,"Renal Insufficiency, Chronic|Coronary Angiography|Angioplasty, Transluminal, Percutaneous Coronary",Iloprost,CC#CCC(C)C(C=CC1C(CC2C1CC(=CCCCC(=O)O)C2)O)O,PHASE2|PHASE3,urinary_system_disease
6414,Diabetic Nephropathies,Levocetirizine,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,PHASE2,urinary_system_disease
6415,Type 2 Diabetes Mellitus|Hypertension,Fluvastatin,CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,APPROVED,urinary_system_disease
6416,Fanconi Anemia,Oxandrolone,CC12CCC3C(C1CCC2(C)O)CCC4C3(COC(=O)C4)C,PHASE1,urinary_system_disease
6418,"Bladder Cancer|Brain and Central Nervous System Tumors|Carcinoma of Unknown Primary|Extragonadal Germ Cell Tumor|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific",Amifostine,C(CN)CNCCSP(=O)(O)O,PHASE2,urinary_system_disease
6419,Kidney Injury|Proteinuria|Hypertension,Isosorbide,C1C(C2C(O1)C(CO2)O)O,PHASE2,urinary_system_disease
6420,Locally Advanced Papillary Renal Cell Carcinoma|Metastatic Papillary Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma,Savolitinib,CC(C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C,PHASE2,urinary_system_disease
6421,Secondary Hypogonadism,Enclomiphene,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,PHASE1,urinary_system_disease
6422,Gout|Hyperuricemia|Arthritis|Joint Disease|Renal Insufficiency,Ulodesine,C1C(C(CN1CC2=CNC3=C2N=CNC3=O)O)CO,PHASE2,urinary_system_disease
6423,Diabetic Nephropathy,Sarpogrelate,CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O,APPROVED,urinary_system_disease
6424,Lupus Membranous Nephropathy,Filgotinib,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,PHASE2,urinary_system_disease
6425,Vomiting,Casopitant,CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C,PHASE1,urinary_system_disease
6426,Locally Advanced Bladder Urothelial Carcinoma|Metastatic Transitional Cell Carcinoma|Metastatic Urothelial Carcinoma|Recurrent Bladder Carcinoma|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7|Stage IV Bladder Urothelial Carcinoma AJCC v7,Sapanisertib,CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N,PHASE2,urinary_system_disease
6427,Renal Impairment,Elinogrel,CNC1=C(C=C2C(=C1)NC(=O)N(C2=O)C3=CC=C(C=C3)NC(=O)NS(=O)(=O)C4=CC=C(S4)Cl)F,PHASE1,urinary_system_disease
6429,Benign Prostatic Hyperplasia,Doxazosin,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,PHASE2,urinary_system_disease
6430,Overactive Bladder Associated With HTLV-1,Propantheline,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C,PHASE1,urinary_system_disease
6431,"Interstitial Fibrosis|Kidney Transplant; Complications|Kidney Transplant Rejection|Kidney Transplant Failure and Rejection|Kidney Transplant Failure|Kidney Failure, Chronic|Graft Rejection",Fingolimod,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,PHASE2,urinary_system_disease
6432,"Kidney Failure, Acute",Ambrisentan,CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,PHASE2,urinary_system_disease
6433,Gout|Chronic Kidney Disease (CKD),Lesinurad,C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O,APPROVED,urinary_system_disease
6435,Infectious Disease,Omeprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,PHASE1,urinary_system_disease
6436,Bladder Cancer Stage IV,Tucidinostat,C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N,PHASE2,urinary_system_disease
6437,Type 2 Diabetes Mellitus,Ipragliflozin,C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F,APPROVED,urinary_system_disease
6438,End Stage Renal Disease,Escitalopram,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,PHASE2,urinary_system_disease
6439,IGA Nephropathy,Budesonide,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,PHASE2,urinary_system_disease
6440,Urinary Tract Infections,Pivmecillinam,CC1(C(N2C(S1)C(C2=O)N=CN3CCCCCC3)C(=O)OCOC(=O)C(C)(C)C)C,APPROVED,urinary_system_disease
6442,Hypertension|Renal Insufficiency,Indapamide,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,APPROVED,urinary_system_disease
6443,Cystinuria,Tiopronin,CC(C(=O)NCC(=O)O)S,APPROVED,urinary_system_disease
6444,Chronic Kidney Disease,Runcaciguat,CC(C(C1=CC=C(C=C1)Cl)C(=O)NC2=C(C=CC(=C2)C(CC(=O)O)C3CC3)Cl)C(F)(F)F,PHASE1,urinary_system_disease
6445,Sickle Cell Disease|Sickle Cell Nephropathy,Voxelotor,CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O,PHASE1|PHASE2,urinary_system_disease
6446,Complicated Urinary Tract Infection|Infection|Pediatric Infectious Disease,Penicillin G,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,APPROVED,urinary_system_disease
6447,Complicated Urinary Tract Infection|Infection|Pediatric Infectious Disease,Benzylpenicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,APPROVED,urinary_system_disease
6448,Relapsed/Refractory Solid Tumors/Hematological Malignancies,Belinostat,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO,PHASE1,urinary_system_disease
6449,Schistosomiasis Haematobia,Artesunate,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C,PHASE2,urinary_system_disease
6450,Schistosomiasis Haematobia,Pyronaridine,COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6,PHASE2,urinary_system_disease
6451,Schistosomiasis Haematobia,Artemether,CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC)C,PHASE2,urinary_system_disease
6452,Schistosomiasis Haematobia,Lumefantrine,CCCCN(CCCC)CC(C1=CC(=CC2=C1C3=C(C2=CC4=CC=C(C=C4)Cl)C=C(C=C3)Cl)Cl)O,PHASE2,urinary_system_disease
6453,Schistosomiasis Haematobia,Artefenomel,C1CC2(CCC1C3=CC=C(C=C3)OCCN4CCOCC4)OC5(C6CC7CC(C6)CC5C7)OO2,PHASE2,urinary_system_disease
6454,Renal Cell Carcinoma,Decitabine,C1C(C(OC1N2C=NC(=NC2=O)N)CO)O,PHASE2,urinary_system_disease
6455,Focal Glomerulosclerosis,Rosiglitazone,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,PHASE1,urinary_system_disease
6459,Chemotherapy-induced Nausea and Vomiting,Fosaprepitant,CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F,PHASE2,urinary_system_disease
6460,Diabetic Nephropathy,Bindarit,CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3,PHASE2,urinary_system_disease
6461,Multiple Myeloma|Renal Impairment,Dextromethorphan,CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC,PHASE1,urinary_system_disease
6462,Parkinson Disease,Preladenant,COCCOC1=CC=C(C=C1)N2CCN(CC2)CCN3C4=C(C=N3)C5=NC(=NN5C(=N4)N)C6=CC=CO6,PHASE1,urinary_system_disease
6464,Healthy|Renal Impairment,Quinine,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O,PHASE1,urinary_system_disease
6465,Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent WHO Grade 2 Glioma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory WHO Grade 2 Glioma|Wilms Tumor,Ivosidenib,C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N,PHASE2,urinary_system_disease
6466,Bladder Cancer,Rogaratinib,CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N,PHASE2,urinary_system_disease
6467,Renal Impairment|Renal Insufficiency|Kidney Diseases|Pharmacokinetics,Elafibranor,CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)C=CC(=O)C2=CC=C(C=C2)SC,PHASE1,urinary_system_disease
6468,Renal Impairment,Telotristat,CC1=NN(C=C1)C2=C(C=CC(=C2)Cl)C(C(F)(F)F)OC3=NC(=NC(=C3)C4=CC=C(C=C4)CC(C(=O)O)N)N,PHASE1,urinary_system_disease
6469,Renal Insufficiency,Aztreonam,CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N,PHASE1,urinary_system_disease
6470,Hypertension,Daglutril,CCOC(=O)C(CCC1=CC=CC=C1)CC2(CCCC2)C(=O)NC3CCC4=CC=CC=C4N(C3=O)CC(=O)O,PHASE2,urinary_system_disease
6471,Chronic Kidney Disease|Hypertension,Rilmenidine,C1CC1C(C2CC2)NC3=NCCO3,APPROVED,urinary_system_disease
6472,Chronic Kidney Disease|Hypertension,Nitrendipine,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,APPROVED,urinary_system_disease
6473,Renal Impairment|Healthy Volunteers,Mobocertinib,CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE1,urinary_system_disease
6475,0.5-14 Year Old Children With Nephroblastoma,Oxytetracycline,CC1(C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,APPROVED,urinary_system_disease
6476,0.5-14 Year Old Children With Nephroblastoma,Pirarubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)OC6CCCCO6,APPROVED,urinary_system_disease
6477,Urothelial Carcinoma|Bladder Cancer|Myelosuppression Adult|Chemotherapy-induced Neutropenia|Metastatic Bladder Cancer,Trilaciclib,CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6,PHASE2,urinary_system_disease
6478,Latent Tuberculosis|Kidney Failure,Isoniazid,C1=CN=CC=C1C(=O)NN,APPROVED,urinary_system_disease
6479,Latent Tuberculosis|Kidney Failure,Rifapentine,CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C,APPROVED,urinary_system_disease
6480,Chronic Kidney Disease,Dasatinib,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,PHASE2,urinary_system_disease
6481,Chronic Kidney Disease,Quercetin,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,PHASE2,urinary_system_disease
6482,Acute Kidney Injury,Nafamostat,C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,APPROVED,urinary_system_disease
6485,Clear Cell Renal Cell Carcinoma|Locally Advanced Pancreatic Cancer|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Metastatic Renal Cell Carcinoma|Metastatic Urothelial Carcinoma|Metastatic Pancreatic Cancer|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Endometrial Cancer|Metastatic Castration-resistant Prostate Cancer,Ceralasertib,CC1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=N)(=O)C)C4=C5C=CNC5=NC=C4,PHASE2,urinary_system_disease
6486,Heart Failure With Preserved Ejection Fraction|Chronic Kidney Diseases,Sacubitril,CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O,PHASE1|PHASE2,urinary_system_disease
6487,Lupus Nephritis,Iptacopan,CCOC1CCN(C(C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC,PHASE2,urinary_system_disease
6488,Renal Cell Cancer|Metastatic Castration Resistant Prostate Cancer,Ciforadenant,CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5,PHASE1,urinary_system_disease
6489,Renal Insufficiency,Lanabecestat,CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2,PHASE1,urinary_system_disease
6490,Contrast-induced Nephropathy,Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,PHASE2,urinary_system_disease
6491,Bladder Cancer|NMIBC|Non-Muscle Invasive Bladder Cancer|Urothelial Carcinoma Recurrent,Pemigatinib,CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5,PHASE2,urinary_system_disease
6492,Bladder Cancer|Urothelial Carcinoma|Metastatic Urothelial Carcinoma|Renal Pelvis Carcinoma|Ureter Carcinoma|Urinary Bladder Carcinoma|Urethra Carcinoma|Muscle Invasive Bladder Cancer,Rucaparib,CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,PHASE2,urinary_system_disease
6493,Renal Insufficiency,Epetraborole,B1(C2=C(C=CC=C2OCCCO)C(O1)CN)O,PHASE1,urinary_system_disease
6494,Clinical Pharmacology,Riociguat,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,PHASE1,urinary_system_disease
6495,"Kidney Failure, Chronic|Arthralgia",Lumiracoxib,CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O,PHASE2,urinary_system_disease
6496,Urinary Tract Infections,Amoxicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,APPROVED,urinary_system_disease
6497,Renal Impairment,Tasimelteon,CCC(=O)NCC1CC1C2=C3CCOC3=CC=C2,PHASE1,urinary_system_disease
6498,Muscle-invasive Bladder Cancer,Epacadostat,C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F,PHASE2,urinary_system_disease
6499,Diabetic Nephropathy,Pyridoxamine,CC1=NC=C(C(=C1O)CN)CO,PHASE2,urinary_system_disease
6500,Cognitive Disorders|Delirium|Acute Kidney Injury,Ketamine,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,PHASE2,urinary_system_disease
6501,Urinary Incontinence,Sildenafil,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,PHASE1,urinary_system_disease
6503,"Carcinoma, Transitional Cell|Bladder Cancer|Bladder Neoplasm",Pralatrexate,C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O,PHASE2,urinary_system_disease
6504,Nocturia|Daytime Sleepiness,Armodafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE2|PHASE3,urinary_system_disease
6505,Nocturia|Daytime Sleepiness,Modafinil,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,PHASE2|PHASE3,urinary_system_disease
6506,Bladder Transitional Cell Carcinoma|Bladder Cancer|Fibroblast Growth Factor Receptor,Infigratinib,CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl,PHASE1,urinary_system_disease
6507,Muscle Invasive Bladder Cancer,Vistusertib,CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=CC=C4)C(=O)NC)N5CCOCC5C,PHASE1,urinary_system_disease
6508,Chronic Kidney Diseases,Quetiapine,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,PHASE1,urinary_system_disease
6509,Renal Insufficiency,Odalasvir,CC(C)C(C(=O)N1C2CCCCC2CC1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)C1CC2CCCCC2N1C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,PHASE1,urinary_system_disease
6510,Renal Impairment,Evobrutinib,C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N,PHASE1,urinary_system_disease
6511,HIV Infections,Raltegravir,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,PHASE2,urinary_system_disease
6512,HIV Infections,Emtricitabine,C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F,PHASE2,urinary_system_disease
6513,HIV Infections,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,PHASE2,urinary_system_disease
6514,HIV Infections,Atazanavir,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,PHASE2,urinary_system_disease
6515,HIV Infections,Darunavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,PHASE2,urinary_system_disease
6516,Nocturia,Fedovapagon,CC1=C(C=CC(=C1)C(=O)N2CCCCC3=CC=CC=C32)CNC(=O)N4CCCC4C(=O)N(C)C,PHASE2|PHASE3,urinary_system_disease
6517,Long QT Syndrome,Eleclazine,C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4,PHASE1,urinary_system_disease
6518,Renal Impairment,Asciminib,C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4,PHASE1,urinary_system_disease
6519,"Carcinoma, Renal Cell",Gefitinib,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,PHASE1|PHASE2,urinary_system_disease
6520,Renal Impaired|Gilteritinib|Normal Renal Function|Pharmacokinetics of ASP2215,Gilteritinib,CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5,PHASE1,urinary_system_disease
6521,Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma,Tivantinib,C1CC2=C3C(=CC=C2)C(=CN3C1)C4C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,PHASE2,urinary_system_disease
6523,Venous Thromboembolism|Renal Impairment,Enoxaparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,APPROVED,urinary_system_disease
6524,Renal Impairment,Hydrocodone,CN1CCC23C4C1CC5=C2C(=C(C=C5)OC)OC3C(=O)CC4,PHASE1,urinary_system_disease
6525,Complicated Skin and Skin Structure Infections|S. Aureus Bacteremia|Renal Impairment,Daptomycin,CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C,APPROVED,urinary_system_disease
6526,Complicated Skin and Skin Structure Infections|S. Aureus Bacteremia|Renal Impairment,Phenoxymethylpenicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,APPROVED,urinary_system_disease
6527,Complicated Skin and Skin Structure Infections|S. Aureus Bacteremia|Renal Impairment,Penicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,APPROVED,urinary_system_disease
6528,Chronic Kidney Disease,Floxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,PHASE1,urinary_system_disease
6529,Chronic Kidney Disease,Flucloxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,PHASE1,urinary_system_disease
6530,Acute Kidney Injury,Deferoxamine,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,PHASE2,urinary_system_disease
6531,Hypertension,Lercanidipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,APPROVED,urinary_system_disease
6532,Somatostatin Analogs|Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney Disease|Autosomal Dominant Polycystic Liver Disease,Pasireotide,C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,PHASE2,urinary_system_disease
6533,Renal Impairment,Teriflunomide,CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O,PHASE1,urinary_system_disease
6534,Renal Impairment,Glepaglutide,CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(C)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC5=CNC=N5)N,PHASE1,urinary_system_disease
6535,Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia,Naftopidil,COC1=CC=CC=C1N2CCN(CC2)CC(COC3=CC=CC4=CC=CC=C43)O,APPROVED,urinary_system_disease
6536,Pruritus|Uremia|Chronic Kidney Diseases,Loratadine,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,APPROVED,urinary_system_disease
6537,Renal Impairment,Glasdegib,CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N,PHASE1,urinary_system_disease
6538,Renal Insufficiency,Dalfampridine,C1=CN=CC=C1N,PHASE1,urinary_system_disease
6540,Renal Impairment,Betrixaban,CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl,PHASE1,urinary_system_disease
6541,Chronic Kidney Disease,Arotinolol,CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O,APPROVED,urinary_system_disease
6542,Renal Dysfunction|Acute Renal Failure|Mortality,Ularitide,CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)CC2=CC=CC=C2)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C3CCCN3C(=O)C(C)NC(=O)C(C(C)O)N)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC4=CC=CC=C4)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC5=CC=C(C=C5)O)C(=O)O)CC(C)C)CO)CCC(=O)N)C,PHASE2,urinary_system_disease
6543,Bladder Cancer,Amrubicin,CC(=O)C1(CC(C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)OC5CC(C(CO5)O)O)N,PHASE2,urinary_system_disease
6544,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Binimetinib,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,PHASE2,urinary_system_disease
6545,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Capivasertib,C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4,PHASE2,urinary_system_disease
6546,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Defactinib,CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F,PHASE2,urinary_system_disease
6547,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Ipatasertib,CC1CC(C2=C1C(=NC=N2)N3CCN(CC3)C(=O)C(CNC(C)C)C4=CC=C(C=C4)Cl)O,PHASE2,urinary_system_disease
6548,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Osimertinib,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC,PHASE2,urinary_system_disease
6549,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Taselisib,CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C,PHASE2,urinary_system_disease
6550,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Trametinib,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,PHASE2,urinary_system_disease
6551,Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,Vismodegib,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,PHASE2,urinary_system_disease
6552,End Stage Renal Disease,Oseltamivir,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,PHASE1,urinary_system_disease
6553,Kidney Calculi,Remifentanil,CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC,APPROVED,urinary_system_disease
6554,Schizophrenia|Renal Impairment,Paliperidone,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,PHASE1,urinary_system_disease
6555,Chronic Hepatitis C|End Stage Renal Disease,Boceprevir,CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,APPROVED,urinary_system_disease
6557,Kidney Disease,Bremelanotide,CCCCC(C(=O)NC1CC(=O)NCCCCC(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C,PHASE2,urinary_system_disease
6558,Non-Muscle Invasive Bladder Urothelial Carcinoma|Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma,Apalutamide,CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F,PHASE1,urinary_system_disease
6559,Advanced Kidney Cancer|Kidney Cancer|Clear Cell Renal Cell Carcinoma,Guadecitabine,C1C(C(OC1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(O)OC4CC(OC4CO)N5C=NC(=NC5=O)N)O,PHASE1|PHASE2,urinary_system_disease
6560,Renal Insufficiency,Certoparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,PHASE1|PHASE2,urinary_system_disease
6561,Chronic Kidney Disease on Hemodialysis|Secondary Hyperparathyroidism,Maxacalcitol,CC(C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)OCCC(C)(C)O,PHASE2,urinary_system_disease
6562,Healthy Subjects|Renal Impairments,Levetiracetam,CCC(C(=O)N)N1CCCC1=O,APPROVED,urinary_system_disease
6563,"Type 2 Diabetes Mellitus, CKD and Albuminuria",Saxagliptin,C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N,PHASE2|PHASE3,urinary_system_disease
6564,Diabetic Kidney Disease|Diabetic Nephropathy|Diabetes Mellitus|Glucagon-Like Peptide 1,Lixisenatide,CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N,APPROVED,urinary_system_disease
6565,Healthy|Renal Impairment,Cenerimod,CCC1=C(C(=CC(=C1)C2=NOC(=N2)C3=CC(=NC(=C3)OC)C4CCCC4)C)OCC(CO)O,PHASE1,urinary_system_disease
6567,Advanced or Metastatic Hepatocellular Cancer|Advanced or Metastatic Ovarian Cancer|Metastatic Renal Cell Cancer|Advanced or Metastatic Gastric Carcinoma,Tasquinimod,CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O,PHASE2,urinary_system_disease
6568,Renal Impairment|Renal Disease|Kidney Disease,Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],PHASE1,urinary_system_disease
